<SEC-DOCUMENT>0001672688-25-000084.txt : 20251112
<SEC-HEADER>0001672688-25-000084.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112161354
ACCESSION NUMBER:		0001672688-25-000084
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Absci Corp
		CENTRAL INDEX KEY:			0001672688
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				853383487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40646
		FILM NUMBER:		251472886

	BUSINESS ADDRESS:	
		STREET 1:		18105 SE MILL PLAIN BLVD
		CITY:			VANCOUVER
		STATE:			WA
		ZIP:			98683
		BUSINESS PHONE:		(360) 949-1041

	MAIL ADDRESS:	
		STREET 1:		18105 SE MILL PLAIN BLVD
		CITY:			VANCOUVER
		STATE:			WA
		ZIP:			98683

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AbSci Corp
		DATE OF NAME CHANGE:	20201026

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AbSci, Inc.
		DATE OF NAME CHANGE:	20201026

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AbSci, LLC
		DATE OF NAME CHANGE:	20160420
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>absi-20250930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a3e69f22-3845-4b88-95f7-36018340f30a,g:dbd2b148-ca4f-47a0-84c9-32244e24e6c1,d:9ac3491acf394da29655edd3b9380996-->
<html xmlns:srt="http://fasb.org/srt/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:absi="http://www.absci.com/20250930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>absi-20250930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-27">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-30">0001672688</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-95">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-96">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-97">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-98">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="absi-20250930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="partner"><xbrli:measure>absi:partner</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>absi:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:ShelfRegistrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:ShelfRegistrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:ShelfRegistrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:TDSecuritiesUSALLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:TDSecuritiesUSALLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:AdvancedMicroDevicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:AdvancedMicroDevicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:AdvancedMicroDevicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2021StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2021StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2023InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2020StockOptionAndGrantPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2020StockOptionAndGrantPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001672688</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9ac3491acf394da29655edd3b9380996_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_13">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September&#160;30, 2025</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 4.35pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _________ to __________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40646</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">ABSCI CORP</ix:nonNumeric>ORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">85-3383487</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">18105 SE Mill Plain Blvd</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Vancouver</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">WA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">98683</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">360</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">949-1041</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock. $0.0001 par value</ix:nonNumeric> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">ABSI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;No</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;N</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">o&#160;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9746;</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">The registrant had outstanding <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">150,371,531</ix:nonFraction> shares of $0.0001 par value common stock as of October&#160;31, 2025.</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_13">Table of Contents</a></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:11.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.731%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_25">Part I Financial Information (Unaudited)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_28">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_28">Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_31">Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_34">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_34">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_37">Unaudited Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the Three and Nine Months Ended September 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_37">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_40">Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_40">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_43">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_43">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_118">Item 2.</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_118">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_118">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_154">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_154">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_154">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_157">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_157">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_157">29</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_160">Part II Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_160">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_163">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_163">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_163">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_166">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_166">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_166">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_175">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_175">Unregistered Sales of Equity Securities</a><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_175"> and</a><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_175"> Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_175">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_178">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_178">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_178">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_181">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_181">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_181">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_184">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_184">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_184">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_187">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_187">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_187">85</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_301">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_301">86</a></span></div></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_13">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RISK FACTOR SUMMARY </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below in Item 1A. - &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission, or the SEC, before making investment decisions regarding our common stock.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Our plans and expectations regarding the initiation, timing, progress, results, and costs of both of our internally developed programs and partnered programs, including current and future preclinical studies and clinical trials, and the period during which the results of such studies and trials will become available, are subject to a high degree of uncertainty;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Our current business has a limited operating history, which may make it difficult to evaluate our business and predict our future performance;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We will need to raise additional capital to fund our operations, including for the advancement of internally developed programs, and to improve our Integrated Drug Creation</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform. If we are unable to raise additional capital on terms acceptable to us or at all, we may not be able to compete successfully, which would harm our business, operations, and financial condition;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Biologic drug development is inherently uncertain, and it is possible that our technology may not succeed in discovering appropriate molecules. Even if we do succeed, it is possible that none of the product candidates created using our Integrated Drug Creation platform that we are developing internally or that are further developed by our partners will achieve development or regulatory milestones, including marketing approval, or become viable commercial technologies, on a timely basis or at all, which would harm our ability to generate revenue;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">If we or our partners experience any of a number of possible unforeseen or negative events in connection with preclinical or clinical development, regulatory approval or commercialization of product candidates generated through our platform, this could negatively affect our revenue opportunity for that program, and/or have broader deleterious effects on our reputation and future partnership prospects;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Preclinical development is uncertain. Our preclinical product candidates may experience delays or may never advance to clinical trials, which would adversely affect our or our partners&#8217; ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Preliminary data and interim results we disclose from our clinical trials may change as more data becomes available or as we make changes to our clinical protocols or processes, and such interim results or results from earlier studies may not be predictive of the final results, or of later studies or future clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The biopharmaceutical platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve and sustain profitability;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We rely and expect to continue to rely on third parties to conduct our preclinical studies and clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or the relationship terminates prematurely, our internally developed programs could be delayed, or become more costly or unsuccessful, and such programs may never obtain regulatory approval or commercialization;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_13">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our programs and validation of our Integrated Drug Creation platform may be delayed and our expenses may increase and, as a result, our stock price may decline;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We are substantially dependent on the successful application of our Integrated Drug Creation platform to initiate and advance partnered programs and to develop our internally developed programs that can be further developed by our current or future partners;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Our partnership strategy significantly depends on the eventual approval and commercialization of product candidates developed under our partnerships for which we may have no control over the clinical development plan, regulatory strategy or commercialization efforts;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">If we cannot maintain our current relationships with partners, fail to expand our relationships with our current partners, or if we fail to enter into new relationships, our future operating results would be adversely affected as a general matter;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We rely on a limited number of suppliers for laboratory equipment and materials and may not be able to find replacements or transition to alternative suppliers on a timely basis, or at all;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Our Integrated Drug Creation platform may not meet the expectations of our partners, which means our business, financial condition, results of operations and prospects could suffer;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The loss of any member of our senior leadership team or our inability to attract and retain highly skilled scientists and business development professionals could adversely affect our business; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We depend on our information technology systems, and any significant disruptions to or failure of these systems could result in significant financial, legal, regulatory, business and reputational harm to our business; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">If we are unable to obtain and maintain sufficient intellectual property protection for our technologies, including for our cell line and expression technologies, generative deep learning technology, proprietary assays and techniques, and antibody and target discovery technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies similar or identical to ours, and our ability to successfully leverage our technologies may be impaired; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Disruptions to federal government operations, including disruptions due to the federal government shutdown beginning October 1, 2025, in addition to substantial uncertainty regarding the U.S. presidential administration&#8217;s initiatives and staffing cuts, could prevent governmental agencies such as the FDA from performing normal business functions on which the operation of our business may rely, including timely reviews, which could negatively impact our business.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q includes &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings &#8220;Business&#8221;, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;, and &#8220;Risk Factors&#8221;. Forward-looking statements can often be identified by the use of terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. In particular, these forward-looking statements include, but are not limited to:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our plans and expectations regarding the initiation, timing, progress, results, and costs of both of our internally developed programs and partnered programs, including current and future preclinical studies and clinical trials, and the period during which the results of such studies and trials will become available;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_13">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability and timing to advance our product candidates in, and to successfully initiate, conduct, enroll and complete, clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our expectations regarding the therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the timing and likelihood of, and our ability to obtain and maintain, regulatory clearances of our Investigational New Drug (IND) applications to initiate clinical trials and regulatory approval to commercialize our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our expectations regarding our further development of, successful application of, and the rate and degree of market acceptance of, our Integrated Drug Creation platform, including progress towards </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biologic drug discovery;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our expectations regarding our ability to leverage our Integrated Drug Creation platform to shorten preclinical development timelines for biologics;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our expectations regarding the markets for our product candidates, if approved, as well as those product candidates developed by our partners using our services and technologies, including the growth rate of the biologics market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to attract new partners and enter into drug creation agreements that contain milestone and royalty obligations in favor of us;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">adverse public perception of the use of artificial intelligence (AI) and product candidates developed using AI may negatively impact demand for, or regulatory approval of, our product candidates and adversely affect investor and marketplace perception of our platform technology; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our potential to receive revenue from the achievement of milestones and from royalties on net sales under agreements with our partners with respect to products originating from our Integrated Drug Creation platform;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to enter into commercial license agreements for our existing partnered programs who do not currently have milestone payment and royalty obligations to us;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to manage and grow our business by expanding our relationships with existing partners or introducing our Integrated Drug Creation platform to new partners and developing product candidates for internally developed programs;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our expectations regarding our current and future partners&#8217; continued development of, and ability to commercialize, biologic drugs generated utilizing our proprietary Integrated Drug Creation platform;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our strategy, including our strategy to advance internally developed programs through preclinical studies and clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability to obtain additional funding before we can expect to generate additional revenue;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our estimates of the sufficiency of our cash, cash equivalents and marketable securities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our calculations and estimates related to the valuation of our intangible assets;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to establish, maintain or expand collaborations, partnerships or strategic relationships;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to provide our partners with a full drug discovery solution and the use of artificial intelligence (AI) across our Integrated Drug Creation platform;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to obtain, maintain and enforce intellectual property protection for our platform, products and other technologies, the duration of such protection and our ability to operate our business without infringing on the intellectual property rights of others;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to attract, hire and retain key personnel and to manage our growth effectively;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our expectations regarding use of our cash, cash equivalents and marketable securities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_13">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our financial performance and that of companies in our industry and the financial markets generally;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the volatility of the trading price of our common stock;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our competitive position and the development of and projections relating to our competitors or our industry;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the impact of laws and regulations on our business and operations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (JOBS Act); and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">global economic conditions, including market volatility, acts of war and civil and political unrest, and our expectations about market trends and effects from inflation and fluctuations in interest rates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. Moreover, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report and the documents that we file with the SEC, with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, references in this Quarterly Report on Form 10-Q to &#8220;Absci,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Absci Corporation and its subsidiaries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_13">Table of Contents</a></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div id="i9ac3491acf394da29655edd3b9380996_28"></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i9ac3491acf394da29655edd3b9380996_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except for share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">9,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">41,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-33">16,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-34">15,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">142,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">71,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">5,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">5,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">174,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">133,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-43">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-44">3,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-45">23,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-46">29,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangibles, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-47">42,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-48">44,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-51">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-52">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-53">244,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-54">213,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">4,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">8,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">6,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">2,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">1,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financing lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-65">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-66">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">29,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">28,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term debt, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermNotesPayable" scale="3" id="f-71">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-72">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">3,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">4,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">1,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-76">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-77">34,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-78">34,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments (See Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-79"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-80"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Preferred stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-83">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-84">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-85">805,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-86">688,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-87">595,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-88">509,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-89">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-90">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TOTAL STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-91">210,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">179,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-93">244,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">213,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except for share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-95"><span style="-sec-ix-hidden:f-96"><span style="-sec-ix-hidden:f-97"><span style="-sec-ix-hidden:f-98">Partner program revenue</span></span></span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-99">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-100">1,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-101">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-102">3,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">19,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">56,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">45,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">8,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">9,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">26,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">27,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-111">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-112">3,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-113">8,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-114">10,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">30,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-116">30,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-117">91,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-118">82,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">30,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">28,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">89,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">79,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-123">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-124">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-125">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-126">456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">5,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-135">28,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">27,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-137">85,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-138">74,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-139">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-140">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-141">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-142">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-143">28,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">27,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">85,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">74,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share:<br/>Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-147"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-148">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-151"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-152">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-154">0.68</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding:<br/>Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-155"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-156">143,769,552</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-158">113,613,488</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-159"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-160">132,114,850</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-161"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-162">108,665,095</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">28,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">27,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">85,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">74,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-167">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-168">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-169">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-170">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-171">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-172">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-173">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-174">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-175">28,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-176">27,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-177">85,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-178">73,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.134%"><tr><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.152%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:28pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except for share data)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - December 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-179">115,362,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-180">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">688,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">509,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-183">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">179,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common shares, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-185">744</ix:nonFraction></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-186">10,983,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-187">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-188">39,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-189">39,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of shares under stock plans, net of shares withheld for tax payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-190">1,195,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-191">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-192">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-193">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-194">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-195">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-196">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-197">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-198">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-199">26,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-200">26,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - March 31, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-201">127,540,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-202">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">734,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">535,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-205">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">198,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of shares under stock plans, net of shares withheld for tax payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-207">136,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" scale="3" id="f-208">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" scale="3" id="f-209">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">4,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-211">4,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-212">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-213">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-214">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-215">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">30,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">30,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - June 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-218">127,677,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-219">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">739,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">566,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-222">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">173,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common shares, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-224">3,710</ix:nonFraction></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-225">21,778,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-226">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-227">60,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-228">60,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of shares under stock plans, net of shares withheld for tax payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-229">290,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" scale="3" id="f-230">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" scale="3" id="f-231">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-232">4,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-233">4,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-234">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-235">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-236">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-237">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">28,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">28,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - September 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-240">149,746,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-241">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">805,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">595,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-244">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">210,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.134%"><tr><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.152%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:28pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except for share data)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-246">93,087,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-247">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">582,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">406,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-250">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">176,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common shares, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-252">411</ix:nonFraction></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-253">19,205,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-254">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-255">80,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-256">80,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of shares under stock plans, net of shares withheld for tax payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-257">706,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-258">1,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-259">1,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-260">3,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-261">3,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeiture of common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-262">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-263">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-264">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-265">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-267">21,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-268">21,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - March 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-269">112,998,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-270">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">668,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">428,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-273">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-274">240,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of shares under stock plans, net of shares withheld for tax payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-275">483,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" scale="3" id="f-276">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" scale="3" id="f-277">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-278">5,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-279">5,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeiture of common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-280">37,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-281">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-282">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-283">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-284">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-286">24,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-287">24,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - June 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-288">113,444,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-289">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-290">674,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-291">453,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-292">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-293">221,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of shares under stock plans, net of shares withheld for tax payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-294">746,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-295">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-296">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-297">5,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-298">5,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-299">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-300">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-301">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-302">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-303">27,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-304">27,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances - September 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-305">114,190,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-306">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-307">681,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-308">480,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-309">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-310">201,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-311">85,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-312">74,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-313">8,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-314">10,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-315">14,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-316">14,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accretion of discount on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-317">2,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-318">2,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-319">308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-320">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-321">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-322">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-323">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-324">992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="absi:IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" scale="3" id="f-325">412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="absi:IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" scale="3" id="f-326">635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-327">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-328">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-329">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-330">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-331">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-332">1,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-333">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-334">2,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-335">63,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-336">55,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-337">1,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-338">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-339">134,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-340">159,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-341">65,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-342">99,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from sales of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-343">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-344">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-345">69,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-346">60,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal payments on long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-347">2,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-348">2,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Principal payments on finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-349">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-350">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-351">102,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-352">84,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock through employee equity plans, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="f-353">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-355">102,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-356">81,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-357">31,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-358">34,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash - Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-359">58,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-360">89,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash - End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-361">26,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-362">55,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Supplemental Disclosure of Non-Cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-364">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i9ac3491acf394da29655edd3b9380996_46"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-365" continuedAt="f-365-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Organization and nature of operations</span></ix:nonNumeric></div><ix:continuation id="f-365-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absci Corporation (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company advancing potential breakthrough antibody therapeutics with generative AI. The Company&#8217;s Integrated Drug Creation platform comprises, in part, cutting edge AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was organized in the State of Oregon in August 2011 as a limited liability company and converted to a limited liability company (&#8220;LLC&#8221;) in Delaware in April 2016. In October 2020, the Company converted from a Delaware LLC to a Delaware corporation. The Company&#8217;s headquarters are located in Vancouver, Washington.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its interim condensed consolidated financial statements that accompany these notes in conformity with accounting principles generally accepted in the United States, consistent in all material respects with those applied in its Annual Report on Form 10-K for the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made estimates and judgments affecting the amounts reported in its condensed consolidated financial statements and the accompanying notes. The actual results that the Company experiences may differ materially from its estimates. The interim financial information is unaudited and reflects all normal adjustments that are, in the Company&#8217;s opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the consolidated financial statements in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024.</span></div></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_55"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-366" continuedAt="f-366-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Revenue recognition</span></ix:nonNumeric></div><ix:continuation id="f-366-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of the satisfaction of performance obligations. As of September&#160;30, 2025 and December&#160;31, 2024, contract liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-367">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-368">1.1</ix:nonFraction>&#160;million, respectively. During the three and nine months ended September 30, 2025, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-369">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-370">0.8</ix:nonFraction> million, respectively, as revenue that had been included in deferred revenue at the beginning of the period. During the three and nine months ended September 30, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-371">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-372">3.0</ix:nonFraction> million, respectively, as revenue that had been included in deferred revenue at the beginning of the period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2025, <ix:nonFraction unitRef="partner" contextRef="c-74" decimals="INF" name="absi:NumberOfPartners" format="ixt-sec:numwordsen" scale="0" id="f-373">two</ix:nonFraction> partners represented approximately <ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-374">93</ix:nonFraction>% and <ix:nonFraction unitRef="partner" contextRef="c-75" decimals="INF" name="absi:NumberOfPartners" format="ixt-sec:numwordsen" scale="0" id="f-375">three</ix:nonFraction> partners represented <ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-376">98</ix:nonFraction>% of total partner program revenue, respectively. During the three and nine months ended September 30, 2024, <ix:nonFraction unitRef="partner" contextRef="c-76" decimals="INF" name="absi:NumberOfPartners" format="ixt-sec:numwordsen" scale="0" id="f-377"><ix:nonFraction unitRef="partner" contextRef="c-77" decimals="INF" name="absi:NumberOfPartners" format="ixt-sec:numwordsen" scale="0" id="f-378">two</ix:nonFraction></ix:nonFraction> partners represented <ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-379"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-380">100</ix:nonFraction></ix:nonFraction>% of total partner program revenue.</span></div></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_58"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-381" continuedAt="f-381-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Collaborative arrangements</span></ix:nonNumeric></div><ix:continuation id="f-381-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company has collaborative arrangements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin that involve joint research and development activities and for which the parties are exposed to significant risks and rewards dependent on the commercial success of such activities. The Company performs drug creation activities to co-develop product candidates. These arrangements include rights for the parties to share in the potential value created by the programs, as well as cost sharing which may result in payments and/or credits between the parties. The Company&#8217;s accounting policy is to present cost sharing payments to and from the Company&#8217;s collaborators within research and development expense on the condensed consolidated statements of operations and comprehensive loss. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="absi:ProceedsFromCollaborativeArrangement" scale="6" id="f-382"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="absi:ProceedsFromCollaborativeArrangement" scale="6" id="f-383">0.8</ix:nonFraction></ix:nonFraction> million of cost sharing payments and credits related to collaborative arrangements during the three and nine months ended September 30, 2025. The Company did <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="absi:ProceedsFromCollaborativeArrangement" format="ixt:fixed-zero" scale="0" id="f-384"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="absi:ProceedsFromCollaborativeArrangement" format="ixt:fixed-zero" scale="0" id="f-385">no</ix:nonFraction></ix:nonFraction>t have cost sharing payments related to collaborative arrangements during the three or nine months ended September 30, 2024.</span></div></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_61"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="f-386" continuedAt="f-386-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Investments</span></ix:nonNumeric></div><ix:continuation id="f-386-1" continuedAt="f-386-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities are classified as available-for-sale and are recorded at fair value on the condensed consolidated balance sheets, with any unrealized gains and losses reported in accumulated </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-386-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive loss, which is reflected as a separate component of stockholders&#8217; equity on the Company&#8217;s condensed consolidated balance sheets, until realized. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company considers all marketable securities to be current assets as they are available for use in current operations.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-387" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of investments are as follows (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair market value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="3" id="f-388">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="f-391">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-392">142,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-393">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-394">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-395">142,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-396">143,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-397">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-398">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-399">143,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="f-400">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-401">142,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-402">143,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair market value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-403">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-406">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-407">71,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-408">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-410">71,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-411">73,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-412">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-414">73,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-415">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-416">71,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-417">73,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities of available-for-sale securities were $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="f-418">39.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-419">65.2</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2025, respectively. Proceeds from maturities of available-for-sale securities were $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="f-420">43.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-421">132.1</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2024, respectively. As of September&#160;30, 2025, the Company held $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="f-422">32.6</ix:nonFraction> million of marketable securities with a remaining maturity of greater than one year. There were <ix:nonFraction unitRef="usd" contextRef="c-86" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-423"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-424"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-425"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-426">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> realized gains or losses on securities for the three and nine months ended September 30, 2025 and 2024. Unrealized gains and losses on securities were primarily due to changes in interest rates.</span></div></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_64"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-427" continuedAt="f-427-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Fair value measurements</span></ix:nonNumeric></div><ix:continuation id="f-427-1" continuedAt="f-427-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value to establish a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices in active markets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-427-2" continuedAt="f-427-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation hierarchy.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2 inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-428" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="f-429">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="f-432">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-433">19,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-434">123,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-436">142,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-437">19,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-438">123,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-440">143,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:num-dot-decimal" scale="3" id="f-443">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:num-dot-decimal" scale="3" id="f-444">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-447">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-448">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-449">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-452">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-454">71,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-456">71,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-457">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-458">71,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-460">73,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:num-dot-decimal" scale="3" id="f-463">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="absi:ContingentConsiderationFairValue" format="ixt:num-dot-decimal" scale="3" id="f-464">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-467">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-468">12,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews trading activity and pricing for its available-for-sale securities as of the measurement date.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change to the value of liabilities measured at fair value using significant unobservable inputs (Level 3) for the nine months ended September 30, 2025. The contingent consideration liability is related to the acquisition of Totient, Inc. and is included in contingent consideration on the condensed consolidated balance sheet as of September&#160;30, 2025 and December&#160;31, 2024. The fair value estimate is based on a probability-weighted approach on conditions that existed as of September 30, 2025 (See Note 11: Subsequent events) . The contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-469"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-470">15.0</ix:nonFraction></ix:nonFraction>&#160;million held in escrow shall be paid upon the achievement of the milestone of either entering into agreements meeting certain financial criteria with third parties using, or relating to, Totient technology or the first commercial sale of a Totient product. The contingent consideration </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-427-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held in escrow is included in restricted cash on the condensed consolidated balance sheets as of September&#160;30, 2025 and December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of long-term debt approximates fair value.</span></div></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_82"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-471" continuedAt="f-471-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Commitments and contingencies</span></ix:nonNumeric></div><ix:continuation id="f-471-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to compute capacity and other services through an agreement with Oracle Cloud Infrastructure (OCI) through early 2028. The remaining financial commitments for the years 2025, 2026, 2027, and 2028 are $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" scale="6" id="f-472">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" scale="6" id="f-473">4.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:OtherCommitmentDueInSecondYear" scale="6" id="f-474">8.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:OtherCommitmentDueInThirdYear" scale="6" id="f-475">2.3</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_85"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-476" continuedAt="f-476-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Common stock</span></ix:nonNumeric></div><ix:continuation id="f-476-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement on Form S-3</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company filed a shelf registration statement on Form S-3 (the Prior Shelf Registration Statement) with the SEC relating to the registration of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="INF" name="absi:SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-477">250.0</ix:nonFraction>&#160;million in shares of the Company&#8217;s common stock, preferred stock, debt securities, warrants and units or any combination thereof. In July 2025, the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-478">16,670,000</ix:nonFraction> shares and received $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-479">46.7</ix:nonFraction> million in net proceeds from the sale of securities pursuant to the Prior Shelf Registration Statement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement) with the SEC relating to the registration of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="INF" name="absi:SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-480">400.0</ix:nonFraction>&#160;million in shares of the Company&#8217;s common stock, preferred stock, debt securities, warrants and units or any combination thereof.  During the nine months ended September 30, 2025, the Company has not issued any shares pursuant to the Shelf Registration Statement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-market offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company entered into a Sales Agreement with Cowen and Company, LLC, as Sales Agent (the &#8220;Prior Sales Agreement&#8221;), with respect to an &#8220;at the market offering&#8221; program under which the Company had the ability to offer and sell, from time to time, shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-481">0.0001</ix:nonFraction> per share, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="absi:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="f-482">100.0</ix:nonFraction>&#160;million through the Sales Agent. The Company agreed to pay the Sales Agent a commission up to <ix:nonFraction unitRef="number" contextRef="c-118" decimals="3" name="absi:SaleOfStockSalesAgentCommissionPercentage" scale="-2" id="f-483">3.0</ix:nonFraction>% of the gross sales proceeds of any shares sold under the Prior Sales Agreement. During the nine months ended September 30, 2025, the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-484">10,377,752</ix:nonFraction> shares and received $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-485">35.7</ix:nonFraction> million in net proceeds from the sale of securities pursuant to the Prior Sales Agreement. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company entered into a Sales Agreement with TD Securities (USA) LLC, as Sales Agent (the &#8220;Sales Agreement&#8221;), with respect to an &#8220;at the market offering&#8221; program under which the Company may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="absi:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="f-486">100.0</ix:nonFraction>&#160;million through the Sales Agent. The Company has agreed to pay the Sales Agent a commission of up to <ix:nonFraction unitRef="number" contextRef="c-122" decimals="3" name="absi:SaleOfStockSalesAgentCommissionPercentage" scale="-2" id="f-487">3.0</ix:nonFraction>% of the gross proceeds of any shares sold under the Sales Agreement. Upon execution, the Sales Agreement terminated and superseded the Prior Sales Agreement in its entirety. During the nine months ended September 30, 2025, the Company did not issue any shares of common stock under the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private investment in public equity</span></div><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2025, the Company entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD) and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-488">5,714,285</ix:nonFraction> shares of the Company&#8217;s common stock to AMD for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-489">20.0</ix:nonFraction> million through a private investment in public equity (PIPE). This strategic collaboration with AMD has a goal to optimize the performance of AMD Instinct</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> accelerators and ROCm</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">software to support the Company&#8217;s AI drug creation, including its de novo antibody design models. The issuance of stock to AMD was at a premium of approximately $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-490">2.5</ix:nonFraction> million over the market price on the issuance date. The premium was recorded to accrued expenses and other long-term liabilities on the condensed consolidated balance sheet and will be recognized as a credit to research and development expense over the collaboration term. The amortization of the premium was $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" sign="-" name="absi:AmortizationOfEquityIssuanceDiscountPremium" scale="6" id="f-491">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" sign="-" name="absi:AmortizationOfEquityIssuanceDiscountPremium" scale="6" id="f-492">0.5</ix:nonFraction> million for the three and nine months ended September 30, 2025, respectively.</span></div></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="f-493" continuedAt="f-493-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Stock-based compensation</span></ix:nonNumeric></div><ix:continuation id="f-493-1" continuedAt="f-493-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options, restricted stock units, and stock appreciation rights (&#8220;SARs&#8221;) under the 2021 Stock Option and Incentive Plan (&#8220;2021 Plan&#8221;) and the 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;). On January 1, 2025, the number of shares of common stock reserved for future issuance under the 2021 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-494">5,768,113</ix:nonFraction> shares pursuant to an automatic annual increase. As of September&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-495">5,483,484</ix:nonFraction> <span id="id6b2bc6cd52b4e3e8449d294cd04927c_1482"></span>shares were available for future grant under the 2021 Plan. As of September&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-496">1,724,200</ix:nonFraction> shares were available for future grant under the 2023 Inducement Plan.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-497" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to all of the Company&#8217;s stock-based awards was recorded in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-498">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-499">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-500">6,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-501">5,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-502">2,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-503">3,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-504">8,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-505">8,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-506">4,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-507">5,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-508">14,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-509">14,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-510" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options is shown below:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Contractual Term (in years)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands $)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-511">19,177,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-512">3.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-137" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-513">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-514">7,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-515">6,512,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-516">3.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-517">864,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-518">2.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-519">1,738</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-520">2,293,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-521">3.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-522">626,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-523">7.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-524">21,905,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-525">3.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-526">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-527">9,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-528">10,105,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-529">3.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-530">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-531">6,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, total unrecognized stock-based compensation related to stock options was $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-532">22.0</ix:nonFraction> million, which the Company expects to recognize over a remaining weighted average period of <ix:nonNumeric contextRef="c-139" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-533">2.1</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determination of fair value</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-534" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant-date fair value of all the Company&#8217;s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.132%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-535">5.8</ix:nonNumeric>-<ix:nonNumeric contextRef="c-141" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-536">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-142" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-537">6.0</ix:nonNumeric>-<ix:nonNumeric contextRef="c-143" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-538">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-144" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-539">5.5</ix:nonNumeric>-<ix:nonNumeric contextRef="c-145" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-540">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-146" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-541">5.5</ix:nonNumeric>-<ix:nonNumeric contextRef="c-147" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-542">6.1</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-543">91</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-141" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-544">91</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-545">82</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-546">84</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-144" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-547">90</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-145" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-548">92</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-549">81</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-147" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-550">84</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-551">3.8</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-552">4.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-553">3.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-554">4.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-555">3.8</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-556">4.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-557">3.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-558">4.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-559">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-560">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-561">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-562">&#8212;</ix:nonFraction>%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-493-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="f-563" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for restricted stock units is shown below:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-564">3,711,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-565">3.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-566">1,667,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-567">3.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-568">469,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-569">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-570">489,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-571">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-572">4,420,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-573">3.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-574">5.9</ix:nonFraction>&#160;million of unrecognized compensation expense related to the outstanding restricted stock units expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="c-149" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-575">1.9</ix:nonNumeric> years.</span></div></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-576" continuedAt="f-576-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Net loss per share</span></ix:nonNumeric></div><ix:continuation id="f-576-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-577" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities, presented based on amounts outstanding at period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would be anti-dilutive:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:65.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.784%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-578">21,905,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-579">19,565,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-153" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-580">4,420,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-581">4,348,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-583">99,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-584">26,325,776</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-585">24,012,997</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ac3491acf394da29655edd3b9380996_16">Table of Contents</a></span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABSCI CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-586" continuedAt="f-586-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.7pt">Segment reporting</span></ix:nonNumeric></div><ix:continuation id="f-586-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-587">one</ix:nonFraction> reportable segment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating performance. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses by expense category and the CODM makes decisions using this information on a consolidated basis. There are no other measures of profitability used by the CODM, other than those disclosed in these condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-588" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the significant segment expenses (in thousands) provided to the Company&#8217;s CODM on a regular basis:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.401%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Drug creation programs and platform </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-589">5,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-590">4,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-591">14,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-592">11,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">External preclinical and clinical development </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-593">3,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-594">2,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-595">11,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-596">5,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Personnel </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-597">10,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-598">9,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-599">30,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-600">29,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-601">4,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-602">5,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-603">14,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-604">14,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General &amp; administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-605">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-606">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-607">11,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-608">11,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asset and goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-610">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-612">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-613">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-614">3,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-615">8,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-616">10,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-617">30,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-618">30,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-619">91,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-620">82,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#8220;Drug creation programs and platform&#8221; consists of research and development costs incurred related to the Company&#8217;s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company&#8217;s Integrated Drug Creation platform.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) &#8220;External preclinical and clinical development&#8221; expense consists of external costs incurred following the Company&#8217;s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) &#8220;Personnel&#8221; expense consists of all employee wages, taxes, benefits, other employee related costs.</span></div></ix:nonNumeric></ix:continuation><div id="i9ac3491acf394da29655edd3b9380996_112"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-621" continuedAt="f-621-1" escape="true"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.7pt">Subsequent events</span></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-621-1">In October 2025, the Company entered into an agreement with the selling stockholders of Totient to settle the contingent consideration liability for a payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-622">7.6</ix:nonFraction>&#160;million and to release the remaining $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-623">8.7</ix:nonFraction>&#160;million, held as restricted cash on the condensed consolidated balance sheets, from escrow to the Company.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i9ac3491acf394da29655edd3b9380996_121"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company advancing potential breakthrough antibody therapeutics with generative AI. Our Integrated Drug Creation platform comprises, in part, cutting edge generative AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibody therapeutics represent a growing market and significant medical opportunity, yet the biopharmaceutical industry faces challenges in bringing these potentially life-changing medicines to patients. Leveraging our synthetic biology roots, we expect our Integrated Drug Creation platform to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. Through these efforts, we aim to shorten time to clinic, while increasing the probability of success. Our approach expands the possibilities in biopharmaceuticals &#8212; shifting from a paradigm of drug discovery to drug creation &#8212; with the goal of bringing best-in-class and first-in-class antibody therapeutics to the patients who need them.</span></div><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is focused on monetizing our Integrated Drug Creation platform by generating internally developed programs that are later partnered or out-licensed following certain value inflection points (anywhere from preclinical through clinical development) or by partnering with third parties who wish to leverage our Integrated Drug Creation platform for early discovery efforts in a variety of deal structures. Our Integrated Drug Creation platform enables our core competencies in three broad areas: target selection and discovery; AI-guided antibody drug creation, such as de novo antibody design; and AI-guided lead optimization. Recently, in collaboration with the California Institute of Technology, we demonstrated the successful de novo design of an antibody that targets a previously difficult-to-drug epitope in the HIV &#8220;caldera&#8221; region.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internally developed programs: </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that by developing our own pipeline, we will create optionality for enhanced monetization and validation of our Integrated Drug Creation platform. Moreover, our pipeline reflects internally developed programs which highlight our differentiated capabilities, including in </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antibody design, multi-parametric lead optimization, and reverse immunology, with an initial focus on cytokine biology. With the ability to selectively choose both novel and fast-follower targets, in addition to develop potentially best-in-class attributes, we aim to take our internally developed programs to certain value inflection points before considering partnering or out-licensing opportunities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November&#160;12, 2025, we have identified five wholly owned, internally developed programs focusing on cytokine biology, as well as several undisclosed internal pipeline programs currently in early discovery phases.</span></div><div style="margin-bottom:8pt"><img src="absi-20250930_g1.jpg" alt="Screenshot 2025-11-12 at 8.36.30&#8239;AM.jpg" style="height:287px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" id="i-1"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABS-101</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first development candidate, ABS-101 is in development as a potential treatment for Inflammatory Bowel Disease (IBD). In May 2025, we initiated the Phase 1 clinical trial in healthy volunteers. In November 2025, we reported interim results of the ongoing Phase 1 clinical trial in healthy volunteers that demonstrated extended half-life as compared to first-generation anti-TL1A competitor programs, but not versus next-generation programs. There was no apparent impact of ADA on PK and the overall safety profile was favorable with no serious adverse events reported to date. The phase 1 trial is on track to complete in the first quarter of 2026. However, we will not pursue further internal clinical development of ABS-101 following the completion of the ongoing phase 1 trial, and will seek a partner for this asset, including exploring the possibility of first-in-class indications outside of IBD with such potential partners.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABS-201</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second development candidate, ABS-201 is in development as a potential treatment for androgenic alopecia (AGA). Preclinical development of ABS-201 is ongoing and we submitted a regulatory filing for a Phase 1 clinical trial for ABS-201 to Human Research Ethics Committee (HREC) in Australia, which was approved in October 2025. We anticipate dosing the first participant in the Phase 1 clinical trial in December 2025, with an interim data read-out in the second half of 2026. In addition, we anticipate initiating a Phase 2 clinical trial for ABS-201 in patients with endometriosis in late 2026, with a potential interim data readout in the second half of 2027.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered programs:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Drug creation programs:</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We enter into collaborations with third parties who are seeking to leverage our platform to solve challenging problems. We work closely with our partners on single and multi-target programs to develop product candidates against targets they have selected. We aim to expand and diversify our portfolio of partnered programs through these collaborations, each of which may include up-front fees and research fees, as well as potential clinical and/or commercial milestones and royalties. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Co-development programs:</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We enter into co-development partnerships with third parties who may offer perceived synergies with our Integrated Drug Creation platform. Our co-development programs are based on a clear alignment to take these programs through to certain value inflection points before considering partnering or out-licensing opportunities. Our co-development partnerships may be directed to either single and multi-target programs and may include mutual cost-sharing and/or technology contributions. We aim to further expand and diversify our portfolio of partnered programs through these co-development partnerships. By sharing both the risks and rewards of these programs, we ensure both parties are motivated for success. </span></div><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have had over 25 partnered programs and anticipate entering into additional partnerships.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our evolving business model is underpinned by our Integrated Drug Creation platform which supports a strategic diversification of our program portfolio through internally developed programs, partnered drug creation programs and co-development programs. This strategic diversification allows us the potential to balance our program portfolio between internally developed programs for which we have more control and may provide more significant economic returns, and partnered programs which broaden our reach into therapeutic areas where our partner has established capabilities and expertise. Thus, the cornerstone of this business model evolution lies in the diversification of risk and potential return on investment. Our business model not only secures a focused set of therapeutic areas, but also gives us greater optionality, enhancing our ability to pivot and adapt as the programs progress. We believe we will grow and diversify our portfolio of programs through our model, ultimately driving innovation and delivering value for all stakeholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was $0.4 million and $2.2 million for the three and nine months ended September 30, 2025, respectively, compared to $1.7 million and $3.9 million for the three and nine months ended September 30, 2024 due to the number of ongoing partnered programs and respective timing of project-based milestones achieved. We incurred a net loss of $28.7 million and $85.6 million for the three and nine months ended September 30, 2025, compared to a net loss of $27.4 million and $74.1 million for the three and nine months ended September 30, 2024. Research and development expenses increased by $10.6 million, or 23%, for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had an accumulated deficit of $595.2 million and cash and cash equivalents and marketable securities totaling $152.5 million. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses in connection with our ongoing activities, including as we:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">develop our internally developed programs across diverse indications, including the advancement of these product candidates through preclinical and clinical development; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">continue to engage in discovery, research and development efforts and scale our activities to meet potential demand from both new and existing partners;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">execute an effective business development strategy to drive adoption of our Integrated Drug Creation platform by new and existing partners and, as relevant, to identify partners for internally developed programs; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">develop, acquire, in-license or otherwise obtain technologies that enable us to expand our Integrated Drug Creation platform capabilities; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">attract, retain and motivate highly qualified personnel.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters and primary research and development facilities are located in Vancouver, Washington in a 77,974 square foot facility that includes general administrative office space and laboratory space. Our AI Research Lab is located in New York, New York and our Innovation Center is located in Zug, Switzerland. Additionally, we have a research and development presence in Belgrade, Serbia.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key factors affecting our results of operations and future performance</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future financial performance will be primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in the &#8220;Risk Factors&#8221; sections of this Quarterly Report on Form 10-Q and those described in the &#8220;Risk Factors&#8221; sections of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 18, 2025.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Build out our internally developed programs:</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We will continue to selectively develop our own programs and intend to advance them to certain value inflection points anywhere from preclinical validation through clinical development, prior to out-licensing for further clinical advancement by a partner or other third party, or potentially through commercialization. We may also utilize significant resources in the design and execution of clinical trials to support our internally developed programs.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Establish and maintain partnerships:</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our potential to grow revenue and long-term earnings will require us to successfully identify, establish and maintain programs with new and existing partners.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Successfully complete our drug creation activities with partners and enter into licensing agreements:</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model relies upon entering into licensing agreements with our partners to advance the product candidates we generate through preclinical validation and clinical development to commercialization. Both our ability to successfully complete drug creation activities to meet the needs of a partner, and the partner&#8217;s prioritization of the relevant program, impact the likelihood and timing of any election by a partner to enter into a follow-on licensing agreement. There is no assurance that a partner will elect to license our intellectual property for the development of any product candidates. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Developing and commercializing product candidates generated with our Integrated Drug Creation</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">platform:</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our business model is dependent on the eventual progression of product candidates discovered or initially developed utilizing our Integrated Drug Creation platform into clinical trials by us or our partners and through commercialization by us, our partners, or other third parties. Given the nature of our relationships with our partners, we often do not fully control the progression, clinical development, regulatory strategy, public disclosure or eventual commercialization, if approved, of our partnered programs. As a result, our future success and our potential eligibility to receive milestone payments and royalties are significantly dependent on our partners&#8217; efforts over which we have no control. The timing and scope of any approval that may be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required by the U.S. Food and Drug Administration (FDA), or any other regulatory body, for drugs that are developed based on molecules discovered and/or manufactured using our Integrated Drug Creation platform can significantly impact our results of operations and future performance.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Continued significant investments in our research and development of new technologies and expansion of our Integrated Drug Creation platform:</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are seeking to further refine and expand the scope of our capabilities, which may or may not be successful. This includes, but is not limited to, novel target identification, </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> discovery, and application of artificial intelligence across our Integrated Drug Creation platform. We expect to incur significant expenses to advance our discovery, research and development efforts or to invest in and/or acquire complementary technologies, but these efforts may not be successful.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Drive commercial adoption of our Integrated Drug Creation platform capabilities: </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Driving the adoption of our Integrated Drug Creation platform across existing and new markets will require significant investment. We plan to further invest in research and development to support the expansion of our capabilities, including to discover and validate new product candidates for existing partners or help expand our capabilities to support new markets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMD strategic collaboration</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD) with a goal to optimize the performance of AMD Instinct</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> accelerators and ROCm</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">software to support our AI drug creation, including our de novo antibody design models. Additionally, AMD invested $20.0 million through the purchase of 5,714,285 shares of our common stock a private investment in public equity (PIPE) at a premium over the market price.</span></div><div id="i9ac3491acf394da29655edd3b9380996_124"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue currently consists primarily of fees earned from our partners in conjunction with drug creation agreements utilizing our Integrated Drug Creation platform, which are presented as partner program revenue in our results of operations. These fees are earned and paid at various points throughout the terms of these agreements including upfront, upon the achievement of specified project-based milestones, and throughout the program. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our revenue will fluctuate from period to period due to, for example, the timing of executing additional partnerships, the contractual structure of future partnerships, the measurement of progress towards completion of each program, the uncertainty of the timing of milestone achievements and dependence on our partners&#8217; program-related decisions. We expect revenue to increase over time as we grant licenses to our partners for the clinical and commercial use of product candidates, and as the partnered product candidates advance into and through clinical development and commercialization. </span></div><div id="i9ac3491acf394da29655edd3b9380996_127"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel-related costs (comprised of salaries, benefits and share-based compensation), contract research services, contract manufacturing, consulting fees, laboratory supplies and facilities, and certain technology costs. These expenses are exclusive of depreciation and amortization. Research and development activities consist of continued development of our Integrated Drug Creation platform, internally developed programs, and partnered programs. We derive improvements to our Integrated Drug Creation platform from each type of activity. Research and development efforts apply to our Integrated Drug Creation platform broadly, as well as across programs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expenses to increase in absolute dollars over the long term as we develop and advance our internally developed programs, enter into additional partnerships, and continue to invest in technology enhancements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general, and administrative </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses include personnel-related costs (comprised of salaries, benefits and share-based compensation) for executive, business development, legal, finance, human resources, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information technology and other administrative functions. Business development expenses include costs associated with attending conferences and other promotion efforts for our Integrated Drug Creation platform. General and administrative expenses include certain professional service expenses, such as external legal, accounting, and other consultants, as well as certain technology costs and allocated facility costs. These expenses are exclusive of depreciation and amortization.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow our operations, we expect personnel-related costs to increase in absolute dollars and we expect to continue to actively manage other general and administrative expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a comprehensive intellectual property portfolio directed towards the many aspects of our Integrated Drug Creation platform, including those related to our internally developed programs, product candidates proprietary cell lines and protein expression technologies, proprietary screening assays, antibody discovery methods, and generative AI models. We regularly file patent applications to protect innovations arising from our research and development. We also hold trademarks and trademark applications in the United States and foreign jurisdictions. Costs to secure and defend our intellectual property are expensed as incurred and are classified as selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and amortization</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense consists of the depreciation expense of our property and equipment and amortization of our intangibles. Our equipment is used most actively as part of our lab operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect depreciation expense to fluctuate in future periods in line with continued growth in absolute dollars as we purchase additional equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, consists primarily of interest related to borrowings under our term debt and financed laboratory equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income, net</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income from our cash, cash equivalents and marketable securities and realized and unrealized gains and losses on foreign currency transactions.</span></div><div id="i9ac3491acf394da29655edd3b9380996_130"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations presented below should be reviewed in conjunction with our condensed consolidated financial statements and notes included elsewhere in this Quarterly Report. The following tables set forth our results of operations for the periods presented (In thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Partner program revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,983&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28,895)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(89,276)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(79,114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28,602)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(85,390)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74,074)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28,706)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(85,621)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74,123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three and Nine Months Ended September 30, 2025 and 2024</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Partner program revenue decreased by $1.3 million, or 78%, for the three months ended September 30, 2025 compared to the three months ended September 30, 2024 and decreased by $1.7 million, or 44%, for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024, driven by a combination of the timing of achieving project-based milestones and the mix of ongoing program activity under our drug creation agreements. For the three and nine months ended September 30, 2025 two partners represented approximately 93% and three partners represented 98% of total partner program revenue, respectively. For the three and nine months ended September 30, 2024, two partners represented approximately 100% of partner program revenue.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our operating expenses for the three and nine months ended September 30, 2025 and 2024 (In thousands, except for percentages):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(905)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $1.3 million, or 7%, for the three months ended September 30, 2025 compared to the three months ended September 30, 2024. The increase was primarily attributable to the advancement of our drug creation programs representing $2.2 million of this increase, including direct costs associated with external preclinical and clinical development, an increase of $0.3 million of personnel costs and stock-based compensation, offset by a decrease of $1.3 million in other lab costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $10.6 million, or 23%, for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024. The increase was primarily attributable to the advancement of our drug creation programs representing $9.9 million of this increase, including direct costs associated with external preclinical and clinical development, and an increase of $2.2 million of personnel costs and stock-based compensation, offset by a decrease of $1.6 million in other lab costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses decreased by $0.8 million, or 9%, for the three months ended September 30, 2025 compared to the three months ended September 30, 2024. The decrease was primarily attributable to a decrease in stock-based compensation of $1.1 million offset by an increase in personnel costs of $0.4 million. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses decreased by $0.9 million, or 3%, for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024. The decrease was primarily attributable to a decrease of $1.1 million in personnel and stock-based compensation costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense decreased by $0.5 million, or 15% for the three months ended September 30, 2025 compared to the three months ended September 30, 2024 and decreased by $1.2 million, or 12%, for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024, primarily due to disposals of lab equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was less than $0.1 million for the three months ended September 30, 2025 compared to $0.1 million for the three months ended September 30, 2024, representing a decrease of $0.1 million, or 65%. Interest expense was $0.2 million for the nine months ended September 30, 2025, compared to $0.5 million for the nine months ended September 30, 2024, representing a decrease of $0.3 million, or 61%. These decreases were primarily attributable to decreased finance lease and long-term debt obligations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income, net </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, was $1.6 million for the three months ended September 30, 2025 compared to $1.7 million for the three months ended September 30, 2024, representing a decrease of $0.1 million, or 4%, primarily attributable to realized and unrealized gains and losses on foreign currency transactions and a decrease in investment income from cash, cash equivalents, and investments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, was $4.1 million for the nine months ended September 30, 2025, compared to $5.5 million for the nine months ended September 30, 2024, representing a decrease of $1.4 million, or 26%, primarily attributable to realized and unrealized gains and losses on foreign currency transactions and a decrease in investment income from cash, cash equivalents and investments.</span></div><div id="i9ac3491acf394da29655edd3b9380996_133"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had $152.5&#160;million of cash, cash equivalents and marketable securities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net operating losses since inception. As of September&#160;30, 2025, our accumulated deficit was $595.2 million. To date, we have funded operations through issuances and sales of equity securities and debt, in addition to revenue generated from our drug creation agreements. We believe that our cash, cash equivalents and marketable securities will be sufficient to meet our operating expenses, working capital and capital expenditure needs over at least the next 12 months following the date of this filing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including, but not limited to our ability to raise additional capital through equity or debt financing, the development of our internally developed programs including the progress and strategy of our preclinical and clinical activities, our ability to successfully enter into additional partnerships with new and existing partners, the advancement of technology development activities with existing and future partners, the successful preclinical and clinical development by us and our partners of product candidates generated using our Integrated Drug Creation platform, and the successful commercialization by us and our partners of any such product candidates that are approved. If we are unable to execute on our business plan and adequately fund operations, or if our business plan requires a level of spending in excess of cash resources, we may be required to change our strategies related to preclinical and clinical development and our approach to negotiating partnerships. Alternatively, we may need to seek additional equity or debt financing, which may not be available on terms acceptable to us or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our programs, making product acquisitions, making capital expenditures, or declaring dividends. If we are unable to generate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sufficient revenue or raise additional capital when desired, our business, financial condition, results of operations and prospects would be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have financed our operations primarily from the issuance and sale of our redeemable convertible preferred stock, issuances of equity securities, borrowings under long-term debt agreements, and to a lesser extent, cash flow from operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equipment financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we received a total of $12.0 million of proceeds from equipment financing arrangements. Terms of the agreements require monthly payments over 42-48 month periods with imputed interest rates ranging from 8%-10%. As of September&#160;30, 2025, the combined outstanding balance on these agreements is $1.4 million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-market offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company entered into a Sales Agreement with Cowen and Company, LLC, as Sales Agent (the &#8220;Prior Sales Agreement&#8221;), with respect to an &#8220;at the market offering&#8221; program under which the Company had the ability to offer and sell, from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $100.0&#160;million through the Sales Agent. The Company agreed to pay the Sales Agent a commission up to 3.0% of the gross sales proceeds of any shares sold under the Prior Sales Agreement. During the nine months ended September 30, 2025, the Company has issued 10,377,752 shares and received $35.7 million in net proceeds from the sale of securities pursuant to the Prior Sales Agreement. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company entered into a Sales Agreement with TD Securities (USA) LLC, as Sales Agent (the &#8220;Sales Agreement&#8221;), with respect to an &#8220;at the market offering&#8221; program under which the Company may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0&#160;million through the Sales Agent. The Company has agreed to pay the Sales Agent a commission of up to 3.0% of the gross proceeds of any shares sold under the Sales Agreement. Upon execution, the Sales Agreement terminated and superseded the Prior Sales Agreement in its entirety. During the nine months ended September 30, 2025, the Company did not issue any shares of common stock under the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public offerings of common stock</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, we sold an aggregate of 19,205,000 shares of our common stock, pursuant to an underwriting agreement with Morgan Stanley &amp; Co. LLC and Cowen and Company, LLC at a public offering price of $4.50 per share, before underwriting discounts and commissions. We received total net proceeds from the offering of $80.8 million after deducting underwriting discounts and commissions and offering expenses payable by us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2025, we sold an aggregate of 16,670,000 shares of our common stock pursuant to an underwriting agreement with Morgan Stanley &amp; Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC and TD Securities (US) LLC at a public offering price of $3.00 per share, before underwriting discounts and commissions. We received total net proceeds from the offering of $46.7 million after deducting underwriting discounts and commissions and offering expenses payable by us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private investment in public equity</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we entered into a strategic collaboration with AMD and sold an aggregate of 5,714,285 shares of our common stock to AMD for net proceeds of $20.0 million through a private investment in public equity (PIPE). The issuance of stock to AMD was at a premium of approximately $2.5 million over the market price on the issuance date.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our cash flows (In thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.692%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by (used in)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(63,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(55,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31,343)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34,518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2025, net cash used in operating activities was $63.7 million and consisted primarily of a net loss of $85.6 million adjusted for non-cash items, including depreciation and amortization expense of $8.9 million, stock-based compensation expense of $14.1 million, and a net decrease in operating assets and liabilities in the amount of $1.2 million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2024, net cash used in operating activities was $55.4 million and consisted primarily of a net loss of $74.1 million adjusted for non-cash items, including depreciation and amortization expense of $10.2 million, stock-based compensation expense of $14.4 million, impairment of $1.1 million for asset that met the held for sale criteria during the period and a net increase in operating assets and liabilities in the amount of $4.2 million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations increased by $8.3 million year-over-year primarily due to increased research and development costs, including external preclinical and clinical development costs related to our internally developed programs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2025, net cash used in investing activities was $69.7 million primarily from purchases of marketable securities of $134.9 million, partially offset by cash provided by maturities of marketable securities of $65.2 million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2024, net cash used in investing activities was $60.6 million primarily from purchases of marketable securities of $159.5&#160;million, partially offset by maturities of marketable securities of $99.0&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2025, net cash provided by financing activities was $102.1 million. The net cash provided resulted primarily from aggregate proceeds of $102.3 million from the issuance of common stock pursuant to the PIPE with AMD, the issuance of common stock pursuant to our July 2025 underwritten offering and pursuant to the ATM, and proceeds of $2.5 million from the issuance of common stock from stock option exercises and our 2021 ESPP, partially offset by principal payments of $2.7 million made for financed equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2024, net cash provided by financing activities was $81.5 million primarily from proceeds of $80.8 million from the issuance of common stock from a public offering and proceeds of $3.8 million from the issuance of common stock from option exercises and our 2021 ESPP, partially offset by principal payments of $3.1 million made for financed equipment.</span></div><div id="i9ac3491acf394da29655edd3b9380996_142"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report should be read in conjunction with the consolidated financial statements in our 2024 Annual Report on Form 10-K where we include additional information on our business, risk factors, critical accounting estimates, policies, and the methods and assumptions used in our estimates, among other important information. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes in our critical accounting policies and estimates during the nine months ended September 30, 2025.</span></div><div id="i9ac3491acf394da29655edd3b9380996_151"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Section 107 of the JOBS Act provides that an emerging growth company may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933 for complying with new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain conditions, as an emerging growth company, we may rely on certain other exemptions and reduced reporting requirements, including without limitation (i) providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the consolidated financial statements, known as the auditor discussion and analysis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are also a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 of the Exchange Act and have elected to take advantage of certain of the scaled back disclosure requirements available to smaller reporting companies such as avoiding the extensive narrative disclosure required of other reporting companies, particularly in the description of executive compensation.  We will remain a smaller reporting company until (a) the last day of the fiscal year in which we have total annual gross revenue of less than $100 million and the market value of our common stock held by non-affiliates exceeds $700.0 million as of the prior June 30th, or (b) the last day of the fiscal year in which we have total annual gross revenue exceeding $100 million and the market value of our common stock held by non-affiliates exceeds $250.0 million. In August 2025, the SEC released a Compliance and Disclosure Interpretation clarifying the filer status transition for registrants that lose their smaller reporting company status based on the revenue tests. Due to this interpretation, we will remain a non-accelerated filer for filings due in the fiscal year immediately following the loss of smaller reporting company status, allowing us to retain the exception from the auditor attestation requirement on internal control over financial reporting. However, the interpretation specifies that we will lose eligibility for all other smaller reporting company accommodations beginning with the Form 10-Q for the first fiscal quarter of the year after losing smaller reporting company status. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the loss of emerging growth status will not impact our &#8220;non-accelerated filer&#8221; status, which also provides an exemption from the auditor attestation requirement with respect to internal control over financial reporting.</span></div><div id="i9ac3491acf394da29655edd3b9380996_154"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosure About Market Risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of disclosure controls and procedure</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on its evaluation, management concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at the reasonable assurance level.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in internal control over financial reporting</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the three months ended September&#160;30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i9ac3491acf394da29655edd3b9380996_160"></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div id="i9ac3491acf394da29655edd3b9380996_163"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material litigation or other legal proceedings. From time to time, we may, however, in the ordinary course of business face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights. Any such claims and associated legal proceedings could, in the opinion of our management, have a material adverse effect on our business, financial condition, results of operations or prospects. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </span></div><div id="i9ac3491acf394da29655edd3b9380996_166"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 18, 2025. The risks described in our Annual Report and this Quarterly Report on Form 10-Q are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks actually occur, our business, results of operations, cash flows or financial condition could suffer.</span></div><div id="i9ac3491acf394da29655edd3b9380996_172"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report and in our other public filings in evaluating our business. The occurrence of any of the events or developments described below could materially harm our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and the market price of our common stock.</span></div><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Financial Condition and Need for Additional Capital</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current business has a limited operating history, which may make it difficult to evaluate our business and predict our future performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business has a limited operating history. We began commercial operations in</span><span style="background-color:#ffffff;color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2018. </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before engaging in commercial operations, we focused primarily on technology development. Our revenue to date has been generated primarily from drug creation activities through partnerships, and we do not anticipate generating any revenue from commercial product sales, if ever, until we successfully complete the clinical development of, and achieve regulatory approval for, any of our internally developed programs, all of which are still in preclinical development. We are still early in the adoption phase of our drug creation model, and, as of October&#160;31, 2025, no partner has entered into a license for clinical or commercial use of any intellectual property rights related to a product candidate or cell lines. We also have only recently begun to develop programs for our own product candidates and may experience difficulties advancing these programs through to clinical development and generating value from them. We may never achieve commercial success and we have limited historical financial data upon which we may base our projected financial performance. We also have limited historical financial data upon which we may base our planned operating expenses or upon which you may evaluate our business and prospects. Based on our limited experience, we may not be able to effectively:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">develop and advance our product candidates from our internally developed programs through preclinical and clinical development and potential marketing approval and commercialization;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">drive adoption of our Integrated Drug Creation platform by validating them through the advancement of our internally developed programs and by attracting and retaining partners;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">enter into, maintain and potentially expand the scope of partnerships with third parties that contain economic terms sufficient to make our business model viable;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">raise sufficient capital or achieve sufficient near term revenue to sustain our business to enable us to recognize value from our internally developed programs and receive the downstream economics of our existing or future partnerships;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">anticipate and adapt to changes in the existing and emerging markets in which we operate;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">focus our efforts related to our Integrated Drug Creation platform in areas that generate returns on these efforts;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">succeed in achieving goals related to our Integrated Drug Creation platform;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">maintain and develop strategic relationships with suppliers to acquire necessary materials and equipment for the development of our Integrated Drug Creation platform and product candidates on appropriate timelines, or at all;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">create a pipeline of internally developed programs that generate future partnership opportunities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">scale our drug creation activities to meet potential demand at a reasonable cost;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">acquire, in-license or otherwise obtain technologies that enable us to expand our capabilities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">avoid infringement of third-party intellectual property rights;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">obtain licenses to third-party intellectual property rights on commercially reasonable terms, as needed for our current and planned operations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">obtain and maintain valid and enforceable patents and other intellectual property rights that give us a competitive advantage;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">protect our proprietary technologies, including our Drug Creation platform and internally developed programs and corresponding product candidates; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a substantial portion of our expenses have been and will continue to be fixed, and we expect our expenses to increase as we advance our internally developed programs into and through clinical development. Accordingly, if we do not generate revenue as and when anticipated, our losses may be greater than expected and our operating results will suffer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. For the nine months ended September 30, 2025 and 2024, we incurred net losses of $85.6 million and $74.1 million, respectively. As of September&#160;30, 2025, we had an accumulated deficit of $595.2 million. We expect that our operating expenses will continue to increase as we grow our business and advance our internally developed programs. Since our inception, we have financed our operations primarily from private placements of our equity securities, convertible promissory notes, the sale of common stock in our initial public offering (IPO), subsequent follow-on offerings, the incurrence of other indebtedness and other financing activities, and to a lesser extent, revenue derived from our drug creation activities leveraging our Integrated Drug Creation platform. We have devoted substantially all of our resources to the development of our Integrated Drug Creation platform and commercialization of resulting drug creation capabilities, and the research and development of our internally developed programs. We will need to generate significant additional revenue to achieve and sustain profitability, and even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. We may never be able to generate sufficient revenue to achieve or sustain profitability and our recent and historical financial and operating results should not be considered indicative of our future performance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional capital to fund our operations and improve our Integrated Drug Creation platform. If we are unable to raise additional capital on terms acceptable to us or at all, we may not be able to compete successfully, which would harm our business, operations, and financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had $152.5 million in cash, cash equivalents and marketable securities. We expect our current cash, cash equivalents and marketable securities and anticipated cash flows from operations will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months. If our available resources and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of higher expenses than we anticipate related to internally developed programs or our investments in our Integrated Drug Creation platform or any other technology, lower demand from existing and potential partners for our Integrated Drug Creation platform, or the realization of other risks described in this "Risk Factors&#8221; section, we will be required to raise additional capital through issuances of equity or convertible debt securities, entrance into a credit facility or another form of third party funding, or seek other sources of financing. Such additional financing may not be available on terms acceptable to us or at all. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. For example, this may include reasons such as to: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">advance our existing internally developed programs through preclinical and clinical development;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">advance new or additional internally developed programs through preclinical and clinical development;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">further advance our AI capabilities, including AI capabilities related to our Integrated Drug Creation platform;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">further expand the capabilities of our Integrated Drug Creation platform into additional areas of biopharmaceutical research and development, such as target discovery or translational medicine; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">increase our business development efforts to drive market recognition of our Integrated Drug Creation platform, our internally developed programs and address competitive developments;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">fund business development efforts for our current or future internally developed programs and partnered programs; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">acquire, license or invest in additional technologies or complementary businesses or assets; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">finance capital expenditures and general and administrative expenses. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present and future funding requirements will depend on many factors, including: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the cost of expanding our operations, including our ongoing and planned preclinical and clinical development activities for our internally developed programs; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">preclinical and clinical development, including costs associated with building our internal clinical and regulatory capabilities and contracting with third-party clinical investigators, contract research organizations (CROs), manufacturers and suppliers, or clinical data management organizations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to achieve and sustain sufficient revenues from partnerships and other business development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our rate of progress in working with partners to leverage our Integrated Drug Creation platform and business development activities associated therewith;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our rate of progress in, and cost of, developing new technologies; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the effect of competing technological and market developments; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">costs related to any domestic and international expansion. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our stockholders would result. Any preferred equity securities issued also would likely provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities may have rights, preferences and privileges senior to those of holders of our common stock. Debt financing and preferred equity financing, if available, may also involve agreements that include covenants restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our programs, making asset acquisitions, making capital expenditures, or declaring dividends. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain adequate financing or financing on terms satisfactory to us, if we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Substantially all of our historical revenue is related to partnered drug creation activities, and we have not demonstrated the ability to enter into a sufficient number of partnerships providing for long-term license arrangements under which we are entitled to receive milestone payments or royalties on net product sales. We have not received any such milestone or royalty revenues to date, and it may be years before we realize any such revenues, if at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, all of our revenue was generated by technology development fees through performing drug creation activities for our partnered programs. To date, such fees have generally been payable upon both the inception of, and the demonstration of technical achievement of program milestones, under drug creation agreements with our partners. Our business model depends, in part, on the successful completion of the drug creation phase under these arrangements and on our subsequent entry into long-term license arrangements with our partners that entitle us to development, regulatory and commercial milestones and/or royalties with respect to product candidates generated through our Integrated Drug Creation platform, as well as product candidates discovered and/or manufactured in cell lines developed by us. We are still in the very early stages of implementing our drug creation model and, to date, no partner has entered into a license for clinical or commercial use of any intellectual property rights related to product candidates discovered thereunder or cell lines developed by us. If we are unable to maintain these partnerships (including if such partnerships are terminated prior to or upon completion of the drug creation phase) or we are otherwise unable to enter into commercial license agreements for our partnered programs, we will not receive any downstream payments, which may have a material and adverse effect on our business prospects. Additionally, any such license agreements that we may enter into may not be on terms that are favorable to us and may not result in meaningful revenues to us, or at all, or such license agreements may be terminated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology development fees are generated by drug creation activities that we perform for our partners, the timing and nature of which are dictated by the timing of program commencement, which depends on various permissions, information and supplies provided by our partners and/or third party vendors as well as the pace </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of program progression and receipt of ongoing input from our partners. Our eligibility to receive milestone payments from our partnerships is generally subject to the negotiation of future arrangements, as described above. As a result, we currently do not generate significant recurring revenue and, until we are able to establish significant recurring revenue, if at all, we will be prone to regular and significant fluctuations in our revenue dependent on the timing of our entry into partnership agreements, our partners advancing such programs, and our partners achieving development milestones or commercial sales with respect to product candidates discovered and/or manufactured in cell lines developed by us. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Biologic Drug Development</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologic drug development is inherently uncertain, and it is possible that our technology may not succeed in discovering appropriate molecules or producing cell lines. Even if we do succeed, it is possible that none of the product candidates created using our Integrated Drug Creation platform, if any, that are further developed by our partners will achieve development or regulatory milestones, including marketing approval, or become viable commercial technologies, on a timely basis or at all, which would harm our ability to generate revenue. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our Integrated Drug Creation platform both to advance our internally developed programs and to create product candidates for partners that are engaged in biologic drug discovery and development. In addition, we may enter into partnerships for the further development and commercialization of our internally developed programs during later stages of clinical development. While we currently receive payments for performing drug creation activities and successfully completing technical program deliverables and milestones for our partners with respect to our partnered programs, we anticipate that the vast majority of the economic value of the agreements that we enter into with our partners will be in the downstream payments that would be payable if certain milestones are met by our partners with respect to product candidates generated utilizing our Integrated Drug Creation platform and royalties on net sales if such product candidates are approved for marketing and successfully commercialized. As a result, our future growth is dependent on our ability to successfully advance our internally developed programs through to clinical development and eventual marketing approval and commercialization, and the ability of our partners to successfully develop and commercialize therapies based on product candidates generated using our Integrated Drug Creation platform. Risks relating to clinical development, including risks related to manufacturing and clinical supply, regulatory clearance, authorization or approval and commercialization apply to us both directly with respect to our internally developed programs and indirectly through the activities of our partners with respect to their programs that are generated pursuant to a drug creation agreement. Even if our Integrated Drug Creation platform is capable of identifying high quality product candidates, there can be no assurance that we or our partners will successfully develop, secure marketing approvals for and commercialize any product candidates discovered and developed under a partnered program. As a result, we may not realize the intended benefits of our internal research and development efforts or our partnerships.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, we or our partners may not successfully develop any product candidates generated using our Integrated Drug Creation platform, or we or our partners may choose to discontinue the development of these product candidates for a variety of reasons, including due to safety, risk versus benefit profile, exclusivity, competitive landscape, commercialization potential, production limitations or prioritization of their resources. It is possible that none of these product candidates will ever receive regulatory approval and, even if approved, such product candidates may never be successfully commercialized. Most product candidates that commence clinical trials are never approved, and there can be no assurance that any of our partnered programs or any internally developed programs will ultimately be successful.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if these product candidates receive regulatory approval in the United States, our partners may never obtain approval or commercialize outside of the United States, which would limit their full market potential and therefore our ability to realize their potential downstream value. In addition, regulatory authorities may approve any of the product candidates that we may develop for fewer or more limited indications than requested. Furthermore, approved drugs may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Likewise, we or our partners have to make decisions about which clinical stage and preclinical product candidates to develop and advance, and we or our partners may not have the resources to invest in all of the product candidates generated using our Integrated Drug Creation platform, or clinical data and other development considerations may not support the advancement of one or more </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates. Decision-making about which product candidates to prioritize involves inherent uncertainty, and we or our partners&#8217; decision-making and resource prioritization decisions, which in the case of our partners are outside of our control, may adversely affect the potential value of those partnerships. Additionally, subject to its contractual obligations to us, if one more of our partners is involved in a business combination, the partner might de-emphasize or terminate the development or commercialization of any product candidate generated using our Integrated Drug Creation platform. If one of our partners terminates its agreement with us, we may find it more difficult to attract new partners. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to industry-wide FDA and other regulatory risk. For example, the number of BLAs approved by the FDA varies significantly over time and if changes in applicable laws, regulations, or policy or other events, such as staffing changes or shortages, lead to an extended reduction in the number of BLAs approved by the FDA or otherwise reduce the number of biologics in development, our industry would contract and our business would be materially harmed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners&#8217; failure to effectively develop or commercialize any product candidates generated using our platform could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common stock to decline. In addition to the inherent uncertainty in drug development addresses above, our ability to forecast our future financial performance and revenues may be limited. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development is uncertain. Our preclinical and clinical product candidates may experience delays or may never advance to and/or through clinical trials, which would adversely affect our or our partners&#8217; ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are very early in our development of product candidates and have focused our efforts to date on platform development, discovery, research, preclinical and early clinical development. We have only recently dosed the first participants in our Phase 1 clinical trial of ABS-101 and all of our other programs are still in the research or preclinical stage of development. Thus, we have limited experience as a company in conducting clinical trials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. For example, despite interim results from the first cohorts of the ongoing Phase 1 clinical trial that demonstrated extended half-life as compared to first-generation anti-TL1A competitor programs but not next-generation programs, and with no apparent impact of ADA on PK or serious adverse events reported to date, we made the strategic decision to seek a partner for ABS-101 rather than advance it through later-stage development ourselves. We also cannot be sure that submission of an IND (or foreign equivalent) will result in the FDA or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. If our preclinical product candidates experience delays or never advance to clinical trials, it would have an adverse effect on our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain FDA approval to market a new biological product, we or our partners must demonstrate proof of safety, purity and potency or efficacy in humans. To meet these requirements we or our partners will have to conduct adequate and well-controlled clinical trials. Before we or our partners can commence clinical trials for a product candidate, we or our partners must complete extensive preclinical testing and studies that support our planned INDs in the United States. We cannot be certain of the timely completion or outcome of our or our partners' preclinical testing and studies and cannot predict if the FDA will accept our or our partners' proposed clinical programs or if the outcome of our or our partners' preclinical testing and studies will ultimately support the further development of our product candidates. As a result, we cannot be sure that we or our partners will be able to submit INDs or similar applications for our product candidates on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. Further, changes and cuts in FDA staffing have been reported by some in the pharmaceutical industry as creating instances of delays in the FDA&#8217;s responsiveness or in its ability to review IND submissions, or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years or more per program. Delays associated with programs for which we are directly conducting preclinical testing and studies may cause us or our partners to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">delays in reaching a consensus with regulatory agencies on study design;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the FDA not allowing us to rely on previous findings of safety and efficacy for other similar but approved products and published scientific literature; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">use of our product candidates could be associated with adverse side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us or our partners to suspend or discontinue preclinical or clinical trials, abandon a product candidate, limit the commercial profile of an approved product or result in other significant negative consequences.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if clinical trials do begin for our product candidates, our or our partners' development efforts may not be successful, and clinical trials that we or our partners conduct or that third parties conduct on our or our partners' behalf may not demonstrate sufficient safety, purity and potency or efficacy to obtain the requisite regulatory approvals for any of product candidates we develop. Even if we or our partners obtain positive results from preclinical studies or initial clinical trials, we or our partners may not achieve the same success in future trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners experience any of a number of possible unforeseen or negative events in connection with preclinical or clinical development, regulatory approval or commercialization of product candidates generated through our platform, this could negatively affect our revenue opportunity for that program, and/or have broader deleterious effects on our reputation and future partnership prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience numerous unforeseen events during, or as a result of, preclinical studies or any clinical trials that could delay or prevent the ability to conduct further development or obtain regulatory approval or licensure of, or commercialize, product candidates, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">preclinical studies designed to enable the submission of IND applications, or other preclinical development activities, by our partners may not result in data sufficient to support the advancement of the applicable product candidates into clinical development, or our partners may abandon development activities for such product candidates prior to any IND submission for a variety of reasons;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">regulatory authorities or ethical review boards, including IRBs, may not authorize commencement of a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">there may be delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the FDA or other regulatory authorities may disagree with a clinical trial design or a sponsor&#8217;s interpretation of data even after such regulatory authorities have reviewed and commented on the clinical trial design;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">differences in trial design between early stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later-stage clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the FDA or other regulatory authorities may disagree about whether study endpoints are clinically meaningful or recommend study endpoints that require lengthy periods of observation;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the number of patients, or amount of data, required to complete clinical trials may be larger than anticipated, patient enrollment in these clinical trials may be slower than anticipated or patients may drop out of clinical trials at a higher rate than anticipated;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">CROs and other contracted third parties may fail to perform their duties in accordance with the study protocol or applicable laws and regulations; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">changes may be made to product candidates after commencing clinical trials, which may require that previously completed stages of clinical testing be repeated or delay later stages of testing;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">clinical trials may fail to satisfy the applicable regulatory requirements of the FDA or other regulatory authorities responsible for oversight of the conduct of clinical trials in other countries;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">regulators may elect to impose a clinical hold, or we or our partners, governing IRBs, data safety monitoring boards or ethics committees may elect to suspend or terminate our or our partners&#8217; clinical research or trials for various reasons, including non-compliance with regulatory requirements or a finding that the participants are being exposed to undesirable side effects that could lead to serious adverse events or other unacceptable risks to their health or the privacy of their health information being disclosed;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the cost of clinical trials of the applicable product candidates, or improvements to such product candidates, may be greater than we or our partners anticipate, causing us or our partners to delay or terminate applicable clinical development efforts;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">CROs and other contracted third parties may fail to perform their duties in accordance with the relevant manufacturing and/or clinical supply agreements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the supply or quality of materials necessary to conduct clinical trials of the applicable product candidates may be insufficient or inadequate;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the outcome of our or our partners&#8217; preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">product candidates may be associated with negative or inconclusive results in clinical trials, and we or our partners may decide to deprioritize or abandon these partnered product candidates, or regulatory authorities may require our partners to abandon them or may impose onerous changes or requirements, which could lead to de-prioritization or abandonment;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the data collected from clinical trials of product candidates that we or our partners may identify and pursue may not be sufficient to support the submission of a BLA or other submission for regulatory approval in the United States or elsewhere; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable, or clinical trials may suggest or demonstrate that products are not safe and effective, or as safe and effective as competing therapies on the market or in development.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disruptions caused by a continued and prolonged public health emergency, such as the COVID-19 pandemic may increase the likelihood that we or our partners encounter such difficulties or delays in initiating, enrolling, conducting or completing planned and ongoing clinical trials. Delays of this nature could also allow competitors to bring products to market before we or our partners do, potentially impairing our or our partners&#8217; abilities to successfully commercialize products generated using our platform technology and harming our business and results of operations. Any delays in, or suspension of, the development of the product candidates developed by us or by our partners using our technology may significantly harm our business, financial condition and prospects. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory clearance, authorization or approval of partnered product candidates in development.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary data and interim results we disclose from our clinical trials may change as more data becomes available or as we make changes to our clinical protocols or processes, and such interim results or results from earlier studies may not be predictive of the final results, or of later studies or future clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time disclose results from preclinical testing or preliminary data or interim results from clinical trials of our product candidates. Such results from preclinical testing, process development and manufacturing activities, and clinical studies, including interim clinical trial results as of specified data cutoff dates and results of earlier preclinical or clinical studies with similar product candidates, are not necessarily predictive of future results, including later clinical trial results. In addition, results in one indication may not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be predictive of results to be expected for the same or a similar product candidate in another indication. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials due to lack of efficacy or unfavorable safety profiles, notwithstanding promising results in preclinical development or earlier trials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of our current and future clinical trials may differ from results achieved in earlier preclinical and clinical studies for a variety of reasons, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we may not demonstrate the potency and efficacy benefits observed in previous studies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our efforts to improve, standardize and automate the manufacture and supply of our product candidates and any resulting deviations in the manufacture of our product candidates, may adversely affect the safety, purity, potency, stability, or efficacy of such product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">differences in study design, including differences in eligibility criteria and patient populations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">advancements in the standard of care may affect our ability to demonstrate efficacy or achieve study endpoints in our future clinical trials; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">safety issues or adverse events in patients who enroll in our clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim, &#8220;top-line,&#8221; or preliminary data from our clinical studies based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, the duration of treatment increases and more patient data become available. For example, we may encounter unacceptable side effects for our product candidates as patient dosing progresses in our clinical trials and additional data become available. Our preliminary or interim results and related conclusions also are subject to change following a more comprehensive review of the data related to the particular study or trial. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Material adverse changes between preliminary, &#8220;top-line,&#8221; or interim data and final data could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The clinical development of our product candidates could be substantially delayed if we are required to conduct unanticipated studies, including preclinical studies or clinical trials, or if the FDA imposes other requirements or restrictions including on the manufacture, of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may require us to generate additional preclinical, product, manufacturing, or clinical data as a condition to initiating and conducting any future clinical trials of our or our partners&#8217; product candidates generated using our platform technology. Additionally, the FDA may in the future have comments, or impose requirements, on the initiation and conduct of our clinical trials or those of our partners, including trial endpoints and the protocols, processes, materials and facilities we or our partners use to manufacture our product candidates in support of clinical trials. Any requirements to generate additional data, or redesign or modify applicable endpoints, protocols, processes, materials or facilities, or other additional comments, requirements or impositions by the FDA, may cause delays in the initiation or conduct of future clinical trials for our or our partners&#8217; product candidates and subsequent development activities, and could require us to incur additional development or manufacturing costs and resources, seek funding for these increased costs or resources or delay our timeline for, or cease, our preclinical or clinical development activities for our product candidates, or could create uncertainty and additional complexity in our ability to obtain regulatory approval for our product candidates and to achieve revenue-generating milestones under our agreements with our partners.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if the results of our clinical trials are inconclusive, or if there are safety concerns or adverse events associated with our or our partners&#8217; product candidates, we or our partners may:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">be delayed in obtaining, or unable to obtain, regulatory approval for such product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">be required to amend the protocols for the applicable clinical trials, perform additional nonclinical studies or clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings or contraindications; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">in the event a product candidate is approved, have regulatory authorities withdraw their approval of the product or impose restrictions on its use.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our planned clinical trials are successful, we will need to conduct additional clinical trials, which may include registrational trials, trials in additional patient populations or under different treatment conditions, and trials using different manufacturing protocols, processes, materials or facilities or under different manufacturing conditions, before we are able to seek approvals for our product candidates from the FDA and regulatory authorities outside the United States to market and sell these product candidates. In addition, changes in regulatory policies under the U.S. presidential administration may result in delays in the regulatory review and approval process and cause uncertainty regarding approval pathways. If we fail to meet the requirements to support continued clinical development, our clinical development activities for any of our product candidates are delayed or suspended, or we fail to obtain or maintain regulatory approvals with an acceptable scope, our business, prospects, financial condition and results of operations will be harmed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners encounter difficulties enrolling patients in clinical trials of product candidates developed using our Integrated Drug Creation platform, our and our partners&#8217; clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to identify and enroll a sufficient number of patients with the disease under investigation for each of our planned clinical trials of internally developed product candidates, and our partners are subject to the same requirements with respect to product candidates they are developing. We or our partners may not be able to identify and enroll a sufficient number of patients, or those with required or desired characteristics and who meet specified enrollment criteria, in a timely manner. In addition, we and our partners may face competition from other clinical trials of product candidates being developed by our competitors in the same therapeutic areas, and potential patients who might be eligible for enrollment in one of our or our partners&#8217; clinical trials may instead choose to enroll in a trial being conducted by a competitor. We and our partners may also face an unwillingness of investigative sites to participate in our clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability, and the ability of our partners, to enroll patients in clinical trials of product candidates developed using our platform technology is affected by factors including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the ability to identify clinical trial sites and recruit clinical trial investigators with the appropriate capabilities, competencies and experience;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the ability to open clinical trial sites;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the ability to identify, solicit and recruit a sufficient number of patients;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the severity of the disease under investigation;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the design of the clinical trial and whether the FDA agrees to the design and implementation of the trial;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the size and nature of the patient populations to be investigated in the applicable clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">eligibility criteria for the clinical trials in question;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">clinicians&#8217; and patients&#8217; perceptions as to the potential risks and benefits of the product candidate under study, including any perceived risks associated with product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">changing medical practices or guidelines related to the indications we or our partners are investigating;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the availability of competing therapies and clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the availability of time and resources at the institutions at which our or our partners&#8217; clinical trials will be conducted, including any constraints on resources, or policies and procedures implemented, at hospitals and clinical trial sites as a result of any public health crisis;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical trial sites may need to delay or pause patient enrollment or treatment in clinical trials as a result of public health crises, supply chain shortages or a variety of factors beyond our control. The extent and duration of such delays and disruptions, and the overall impact on the timing and conduct of our or our partners&#8217; clinical trials, are uncertain. If we or our partners have difficulties enrolling a sufficient number of patients to conduct clinical trials as planned, we or our partners may need to delay or terminate ongoing or planned clinical trials, which would have an adverse effect on our business, prospects, financial condition, results of operations, and the market price of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biopharmaceutical platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve and sustain profitability. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in the biopharmaceutical platform technology market, including from other pharmaceutical and biotechnology companies seeking to develop AI capabilities for biologic drug design. Our technologies address therapeutic discovery and bioproduction challenges that are addressed by other platform technologies controlled by companies that have a variety of business models, including the development of internally developed programs, technology licensing, discovery screening, cell line generation and the sale of instruments and devices. Potential competitors addressing certain steps in the target identification, drug discovery, or adjacent aspects of these broad processes include the following:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we may face competition from companies attempting to use AI to design novel biologic drugs such as Generate Biomedicines, Inc., and Xaira Therapeutics, Inc., among others;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we may face competition from companies currently offering adjacent technology (e.g. AI-enabled small molecule design) that may seek to develop antibody design capabilities, such as Recursion Pharmaceuticals, Inc., Relay Therapeutics, Inc., Isomorphic Labs Limited, and Schrodinger, Inc., among others; and;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we may face competition from academic, pharmaceutical, and biotechnology research initiatives, as well as from private and publicly traded companies focused on novel methods for target identification, including GV20 Therapeutics, Alchemab Therapeutics, and 3T Biosciences, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, in some cases, we may wish to collaborate with such companies if synergies with our Integrated Drug Creation platform are identified.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the broader field of antibody therapeutic development, we may face competition from pharmaceutical and biotechnology companies that are developing therapeutics that address the same disease targets and/or indications addressed by our internally developed programs, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">in the field of developing antibody therapeutics targeting TL1A for the treatment of inflammatory bowel disease, we are aware of several companies with product candidates in clinical development, including Merck&#8217;s MK-7240, Roche/Roivant&#8217;s RVT-3101, Sanofi/Teva&#8217;s TEV-48574 TL1A, Spyre&#8217;s SPY002, and Xencor&#8217;s XmAb942; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">in the field of developing antibody therapeutics targeting PRLR for the treatment of androgenic alopecia, we are aware of Hope Medicine&#8217;s HMI-115. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners may also elect to develop their processes on in-house systems, or using other methods, rather than implementing our technologies and may decide to stop using our technologies. These companies are likely to exhaust all internal alternatives to our technology before adopting our technologies. In addition, there are many large established companies in the life science technology market that we do not currently compete with but that could develop systems, technologies, tools or other products that will compete with us in the future. These large established companies have substantially greater financial and other resources than us, including larger research and development organizations or more established marketing and sales forces. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors may enjoy a number of competitive advantages over us. For example, these may include: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">longer operating histories; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">larger partner bases; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">greater brand recognition and market penetration; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">greater financial resources; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">greater technological and research and development resources; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">better system reliability and robustness; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">greater business development capabilities; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">better established, larger scale and lower cost manufacturing capabilities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our competitors and potential competitors may be able to respond more quickly to changes in partner requirements, devote greater resources to the development, promotion and sale of their platforms or solutions than we can, or sell their platforms or solutions, or offer solutions competitive with our Integrated Drug Creation platform and solutions at prices designed to win significant levels of market share. In addition, we may encounter challenges in marketing our solutions with our pricing model, which is structured to capture the potential downstream revenues associated with product candidates that were discovered using our platform. Our partners and potential partners may prefer one or more pricing models employed by our competitors that involve upfront payments rather than downstream revenues. We may not be able to compete effectively against these organizations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to technology and platform development than we can. If we are unable to compete successfully against current and future competitors, we may be unable to increase market adoption of our platform technologies for the biologic drug discovery and cell line development, which could prevent us from increasing our revenue or achieving and sustaining profitability. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have made substantial investments into the rapid development of novel treatments for the therapeutic indications in which we are engaged in partnered programs and internally developed programs, including large and specialty pharmaceutical and biotechnology companies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discovery and development of therapies is highly competitive. Many of our competitors have significantly greater resources and experience than we do and we or our partners may not be able to successfully compete in therapeutic development. We will likely face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, hospitals and clinics, academic research institutions and governmental agencies and public and private research institutions, some of which have more advanced product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, and related data, emerge.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To compete successfully, we and our partners must demonstrate that the relative cost, method of administration, safety, tolerability or efficacy of the related product candidates provides a better alternative to existing and future therapies and, we must do the same with respect to any future internally developed product candidates. Our commercial opportunity and likelihood of success will be reduced or eliminated if these product candidates are not ultimately demonstrated to be safer, more effective, more conveniently administered, or less expensive than the then current standard of care. Furthermore, even if these product candidates demonstrate meaningful improvements in these attributes, acceptance of our products may be inhibited by the reluctance of physicians to switch from existing therapies to our products, or if physicians choose to reserve our products for use in limited circumstances.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market for our platform, including potential partners and potential investors, may be skeptical of the viability and benefits of our Integrated Drug Creation platform because it is based on novel and complex synthetic biology and AI technologies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our Integrated Drug Creation platform, including potential partners and potential investors, may be skeptical of the viability and benefits of our technology platform because it is based on novel and complex synthetic biology and AI technologies. There can be no assurance that our technologies will be understood, approved, or accepted by potential partners and potential investors or that we will be able to enter into new partnerships with new or existing partners. The synthetic biology and AI-powered drug discovery markets are relatively new, and potential partners may be hesitant to allocate resources in relatively unproven fields. If we are unable to convince these potential partners of the utility and value of our technologies or that our technologies are superior to the technologies they currently use, we will not be successful in entering these markets and our business and results of operations will be adversely affected. If potential investors are skeptical of the success of our technologies, our ability to raise capital and the value of our stock may be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to conduct our preclinical studies and any eventual clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or the relationship terminates prematurely, our internally developed programs could be delayed, more costly or unsuccessful, and such programs may never obtain regulatory approval or commercialization.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied and intend to rely in the future on third-party clinical investigators, contract development and manufacturing organizations (CDMOs), CROs, and clinical data management organizations to conduct, supervise and monitor preclinical studies and any eventual clinical trials of our current or future internally developed programs. Because we currently rely and intend to continue to rely on these third parties, we will have less control over the timing, quality and other aspects of preclinical studies and any eventual clinical trials than if we conducted them independently. These parties are not, and will not be, our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. Additionally, such parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we will remain responsible for ensuring that each of our preclinical studies are conducted in accordance with good laboratory practices and that our clinical trials are conducted in accordance with GCPs. Moreover, our business may be significantly impacted if our CROs, clinical investigators or other third parties violate federal or state healthcare fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we are required to repeat, extend, delay or terminate our preclinical or clinical development activities due to one or more third parties not successfully carrying out its contractual duties, meeting expected deadlines, or conducting development activities in accordance with regulatory requirements or our stated protocols, we may not be able to achieve, or may be delayed in achieving, product development milestones, including our internal timelines or certain regulatory requirements. As a result, our results of operations and the commercial prospects for our internally developed programs would be harmed, our costs could increase, and our ability to generate revenue and platform validation could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, from time to time we have relied upon, and may continue to rely upon, third parties that are based in jurisdictions outside the United States. Legislative proposals are pending that, if enacted, could negatively impact U.S. funding for certain biotechnology providers having relationships with foreign adversaries or which pose a threat to national security. If any of the third parties upon whom we rely are impacted by these legislative proposals, the potential downstream adverse impacts are unknown but may include supply chain disruptions or delays.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third parties terminate for any reason, including due to involuntary termination, regulatory or other compliance requirements, or strategic reprioritization, we may not be able to enter into alternative arrangements or do so on commercially reasonable terms. Switching or adding additional contractors requires additional resources and demands management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could compromise our ability to meet our internal development timelines. In addition, if an agreement with any of our partners terminates, our access to technology and intellectual property licensed to us by that partner may be restricted or terminate entirely, which may delay our continued development of our internally developed programs utilizing the partner&#8217;s technology or intellectual property or require us to stop development of those internally developed programs completely.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and/or a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could experience clinical supply and manufacturing problems that result in delays in the development, approval or commercialization of our product candidates or otherwise harm our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process used to produce antibodies may be complex. Several factors could cause production interruptions, including inability to develop appropriate manufacturing processes, equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, including pandemics, disruption in utility services, human error or disruptions in the operations of our suppliers, including acquisition of a supplier by a third party or declaration of bankruptcy. The expertise required to manufacture our product candidates may be unique to a particular third-party contract manufacturing organization, and as a result, it would be difficult and time consuming to find an alternative third-party contract manufacturing organization. Failure or process defects in any of the interrelated systems at either our manufacturing facility or those of our third-party manufacturers, could adversely impact our ability to manufacture and supply cell therapy product candidates and certain components thereof intended for research, clinical and, if approved, commercial production. In addition, we may rely on third-party contract manufacturers outside the United States for certain components of our product candidates, and may be subject to importation regulations that may affect our ability to manufacture or increase the cost of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates will require processing steps that are more complex than those required for most small molecule drugs. Moreover, unlike small molecules, the physical and chemical properties of biologics such as antibody therapeutics generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we will employ multiple steps to control the manufacturing process to assure that the process works and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory, or other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, production at such manufacturing facilities may be interrupted for an extended period of time to investigate and remedy the contamination. We may encounter problems achieving adequate quantities and quality of clinical grade materials that meet FDA, the EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may encounter problems hiring and retaining directly or through third-party contract manufacturing organizations the experienced scientific, quality assurance, quality control and manufacturing personnel needed to operate our manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our supply chain, manufacturing process or facilities could result in delays in ongoing or planned clinical trials and increased costs, and could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institution. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our programs and validation of our Integrated Drug Creation platform may be delayed and our expenses may increase and, as a result, our stock price may decline.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials, as well as the submission of regulatory filings. From time to time, we may publicly announce the expected timing of achieving certain of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our programs or the validation of our platform technologies based on anticipated achievement of these milestones, may be delayed or never achieved and, as a result, our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The medical insurance coverage and reimbursement status of newly approved therapeutics is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products and services could limit our partners&#8217; ability to successfully commercialize product candidates, which would decrease our ability to generate revenue.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford any antibody therapeutics generated using our Integrated Drug Creation platform. In addition, because the product candidates we generate may represent new classes of treatments for diseases, we and our partners cannot accurately estimate how such future antibody therapeutics would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of such antibody therapeutics will depend substantially, both domestically and internationally, on the extent to which the costs of such antibody therapeutics are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, our partners may not be able to successfully commercialize some antibody therapeutics generated with our technology. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow our partners to establish or maintain pricing sufficient to realize an adequate return on their investment in such antibody therapeutics, and may lead to discontinuation or deprioritization of development, marketing and sales efforts for such products. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our drug creation services and/or product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly cleared, authorized or approved antibody therapeutics in the United States and other jurisdictions. Due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes, we expect our partners to experience pricing pressures on antibody therapeutics generated using our Integrated Drug Creation platform that our partners may commercialize. The downward pressure on healthcare costs in general, particularly novel therapeutics, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products, which would negatively impact our ability to generate revenues. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target, including IBD. Many of our competitors have: </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; more extensive experience in designing and conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing, marketing and selling pharmaceutical products; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; product candidates that are based on previously tested or accepted technologies; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; products that have been approved or are in late stages of development; and </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; collaborative arrangements in our target markets with leading companies and research institutions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop products. We also expect to face competition from new drugs that enter the market. We believe a significant number of drugs are currently under development, and may become commercially available in the future, for the treatment of conditions that our current or future product candidates are or may be designed to treat. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop. Our competitors may develop or commercialize products with significant advantages over any products we are able to develop and commercialize based on many different factors, including: </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the safety and effectiveness of our products relative to alternative products, if any; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the timing and scope of regulatory approvals for these products; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the availability and cost of manufacturing, marketing and sales capabilities; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; price; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; more extensive coverage and higher levels of reimbursement; and </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; patent position. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may therefore be more successful in developing and/or commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our product candidates.  </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform efforts aimed at lowering the price of biopharmaceutical products may impact our ability to maintain sufficient profits.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. If efforts to contain the price of biopharmaceutical products are successful, the magnitude of milestone payments and royalties we would expect to receive in connection with our partners&#8217; future prioritization and investment in developing novel biologics may be impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growing legislative and enforcement interest in the United States with respect to drug pricing practices has resulted in several U.S. Congressional inquiries and federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs, and review the relationship between pricing and manufacturer patient programs. The Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), for example, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025, eliminating the prescription drug coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of an HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs were previously exempted from the Medicare drug price negotiation program; however, this exemption was restricted to drugs with only one orphan designation and for which the only approved indication is for that disease or condition. If a product received multiple orphan designations or had multiple approved indications, it would not qualify for the orphan drug exemption. Under the One Big Beautiful Bill Act of 2025, this restriction was eliminated; and effective for the 2028 initial price applicability year, all orphan drugs, regardless of the number of orphan designations or indications, are exempt from the Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2025, the Trump Administration published Executive Order 14273, &#8220;Lowering Drug Prices by Once Again Putting Americans First,&#8221; which generally directs the federal government to take measures to reduce drug prices, including eliminating the so-called &#8220;pill penalty&#8221; under the IRA that creates a distinction between small molecule and large molecule products for purposes of determining when a drug may be eligible for drug price negotiation.  On May 12, 2025, the Trump Administration published Executive Order 14297, &#8220;Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients&#8221; which generally, among other things, directs the federal government to establish and communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations. Further, the Executive Order directs the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets.  It also states that the Administration will take additional aggressive action (for example, examining whether marketing approvals should be modified or rescinded or opening the door for individual drug importation waivers) should manufacturers fail to offer American consumers the most-favored-nation lowest price. It also directs the Secretary of Commerce and the U.S. Trade Representative to &#8220;take all necessary and appropriate action to ensure foreign countries are not engaged in any act, policy, or practice that may be unreasonable or discriminatory or that may impair United States national security . . . including by suppressing the price of pharmaceutical products below fair market value in foreign countries.&#8221;  Notably, a similar &#8220;Most Favored Nation&#8221; pricing rule enacted under the first Trump Administration was subject to an injunction resulting from judicial challenges to the rule, which was formally rescinded by the former Biden Administration in August 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the U.S. Supreme Court overruled the Chevron doctrine, which gave deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This decision may result in more lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, any of which could delay the FDA&#8217;s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the operations of the FDA, the SEC and other government agencies, including from funding shortages, government shutdowns or global health concerns, in addition to substantial uncertainty regarding the U.S. presidential administration&#8217;s initiatives and staffing cuts and how these might impact the FDA, its implementation of laws, regulations, policies and guidance, and its personnel, could hinder government agencies&#8217; ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, including timely reviews, which could negatively impact our business.</span></div><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition, government funding of the SEC and other government agencies or comparable foreign regulatory authorities on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other federal agencies, including substantial leadership departures, personnel cuts, and policy changes, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would harm our business. Changes and cuts in FDA staffing have been reported by some within the pharmaceutical industry as creating instances of delays in the FDA&#8217;s responsiveness or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar consequences would also result in the event of another significant shutdown of the federal government. For example, over the last several years, including beginning on October 1, 2025, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. The duration of the current government shutdown is unknown. If a prolonged government shutdown occurs, or if geopolitical or global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Such changes could significantly impact the ability of the FDA to timely review and take action on our regulatory submissions, which could have a material adverse effect on our business, including INDs placed on clinical holds or delayed new drug approvals. If the FDA is constrained in its ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. Further, in our operations as a public company, future government shutdowns or substantial leadership, personnel, and policy changes could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the change in the U.S. Presidential Administration in 2025, there continues to be substantial uncertainty as to the extent to which and how the current administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates and any products for which we obtain approval. This uncertainty could present new challenges and/or opportunities as we navigate development and approval of our product candidates. Some of these efforts have manifested to date in the form of personnel cuts and measures that could impact the FDA&#8217;s ability to hire and retain key personnel, which could result in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite regulatory approvals in the future. There remains general uncertainty regarding future activities. The current Administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products. Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations, policies or guidance as a result of the current Administration or otherwise, there could be a material adverse effect on us and our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to make significant investments in our continued research and development of new technology, which may not be successful.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking to expand the scope of our capabilities, which may or may not be successful. This includes, but is not limited to, drug discovery, and application of AI across our Integrated Drug Creation platform. We expect to incur significant expenses to advance these research and development efforts or to invest in, or acquire complementary technologies, but these efforts may not be successful. For instance, we have limited experience with the discovery and development of antibody therapeutics. Additional development will be required for the routine and robust use of these technologies in both our internally developed and partnered </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs. Through the course of additional technology development, significant unanticipated challenges may arise that adversely affect our future internally developed programs and partnership prospects. We continue to invest in the development and identification of new technologies to further broaden and deepen our capabilities and expertise in AI-powered drug creation and integrate generative AI deep learning technology and computational antibody and target discovery technology into our Integrated Drug Creation platform to shorten drug discovery timelines. Our long-term goals for this technology, such as constructing deep learning models capable of in silico target identification and drug and cell line design, continue to require significant investment and long development timelines and may ultimately never fully materialize.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing new technologies is a speculative and risky endeavor. Technologies that initially show promise may fail to achieve the desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our technologies in development before we identify a potentially successful technology. Technology development is expensive, may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. Additionally, development of any technology may be disrupted or made less viable by the development of competing technologies, and changes in the industry in which our technologies are applied could obsolete our technologies. New potential technologies may fail any stage of development or commercialization and if we determine that any of our current or future technologies are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful in developing or acquiring additional technologies, our potential for growth may be impaired.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The industries in which we operate are characterized by significant enhancements and evolving industry standards. As a result, our partners&#8217; needs are rapidly evolving. If we do not successfully innovate and invest in new technologies, including within the field of AI, our platform may become less competitive, we may fail to advance our internally developed programs, and our partners could move to new technologies or engage in drug creation activities themselves. Without the timely introduction of technological advancements, our technologies will likely become less competitive over time, in which case our competitive position and results of operations could suffer. To the extent we fail to timely introduce new and innovative technologies, adequately predict our partners&#8217; needs or fail to obtain desired levels of market acceptance, our business may suffer and our results of operations could be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Partnership Business Strategy</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends on the technological capabilities of our Integrated Drug Creation platform and the advancement of our internally developed programs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our Integrated Drug Creation platform to identify promising opportunities for development and potential commercialization by our partners. As a result, the quality and sophistication of our Integrated Drug Creation platform and technologies are critical to our ability to conduct our drug creation activities and to generate more promising product candidates and cell lines and to shorten and lower the costs of therapeutic development for our existing and potential partners, as compared to other methods. In particular, our business depends, among other things, on:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to successfully identify product candidates and production cell lines through our Integrated Drug Creation platform and provide them to our partners on the desired timeframes and for further development;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our partners&#8217; determination that the product candidates and/or cell lines that we provide to them can ultimately be used to advance our partners&#8217; clinical development programs; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our partners' entering into license agreements with economic terms that are acceptable to us, which is based substantially on the value our partners believe can be recognized from the product candidates and/or cell lines that we provide to them;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to execute on our strategy to enter into new partnerships with new or existing partners on terms that are acceptable to us;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to identify partners to license or acquire rights to our internally developed programs for further preclinical or clinical development;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to use our generative AI models to create actionable biological insights;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to increase awareness of the capabilities of our technologies and solutions; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our partners&#8217; and potential partners&#8217; willingness to adopt our Integrated Drug Creation platform ; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">whether our Integrated Drug Creation platform reliably provides advantages over legacy and other alternative technologies and is perceived by partners to be cost effective; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the rate of adoption of our technologies by pharmaceutical companies, biotechnology companies of all sizes, government organizations and non-profit organizations and others; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">prices we charge for our technology and the discoveries that we make;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the relative reliability and robustness of our Integrated Drug Creation platform; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to develop new technologies for partners; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our Integrated Drug Creation platform&#8217;s ability to offer sufficient cost effectiveness, efficiency, and performance to warrant partners&#8217; continued adoption of and ongoing reliance on our technologies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our Integrated Drug Creation platform&#8217;s ability to screen a high number of cells and product candidates and leverage this data to train our generative AI models;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">whether competitors develop a platform that enables drug creation more effectively than our platform; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to bioengineer our proprietary </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">E. coli </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SoluPro and Bionic SoluPro strains to produce certain types of proteins, validate protein sequences and further train our AI models;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to adapt our assays to screen effectively for certain types of therapeutic modalities or targets;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to adapt our assays to de-orphan antibodies we create using our technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to construct diverse genetic libraries covering sufficient diversity of protein sequence variants and folding and expression solutions combinations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to reliably adapt our assays to each program to screen large strain libraries and routinely identify molecules/strains that meet the program deliverable requirements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to optimize our fermentation conditions to scale at an effective level;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our platform&#8217;s ability to create new drug modalities and novel conjugates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the timing and scope of any approval that may be required by the FDA or any other regulatory body for drugs that are developed based on molecules discovered and/or manufactured using our Integrated Drug Creation platform technologies; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our partners&#8217; and the biopharmaceutical industry&#8217;s continued interest and investment in antibody therapeutics development, and the continued market growth and clinical and regulatory success of this category collectively;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the impact of our investments in innovation and commercial growth; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">negative publicity regarding our or our competitors&#8217; technologies resulting from defects or errors; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to further validate and enhance our Integrated Drug Creation platform through research and development activities; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our ability to leverage our Integrated Drug Creation platform technologies to create product candidates for internal development and advancement into clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will successfully address any of these or other factors that may affect the market acceptance of our Integrated Drug Creation platform or our technology. If we are unsuccessful in achieving and maintaining market acceptance of our Integrated Drug Creation platform, our business, financial condition, results of operations and prospects could be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the successful application of our Integrated Drug Creation platform to initiate and advance partnered programs and to develop our internally developed programs that can be further developed by our current or future partners.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The antibody therapeutic development business is capital intensive. Our success significantly depends on our ability to apply our Integrated Drug Creation platform for partnered programs, develop promising internally developed programs, and enter into agreements with our current and future partners to further develop these programs. We have only recently expanded our Integrated Drug Creation platform into antibody therapeutic discovery, both for programs that we develop with our partners and those that we internally develop. In order to realize the full benefits of our Integrated Drug Creation platform, we will need to succeed in advancing it, developing our internally developed programs and marketing our expanded capabilities to existing and potential new partners.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future revenue growth and market potential will depend on our ability to continue leveraging our Integrated Drug Creation platform, together with our custom libraries, data sets and other proprietary tools, for drug creation and other areas of biopharmaceutical drug development. However, we may not be able to successfully validate that our Integrated Drug Creation platform will shorten the hit identification and lead optimization steps of biologic drug creation or that our platform will enable us to create promising biologic candidates for further development.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to continue these initiatives and advance new drug creation efforts could result in a failure to develop our platform, improve upon existing technologies, partner internally developed programs for clinical development, and expand our addressable market, each of which could have a material and adverse impact on our business development, business, financial position and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate significant recurring revenue from our partnership arrangements unless and until such time as we enter into further agreements that, in the aggregate, result in regular and continuous fees for our performance of drug creation activities or agreements under which we would be eligible for future payments upon our partners&#8217; achievement of development and regulatory milestones or commencement of commercial sales with respect to any product candidates generated using our platform. We are unable to predict whether and the extent to which payments will be made to us under our partnership arrangements, and whether and the extent to which we will be able to enter into future arrangements under which we are eligible to generate additional revenues, or the timing of the achievement of any milestones under these agreements, if they are achieved at all. The timing and likelihood of payments to us under these agreements is dependent on our partners&#8217; successful development and commercialization of the molecules created using our platform, which may be outside of our control. Because of these factors, our operating results are difficult to predict and could vary materially from quarter to quarter. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partnership strategy significantly depends on the eventual approval and commercialization of product candidates developed under our partnerships for which we may have no control over the clinical development plan, regulatory strategy or commercialization efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partnership strategy depends on the eventual progression of biologic product candidates discovered or initially developed utilizing our Integrated Drug Creation platform into clinical trials and commercialization. This requires us to attract partners and enter into agreements with them that contain obligations for the partners to pay us milestone payments as well as royalties on sales of approved products for the product candidates that they develop and were generated utilizing our Integrated Drug Creation platform. Given the nature of our relationships with our partners and future partners, we often do not fully control the progression, clinical development, regulatory strategy or eventual commercialization, if approved, of these partnered product candidates. As a result, our future success and the potential to receive milestones and royalties are significantly dependent on our partners&#8217; efforts, over which we have little control. If a partner determines not to proceed with the future development of a product candidate discovered or initially developed utilizing our Integrated Drug Creation platform, if it implements a clinical or regulatory strategy that ultimately does not enable the further development, approval or commercialization of the product candidate, or if we cannot find a partner to advance an internally developed program, we will not receive the benefits of our partnerships, which may have a material and adverse effect on our operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, antibody therapeutic development is inherently uncertain and very few product candidates ultimately progress through clinical development and receive approval for commercialization. See the risk factor section titled, &#8220;Risks Related to Biologic Drug Development&#8221; for additional information related to the risks of biologic drug development. If our partners do not receive regulatory approval for a sufficient number </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of product candidates originating from our Integrated Drug Creation platform, we may not be able sustain our business model.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While as a general matter we intend to periodically report on the status of our business development initiatives, including anticipated next steps, we may not provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosure by our partners of any milestones or other information related to product candidates generated using our Integrated Drug Creation platform. Any disclosure by us or our partners of data or other information regarding any such product candidates that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may also decline as a result of negative results from any eventual clinical trial, including adverse safety events, involving any product candidate that is subject to one of our partnerships. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot maintain our current relationships with partners, fail to expand our relationships with our current partners, or if we fail to enter into new relationships, our future operating results would be adversely affected as a general matter.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2025 and 2024, revenue from three partners accounted for 98% of our partner program revenue and two partners accounted for 100% of our partner program revenue, respectively. The revenue attributable to these partnerships may fluctuate in the future, which could have an adverse effect on our business, financial condition, results of operations and prospects. Our existing partners may cease to use our technologies depending on their own technological developments, availability of other competing technologies, and internal decisions regarding allocation of time and resources to the discovery and development of biologic product candidates, over which we have no control. Our existing and potential future partners may have limited resources to initiate new programs, which could limit their adoption or scale of application of our technologies. In addition, existing partners may choose to produce some or all of their requirements internally by using or internally developing their own capabilities or by using capabilities from acquisitions of assets or entities from third parties with such capabilities. While our business is not substantially dependent on partner program revenues from any individual partner, because we currently have a limited number of partnerships, a loss of one of our partners could adversely impact our revenue, results of operations, cash flows or reputation in any given period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partnership strategy&#8217;s future success also depends on our ability to expand relationships with our existing partners and to establish relationships with new partners. We engage in discussions with third parties regarding potential drug creation, license, and asset sale opportunities on an ongoing basis, which can be time consuming. There is no assurance that any of these discussions will result in a drug creation, asset sale, and/or license agreement, or if an agreement is reached, that the resulting relationship will be successful, or that the terms of such agreement will be favorable to us. We target partnerships with biotechnology and pharmaceutical companies. Macro-economic market conditions have had, and may continue to have, a significant effect on the formation, funding and research and development budgets of these types of entities and could have a significant effect on the number of viable companies with whom we may partner or the programs viable partners may elect to pursue. Our partners and future partners may also determine their research and development budgets based on other factors, including conservation of cash resources, changes in business priorities, the need to develop new products, technological expertise, continued availability of governmental and other funding, competition, and intellectual property landscape. If research and development budgets of viable partners are reduced or the number of viable partners decline, the impact could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to monitor the achievement of clinical, regulatory and commercial milestones by our partners and enforce the payment of any corresponding fees is limited. Furthermore, the termination of any of these relationships could result in a temporary or permanent loss of revenue. Additionally, speculation in the industry about our existing or potential commercial relationships can be a catalyst for adverse speculation about us and our technology, which can adversely affect our reputation and our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure investors that we will be able to maintain or expand our existing partnerships or that our technologies will achieve adequate market adoption among new partners. Any failure to increase penetration in our existing markets or new markets would adversely affect our ability to improve our operating results from our partnership strategy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue under our partnered programs for any particular period, or on an absolute basis, can be difficult to forecast.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the complexities and long development timelines inherent in the biologic drug development business, it is difficult to predict the timing of payments under our drug creation and other partner agreements. In particular, payments under our drug creation agreements are subject to the achievement of project milestones and our partners&#8217; decisions to initiate or continue the drug creation work, and any future downstream payments with respect to product candidates generated using our Integrated Drug Creation platform will be subject to our partners&#8217; advancement of the product candidates, over which we have no control. As a result, our revenue for any particular period can be difficult to forecast. Our revenue may grow at a slower rate than in past periods or even decline on a year-over-year basis. Because of these factors, our operating results could vary materially from quarter to quarter from our forecasts. Also, due to the limited probability of success for advancement of a product candidate by a partner at any given stage of development and the unpredictability of when a partner may choose to continue development of a product candidate and whether any milestone payments will be due to us, our revenue may be difficult to forecast on an absolute basis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we recognize revenue either as we perform our drug creation activities, upon completion of performing our drug creation activities or upon achieving certain licensing, clinical, regulatory, and commercialization milestones. As a result, much of our revenue is generated from agreements entered into during previous periods. Consequently, a decline in demand for our platform, a decline in new or renewed business in any one quarter or any delays in the achievement, or any failure to achieve, development, regulatory and commercial milestones by our partners with respect to product candidates generated using our platform, may not significantly reduce our revenue for that quarter but could negatively affect our revenue in future quarters. Our revenue recognition model also makes it difficult for us to rapidly increase our revenue through increased operations in any period, as revenue from partners is recognized over the course of their drug development and commercialization efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure of our drug creation partners to meet their contractual obligations to us could adversely affect our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us to our standards, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of products generated using our platform or result in litigation or arbitration. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our partners are large, multinational organizations that run many programs concurrently, and we are dependent on their ability to accurately track and make milestone payments to us pursuant to the terms of our agreements with them. Any failure by them to inform us when milestones are reached and make related payments to us could adversely affect our results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, some of our future partners may be located in markets subject to political and social risk, armed conflict, corruption and infrastructure problems, and could be subject to country-specific privacy and data security risk as well as burdensome legal and regulatory requirements. Any of these factors could adversely impact their financial condition and results of operations, which could impair their ability to meet their contractual obligations to us and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and our anticipated revenue. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may make public statements regarding the expected timing of certain milestones and key events, as well as regarding developments and milestones under our partnerships, to the extent that our partners have publicly disclosed such information or permit us to make such disclosures. Certain of our partners may in the future make statements about their goals and expectations for partnerships with us. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or our current and future partners&#8217; drug discovery and development programs, the amount of time, effort, and resources committed by us and our current and future partners, and the numerous uncertainties inherent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the development of drugs. Additionally, to date, none of our partners has successfully completed a regulatory submission, such as an IND application or BLA, for a product candidate generated using our Integrated Drug Creation platform. There can be no assurance that our partners&#8217; current and future programs will advance or be completed in the time frames we or they expect. If our partners fail to achieve one or more of these milestones or other key events as planned, our business could be materially adversely affected and we may never receive the anticipated revenues from these partnerships.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing partnered programs, and the price of our common stock may decline as a result of announcements of unexpected or negative results or developments. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners have significant discretion in determining when and whether to make announcements about the status of our partnerships, including about preclinical and clinical developments and timelines for advancing product candidates generated using our Integrated Drug Creation platform. We do not plan to disclose the development status and progress of individual product candidates of our partners, unless and until those partners do so first. Our partners may wish to report such information more or less frequently than we expect, or they may not report such information at all, in which case we would not report that information either, unless material to our financial statements. In addition, if a partner chooses to announce a partnership with us, there is no guarantee that we will receive payments related to partner program revenue in that quarter or even the following quarter, as such payments are only payable to us in accordance with the terms of the agreements governing such partnerships. The price of our common stock may decline as a result of the public announcement of unexpected results or developments in our partnerships, or as a result of our partners withholding such information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of suppliers for laboratory equipment and materials and may not be able to find replacements or transition to alternative suppliers on a timely basis, or at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a limited number of suppliers to provide certain consumables and equipment that we use in our laboratory operations, as well as reagents and other laboratory materials involved in the development of our technology. Fluctuations in the availability and price of laboratory materials and equipment could have an adverse effect on our ability to meet our manufacturing and supply requirements for our internally developed programs or our drug creation goals with our partners and thus our results from operations as well as future partnership opportunities. An interruption in our laboratory operations or technology transfer activities could occur if we encounter delays, quality issues or other difficulties in securing these consumables, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In addition, we would likely be required to incur significant costs and devote significant efforts to find new suppliers, acquire and qualify new equipment, validate new reagents and revalidate aspects of our existing assays, which may cause delays in our processing of samples or development and commercialization of our technology. Any such interruption could significantly affect our business, financial condition, results of operations and reputation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, we have purchased and rely on a bioreactor system and related equipment, consumables and liquid handling robotics, and associated consumables. We obtain our supplies of equipment and materials under purchase orders and do not have supply contracts in place with certain suppliers. Any disruption in the supply chain for these products could materially affect our business. While there are alternative types of equipment that we could use as a replacement, switching to different systems could require significant capital investment, long lead times and significant training and validation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Integrated Drug Creation platform may not meet the expectations of our partners, which means our business, financial condition, results of operations and prospects could suffer. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on, among other things, the market&#8217;s confidence that our Integrated Drug Creation platform is capable of substantially shortening the amount of time necessary to perform certain activities as compared to the use of legacy and other alternative technologies, and will enable more efficient or improved preclinical and clinical development and/or biomanufacturing. There is no assurance that we will be able to fully accomplish this in the future, or at all. To date, we have only advanced one product candidate, ABS-101, from our Integrated Drug Creation platform into clinical testing, and any inability to advance additional </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates into clinical development may reduce our existing and prospective partners' confidence in our platform. We also believe that pharmaceutical and biotechnology companies are likely to be particularly sensitive to defects in, or suboptimal performance of, our Integrated Drug Creation platform, including if it fails to deliver meaningful reduction of certain research timelines accompanied by results at least as good as the results generated using legacy or other alternative technologies. There can be no guarantee that our Integrated Drug Creation platform will meet the expectations of pharmaceutical and biotechnology companies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to develop and expand our workforce, commercial infrastructure and laboratory operations to support anticipated growth in demand for our drug creation programs, and we may encounter difficulties in managing this development and expansion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to expand our workforce, commercial infrastructure and laboratory operations to support anticipated growth in demand for our drug creation programs. If we are unable to support fluctuations in the demand for our drug creation programs, including ensuring that we have adequate capacity to meet increased demand, our business could suffer. We expect to continue to develop our employees and the scope of our operations as we continue to enhance our technologies and expand our number of programs. As we seek to pursue and advance internally developed programs, increase the number of our partnerships, expand the scope of our existing partnerships, and further develop our technological capabilities, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher research and development costs, declining drug creation program quality, deteriorating alliance management success, and slower responses to competitive challenges. Moreover the successful execution of our programs requires ongoing integration amongst our employees who come from a variety of technical backgrounds. As we increase the number of partnered and internally developed programs, we must ensure alignment and effective collaboration between our wet-lab biologists and AI scientists which we may not achieve due to the challenge of integrating these disparate domains. A failure in any one of these areas could make it difficult for us to meet market expectations for our technologies, and could damage our reputation and the prospects for our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management team may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing growth activities. Due to our limited resources and early stage of growth, we may not be able to effectively manage this simultaneous execution and the expansion of our operations. This may result in weaknesses in our infrastructure, operational mistakes, slower development of our drug creation partnered programs and internally developed programs, loss of business opportunities, loss of employees and reduced productivity among our employees.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to effectively manage our expected development and growth, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, and our ability to develop and commercialize our technologies and compete effectively, will depend, in part, on our ability to effectively manage our future development and growth.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of any member of our senior leadership team or our inability to attract and retain highly skilled scientists and business development professionals could adversely affect our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on the skills, experience and performance of key members of our senior leadership team, as well as highly skilled employees in certain technical fields. The individual and collective efforts of these employees will be important as we continue to develop our Integrated Drug Creation platform and our technology, and as we expand our commercial and development activities. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. While our executive officers are party to employment contracts with us, their employment with us is at-will, which means that either we or the executive may terminate their employment at any time, and we therefore cannot guarantee their retention for any period of time. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities depend on our ability to attract and retain highly skilled personnel. We may not be able to attract or retain qualified personnel due to the intense competition for highly skilled scientists, including those focused on AI-powered biologic drug discovery and cell line development, as well as qualified business development and sales professionals, among life sciences companies. Competition for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel with expertise in AI-powered drug discovery is particularly intense. Additionally, our headquarters located in Vancouver, Washington, which does not have as high a concentration of innovative biotechnology or AI companies as other geographic locations, may negatively impact our ability to attract and retain top talent. Further, some of the qualified personnel that we hire and recruit may not be U.S. citizens. Changes to U.S. immigration policies, particularly to H-1B and other visa programs, could restrain the flow of technical and professional talent into the United States and may inhibit our ability to hire qualified personnel, as well as increase related hiring costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and business development programs. A key risk in the area of retention is that all of our employees are at-will.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We in the past have, and in the future may, make technology acquisitions, acquire businesses or assets, or make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made technology acquisitions in the past and may, in the future, pursue acquisitions of businesses and assets in the future. We also may pursue strategic alliances, joint ventures or other commercial deal structures that leverage our technologies and industry experience to expand our offerings. Additionally, we intend to invest in certain wholly-owned preclinical and/or clinical development programs with the goal of licensing or selling them to partners for clinical development. Although we have acquired other businesses or assets in the past, we may not be able to find suitable partners or acquisition or asset purchase candidates in the future, and we may not be able to complete such transactions on favorable terms, if at all. The competition for partners or acquisition candidates may be intense, and the negotiation process will be time-consuming and complex. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, these acquisitions may not strengthen our competitive position, the transactions may be viewed negatively by partners or investors, we may be unable to retain key employees of any acquired business, relationships with key suppliers, manufacturers or partners of any acquired business may be impaired due to changes in management and ownership, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. We cannot guarantee that we will be able to fully recover the costs of any acquisition. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture, or other commercial deal structure. We also may experience losses related to investments in other companies, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Acquisitions may also expose us to a variety of international and business related risks, including intellectual property, regulatory laws, local laws, tax and accounting. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or asset purchase, we may choose to issue securities as consideration, which would dilute the ownership of our stockholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire companies or assets using our securities as consideration. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our equipment financing agreements may contain covenants that restrict our operating activities, and we may be required to repay the outstanding indebtedness in an event of default, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a Master Financing Agreement (MFA) pursuant to which the lender agreed to provide us equipment financing. Until we have repaid such indebtedness, the MFA subjects us to various customary covenants, including requirements as to financial reporting, liquidity ratios and maintaining insurance. Our business may be adversely affected by these restrictions on our ability to operate our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to repay the outstanding indebtedness under the MFA if an event of default occurs under the MFA. An event of default will occur if, among other things, we fail to make required payments under the MFA; we breach any of our covenants under the MFA, subject to specified cure periods with respect to certain breaches; the lender determines that a material adverse change (as defined in the MFA) has </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit the third party to accelerate the maturity of such indebtedness or that could have a material adverse change on us. We may not have enough available cash, cash equivalents and marketable securities or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In such a case, we may be required to delay, limit, reduce or terminate our operations or grant to other parties the rights to develop and market our Integrated Drug Creation platform that we would otherwise prefer to develop and market ourselves. The lender could also exercise its rights as secured lender to take possession of and to dispose of the collateral securing the MFA, which collateral includes substantially all of our property. Our business, financial condition, results of operations and prospects could be materially adversely affected as a result of any of these events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to collect on our accounts receivable by a significant number of partners may have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invoices issued to our partners are generally made on open credit terms. While we have not experienced any significant challenges in collecting on accounts receivable from our partners historically, they may occur in the future. Management assesses the need to maintain an allowance for potential credit losses each reporting period. If our partners&#8217; cash flow, working capital, financial conditions or results of operations deteriorate, they may be unable or even unwilling to pay trade receivables owed to us promptly or at all. As a result, we could be exposed to a certain level of credit risk. If a major partner experiences, or a significant number of partners experience, financial difficulties, the effect on us could be material and have an adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our operating facility becomes damaged or inoperable or we are required to vacate our facility, our ability to conduct and pursue our drug creation and internal research and development efforts may be jeopardized. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate primarily through a single facility located in Vancouver, Washington. Our facility and equipment could be harmed or rendered inoperable or inaccessible by natural or man-made disasters or other circumstances beyond our control, including fire, earthquake, power loss, communications failure, war or terrorism, or another catastrophic event, such as a pandemic or similar outbreak or public health crisis, which may render it difficult or impossible for us to support our partners, advance internal research and development activities, and develop updates, upgrades and other improvements to our technology and platform, advanced automation systems, and advanced application for some period of time. We may be unable to execute on our drug creation and additional research and development activities if our facility is inoperable or suffers a loss of utilization for even a short period of time. This may result in the loss of partners or harm to our reputation, which we may be unable to regain or repair in the future. This may interrupt the development of our internally developed programs, which may delay our ability to monetize such programs. Furthermore, our facility and the equipment we use to perform our drug creation activities could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility, to locate and qualify a new facility or license or transfer our proprietary technology to a third party. Even in the event we are able to find a third party to assist in drug creation efforts, we may be unable to negotiate commercially reasonable terms to engage with the third party. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future use of evolving technologies, such as artificial intelligence (AI), may present risks and challenges that can impact our business, including by posing cybersecurity and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to operational challenges, reputational harm and potential liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology development activities depend on sophisticated AI algorithms and computational systems to conduct drug creation activities. These activities require substantial computational resources, including high-performance computing systems and cloud computing services. The availability of these resources is critical to our ability to efficiently process large datasets, perform complex simulations, and analyze vast amounts of genetic and molecular information. Limited access to, or the inability to expand, these computational resources could pose significant risks to our business and operations in the following ways:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Insufficient computational power could slow down our R&amp;D activities, leading to delays in drug creation partnerships, internally developed programs and technology development activities. This </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">slowdown could adversely affect our ability to meet project milestones and delay program development;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Relying on external providers for additional computational resources can significantly increase our operational costs. Unexpected increases in these costs could impact our financial condition, especially if we are unable to pass these costs onto our customers or adequately budget for them;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Our ability to remain competitive depends on our capacity to leverage cutting-edge AI technologies and computational methods. Limited access to computational resources could hinder our ability to innovate and maintain our technological advantage;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Limited computational resources may lead to operational bottlenecks, affecting our ability to process data and execute tasks efficiently. This inefficiency could impair our productivity and operational effectiveness, impacting our overall business performance; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Expanding our computational infrastructure or resorting to third-party cloud services to meet our computational needs could expose us to increased compliance and security risks. Ensuring data protection and meeting regulatory requirements become more challenging as we scale our computational resources, potentially leading to financial penalties and reputational damage.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess our computational need&#160;&#160;&#160;&#160;s and strategically invest in our infrastructure, including access to compute via cloud computing arrangements, to mitigate these risks. However, there is no assurance that these measures will be sufficient to prevent the adverse effects associated with limited access to computational resources. Our failure to effectively manage and scale our computational resources could have a material adverse effect on our business, financial condition, and operational results.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we enable or use solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm or legal liability. A growing number of legislators and regulators are adopting laws and regulations and have focused enforcement efforts on the adoption of artificial intelligence, and use of such technologies in compliance with ethical standards and societal expectations. These developments may increase our compliance burden and costs in connection with use of artificial intelligence and lead to legal liability if we fail to meet evolving legal standards or if use of such technologies results in harms or other causes of action we did not predict. For example, the EU&#8217;s Artificial Intelligence Act (&#8220;AI Act&#8221;) entered into force on August 1, 2024, with most provisions becoming effective on August 2, 2026. This legislation imposes significant obligations on providers and deployers of artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on legal and risk determinations that rely on novel legal provisions that have not yet been interpreted by courts or regulators, and non-compliance can lead to significant fines. Likewise, in the U.S., several states, including Colorado and California, passed laws that will take effect in 2026, to regulate various uses of artificial intelligence, including to make consequential decisions. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. If we develop or use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality, transparency, monitoring and human oversight, and we would need to adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements, with the potential for significant enforcement or litigation in the event of any perceived non-compliance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid evolution of artificial intelligence will require the application of significant resources to design, develop, test and maintain such systems to help ensure that artificial intelligence is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. The use of certain artificial intelligence technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary intellectual property, or by undermining our ability to assert or defend ownership rights in intellectual property created with the assistance of artificial intelligence tools. Our vendors may in turn incorporate artificial intelligence tools into their offerings, and the providers of these artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our information technology systems, and any significant disruptions to or failure of these systems could result in significant financial, legal, regulatory, business and reputational harm to our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant disruptions to our and our service providers&#8217; information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us. We are increasingly dependent on information technology systems and infrastructure, including services licensed, leased or purchased from third parties such as cloud computing infrastructure and operating systems, for significant elements of our business operations, including the operation of our Integrated Drug Creation platform (which includes for example our proprietary AI models, our antibody discovery software platform, our computational biology system), our knowledge management system, our partner reporting, our advanced automation systems, and advanced application software. These systems involve computational resources and data storage distributed between onsite servers, cloud computing infrastructure hosted by third-party providers, and a private graphics processing unit cluster owned by us but located and maintained at a facility in Texas. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, procurement, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. These implementations were expensive and required significant time and effort. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may have access to our networks or our confidential information. While we take measures to safeguard and protect this information, threats to network and data security are constantly evolving and growing in frequency and sophistication. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. We intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including manufacturing operations, laboratory operations, data analysis, quality control, partner service and support, billing, research and development activities, scientific and general administrative activities. A significant risk in implementing these systems includes the integration and communication between separate IT systems, and any failure to integrate these systems effectively could adversely affect various aspects of our operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we currently market our technologies and our partners may market products derived from our technologies outside of the United States and we or our partners may market future technologies, products and services outside of the United States, if cleared, authorized or approved, our business is subject to risks associated with doing business outside of the United States, including an increase in our expenses, disruptions to our supply chain, security threats and diversion of our management&#8217;s attention from the development of future products and services. In addition, we currently maintain offices and have employees located in Zug, Switzerland and Belgrade, Serbia. Our current and planned international operations could expose us to additional risks that may adversely affect our business and financial results, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">multiple, conflicting and changing laws and regulations such as privacy security and data use regulations, tax laws, export and import controls and restrictions, tariffs, economic sanctions and embargoes, employment laws, anticorruption laws, regulatory requirements, reporting and disclosure obligations, reimbursement or payor regimes and other governmental approvals, permits and licenses;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">failure by us, our partners or our distributors to obtain regulatory clearance, authorization or approval for the use of our technologies in various countries;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">additional potentially relevant third-party patent rights;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">difficulties in staffing and managing foreign operations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">difficulties in negotiating favorable reimbursement arrangements with governmental authorities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">complexities in technology transfer regulations and logistics related to delivery of our bioengineered </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">E. coli</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to partners;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">logistics and regulations associated with shipping samples, including infrastructure conditions and transportation delays;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">limits in our ability to penetrate international markets if we are not able to conduct our operations locally;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our technologies, exposure to foreign currency exchange rate fluctuations and different tax jurisdictions;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">natural disasters, political and economic instability, including wars, terrorism, political unrest and global conflicts such as Russia&#8217;s invasion of Ukraine, ongoing conflicts in the Middle East and heightened tensions in the Pacific region, outbreak of disease or other public health crises, such as the COVID-19 pandemic, boycotts, curtailment of trade, including as a result of tariffs, export controls and sanctions implemented by or against the United States in relation to other countries or jurisdictions, and other business restrictions;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">certain expenses, including expenses for travel, translation services, labor and employment costs and insurance;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act (FCPA), its books and records provisions, or its anti-bribery provisions; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">onerous anti-bribery requirements under laws similar to the FCPA in other jurisdictions in which we may now or in the future operate, including those of several member states in the European Union (EU), such as the United Kingdom&#8217;s Bribery Act of 2010, and other countries that are constantly changing and require disclosure of information to which U.S. legal privilege may not extend.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities are subject to the FCPA and other anti-bribery and anti-corruption laws of the United States and other countries in which we operate, as well as U.S. and certain foreign export controls and trade sanctions. Violations of such legal requirements could subject us to liability. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the FCPA, which among other things prohibits companies and their third-party intermediaries from offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Companies in the biotechnology and biopharmaceutical field are highly regulated and therefore involve interactions with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FCPA. These laws are complex and far-reaching in nature, and, as a result, there is no certainty that all of our employees, agents or contractors will comply with such laws and regulations. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, financial condition, results of operations and prospects. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with materials, including chemicals, biological agents and compounds that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Our SoluPro system is based on bioengineered E. coli, which could pose a health risk if improperly handled. Additionally, we employ various synthetic biology processes, which could involve the use or emission of harmful materials. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. We may be subject to periodic inspections by relevant authorities to ensure compliance with applicable laws. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, drug creation partnered programs and internally developed programs and business operations, as well as environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations. In the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises such as pandemics or similar outbreaks could cause a disruption of the development of our platform technologies, and adversely impact our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of public health crises, such as the COVID-19 pandemic, we have previously experienced and may in the future experience severe delays and disruptions, including, for example:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">interruption of or delays in receiving products and supplies from third parties; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">limitations on our business operations by local, state and/or federal governments that could impact our ability to conduct our technology development and other activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">delays in negotiations with partners and potential partners; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">increases in facilities costs to comply with physical distancing guidance; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working from home, travel limitations, cyber security and data accessibility, or communication or mass transit disruptions; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">limitations on employee resources that would otherwise be focused on the conduct of our activities, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could severely impact drug creation, internal program, manufacturing, other research and development activities, business operations and business development, or delay necessary interactions with local regulators, and other important contractors and partners. These and other factors may adversely impact our ability to conduct our business generally and have a material adverse impact on our operations and financial condition and results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect in the future to rely on a limited number of outside parties to perform the cGMP manufacturing for preclinical development, clinical development and commercialization of any biologic product candidates produced using our technology. Limitations in this global cGMP manufacturing capacity could delay or prevent preclinical development, clinical development and/or commercialization efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop manufacturing processes that are required to use our cell lines, but we do not currently have capabilities to manufacture products in accordance with cGMPs. We rely on the in-house manufacturing capabilities of our partners or capabilities of established third-party CDMOs to manufacture our and our partners product candidates. Manufacturing capacity maintained by our partners or third-party CDMOs is a finite resource that is in demand. Shortages in cGMP manufacturing capacity are difficult to predict and could hamper our operations and harm our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, from time to time we have relied upon, and may continue to rely upon, third party CDMOs that are based in jurisdictions outside the United States. Legislative proposals are pending that, if enacted, could negatively impact U.S. funding for certain biotechnology providers having relationships with foreign adversaries or which potentially pose a threat to national security. If any of our third party CDMOs are impacted by these legislative proposals, the potential downstream adverse impacts on us are unknown but may include supply chain disruptions or delays.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have no active plans to operate a manufacturing facility designed to comply with cGMPs, future market pressures or the lack of available capacity at third-party cGMP manufacturing facilities may necessitate our entry into this market, which could result in our incurring additional time and expenses to establish our own cGMP manufacturing capabilities and have an adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our technologies, including for our cell line and expression technologies, generative deep learning technology, proprietary assays and techniques, and antibody and target discovery technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies similar or identical to ours, and our ability to successfully leverage our technologies may be impaired.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict the use of our intellectual property. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products and services, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain adequate protection of the intellectual property we may own solely and jointly with others or otherwise have rights to, particularly patents, in the United States and in other countries with respect to our platform, our software and our technologies, without infringing the intellectual property rights of others. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our Integrated Drug Creation platform and related technologies and uses thereof, as we deem appropriate. Our patents and patent applications in the United States and certain foreign jurisdictions relate to our technology. However, obtaining and enforcing patents in our industry is costly, time-consuming, and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. There can be no assurance that the claims of our patents (or any patent application that is issued to us as a patent), will exclude others from making, using, or selling our technology or technology that is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially similar to ours. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our technology without our permission, and we may not be able to stop them from doing so. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce, and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our technology development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own issued, or granted, patents and have pending patent applications worldwide, which include issued U.S. patents and pending U.S. patent applications. It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. As a result, our owned and licensed patents and patent applications comprising our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar to any of our technology. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that in the future some of our patents, licensed patents and patent applications may be challenged at the USPTO or in proceedings before the patent offices of other jurisdictions. We may not be successful in defending any such challenges made against our patents or patent applications. Any successful third party challenge to our patents could result in loss of exclusivity or freedom to operate, patent claims being narrowed, the unenforceability or invalidity of such patents, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, limit the duration of the patent protection of our technology, and increased competition to our business. We may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example, the European Unified Patent Court (UPC) came into force in June 2023. The UPC is a common patent court to hear patent infringement and revocation proceedings effective for member states of the European Union. Should we file under the UPC and have one or more issued patents through this new system we could be adversely affected. A single forum could enable third parties to seek revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patents have previously been issued. Any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time and may adversely affect the breadth of patents filed thereunder, or our ability to defend any such patent and/or our ability to enforce our European patents or defend the validity thereof. We may decide to opt out our European patents and patent applications from the UPC. If certain formalities and requirements are not met, however, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. Likewise, at this point we cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC, even if we decide to opt out of the UPC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes we make to our technology, including changes that may be required for commercialization or that cause them to have what we view as more advantageous properties may not be covered by our existing patent portfolio, and we may be required to file new applications and/or seek other forms of protection for any such alterations to our technology. There can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to our technology. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technologies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents. We may not develop additional proprietary platforms, methods and technologies that are patentable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or after March 16, 2013, under the Leahy-Smith America Invents Act (America Invents Act) enacted on September 16, 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Because patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our technology or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or any future in-licensed patent applications and the enforcement or defense of our owned or any future in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent position of companies in the biotechnology field is particularly uncertain. Various courts, including the United States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon, or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered natural laws.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In another example, in Amgen Inc. v. Sanofi, or Amgen, the U.S. Supreme Court held that certain of Amgen&#8217;s patent claims defined a class of antibodies by their function of binding to a particular antigen and not by structure and that a skilled artisan would have to use significant trial and error to identify and make all of the molecules in that class. The U.S. Supreme Court ultimately held that Amgen failed to properly enable its patent claims. While we do not believe that any of our patents will be found invalid based on this or other decisions, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. In 2023, the Federal Circuit issued a decision in In re Cellect, LLC involving the interaction of patent term adjustment, or PTA, terminal disclaimers, and obviousness-type double patenting which may affect the patent term of any issued patents that rely on any PTA. In 2022, Congress passed the IRA, which authorizes the Secretary of the Department of Health and Human Services, or HHS, to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain that it will not affect our patent strategy in the long run. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our Integrated Drug Creation platform and other technologies could be found invalid or unenforceable if challenged. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability. Some of our patents or patent applications (including licensed patents) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Any successful third party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to our patents in such a way that they no longer cover our Integrated Drug Creation platform and our technology, which may lead to increased competition to our business, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our platform technologies. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be aware of all third party intellectual property rights potentially relating to our Integrated Drug Creation platform or technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and we or our licensors might not have been the first to file patent applications for these inventions. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications, or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity or prevent a patent from issuing from a pending patent application. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may come to rely on in-licenses from third parties. If we were to lose these rights, our business could be materially adversely affected, our ability to develop improvements to our Integrated Drug Creation platform or technologies could be negatively and substantially impacted, and if disputes arise, we could be subjected to future litigation as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses from third parties to advance our research, development, and commercialization activities. We expect that any future exclusive in-license agreements will impose various development, diligence, commercialization, and other obligations on us. We may enter into engagements in the future with other licensors under which we obtain certain intellectual property rights relating to our Integrated Drug Creation platform and technologies. These engagements may take the form of an exclusive license or of actual ownership of intellectual property rights or technologies from third parties. Our rights to use the technologies we license may be subject to the continuation of and compliance with the terms of those agreements. In some cases, we may not control the prosecution, maintenance or filing of the patents to which we hold licenses, or the enforcement of those patents against third parties. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise with respect to our licensing or other upstream agreements, including: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the scope of rights granted under the agreements and other interpretation-related issues; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the extent to which our technology development processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the sublicensing of patent and other rights under our partnership agreements; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our diligence obligations under the license agreements and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the priority of invention of patented technology. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our efforts to comply with our obligations under any future in-license agreements, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore, including in connection with any aforementioned disputes, terminate the relevant license agreement, thereby removing or limiting our ability to develop and commercialize technology covered by these license agreements. If any such in-license is terminated, or if the licensed patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop technologies similar to ours. In addition, absent the rights granted to us under such license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to our licensor, or we may be required to cease our technology development and commercialization activities which are deemed infringing, and in such event we may ultimately need to modify our activities or technologies to design around such infringement, which may be time- and resource-consuming, and which may not be ultimately successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our rights to future components of our Integrated Drug Creation platform may be licensed to us on a non-exclusive basis. The owners of these non-exclusively licensed technologies would therefore be free to license them to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, certain of our agreements with third parties may provide that intellectual property arising under these agreements, such as data that could be valuable to our business, will be owned by the counterparty, in which case, we may not have adequate rights to use such data or have exclusivity with respect to the use of such data, which could result in third parties, including our competitors, being able to use such data to compete with us. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot acquire or license rights to use technologies on reasonable terms or if we fail to comply with our obligations under such agreements, we may not be able to commercialize new technologies or services in the future and our business could be harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may identify third party intellectual property and technologies we may need to acquire or license in order to engage in our business, including to develop or commercialize new technologies or services, and the growth of our business may depend in part on our ability to acquire, in-license or use these technologies. However, we may not be able to acquire or in-license rights to these technologies on acceptable terms or at all. The licensing or acquisition of third party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater technological development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if such licenses are available, we may be required to pay the licensor in return for the use of such licensor&#8217;s technology, upfront or technology access fees, payments based on certain development, regulatory or commercial milestones such as sales volumes, or royalties based royalties received or milestones achieved by our partners. In addition, such licenses may be non-exclusive, which could give our competitors access to the same intellectual property licensed to us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize technologies covered by these license agreements. If these licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Additionally, termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technologies or impede, or delay or prohibit the further development or commercialization of one or more technologies that rely on such agreements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our or our partners&#8217; ability to further commercialize our technologies or products generated using our technologies may be materially harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may not have the right to control the prosecution, maintenance, and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our licensors may have relied on third-party consultants or partners or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing technologies and services. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, results of operations and prospects could be materially and adversely affected if we are unable to enter into necessary agreements on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the acquired or licensed patents or other rights are found to be invalid or unenforceable. Moreover, we could encounter delays in advancing ongoing or initiating new technology development programs while we attempt to develop alternatives. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from developing technologies or advancing partnerships, which could harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on our Integrated Drug Creation platform, technologies, software, systems, and processes in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and even where such protection is nominally available, judicial, and governmental enforcement of such intellectual property rights may be lacking. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. Further, we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in some or all countries outside the United States, or from selling or importing products made using our inventions in and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own platform or technologies and may also sell their products or services to territories where we have patent protection, but enforcement is not as strong as that in the United States. These platforms and technologies may compete with ours. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may result in patent protection that does not adequately cover our technologies in those countries. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, or that are initiated against us, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">others may be able to make products that are similar to any product candidates generated by our Integrated Drug Creation platform that our partners may develop but that are not covered by the claims of the patents that we own or may license or own in the future; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we, or our current or future partners, might not have been the first to make the inventions covered by the issued patents and pending patent applications that we own or may license or own in the future; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we, or our current or future partners, might not have been the first to file patent applications covering certain of our or their inventions; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or any future licensed intellectual property rights; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we cannot ensure that any patents issued to us, or our licensors will provide a basis for an exclusive market for our commercially viable technologies or will provide us with any competitive advantages; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we cannot ensure that our commercial activities or technologies will not infringe upon the patents of others; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we cannot ensure that we or our partners or future licensees will be able to further commercialize our technologies on a substantial scale, if approved, before the relevant patents that we own or may license expire; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our technology; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we may not develop additional proprietary technologies that are patentable; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the patents or intellectual property rights of others may harm our business; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technologies could be materially adversely affected, and our business could be harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on trade secrets and confidentiality agreements to protect our unpatented know-how, technologies, and other proprietary information, including parts of our Integrated Drug Creation platform, and to maintain our competitive position. However, trade secrets and know-how can be difficult to protect. In addition to pursuing patents on our technologies, we take steps to protect our intellectual property and proprietary technologies by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate and/or strategic partners, potential or existing investors and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market. If we are required to assert our rights against such party, it could result in significant cost and distraction. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, some courts both within and outside the United States may be less willing, or unwilling, to protect trade secrets. Further, we may need to share our trade secrets and confidential know-how with current or future business partners, collaborators, contractors, and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could harm our business, financial condition, results of operations and prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employed and expect to employ individuals who were previously employed at universities or other companies. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, advisors, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential technologies and solutions, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic, lapsed, or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such rights, we may not be able to use these trademarks to develop brand recognition of our technologies or platform. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Further, we have and may in the future enter into agreements with owners of such third party trade names or trademarks to avoid potential trademark litigation which may limit our ability to use our trade names or trademarks in certain fields of business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have registered some of our trademarks with the USPTO and certain other jurisdictions, we have not yet registered certain of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business. If we apply to register these trademarks in other countries, and/or other trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all; and further, our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may in the future be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third party rights, we may not be able to use these trademarks to market our technologies in those countries. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, which could harm our business, financial condition, results of operations and prospects. And, over the long-term, if we are unable to establish name recognition based on our trademarks, then our business development abilities may be materially adversely impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pursue litigation, quasi-litigation, quasi-arbitral, or adversarial proceedings before trademark offices, courts, or other administrative tribunals or courts in order to enforce our trademark rights or to determine the scope, coverage and validity of our rights. The outcome of any such action might not be favorable to us, and even if we were to prevail, such litigation or administrative ruling could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or any future licensors may be subject to claims that former employees, partners or other third parties have an interest in our patents or any future in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Litigation may be necessary to defend against these and other claims challenging inventorship of our or such licensors&#8217; ownership of our owned or any future in-licensed patents, trade secrets or other intellectual property. If we or our future licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our systems. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our development and commercialization efforts of our technologies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the life sciences, clinical diagnostics and drug discovery industries, including patent infringement lawsuits, declaratory judgment litigation and adversarial proceedings before the USPTO, including interferences, derivation proceedings, ex parte reexaminations, post-grant review and inter partes review, as well as corresponding proceedings in foreign courts and foreign patent offices.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, become involved with litigation or actions at the USPTO or foreign patent offices with various third parties. We expect that the number of such claims may increase as our business, visibility and partnership base expand and the number of our technology development programs and resultant licensed technologies increases, and as the level of competition in our industry increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of our business, requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs, and expenses) or royalty payments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage, and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results, or financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we move into new markets and expand our technology offerings, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. Given that biologic drug discovery and cell line development platform technology fields are highly competitive areas, there may be third-party intellectual property rights that others believe could relate to our technologies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future products, technologies and services may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringe. We cannot be certain that we have identified or addressed all potentially significant third-party patents in advance of an infringement claim being made against us. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell, or importing our technologies infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs, and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our technologies could materially affect our business and our ability to gain market acceptance for our technologies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our agreements with some of our partners, suppliers, or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on issued United States and most foreign patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications in order to maintain such patents and patent applications. We have systems in place to remind us to pay these fees, and we engage an outside service to pay such fees due to patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, if we or any future licensors fail to maintain the patents and patent applications covering technologies our competitors may be able to enter the market with similar or identical products or technology without infringing our patents and this circumstance would have a material adverse effect on our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position with our technology for an adequate amount of time. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our platform or technologies are obtained, once the patent life has expired, we may be open to competition from others. If our platform or technologies require extended development and/or regulatory review, patents protecting our platform or technologies might expire before or shortly after we are able to successfully commercialize them. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing processes or technologies similar or identical to ours. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our jointly owned intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights and our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants&#8221; if it determines that (1) adequate steps have not been taken to commercialize the invention and achieve practical application of the government-funded technology, (2) government action is necessary to meet public health or safety needs, (3) government action is necessary to meet requirements for public use under federal regulations or (4) we fail to meet requirements of federal regulations. If the patent owner refuses to do so, the government may grant the license itself. Some of our jointly owned or licensed patents are subject to the provisions of the Bayh-Dole Act. If our licensors fail to comply with the regulations of the Bayh-Dole Act, they could lose title to any patents subject to such regulations, which could affect our license rights under the patents and our ability to stop others from using or commercializing similar or identical technology and products, or limit patent protection for our technology and products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our share price may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is volatile and subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">adverse results or delays in our preclinical studies or clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">any delay in filing an IND (or foreign equivalent) or BLA (or foreign equivalent) for our product candidates and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that IND or BLA;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our failure to successfully develop and commercialize, or otherwise generate revenues from partnered and/or internally developed programs;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our inability to obtain sufficient funding to advance our internally developed programs and invest in our Integrated Drug Creation platform;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in our quarterly and annual results; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the termination of partnership agreements by our partners or announcements that our partners will cease developing a product candidate from our Integrated Drug Creation platform;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the introduction of new technologies or enhancements to existing technology by us or others in our industry; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our inability to establish additional partnerships or expand the scope of existing partnerships; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the recruitment or departures of key personnel; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">changes in the regulatory landscape that subject us to additional regulatory and legal requirements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">publication of research reports about us, our industry or our competitors, or biologic drug discovery in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">release of unfavorable publicity about us, our partners, our competitors, or the biopharmaceutical industry, including through press coverage or social media; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">changes in the market valuations of similar companies; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">overall performance of the equity markets; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">sales of our common stock by us or our stockholders in the future; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">trading volume of our common stock; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">significant lawsuits, including patent or stockholder litigation; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the impact of public health crises, including the COVID-19 pandemic, on our business; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">general political and economic conditions; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">other events or factors, many of which are beyond our control. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the Nasdaq Global Select Market and technology and life sciences companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated and/or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We in the past have had, and in the future may have, a material weakness in our internal control over our financial reporting process. If we are unable to remediate an identified material weakness, we may not be able to accurately or timely report our financial condition or results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we and our independent registered public accounting firm identified control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. Although we were able to remediate this past material weakness, there is no guarantee that we will not identify material weaknesses or significant deficiencies in our internal control over financial reporting in the future or that we will be able to remediate any such material weakness or significant deficiency in a timely manner or at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we identify future material weaknesses or significant deficiencies in our internal control over financial reporting, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate any </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such material weakness, our reputation, results of operations and financial condition could suffer and our stock price may decline.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are obligated to develop and maintain proper and effective internal control over financial reporting. These internal controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required, pursuant to Section 404 of the Sarbanes&#8211;Oxley Act, to furnish a report by management on the effectiveness of our internal control over financial reporting on an annual basis. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Any failure to remediate new significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we identify one or more material weaknesses in the future, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements, which may harm the market price of our common stock, and we may be subject to investigation or sanctions by the SEC. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically identified, and may continue to identify, key business metrics to evaluate our business and technology, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions, and any such metrics may not accurately reflect all aspects of our business needed to make such evaluations and decisions, in particular as our business continues to grow.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our financial results, we have historically reviewed a number of operating and financial metrics, including number of programs under contract, the trend of potential downstream revenue terms (milestone payments and royalties) of the portfolio, the performance of the portfolio in probability of success in achieving clinical milestones as compared to historical averages and the performance of the portfolio in the time taken to achieve clinical milestones on a Net Present Value (NPV) basis, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. To date, we have only entered into a limited number of programs with respect to which we have or are positioned to negotiate royalty- and milestone-bearing licenses. Accordingly, we do not presently have sufficient information to make accurate predictions regarding our potential revenue and future financial performance.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any metrics that we may identify may not accurately reflect all aspects of our business and we anticipate that these metrics may change or may be substituted for additional or different metrics as our business grows and as we introduce new solutions. For example, we have historically applied the number of Active Programs to assess the adoption of our platform technology and our ability to generate future revenues; however, as our business strategy has evolved to have a greater focus on internally developed programs , we currently do not intend to continue using Active Programs as a key business metric. We continue to evaluate our key business metrics in light of our current strategy and determine how to accurately measure the initiation, advancement, and overall progress of our internally developed programs. We cannot guarantee that the business metrics we choose to disclose related to our internally developed programs will be effective in measuring the potential of our pipeline or accurately predict the future development progress of any of our current or future programs. If we fail to review other relevant information or change or substitute the key business metrics we review as our business grows, our ability to accurately formulate financial projections and make strategic decisions may be compromised and our business, financial results and future growth prospects may be adversely impacted. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations, including for expanded drug creation and technology development activities. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dilution to our existing stockholders, and new investors could gain rights, preferences, and privileges senior to the holders of our common stock. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our 2021 Stock Option and Incentive Plan (2021 Plan) we are authorized to grant stock options, restricted stock units, stock appreciation rights and other stock-based awards to our employees, directors and consultants. Pursuant to our 2021 Employee Stock Purchase Plan (2021 ESPP), we may sell shares of our common stock to eligible employees at a discount to the market price of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025 the aggregate number of shares of our common stock that may be issued pursuant to our 2021 Plan, 2021 ESPP, and 2023 Inducement Plan are 5,483,484 shares, 3,132,960 shares, and 1,724,200 shares, respectively. The number of shares of common stock that may be issued pursuant to the 2021 Plan does not include outstanding equity awards. The number of shares of common stock reserved for issuance under the 2021 Plan and 2021 ESPP are automatically increased on each January 1 by&#160;5% and 1%, respectively, of the total number of shares of common stock outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future issuance each year, our stockholders will experience additional dilution, which could cause our share price to fall.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have filed a universal shelf registration statement on Form S-3 (which allows us to offer and sell securities from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale) subject to an aggregate offering amount stated therein, as well as registration statements on Form S-8 registering all shares of common stock that we may issue under our equity compensation and equity inducement plans or pursuant to equity awards made to newly hired employees outside of equity compensation plans. Such registered shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our common stock. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation, expansion and continued investment into our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their common stock, which may never occur.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our shares and will be able to exert significant influence over matters subject to stockholder approval. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;31, 2025, our executive officers, directors, and 5% stockholders beneficially owned over 39% of our common stock. Therefore, these stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock in the public market could cause our share price to fall.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, including any time following the expiration of legal restrictions on resale or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. In August 2025, we filed a registration statement on Form S-3 with respect to potential future sales of our securities, which was declared effective in August 2025. We have also filed registration statements on Form S-8 to register our common stock issuable pursuant to our equity incentive plans. Shares registered under the registration statements on Form S-8 will be available for sale in the public market subject to vesting arrangements and exercise of options. Additionally, certain holders of our common stock are entitled to rights with respect to registration of such shares under the Securities Act pursuant to a registration rights agreement between such holders and us. If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in August 2025, we entered into the Sales Agreement with TD</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Securities (USA) LLC (the Sales Agent) with respect to an &#8220;at the market offering&#8221; program under which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $100.0&#160;million through the Sales Agent. </span><span style="background-color:#ffffff;color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay the Sales Agent a commission up to 3.0% of the gross sales proceeds of any shares sold under the Sales Agreement. Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not continue to be maintained.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock began trading on the Nasdaq Global Select Market in July 2021, and we can provide no assurance that we will be able to continue maintaining an active trading market on the Nasdaq Global Select Market or any other exchange in the future. If an active trading market for our common stock is not maintained, or if we fail to satisfy the continued listing standards of the Nasdaq Global Select Market for any reason and our common stock is delisted, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. An inactive market may also impair our ability to raise additional capital by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation (the &#8220;Restated Certificate&#8221;) and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions include that:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our board of directors has the right to expand the size of our board of directors and to elect directors to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our stockholders may not act by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a special meeting of stockholders may be called only by the chairperson of the board of directors, the chief executive officer, or a majority of the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our amended and restated certificate of incorporation prohibits cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our board of directors may alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the required approval of the holders of at least 75% of the voting power of all of the then outstanding shares of voting stock to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">stockholders must provide advance notice and additional disclosures in order to nominate individuals for election to the board of directors or to propose matters that can be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">stockholders must include management&#8217;s nominees on its proxy card in contested director elections, which may decrease the likelihood that a potential acquiror can replace a majority of the Board; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">our board of directors is authorized to issue shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders and that the federal district courts of the United States will be the exclusive forum for certain actions under federal securities laws, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders; provided that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated bylaws also provide that the federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. The choice of forum provisions do not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find these types of provisions to be inapplicable or unenforceable, and if a court were to find the exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could materially adversely affect our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses and certain other tax attributes may be limited.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a cumulative change of more than 50 percentage points (by value) in its equity ownership by certain stockholders over a rolling three-year period, the corporation&#8217;s ability to use its pre-change net operating loss (NOL) carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income or taxes may be limited. We have experienced at </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">least one ownership change in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law may adversely affect us or our investors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. For example, on July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to expensing of domestic research and development expenses, increasing the limit of the deduction of interest expense deduction to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. We are currently evaluating the impact the new tax law will have on our financial condition and results of operations. Preliminarily, we do not anticipate a material change to our effective income tax rate and our net deferred federal income tax assets as we maintain a full valuation allowance. In recent years, many such changes have been made, and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our shareholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General Risk Factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If an insufficient number of securities or industry analysts commence and continue coverage of our company, the trading price for our common stock would likely be negatively impacted. After securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrades our common stock or publishes inaccurate or unfavorable research about our business, our share price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our share price and trading volume to decline. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our technologies and our ability to raise additional capital when needed on favorable terms, if at all. Recently, the rate of inflation has increased throughout the U.S. economy. Inflation may adversely affect us by increasing the costs associated with performing research and development on internal research initiatives and partnered programs. We may experience significant increases in the prices of labor, consumables, and other costs of doing business. In an inflationary environment, such cost increases may outpace our expectations, causing us to use cash faster than forecasted. A weak or declining economy may also strain our partners, possibly resulting in supply disruption, or cause delays in their payments to us. In addition, the U.S. has recently imposed blanket tariffs of at least 10% on virtually all imports to the U.S. and significantly higher tariffs applicable to imports from many countries, which have resulted in other countries imposing additional tariffs on imports from the U.S. The Trump administration has threatened to impose additional significant tariffs on pharmaceutical products, which could lead to corresponding punitive actions by the countries with which the U.S. trades. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Although a statement by the U.S. Department of the Treasury, the Federal Reserve and the FDIC indicated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder. Although we are not a borrower or party to any such instruments with SVB or any other financial institution currently in receivership, if any of our customers, suppliers or other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our partners or vendors, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a partner may fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy, or a vendor may determine that it will no longer deal with us as a customer. In addition, a partner or vendor could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on us, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any partner or vendor bankruptcy or insolvency, or the failure of any partner to make payments when due, or any breach or default by a partner or vendor, or the loss of any significant vendor relationships, could result in material losses to us and may have a material adverse impact on our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Any incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or grant licenses on terms unfavorable to us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the ATM, the number of shares that are sold by the Sales Agent, if any, after we request that sales be made will fluctuate based on the market price of our common stock during the sales period and limits we set with Sales Agent. Therefore, it is not possible to predict the number of shares that will be ultimately issued and sold by us pursuant to the Sales Agreement, but any additional sales will cause immediate dilution to our then existing stockholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, and insider trading. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, consultants, advisors, and partners. Misconduct by these parties could include intentional failures to comply with the applicable laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, discounting and other business arrangements. Such misconduct could result in legal or regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and any other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter and our policies have limits and significant deductibles. Some of the policies we currently maintain include general liability, property, umbrella and directors&#8217; and officers&#8217; insurance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. A successful liability claim or series of claims in which judgments exceed our insurance coverage could adversely affect our business, financial condition, results of operations and prospects, including preventing or limiting the use of our platform to generate products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating as a public company makes it difficult and more expensive for us to maintain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage than as a private company. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity incidents, data breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we generate and store confidential and sensitive data, including research data, intellectual property and proprietary business information owned or controlled by ourselves or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our employees, partners and other third parties upon which we rely. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, accidental exposure, unauthorized access, inappropriate modification, wrongful conduct by employees or vendors, remediation costs, lost revenues, damages to our competitiveness, stock price and long-term stockholder value, and the risk of our being unable to adequately monitor and audit and modify our controls over our critical information. This risk extends to the third party vendors, subcontractors and partners we use to manage this sensitive data or otherwise process it on our behalf. Further, to the extent our employees may work remotely, additional risks may arise as a result of depending on the networking and security put into place by the employees and where they choose to work, including at home, while in transit or in other public locations. The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in our industry, we, and our third-party vendors, have experienced threats and cybersecurity incidents relating to our information technology systems and infrastructure. Although we seek to take reasonable measures to protect confidential and sensitive data from unauthorized access, use or disclosure, no security measures can be perfect and our information technology systems and infrastructure, and those of our vendors, subcontractors, and partners upon which we rely, are vulnerable to cyberattacks, computer viruses, bugs, worms, or other malicious codes, malware (including as a result of advanced persistent threat intrusions), and other attacks by computer hackers, cracking, application security attacks, ransomware, extortion events, social engineering fraud (including through phishing attacks), supply chain attacks and vulnerabilities through our third-party service providers, denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, and other similar threats by hackers or breaches or compromises caused by erroneous actions or inactions by our employees, consultants, third parties or their contracted service providers, malfeasance or other malicious or inadvertent disruptions. Any such cybersecurity incident, data breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost, misused, or stolen. Any such access, breach, or other loss of information could require us to notify impacted stakeholders (including affected individuals, regulators and investors) and result in legal claims or proceedings and related legal exposure and liabilities, including fines and penalties. Unauthorized access, loss, misuse, or dissemination could also disrupt our operations and damage our reputation, any of which could adversely affect our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities of cyber threat actors and other third parties, including nation-state actors directly and indirectly associated with military geopolitical conflicts and defense activities have been increasing in number and sophistication. During times of war and other major conflicts, we, the third parties upon which we rely, and our partners may be vulnerable to a heightened risk of such cyber-attacks, including retaliatory cyberattacks, that could materially disrupt our systems and operations, supply chain, and ability to develop our programs. In the event we experience a cyber-attack, data breach, cybersecurity incident, or other security event, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization, which could be used to undermine our competitive advantage or market position.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs related to cybersecurity incidents, data breaches, disruptions or other security events could be significant and cause reputational damage and loss of existing and future business and could cause us to incur substantial fines and related expenses and legal exposure. If the information technology systems of our partners, contractors or consultants become subject to disruptions or cybersecurity incidents or data breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources in connection with our efforts to mitigate the impact of such events, and to develop and implement processes and other remedial measures to address future impacts to our business. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain cybersecurity insurance coverage, we cannot be certain that such coverage will be adequate for data security liabilities actually incurred, will cover any indemnification claims against us </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relating to any incident, will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could adversely affect our reputation, business, financial condition and results of operations. Additionally, our cybersecurity insurance coverage is unlikely to cover indirect or consequential damages, such as reputational harm or loss of current or future business relationships as a result of a security incidents or cyber-attack. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural and man-made disasters, including cyber-attacks and other events beyond our control could severely disrupt our operations, or those of our partners, and have a material adverse impact on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, cybersecurity attack or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our laboratory facilities or those of our partners, limited our or our partners&#8217; ability to access or use our respective digital information systems or that otherwise disrupted our respective operations, it may be difficult or, in certain cases, impossible for us or our partners to continue our respective businesses for a substantial period of time. The disaster recovery and business continuity plans we and our partners currently have in place may not prove adequate in the event of a serious disaster or similar event, which could have a material adverse impact on our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Social media platforms present new risks and challenges to our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As social media continues to expand, it also presents us with new risks and challenges. Social media is increasingly being used to communicate information about us, our technology and our programs. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. In addition, there is risk of inaccurate disclosure of information about us, our technology, or our programs on any social media platform. Although we have adopted policies and procedures around the use of social media by our employees, we may be unable to control the disclosure of non-public information by our workforce. Any of these events or our failure to comply with applicable regulations could expose us to liability, restrictive regulatory actions, irreversible damage to our reputation, brand image and goodwill, or have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an emerging growth company, and the reduced reporting requirements applicable to emerging growth companies could make our common stock less attractive to investors. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved, and an exemption from compliance with the requirement of the PCAOB regarding the communication of critical audit matters in the auditor&#8217;s report on the financial statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are also a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 of the Exchange Act and have elected to take advantage of certain of the scaled back disclosure requirements available to smaller reporting companies such as avoiding the extensive narrative disclosure required of other reporting companies, particularly in the description of executive compensation.  We will remain a smaller reporting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company until (a) the last day of the fiscal year in which we have total annual gross revenue of less than $100 million and the market value of our common stock held by non-affiliates exceeds $700.0 million as of the prior June 30th, or (b) the last day of the fiscal year in which we have total annual gross revenue exceeding $100 million and the market value of our common stock held by non-affiliates exceeds $250.0 million. In August 2025, the SEC released a Compliance and Disclosure Interpretation clarifying the filer status transition for registrants that lose their smaller reporting company status based on the revenue tests. Due to this interpretation, we will remain a non-accelerated filer for filings due in the fiscal year immediately following the loss of smaller reporting company status, allowing us to retain the exception from the auditor attestation requirement on internal control over financial reporting. However, the interpretation specifies that we will lose eligibility for all other smaller reporting company accommodations beginning with the Form 10-Q for the first fiscal quarter of the year after losing smaller reporting company status. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the loss of emerging growth status will not impact our &#8220;non-accelerated filer&#8221; status, which also provides an exemption from the auditor attestation requirement with respect to internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict if investors will find our common stock less attractive because we may rely on the reporting exemptions and the extended transition period for complying with new or revised accounting standards. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have incurred and will continue to incur significant legal, accounting, insurance and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC, and the Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as &#8220;say-on-pay&#8221; and proxy access. The JOBS Act permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We intend to take advantage of the reduced reporting requirements available to emerging growth companies under the JOBS Act, but we cannot guarantee that we will not be required to implement the more stringent requirements sooner than budgeted or planned and thereby incur unexpected expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. In the ordinary course as a public company, the SEC and other U.S. and foreign regulatory and governmental agencies have initiated and may in the future initiate requests, comments and/or investigations regarding legal, regulatory and compliance matters of the Company, which could require us to devote significant time, attention and resources to respond to these, and, if unfavorably resolved, could result in our being subject to sanctions or civil penalties or fines, all of which could have a material adverse impact on our business, results of operation and financial condition. We cooperate with any requests from any regulatory and governmental agencies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These rules and regulations applicable to public companies have increased and will continue to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business, limit our investments in business expansion, or increase the technology development fees and other payment terms we negotiate with partners. For example, these rules and regulations have made it more difficult and more expensive for us to obtain director and officer liability </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting. To achieve compliance with Section 404 annually, we will engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants, execute our detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm the market price of our stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition could be materially adversely affected by changes in accounting principles.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for our business is subject to change based on the evolution of our business model, interpretations of relevant accounting principles, enforcement of existing or new regulations and changes in policies, rules, regulations and interpretations, of accounting and financial reporting requirements of the SEC or other regulatory agencies. Adoption of a change in accounting principles or interpretations could have a significant effect on our reported results of operations and could affect the reporting of transactions completed before the adoption of such change. It is difficult to predict the impact of future changes to accounting principles and accounting policies over financial reporting, any of which could adversely affect our results of operations and financial condition and could require significant investment in systems and personnel.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Estimates.&#8221; The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our consolidated financial statements include the estimated variable consideration included in the transaction price in our contracts with partners, contingent consideration, goodwill impairment, and long-lived asset impairment evaluations. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect on our reputation, business, financial position, and profit. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div id="i9ac3491acf394da29655edd3b9380996_175"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9ac3491acf394da29655edd3b9380996_178"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9ac3491acf394da29655edd3b9380996_181"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9ac3491acf394da29655edd3b9380996_184"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(c) Insider Trading Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September&#160;30, 2025, none of the Company&#8217;s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-624"><ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-625">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-626"><ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-627">terminated</ix:nonNumeric></ix:nonNumeric> a plan or other arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangements under the Exchange Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_187"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000119312525179074/d945863dex12.htm">Sales Agreement, dated August 12, 2025, by and between Absci Corporation and TD Securities (USA) LLC (filed as Exhibit 1.2 to the Form S-3, File No. 333-289541, filed by Absci Corporation on August 12, 2025 and incorporated herein by reference).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000162828021013661/exhibit21-sx1a1.htm">Agreement and Plan of Merger by and among Absci Corporation, Target Discovery Merger Sub I, Inc., Target Discovery Merger Sub II, LLC and Totient, Inc., dated June 4, 2021 (filed as Exhibit 2.1 to the Form S-1, File No. 333-257553, filed by Absci Corporation on July 8, 2021 and incorporated herein by reference).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000162828023022479/a31-23x06x14abscixamendeda.htm">Amended and Restated Certificate of Incorporation of Absci Corporation (filed as Exhibit 3.1 to the Form 8-K, File No. 001-40646, filed by Absci Corporation on June 16, 2023 and incorporated herein by reference).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000162828022032103/exhibit31-8xkbylaws.htm">Amended and Restated Bylaws of the Absci Corporation (filed as Exhibit 3.1 to the Form 8-K, File No. 001-40646, filed by Absci Corporation on December 15, 2022 and incorporated herein by reference).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000162828021014027/exhibit41s-1a3.htm">Specimen Common Stock Certificate (filed as Exhibit 4.1 to the Form S-1, File No. 333-257553, filed by Absci Corporation on July 19, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000162828021013214/exhibit42-sx1.htm">Investors&#8217; Rights Agreement by and among the Registrant and certain of its stockholders dated October 19, 2020 (filed as Exhibit 4.2 to the Form S-1, File No. 333-257553, filed by Absci Corporation on June 30, 2021 and incorporated herein by reference).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000162828025013464/exhibit44-202410xk.htm">Registration Rights Agreement by and between the Registrant and Advanced Micro Devices, Inc., dated as of January 7, 2025 (filed as Exhibit 4.4 to the Form 10-K, File No. 002-40646, filed by Absci Corporation on March 18, 2025)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1672688/000162828025013464/exhibit44-202410xk.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit311-2025q310xq.htm">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit312-2025q310xq.htm">Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit321-2025q310xq.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit322-2025q310xq.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i9ac3491acf394da29655edd3b9380996_301"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:51.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABSCI CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;12, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Zachariah Jonasson</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zachariah Jonasson, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial Officer) and Chief Business Officer</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;12, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Todd Bedrick</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Bedrick</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Accounting Officer (Principal Accounting Officer)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-2025q310xq.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia3acaf4d549d4de9a267c3de86a3696a_1"></div><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Sean McClain, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">I have reviewed this Quarterly Report on Form 10-Q of Absci Corporation&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Sean McClain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Sean McClain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Founder and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:49.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-2025q310xq.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic77bdfb8d41d48998a58e13017baeea4_1"></div><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Zachariah Jonasson, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">I have reviewed this Quarterly Report on Form 10-Q of Absci Corporation&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Zachariah Jonasson</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Zachariah Jonasson</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:49.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-2025q310xq.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5dfc27755e27404e8782279ff0526c2f_1"></div><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Absci Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending September&#160;30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Sean McClain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Sean McClain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Founder and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:49.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322-2025q310xq.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0b3ea0f52f99488294015bc721c97af5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Absci Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending September&#160;30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.857%"><tr><td style="width:1.0%"></td><td style="width:44.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Zachariah Jonasson</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Zachariah Jonasson</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>absi-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a3e69f22-3845-4b88-95f7-36018340f30a,g:dbd2b148-ca4f-47a0-84c9-32244e24e6c1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:absi="http://www.absci.com/20250930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.absci.com/20250930">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="absi-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="absi-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="absi-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="absi-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.absci.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>9952152 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>9952153 - Statement - UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>9952154 - Statement - UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organizationandnatureofoperations" roleURI="http://www.absci.com/role/Organizationandnatureofoperations">
        <link:definition>9952156 - Disclosure - Organization and nature of operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuerecognition" roleURI="http://www.absci.com/role/Revenuerecognition">
        <link:definition>9952157 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborativearrangements" roleURI="http://www.absci.com/role/Collaborativearrangements">
        <link:definition>9952158 - Disclosure - Collaborative arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.absci.com/role/Investments">
        <link:definition>9952159 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://www.absci.com/role/Fairvaluemeasurements">
        <link:definition>9952160 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentsandcontingencies" roleURI="http://www.absci.com/role/Commitmentsandcontingencies">
        <link:definition>9952161 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commonstock" roleURI="http://www.absci.com/role/Commonstock">
        <link:definition>9952162 - Disclosure - Common stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.absci.com/role/Stockbasedcompensation">
        <link:definition>9952163 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netlosspershare" roleURI="http://www.absci.com/role/Netlosspershare">
        <link:definition>9952164 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentreporting" roleURI="http://www.absci.com/role/Segmentreporting">
        <link:definition>9952165 - Disclosure - Segment reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Subsequentevents" roleURI="http://www.absci.com/role/Subsequentevents">
        <link:definition>9952166 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.absci.com/role/InvestmentsTables">
        <link:definition>9955511 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://www.absci.com/role/FairvaluemeasurementsTables">
        <link:definition>9955512 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTables" roleURI="http://www.absci.com/role/StockbasedcompensationTables">
        <link:definition>9955513 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareTables" roleURI="http://www.absci.com/role/NetlosspershareTables">
        <link:definition>9955514 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentreportingTables" roleURI="http://www.absci.com/role/SegmentreportingTables">
        <link:definition>9955515 - Disclosure - Segment reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionDetails" roleURI="http://www.absci.com/role/RevenuerecognitionDetails">
        <link:definition>9955516 - Disclosure - Revenue recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativearrangementsDetails" roleURI="http://www.absci.com/role/CollaborativearrangementsDetails">
        <link:definition>9955517 - Disclosure - Collaborative arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAmortizedandFairValueofourInvestmentsDetails" roleURI="http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails">
        <link:definition>9955518 - Disclosure - Investments - Amortized and Fair Value of our Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativesDetails" roleURI="http://www.absci.com/role/InvestmentsNarrativesDetails">
        <link:definition>9955519 - Disclosure - Investments - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9955520 - Disclosure - Fair value measurements - Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativesDetails" roleURI="http://www.absci.com/role/FairvaluemeasurementsNarrativesDetails">
        <link:definition>9955521 - Disclosure - Fair value measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesDetails" roleURI="http://www.absci.com/role/CommitmentsandcontingenciesDetails">
        <link:definition>9955522 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonstockDetails" roleURI="http://www.absci.com/role/CommonstockDetails">
        <link:definition>9955523 - Disclosure - Common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationNarrativesDetails" roleURI="http://www.absci.com/role/StockbasedcompensationNarrativesDetails">
        <link:definition>9955524 - Disclosure - Stock-based compensation - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails" roleURI="http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails">
        <link:definition>9955525 - Disclosure - Stock-based compensation - Allocated Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockOptionRollforwardDetails" roleURI="http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails">
        <link:definition>9955526 - Disclosure - Stock-based compensation - Stock Option Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationDeterminationofFairValueDetails" roleURI="http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails">
        <link:definition>9955527 - Disclosure - Stock-based compensation - Determination of Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationRestrictedStockDetails" roleURI="http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails">
        <link:definition>9955528 - Disclosure - Stock-based compensation - Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareAntidilutiveSecuritiesDetails" roleURI="http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails">
        <link:definition>9955529 - Disclosure - Net loss per share - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentreportingNarrativeDetails" roleURI="http://www.absci.com/role/SegmentreportingNarrativeDetails">
        <link:definition>9955530 - Disclosure - Segment reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentreportingSegmentExpensesDetails" roleURI="http://www.absci.com/role/SegmentreportingSegmentExpensesDetails">
        <link:definition>9955531 - Disclosure - Segment reporting - Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequenteventsDetails" roleURI="http://www.absci.com/role/SubsequenteventsDetails">
        <link:definition>9955532 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" abstract="false" name="IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="absi_TechnologyDevelopmentRevenueMember" abstract="true" name="TechnologyDevelopmentRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_NumberOfPartners" abstract="false" name="NumberOfPartners" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="absi_ProceedsFromCollaborativeArrangement" abstract="false" name="ProceedsFromCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="absi_ContingentConsiderationFairValue" abstract="false" name="ContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="absi_CowenAndCompanyLLCMember" abstract="true" name="CowenAndCompanyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_AdvancedMicroDevicesIncMember" abstract="true" name="AdvancedMicroDevicesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_TDSecuritiesUSALLCMember" abstract="true" name="TDSecuritiesUSALLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_ShelfRegistrationMember" abstract="true" name="ShelfRegistrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_AtTheMarketOfferingProgramMember" abstract="true" name="AtTheMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" abstract="false" name="SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="absi_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="absi_SaleOfStockSalesAgentCommissionPercentage" abstract="false" name="SaleOfStockSalesAgentCommissionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="absi_AmortizationOfEquityIssuanceDiscountPremium" abstract="false" name="AmortizationOfEquityIssuanceDiscountPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="absi_A2021StockOptionAndGrantPlanMember" abstract="true" name="A2021StockOptionAndGrantPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_A2023InducementPlanMember" abstract="true" name="A2023InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_A2020StockOptionAndGrantPlanMember" abstract="true" name="A2020StockOptionAndGrantPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_DrugCreationAndPlatformMember" abstract="true" name="DrugCreationAndPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_ExternalPreClinicalAndClinicalDevelopmentMember" abstract="true" name="ExternalPreClinicalAndClinicalDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="absi_SegmentOneMember" abstract="true" name="SegmentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>absi-20250930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a3e69f22-3845-4b88-95f7-36018340f30a,g:dbd2b148-ca4f-47a0-84c9-32244e24e6c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63371e25-980a-46c4-a33e-bf1aa38ec08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49aa8dc9-9620-4730-a854-7320655140bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63371e25-980a-46c4-a33e-bf1aa38ec08e" xlink:to="loc_us-gaap_StockholdersEquity_49aa8dc9-9620-4730-a854-7320655140bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_47e2ead2-f6fa-42ac-8227-75aa112484b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63371e25-980a-46c4-a33e-bf1aa38ec08e" xlink:to="loc_us-gaap_Liabilities_47e2ead2-f6fa-42ac-8227-75aa112484b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8f131337-d68c-4f25-bd81-1f7c6f4a1203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_47b73b26-6619-4bc1-a8fb-84e7fb4e28c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8f131337-d68c-4f25-bd81-1f7c6f4a1203" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_47b73b26-6619-4bc1-a8fb-84e7fb4e28c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_959523d6-d2e1-4693-9291-33f741dc9d03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8f131337-d68c-4f25-bd81-1f7c6f4a1203" xlink:to="loc_us-gaap_RestrictedCash_959523d6-d2e1-4693-9291-33f741dc9d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9efc7f3-b9f9-4f27-b875-b5401632aafe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8f131337-d68c-4f25-bd81-1f7c6f4a1203" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9efc7f3-b9f9-4f27-b875-b5401632aafe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf58e8a3-f4fd-497e-aa67-a4fb343d46e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8f131337-d68c-4f25-bd81-1f7c6f4a1203" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf58e8a3-f4fd-497e-aa67-a4fb343d46e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7afec906-7161-4094-8fce-3f48afa51265" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8f131337-d68c-4f25-bd81-1f7c6f4a1203" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7afec906-7161-4094-8fce-3f48afa51265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_13ce8915-434e-41c0-a872-3bd7c2296e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_13ce8915-434e-41c0-a872-3bd7c2296e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6a0bd35a-7e31-4e72-9bb9-a1261f9a7393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6a0bd35a-7e31-4e72-9bb9-a1261f9a7393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_917a7a3a-c413-461d-a2c8-c3c675645d91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_917a7a3a-c413-461d-a2c8-c3c675645d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_de2b9529-2c00-49a8-b9b0-39004ae8c7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_de2b9529-2c00-49a8-b9b0-39004ae8c7b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_41a5deff-aabe-4eb9-af27-6675742a61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:to="loc_us-gaap_NotesPayableCurrent_41a5deff-aabe-4eb9-af27-6675742a61b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_828bbb96-d36b-4b36-9d27-281d4b0925e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_828bbb96-d36b-4b36-9d27-281d4b0925e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5e909eb5-d4d1-4d2f-be5b-facf96f1982e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0587ef6-293b-417e-bb24-209d5a4ca9b4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5e909eb5-d4d1-4d2f-be5b-facf96f1982e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_45702bef-a49f-450c-ae7c-e72130852c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_88755bbe-25bc-4199-873e-4e9302602ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_45702bef-a49f-450c-ae7c-e72130852c0f" xlink:to="loc_us-gaap_LongTermNotesPayable_88755bbe-25bc-4199-873e-4e9302602ed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_216d24b4-839c-4c99-b9c9-bcb138657f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_45702bef-a49f-450c-ae7c-e72130852c0f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_216d24b4-839c-4c99-b9c9-bcb138657f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4cc55c46-7d25-4a50-8cd1-ff2489550091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_45702bef-a49f-450c-ae7c-e72130852c0f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4cc55c46-7d25-4a50-8cd1-ff2489550091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4cf32d54-2375-41ca-91d6-f75c1ac9de77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_45702bef-a49f-450c-ae7c-e72130852c0f" xlink:to="loc_us-gaap_LiabilitiesCurrent_4cf32d54-2375-41ca-91d6-f75c1ac9de77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1f8c0107-b33b-4dbb-9a05-9e0156d6bfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_43683e14-72ea-4e90-ac19-3ec5d963287d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f8c0107-b33b-4dbb-9a05-9e0156d6bfc7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_43683e14-72ea-4e90-ac19-3ec5d963287d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19432e20-b8fa-4f07-b7a2-5daa4763f93b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f8c0107-b33b-4dbb-9a05-9e0156d6bfc7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19432e20-b8fa-4f07-b7a2-5daa4763f93b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_19b3639a-d175-4e70-8c82-776cc7b5b0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f8c0107-b33b-4dbb-9a05-9e0156d6bfc7" xlink:to="loc_us-gaap_CommonStockValue_19b3639a-d175-4e70-8c82-776cc7b5b0f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08ead5df-8b91-4853-ad49-33b8f0d278fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f8c0107-b33b-4dbb-9a05-9e0156d6bfc7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08ead5df-8b91-4853-ad49-33b8f0d278fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2fb4f485-e1a9-4c71-b1df-20db12bab77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1f8c0107-b33b-4dbb-9a05-9e0156d6bfc7" xlink:to="loc_us-gaap_PreferredStockValue_2fb4f485-e1a9-4c71-b1df-20db12bab77d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_43480c60-c446-4707-9643-09f4404224a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a1ac6ba9-2ac5-41a9-996d-c294460409d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43480c60-c446-4707-9643-09f4404224a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a1ac6ba9-2ac5-41a9-996d-c294460409d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_60978edb-4717-4b58-8850-ee43276db42c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43480c60-c446-4707-9643-09f4404224a7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_60978edb-4717-4b58-8850-ee43276db42c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6096bb78-c621-4e3f-a63b-bee58633e8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43480c60-c446-4707-9643-09f4404224a7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6096bb78-c621-4e3f-a63b-bee58633e8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f68453e8-389f-41c7-af41-398949c77849" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43480c60-c446-4707-9643-09f4404224a7" xlink:to="loc_us-gaap_AssetsCurrent_f68453e8-389f-41c7-af41-398949c77849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_da686516-5ee8-4266-bb2d-e83f2aa72de5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43480c60-c446-4707-9643-09f4404224a7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_da686516-5ee8-4266-bb2d-e83f2aa72de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0e2a1963-cb48-4367-8971-921669b28180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43480c60-c446-4707-9643-09f4404224a7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0e2a1963-cb48-4367-8971-921669b28180" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05cc2af3-e628-4f82-9a44-cbf1bf3e0be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d9ba05a-aea1-4544-8df6-c35565e501ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_05cc2af3-e628-4f82-9a44-cbf1bf3e0be7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d9ba05a-aea1-4544-8df6-c35565e501ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cfabac08-569c-4768-9a90-501c7f71abce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_05cc2af3-e628-4f82-9a44-cbf1bf3e0be7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cfabac08-569c-4768-9a90-501c7f71abce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ed88488-840e-4fff-896b-190f632b67e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_892f6a94-006b-4274-93cb-022a18464b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ed88488-840e-4fff-896b-190f632b67e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_892f6a94-006b-4274-93cb-022a18464b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_805a9211-832d-4ca8-ac0e-e6bf893c53b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ed88488-840e-4fff-896b-190f632b67e5" xlink:to="loc_us-gaap_NetIncomeLoss_805a9211-832d-4ca8-ac0e-e6bf893c53b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5796a562-f2c0-40c1-aed3-dafd3db9d652" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ed88488-840e-4fff-896b-190f632b67e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5796a562-f2c0-40c1-aed3-dafd3db9d652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a7849fc9-4074-442b-815a-4cb73f3f9680" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2b4dc566-7454-4d16-8d15-e0cc45529081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a7849fc9-4074-442b-815a-4cb73f3f9680" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2b4dc566-7454-4d16-8d15-e0cc45529081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_28fbecf8-4387-46cf-9ead-a1c9af576a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a7849fc9-4074-442b-815a-4cb73f3f9680" xlink:to="loc_us-gaap_InterestExpenseNonoperating_28fbecf8-4387-46cf-9ead-a1c9af576a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cd72458a-7e74-4a3f-a0de-c584436d01cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fe7ec34b-10af-4823-a1b1-a8d2fdaabd08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd72458a-7e74-4a3f-a0de-c584436d01cd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fe7ec34b-10af-4823-a1b1-a8d2fdaabd08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e583529d-31b3-4700-b5f5-aff93eaa7838" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd72458a-7e74-4a3f-a0de-c584436d01cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e583529d-31b3-4700-b5f5-aff93eaa7838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a0ddae15-a813-4fb4-a693-1f1827725d35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd72458a-7e74-4a3f-a0de-c584436d01cd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a0ddae15-a813-4fb4-a693-1f1827725d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ac18499-d3fe-4a87-bd05-e9e8b231eeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2fa9d7da-e864-4e66-8d8a-a2e7d62c2fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ac18499-d3fe-4a87-bd05-e9e8b231eeb8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2fa9d7da-e864-4e66-8d8a-a2e7d62c2fcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b4180963-5ca3-411b-9731-6260f7577072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ac18499-d3fe-4a87-bd05-e9e8b231eeb8" xlink:to="loc_us-gaap_OperatingIncomeLoss_b4180963-5ca3-411b-9731-6260f7577072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d50fb416-3619-4d11-b0b4-f4f2c99884f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_98396601-543f-4bba-a974-4d85b3bd10ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d50fb416-3619-4d11-b0b4-f4f2c99884f9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_98396601-543f-4bba-a974-4d85b3bd10ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e3ea8e06-37e0-4747-b095-e3d110ef2152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d50fb416-3619-4d11-b0b4-f4f2c99884f9" xlink:to="loc_us-gaap_OperatingExpenses_e3ea8e06-37e0-4747-b095-e3d110ef2152" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93747e4a-4915-4a47-a734-8451e5ac3e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c2910644-7a51-470a-99bf-58b09ee95ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93747e4a-4915-4a47-a734-8451e5ac3e8c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c2910644-7a51-470a-99bf-58b09ee95ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c94adbf6-7a0d-4a11-b641-9b2657d3f532" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93747e4a-4915-4a47-a734-8451e5ac3e8c" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c94adbf6-7a0d-4a11-b641-9b2657d3f532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_d02c8801-8dc3-4c58-843b-ab79b18ebc43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93747e4a-4915-4a47-a734-8451e5ac3e8c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_d02c8801-8dc3-4c58-843b-ab79b18ebc43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_66d807d5-6da6-4c12-a767-c3d98b82f850" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93747e4a-4915-4a47-a734-8451e5ac3e8c" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_66d807d5-6da6-4c12-a767-c3d98b82f850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities_7519536e-ed8c-49a4-b7d5-86acf27a621e" xlink:href="absi-20250930.xsd#absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities_7519536e-ed8c-49a4-b7d5-86acf27a621e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8453130b-9319-4587-8024-c519c81c6c18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8453130b-9319-4587-8024-c519c81c6c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fea955d9-82ac-4f10-b0c4-0d0ccfdbb26c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fea955d9-82ac-4f10-b0c4-0d0ccfdbb26c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aa125103-9748-4431-9c12-c86e08e775c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_NetIncomeLoss_aa125103-9748-4431-9c12-c86e08e775c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e9c3e90d-05d1-4845-b997-ff23d5f21d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_ShareBasedCompensation_e9c3e90d-05d1-4845-b997-ff23d5f21d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6999f800-3250-4cd8-ae70-35e7b5b85490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6999f800-3250-4cd8-ae70-35e7b5b85490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ffdd6741-c695-4edb-a91b-0944ecb0ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ffdd6741-c695-4edb-a91b-0944ecb0ebd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_f51b9ccb-776e-4482-9146-e2cb0d2826af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_f51b9ccb-776e-4482-9146-e2cb0d2826af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc85fc13-b9aa-49b2-893e-5d2da5638dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc85fc13-b9aa-49b2-893e-5d2da5638dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_95836c76-079e-43d5-b457-981a838b9fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_95836c76-079e-43d5-b457-981a838b9fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_da4d6926-ec87-44d7-831a-06e2d2db057d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_da4d6926-ec87-44d7-831a-06e2d2db057d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_610386ba-54f9-47c0-95c2-3d4d810694fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_effd07f1-ae9d-457d-90c5-88f30fcffca3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_610386ba-54f9-47c0-95c2-3d4d810694fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_465f53e1-2793-49d7-84e5-99471d852295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ea27ac7e-2e0f-4456-be19-141cd3abf07f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_465f53e1-2793-49d7-84e5-99471d852295" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ea27ac7e-2e0f-4456-be19-141cd3abf07f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_44d555ff-e2eb-4070-a4e6-48c3ef026026" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_465f53e1-2793-49d7-84e5-99471d852295" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_44d555ff-e2eb-4070-a4e6-48c3ef026026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c89de93a-fa8e-44eb-a656-ab4fe30275ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_465f53e1-2793-49d7-84e5-99471d852295" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c89de93a-fa8e-44eb-a656-ab4fe30275ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a3122e45-81d5-4b05-aad4-368494f84ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_465f53e1-2793-49d7-84e5-99471d852295" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a3122e45-81d5-4b05-aad4-368494f84ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f374b41f-c098-4fa3-9fb2-f9e23e6594c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0317d7e9-a7dd-421a-8f0a-804d07ab50f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f374b41f-c098-4fa3-9fb2-f9e23e6594c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0317d7e9-a7dd-421a-8f0a-804d07ab50f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35cc1434-0f8f-4145-991f-2f101667cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f374b41f-c098-4fa3-9fb2-f9e23e6594c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35cc1434-0f8f-4145-991f-2f101667cc18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5d6712-8c42-4fde-b26e-aebf9ce64240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f374b41f-c098-4fa3-9fb2-f9e23e6594c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5d6712-8c42-4fde-b26e-aebf9ce64240" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#InvestmentsAmortizedandFairValueofourInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b4eae310-4dfc-43ec-afdb-ad14ab110d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c93b3b4-b248-4479-95e6-34fa0f7e8483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b4eae310-4dfc-43ec-afdb-ad14ab110d4f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c93b3b4-b248-4479-95e6-34fa0f7e8483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a1962e92-7f2d-4143-b25e-c8ad6e01e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b4eae310-4dfc-43ec-afdb-ad14ab110d4f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a1962e92-7f2d-4143-b25e-c8ad6e01e67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ca4e46cb-c6f9-493e-ad1c-aee21931bc98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b4eae310-4dfc-43ec-afdb-ad14ab110d4f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ca4e46cb-c6f9-493e-ad1c-aee21931bc98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_93681602-35aa-40de-bd29-45092d143e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_d9ae0627-c782-4fb2-98ff-d1698f3208d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_93681602-35aa-40de-bd29-45092d143e40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_d9ae0627-c782-4fb2-98ff-d1698f3208d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_e289b528-a036-4a69-aa7d-fb7796068ead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ContingentConsiderationFairValue_b822a787-9841-4550-95c4-8fdb87af9b4f" xlink:href="absi-20250930.xsd#absi_ContingentConsiderationFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_e289b528-a036-4a69-aa7d-fb7796068ead" xlink:to="loc_absi_ContingentConsiderationFairValue_b822a787-9841-4550-95c4-8fdb87af9b4f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>absi-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a3e69f22-3845-4b88-95f7-36018340f30a,g:dbd2b148-ca4f-47a0-84c9-32244e24e6c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e6419b30-1046-488f-a286-1531b283e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9b0aa124-6540-46b1-9b06-dc279daa51c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e6419b30-1046-488f-a286-1531b283e0aa" xlink:to="loc_us-gaap_StatementTable_9b0aa124-6540-46b1-9b06-dc279daa51c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fd67adc-d3da-47fc-b500-1bf102df55fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9b0aa124-6540-46b1-9b06-dc279daa51c2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fd67adc-d3da-47fc-b500-1bf102df55fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5fd67adc-d3da-47fc-b500-1bf102df55fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fd67adc-d3da-47fc-b500-1bf102df55fe" xlink:to="loc_us-gaap_EquityComponentDomain_5fd67adc-d3da-47fc-b500-1bf102df55fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fd67adc-d3da-47fc-b500-1bf102df55fe" xlink:to="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_38b243e9-12e0-4d12-b11c-506605bcbcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_CommonStockMember_38b243e9-12e0-4d12-b11c-506605bcbcc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3fd7f887-d108-4ffa-a7d8-f7ceb684b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3fd7f887-d108-4ffa-a7d8-f7ceb684b7c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_87ae5977-f44a-4b81-9d67-fd996054afe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_RetainedEarningsMember_87ae5977-f44a-4b81-9d67-fd996054afe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1ddbeb94-2e8b-4171-95ff-d60f024d90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1ddbeb94-2e8b-4171-95ff-d60f024d90e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e6419b30-1046-488f-a286-1531b283e0aa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_24425bad-6a4d-4056-a938-07831de0e3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_24425bad-6a4d-4056-a938-07831de0e3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fef92bb-55b6-4df4-98de-ec4000b380d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockholdersEquity_9fef92bb-55b6-4df4-98de-ec4000b380d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d58002ee-baa9-4613-a92c-ea42d297775d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d58002ee-baa9-4613-a92c-ea42d297775d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a19dbcc1-e025-45d9-9832-57217f548aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a19dbcc1-e025-45d9-9832-57217f548aa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6a55307d-dd33-4799-ab5c-e7b0d45937e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6a55307d-dd33-4799-ab5c-e7b0d45937e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures_87b3b631-feb1-4b4c-82ad-fad8e35f4af8" xlink:href="absi-20250930.xsd#absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures_87b3b631-feb1-4b4c-82ad-fad8e35f4af8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acae3637-887f-4f6d-bbff-4bd5d1890cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acae3637-887f-4f6d-bbff-4bd5d1890cc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4fa0809-f133-4eb3-b91b-20c92022af3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4fa0809-f133-4eb3-b91b-20c92022af3b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_31c89a5a-8ed5-4676-8eca-f15ecdf06111" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_31c89a5a-8ed5-4676-8eca-f15ecdf06111" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_110460d4-e890-4275-8d1f-e8da1bc730e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_110460d4-e890-4275-8d1f-e8da1bc730e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_09002622-cfda-4def-85cf-74101f8a62f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_09002622-cfda-4def-85cf-74101f8a62f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_972ffd66-082b-4c83-a936-fa15faecd4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_NetIncomeLoss_972ffd66-082b-4c83-a936-fa15faecd4be" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6db64b48-5bf3-47aa-8215-a1b1371088e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e92aabbb-3fc6-4b25-ad01-1f946fdb4c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/RevenuerecognitionDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#RevenuerecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/RevenuerecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3d3f604-f030-4a82-8b4b-74c942363453" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:to="loc_srt_ProductOrServiceAxis_d3d3f604-f030-4a82-8b4b-74c942363453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3d3f604-f030-4a82-8b4b-74c942363453_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d3d3f604-f030-4a82-8b4b-74c942363453" xlink:to="loc_srt_ProductsAndServicesDomain_d3d3f604-f030-4a82-8b4b-74c942363453_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ceffb6e-c2b0-47db-8fca-af73edbb7702" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d3d3f604-f030-4a82-8b4b-74c942363453" xlink:to="loc_srt_ProductsAndServicesDomain_7ceffb6e-c2b0-47db-8fca-af73edbb7702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_TechnologyDevelopmentRevenueMember_27cb5605-a366-416b-bcad-67baecb370ea" xlink:href="absi-20250930.xsd#absi_TechnologyDevelopmentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ceffb6e-c2b0-47db-8fca-af73edbb7702" xlink:to="loc_absi_TechnologyDevelopmentRevenueMember_27cb5605-a366-416b-bcad-67baecb370ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f8de441-6ecb-42b5-80a4-f9e9db8dc261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f8de441-6ecb-42b5-80a4-f9e9db8dc261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f8de441-6ecb-42b5-80a4-f9e9db8dc261_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f8de441-6ecb-42b5-80a4-f9e9db8dc261" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f8de441-6ecb-42b5-80a4-f9e9db8dc261_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c9a2e6c-81ea-4375-a343-f98b0db0449a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f8de441-6ecb-42b5-80a4-f9e9db8dc261" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c9a2e6c-81ea-4375-a343-f98b0db0449a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7f739cad-f75e-480e-8136-80362954f765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c9a2e6c-81ea-4375-a343-f98b0db0449a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7f739cad-f75e-480e-8136-80362954f765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d97ba9c9-f355-4953-afdb-4459c846f85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d97ba9c9-f355-4953-afdb-4459c846f85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f9b3ba98-1f34-44aa-a570-82ab80ff2d82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d97ba9c9-f355-4953-afdb-4459c846f85b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f9b3ba98-1f34-44aa-a570-82ab80ff2d82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9deb89e4-3a67-4b5c-a30c-28ef9bb6a548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9deb89e4-3a67-4b5c-a30c-28ef9bb6a548" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cb1a2763-3e4a-4438-95b3-311be9e6821f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cb1a2763-3e4a-4438-95b3-311be9e6821f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_NumberOfPartners_fb1cb6ab-7d40-4256-8397-ec881bcdb05c" xlink:href="absi-20250930.xsd#absi_NumberOfPartners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_absi_NumberOfPartners_fb1cb6ab-7d40-4256-8397-ec881bcdb05c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f51bde1d-12e1-4048-ace6-a7ffbed2ba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f51bde1d-12e1-4048-ace6-a7ffbed2ba1f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#InvestmentsAmortizedandFairValueofourInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_29b8ad27-c588-4f37-ac15-960e613c5a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:to="loc_us-gaap_FinancialInstrumentAxis_29b8ad27-c588-4f37-ac15-960e613c5a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_29b8ad27-c588-4f37-ac15-960e613c5a74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_29b8ad27-c588-4f37-ac15-960e613c5a74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_29b8ad27-c588-4f37-ac15-960e613c5a74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_29b8ad27-c588-4f37-ac15-960e613c5a74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_93ef39f4-5d04-4c6c-bdb3-75496aff7c06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_93ef39f4-5d04-4c6c-bdb3-75496aff7c06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_334ba361-6c43-4d94-8c85-4d8335aee695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_334ba361-6c43-4d94-8c85-4d8335aee695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_248d3933-ce6e-4fba-80d8-8efac1877087" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_248d3933-ce6e-4fba-80d8-8efac1877087" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_248d3933-ce6e-4fba-80d8-8efac1877087_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_248d3933-ce6e-4fba-80d8-8efac1877087" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_248d3933-ce6e-4fba-80d8-8efac1877087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_248d3933-ce6e-4fba-80d8-8efac1877087" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_9e648a06-1c44-440c-809c-df70e28d5de5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:to="loc_us-gaap_CashEquivalentsMember_9e648a06-1c44-440c-809c-df70e28d5de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_92a7f438-f37e-45a0-882f-ae87cb392b26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_92a7f438-f37e-45a0-882f-ae87cb392b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6cc5c98c-53cf-4534-b59b-0935326a228d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6cc5c98c-53cf-4534-b59b-0935326a228d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa1c8e5d-5c24-42e6-a72c-9af1c5ac1307" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa1c8e5d-5c24-42e6-a72c-9af1c5ac1307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_52c550f8-5117-4bf3-a31e-c24969a386dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_52c550f8-5117-4bf3-a31e-c24969a386dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d3a52f7-789d-4636-b3b1-b9a90ffdd25b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d3a52f7-789d-4636-b3b1-b9a90ffdd25b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/InvestmentsNarrativesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#InvestmentsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/InvestmentsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e758db3b-d35a-47ee-b3f0-9384a6a1dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e758db3b-d35a-47ee-b3f0-9384a6a1dca6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38555f66-a2e1-4d78-b56e-7eb3e5668cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e758db3b-d35a-47ee-b3f0-9384a6a1dca6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38555f66-a2e1-4d78-b56e-7eb3e5668cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38555f66-a2e1-4d78-b56e-7eb3e5668cd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38555f66-a2e1-4d78-b56e-7eb3e5668cd8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38555f66-a2e1-4d78-b56e-7eb3e5668cd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b566bf8e-d166-4fb3-9200-5ed683790c59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38555f66-a2e1-4d78-b56e-7eb3e5668cd8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b566bf8e-d166-4fb3-9200-5ed683790c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_aa26660b-ae17-4ca3-868e-aebc482c5428" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b566bf8e-d166-4fb3-9200-5ed683790c59" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_aa26660b-ae17-4ca3-868e-aebc482c5428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_15a471ae-d9ff-4b4f-8b61-963bac78946d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_15a471ae-d9ff-4b4f-8b61-963bac78946d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_9d848b22-c6e6-4692-9b30-9eb33f2170f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_9d848b22-c6e6-4692-9b30-9eb33f2170f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_0f242a15-7602-49a4-a086-e1af3c2d4978" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_0f242a15-7602-49a4-a086-e1af3c2d4978" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ae336d1e-bb5c-49da-9c4e-2a91c921c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ae336d1e-bb5c-49da-9c4e-2a91c921c00c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d3da3ec1-9875-4513-afa2-1e4a9d2acb66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d3da3ec1-9875-4513-afa2-1e4a9d2acb66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_726abf1b-b6a5-468d-b57d-82d98b3ce9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_726abf1b-b6a5-468d-b57d-82d98b3ce9a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b7f9efb4-04ae-469c-8236-ee6210888688" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b7f9efb4-04ae-469c-8236-ee6210888688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7f9efb4-04ae-469c-8236-ee6210888688_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b7f9efb4-04ae-469c-8236-ee6210888688" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7f9efb4-04ae-469c-8236-ee6210888688_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbdfa7ff-6548-4648-9ce6-05ef2721450d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b7f9efb4-04ae-469c-8236-ee6210888688" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbdfa7ff-6548-4648-9ce6-05ef2721450d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_71d44cc5-83de-4721-9093-8bd2954c4110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbdfa7ff-6548-4648-9ce6-05ef2721450d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_71d44cc5-83de-4721-9093-8bd2954c4110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ff8e4a25-2dd7-46eb-abad-7281bbb26196" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ff8e4a25-2dd7-46eb-abad-7281bbb26196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a31daefd-073f-4af5-ad09-7e4099006995" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a31daefd-073f-4af5-ad09-7e4099006995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_2648e512-19ea-4f09-966e-cf8ccdc903a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_2648e512-19ea-4f09-966e-cf8ccdc903a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a51ceb83-9bbc-4657-a48f-ec1894b0f653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a51ceb83-9bbc-4657-a48f-ec1894b0f653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ContingentConsiderationFairValue_c977aa55-a26b-46c9-a6f5-809afa8f9350" xlink:href="absi-20250930.xsd#absi_ContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:to="loc_absi_ContingentConsiderationFairValue_c977aa55-a26b-46c9-a6f5-809afa8f9350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_867596e1-1cd1-476f-9606-8ed51229fe1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_867596e1-1cd1-476f-9606-8ed51229fe1e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/CommonstockDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#CommonstockDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/CommonstockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCapitalUnitsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:to="loc_srt_RangeAxis_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d" xlink:to="loc_srt_RangeMember_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4fa31b0e-490b-44e9-949b-dedffaf8d661" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d" xlink:to="loc_srt_RangeMember_4fa31b0e-490b-44e9-949b-dedffaf8d661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_927bab20-0316-48f5-935f-8a8e0f4474e5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4fa31b0e-490b-44e9-949b-dedffaf8d661" xlink:to="loc_srt_MaximumMember_927bab20-0316-48f5-935f-8a8e0f4474e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:to="loc_srt_CounterpartyNameAxis_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_CowenAndCompanyLLCMember_7fa108ff-59aa-4481-b5cd-de6c37b4cd9c" xlink:href="absi-20250930.xsd#absi_CowenAndCompanyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:to="loc_absi_CowenAndCompanyLLCMember_7fa108ff-59aa-4481-b5cd-de6c37b4cd9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AdvancedMicroDevicesIncMember_c7744076-c748-4449-af09-190869b447fa" xlink:href="absi-20250930.xsd#absi_AdvancedMicroDevicesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:to="loc_absi_AdvancedMicroDevicesIncMember_c7744076-c748-4449-af09-190869b447fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_TDSecuritiesUSALLCMember_f7266482-3c90-4317-af9b-427d6ca0848a" xlink:href="absi-20250930.xsd#absi_TDSecuritiesUSALLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:to="loc_absi_TDSecuritiesUSALLCMember_f7266482-3c90-4317-af9b-427d6ca0848a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_226a1bcf-5270-4649-8398-2163c8ed1504" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_226a1bcf-5270-4649-8398-2163c8ed1504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_226a1bcf-5270-4649-8398-2163c8ed1504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_226a1bcf-5270-4649-8398-2163c8ed1504" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_226a1bcf-5270-4649-8398-2163c8ed1504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_226a1bcf-5270-4649-8398-2163c8ed1504" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ShelfRegistrationMember_1100d8cf-d626-460c-bcfc-b18dd96ccd18" xlink:href="absi-20250930.xsd#absi_ShelfRegistrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:to="loc_absi_ShelfRegistrationMember_1100d8cf-d626-460c-bcfc-b18dd96ccd18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AtTheMarketOfferingProgramMember_290b0b43-a5d5-4f15-8fc6-2bf41ee2b70f" xlink:href="absi-20250930.xsd#absi_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:to="loc_absi_AtTheMarketOfferingProgramMember_290b0b43-a5d5-4f15-8fc6-2bf41ee2b70f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_eb5c2ad4-6bb9-4a9b-b2dd-29c25792f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:to="loc_us-gaap_PrivatePlacementMember_eb5c2ad4-6bb9-4a9b-b2dd-29c25792f8c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction_8eaa5517-c38b-470d-bd40-bc26a19cedb2" xlink:href="absi-20250930.xsd#absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction_8eaa5517-c38b-470d-bd40-bc26a19cedb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0194d2ab-8576-4b38-af32-beffe9315836" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0194d2ab-8576-4b38-af32-beffe9315836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99d8ee75-1b85-4257-9a9e-1c011b7b1851" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99d8ee75-1b85-4257-9a9e-1c011b7b1851" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e579c27c-f023-4763-9497-8a5b0aee2a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_SharePrice_e579c27c-f023-4763-9497-8a5b0aee2a37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockMaximumAggregateOfferingPrice_3604b00a-84ae-4654-b913-186821be3d5c" xlink:href="absi-20250930.xsd#absi_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_SaleOfStockMaximumAggregateOfferingPrice_3604b00a-84ae-4654-b913-186821be3d5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockSalesAgentCommissionPercentage_7cb2d907-6e26-4a97-a3df-c132868ead59" xlink:href="absi-20250930.xsd#absi_SaleOfStockSalesAgentCommissionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_SaleOfStockSalesAgentCommissionPercentage_7cb2d907-6e26-4a97-a3df-c132868ead59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_414f01b9-f8e1-4e62-bca4-f81ae80708f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_414f01b9-f8e1-4e62-bca4-f81ae80708f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AmortizationOfEquityIssuanceDiscountPremium_2033b8c7-5f88-43fd-92cb-a21eedf11b6f" xlink:href="absi-20250930.xsd#absi_AmortizationOfEquityIssuanceDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_AmortizationOfEquityIssuanceDiscountPremium_2033b8c7-5f88-43fd-92cb-a21eedf11b6f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationNarrativesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/StockbasedcompensationNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_61247106-49e7-4c19-b9cc-cb27662d9d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:to="loc_us-gaap_PlanNameAxis_61247106-49e7-4c19-b9cc-cb27662d9d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_61247106-49e7-4c19-b9cc-cb27662d9d67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_61247106-49e7-4c19-b9cc-cb27662d9d67" xlink:to="loc_us-gaap_PlanNameDomain_61247106-49e7-4c19-b9cc-cb27662d9d67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_61247106-49e7-4c19-b9cc-cb27662d9d67" xlink:to="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2021StockOptionAndGrantPlanMember_db715a69-3450-440c-b70b-d3a095b4efb7" xlink:href="absi-20250930.xsd#absi_A2021StockOptionAndGrantPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:to="loc_absi_A2021StockOptionAndGrantPlanMember_db715a69-3450-440c-b70b-d3a095b4efb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2023InducementPlanMember_620d7fc2-e55a-473a-95ac-9b4c80cfccbe" xlink:href="absi-20250930.xsd#absi_A2023InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:to="loc_absi_A2023InducementPlanMember_620d7fc2-e55a-473a-95ac-9b4c80cfccbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2020StockOptionAndGrantPlanMember_f2b1120a-9656-4f31-a928-7102df2ef4d3" xlink:href="absi-20250930.xsd#absi_A2020StockOptionAndGrantPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:to="loc_absi_A2020StockOptionAndGrantPlanMember_f2b1120a-9656-4f31-a928-7102df2ef4d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c644151-fe65-46c0-86c5-135df633f2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:to="loc_us-gaap_AwardTypeAxis_7c644151-fe65-46c0-86c5-135df633f2fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c644151-fe65-46c0-86c5-135df633f2fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c644151-fe65-46c0-86c5-135df633f2fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c644151-fe65-46c0-86c5-135df633f2fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c644151-fe65-46c0-86c5-135df633f2fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_95ab9ed6-53e4-4cd5-aacc-6e3fd99749f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:to="loc_us-gaap_EmployeeStockOptionMember_95ab9ed6-53e4-4cd5-aacc-6e3fd99749f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_45f9ef25-b1c9-4df9-8626-78d96c977604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_45f9ef25-b1c9-4df9-8626-78d96c977604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9e66bf7-2571-4e6c-94a5-2f61d81375fb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:to="loc_srt_RangeAxis_f9e66bf7-2571-4e6c-94a5-2f61d81375fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9e66bf7-2571-4e6c-94a5-2f61d81375fb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f9e66bf7-2571-4e6c-94a5-2f61d81375fb" xlink:to="loc_srt_RangeMember_f9e66bf7-2571-4e6c-94a5-2f61d81375fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f9e66bf7-2571-4e6c-94a5-2f61d81375fb" xlink:to="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b072d89-9696-456f-b205-f01ffb0400b6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:to="loc_srt_MinimumMember_9b072d89-9696-456f-b205-f01ffb0400b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5d37135-fe1d-458e-80c3-6bb044e2618f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:to="loc_srt_MaximumMember_f5d37135-fe1d-458e-80c3-6bb044e2618f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d1971794-1c91-46d9-85c2-4ed30be76aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d1971794-1c91-46d9-85c2-4ed30be76aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b40a1101-47ca-4ebc-9964-4bd8661f8c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b40a1101-47ca-4ebc-9964-4bd8661f8c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c57b3d1-ee59-4101-92c7-0583ca407453" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c57b3d1-ee59-4101-92c7-0583ca407453" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_817852d2-d60c-49ea-86bf-61df19e5be01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_817852d2-d60c-49ea-86bf-61df19e5be01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b38135d-3e33-4dc6-8355-54d8e46d8642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b38135d-3e33-4dc6-8355-54d8e46d8642" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d8ff2a7b-b7a1-41e6-9ff8-f78cc37d0635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d8ff2a7b-b7a1-41e6-9ff8-f78cc37d0635" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e661a71e-dde2-4657-9b21-0128177a97e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e661a71e-dde2-4657-9b21-0128177a97e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9b48f84-ae28-41ae-905d-33c3fe6f6878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9b48f84-ae28-41ae-905d-33c3fe6f6878" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_48076e43-aae4-4d4c-99dc-d55c00780ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b8c6c192-573d-4a03-95bc-006465a81712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_48076e43-aae4-4d4c-99dc-d55c00780ffa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b8c6c192-573d-4a03-95bc-006465a81712" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4acb91b2-2024-42de-936b-e36c1378f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b8c6c192-573d-4a03-95bc-006465a81712" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4acb91b2-2024-42de-936b-e36c1378f6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4acb91b2-2024-42de-936b-e36c1378f6ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4acb91b2-2024-42de-936b-e36c1378f6ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4acb91b2-2024-42de-936b-e36c1378f6ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4acb91b2-2024-42de-936b-e36c1378f6ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_41b5ba0c-3232-477c-af55-e0e39613df10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_41b5ba0c-3232-477c-af55-e0e39613df10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f1154a80-3853-4f96-91f9-192501449268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f1154a80-3853-4f96-91f9-192501449268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f32a40a4-e2c2-4b9c-9e28-f69c90a9d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_48076e43-aae4-4d4c-99dc-d55c00780ffa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f32a40a4-e2c2-4b9c-9e28-f69c90a9d64a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationDeterminationofFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eae1412-c80d-402e-a562-9ce66b931aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fdc9950-0205-4521-a123-646deb9c3088" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eae1412-c80d-402e-a562-9ce66b931aa0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fdc9950-0205-4521-a123-646deb9c3088" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7298065-ff72-4d8b-9da2-60f508a4459d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fdc9950-0205-4521-a123-646deb9c3088" xlink:to="loc_srt_RangeAxis_e7298065-ff72-4d8b-9da2-60f508a4459d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7298065-ff72-4d8b-9da2-60f508a4459d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e7298065-ff72-4d8b-9da2-60f508a4459d" xlink:to="loc_srt_RangeMember_e7298065-ff72-4d8b-9da2-60f508a4459d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e7298065-ff72-4d8b-9da2-60f508a4459d" xlink:to="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ccbda978-829a-489b-a9e8-7ea1865a0bf0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:to="loc_srt_MinimumMember_ccbda978-829a-489b-a9e8-7ea1865a0bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be3fac38-b5dd-408d-a37c-5265fc7c1ad7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:to="loc_srt_MaximumMember_be3fac38-b5dd-408d-a37c-5265fc7c1ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eae1412-c80d-402e-a562-9ce66b931aa0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92317b3c-8321-4757-bc8a-fe802013e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92317b3c-8321-4757-bc8a-fe802013e56c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1af57e54-6c77-463b-a793-69e975ffe1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1af57e54-6c77-463b-a793-69e975ffe1c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_aa3c7cb9-9331-43a9-b306-4079cb4da3af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_aa3c7cb9-9331-43a9-b306-4079cb4da3af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_89fafd7d-d028-4850-9a3d-419f325f1d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_89fafd7d-d028-4850-9a3d-419f325f1d67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3363a508-ecaa-482c-85a0-b9e5ae066a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3363a508-ecaa-482c-85a0-b9e5ae066a7a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb35aa83-4074-471f-bed8-4610ecda9651" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb35aa83-4074-471f-bed8-4610ecda9651" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac05ac56-ec10-4c2e-a245-1ef4d8008818" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb35aa83-4074-471f-bed8-4610ecda9651" xlink:to="loc_us-gaap_AwardTypeAxis_ac05ac56-ec10-4c2e-a245-1ef4d8008818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac05ac56-ec10-4c2e-a245-1ef4d8008818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac05ac56-ec10-4c2e-a245-1ef4d8008818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac05ac56-ec10-4c2e-a245-1ef4d8008818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c319ced9-7061-4b95-94a2-11c955bb630f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac05ac56-ec10-4c2e-a245-1ef4d8008818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c319ced9-7061-4b95-94a2-11c955bb630f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_27ffc012-3707-40fe-8f9f-13b5114a1068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c319ced9-7061-4b95-94a2-11c955bb630f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_27ffc012-3707-40fe-8f9f-13b5114a1068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c41832fd-7371-4e81-8822-1bc6fb867a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c41832fd-7371-4e81-8822-1bc6fb867a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c2ececd5-5588-4da4-9b62-1aa7c9b68b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c2ececd5-5588-4da4-9b62-1aa7c9b68b50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d82a6d82-74d9-454f-b7c2-8ebd31d72155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d82a6d82-74d9-454f-b7c2-8ebd31d72155" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4bf1627-e073-4e7d-ab24-4ffc01ae8084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4bf1627-e073-4e7d-ab24-4ffc01ae8084" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_479dc7b1-400d-4e3f-b4ed-071d581a1500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef37900-ce5d-4def-8192-cc2c26178e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef37900-ce5d-4def-8192-cc2c26178e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4ed159da-14ab-4f8e-a69c-727251d9fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4ed159da-14ab-4f8e-a69c-727251d9fd23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0c37afd4-07e5-4dc1-b777-d7c787b70ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0c37afd4-07e5-4dc1-b777-d7c787b70ef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72241d62-82ec-49dd-a18e-8ee36543ba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72241d62-82ec-49dd-a18e-8ee36543ba4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_294a670f-6da8-4003-97fb-43b341dd204a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#NetlosspershareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91ae3295-4545-424d-acb1-c31da7d21a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc59d41a-60db-4745-823f-6be449b2dc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91ae3295-4545-424d-acb1-c31da7d21a6c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc59d41a-60db-4745-823f-6be449b2dc5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c322f2f-adf7-493f-83ff-0e32f489a3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc59d41a-60db-4745-823f-6be449b2dc5d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c322f2f-adf7-493f-83ff-0e32f489a3c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5c322f2f-adf7-493f-83ff-0e32f489a3c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c322f2f-adf7-493f-83ff-0e32f489a3c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5c322f2f-adf7-493f-83ff-0e32f489a3c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c322f2f-adf7-493f-83ff-0e32f489a3c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf109cbd-d6ba-4852-8dbd-afc912e3f22b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf109cbd-d6ba-4852-8dbd-afc912e3f22b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2676f861-335e-4063-8e6f-51a6bc3992a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2676f861-335e-4063-8e6f-51a6bc3992a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_beda3ed1-3dec-45df-acb4-9e5ce70fd1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:to="loc_us-gaap_RestrictedStockMember_beda3ed1-3dec-45df-acb4-9e5ce70fd1e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6aa0b159-e58f-4c69-9ea1-f229852bfa56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91ae3295-4545-424d-acb1-c31da7d21a6c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6aa0b159-e58f-4c69-9ea1-f229852bfa56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/SegmentreportingSegmentExpensesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#SegmentreportingSegmentExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/SegmentreportingSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60fb9f62-4c30-4e8a-a163-6c8c59424146" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:to="loc_srt_ProductOrServiceAxis_60fb9f62-4c30-4e8a-a163-6c8c59424146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_60fb9f62-4c30-4e8a-a163-6c8c59424146_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_60fb9f62-4c30-4e8a-a163-6c8c59424146" xlink:to="loc_srt_ProductsAndServicesDomain_60fb9f62-4c30-4e8a-a163-6c8c59424146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_60fb9f62-4c30-4e8a-a163-6c8c59424146" xlink:to="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_DrugCreationAndPlatformMember_add2e83d-9bfc-4506-81e2-1e5e253b60b9" xlink:href="absi-20250930.xsd#absi_DrugCreationAndPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:to="loc_absi_DrugCreationAndPlatformMember_add2e83d-9bfc-4506-81e2-1e5e253b60b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ExternalPreClinicalAndClinicalDevelopmentMember_c2f776d2-3f20-4109-8f53-ac54b5efb375" xlink:href="absi-20250930.xsd#absi_ExternalPreClinicalAndClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:to="loc_absi_ExternalPreClinicalAndClinicalDevelopmentMember_c2f776d2-3f20-4109-8f53-ac54b5efb375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26" xlink:to="loc_us-gaap_SegmentDomain_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4e973121-f2a1-4aaa-b908-a9606704e65f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26" xlink:to="loc_us-gaap_SegmentDomain_4e973121-f2a1-4aaa-b908-a9606704e65f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SegmentOneMember_bd521cff-f43b-46ef-87e3-d40c549e6ab3" xlink:href="absi-20250930.xsd#absi_SegmentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4e973121-f2a1-4aaa-b908-a9606704e65f" xlink:to="loc_absi_SegmentOneMember_bd521cff-f43b-46ef-87e3-d40c549e6ab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_def5f57b-0c63-4d6f-accf-40563f96b86c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_def5f57b-0c63-4d6f-accf-40563f96b86c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_49ffa246-ccca-4303-bf11-0f26be7064f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_LaborAndRelatedExpense_49ffa246-ccca-4303-bf11-0f26be7064f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0d44d028-8a4c-4aa4-a870-e6c853368b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0d44d028-8a4c-4aa4-a870-e6c853368b0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fed4647d-082e-4080-9e8f-98ba88df527a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fed4647d-082e-4080-9e8f-98ba88df527a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f7c7d944-6968-4c91-8b27-377e9243733c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f7c7d944-6968-4c91-8b27-377e9243733c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_55324c7e-7f5e-4ce0-a937-53d63ca142ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_OperatingExpenses_55324c7e-7f5e-4ce0-a937-53d63ca142ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5ecae61b-9b2d-4863-9898-bb8243d98073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_AssetImpairmentCharges_5ecae61b-9b2d-4863-9898-bb8243d98073" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.absci.com/role/SubsequenteventsDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#SubsequenteventsDetails"/>
  <link:definitionLink xlink:role="http://www.absci.com/role/SubsequenteventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6a29e891-eb9b-485b-8a01-1ced33ffad23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:to="loc_us-gaap_SubsequentEventTable_6a29e891-eb9b-485b-8a01-1ced33ffad23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e83a7048-38f7-4cda-b558-7e7f46d6864b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6a29e891-eb9b-485b-8a01-1ced33ffad23" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e83a7048-38f7-4cda-b558-7e7f46d6864b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e83a7048-38f7-4cda-b558-7e7f46d6864b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e83a7048-38f7-4cda-b558-7e7f46d6864b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e83a7048-38f7-4cda-b558-7e7f46d6864b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ce0ef8d9-397a-415f-9f9e-762c4f4880f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e83a7048-38f7-4cda-b558-7e7f46d6864b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ce0ef8d9-397a-415f-9f9e-762c4f4880f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2f7ad705-4619-4072-97e5-a6479be8de53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ce0ef8d9-397a-415f-9f9e-762c4f4880f0" xlink:to="loc_us-gaap_SubsequentEventMember_2f7ad705-4619-4072-97e5-a6479be8de53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7fe4e5c7-7296-49e1-ad9e-54c60dfbf154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7fe4e5c7-7296-49e1-ad9e-54c60dfbf154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81b06c5c-860b-4cec-aa17-fd77899ed011" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81b06c5c-860b-4cec-aa17-fd77899ed011" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>absi-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a3e69f22-3845-4b88-95f7-36018340f30a,g:dbd2b148-ca4f-47a0-84c9-32244e24e6c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RangeMember_4f99c519-a02d-4bee-82ec-2dffcc0f0a93_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_369688ea-d2b6-495b-9374-3b766967fe97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2d60c895-461b-49a4-8dae-c187035c1b9d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4b2e07e6-6005-42da-bf70-abadada1ec4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2b46a064-af4e-44ee-aa33-67cc2d921c81_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9ae6e18-4796-49a6-8735-01e1841e8680_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2866e6ff-4f46-4de6-9000-74461c9e4ea3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_48f922cb-741f-4e90-ad12-8b46f609dd4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial commitment 2027</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:to="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0683519c-7879-477a-a1f9-947815458907_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share: basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_e01a077f-48b8-46ea-918f-f07764eb0b00_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_cc77d753-67b9-4138-bb1d-7c69544df502_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8612636c-383a-499d-962f-315710062fcc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6a4520ff-e10f-4a79-9e1f-0de67f716f4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amortized and Fair Value of Our Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6ccc6ff9-cb96-479a-b386-52c96ce47414_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7b2c4848-396e-4b4a-90da-19cc68c2a700_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_74a8ad9f-1bc6-4bf9-9388-40e26b8747e9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0b0057e8-b393-4e8a-a7a2-3b3c365204d5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_AmortizationOfEquityIssuanceDiscountPremium_a106b3e3-3cfd-409c-8365-0c315e228c7f_negatedLabel_en-US" xlink:label="lab_absi_AmortizationOfEquityIssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of the premium</link:label>
    <link:label id="lab_absi_AmortizationOfEquityIssuanceDiscountPremium_label_en-US" xlink:label="lab_absi_AmortizationOfEquityIssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Equity Issuance Discount (Premium)</link:label>
    <link:label id="lab_absi_AmortizationOfEquityIssuanceDiscountPremium_documentation_en-US" xlink:label="lab_absi_AmortizationOfEquityIssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of Equity Issuance Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AmortizationOfEquityIssuanceDiscountPremium" xlink:href="absi-20250930.xsd#absi_AmortizationOfEquityIssuanceDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_AmortizationOfEquityIssuanceDiscountPremium" xlink:to="lab_absi_AmortizationOfEquityIssuanceDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_9c550654-3671-4d5b-9dbf-079924cae3ff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f0e2364e-788c-4740-9c77-8c4285ec4875_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5bc31849-4dea-4b09-856d-fe36d1fbe66d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5b1a6b6f-3429-4b7a-976a-c55d1c51bf59_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_04aa931c-4553-4266-b655-17af0d57b6f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e2533513-573d-4f06-8036-7789a6aa551c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b22eb1f8-841d-49a3-89ab-a62a6b77016f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f582f372-efbc-4315-8a21-579642c1d43a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3a746f94-1cf0-43e6-8d47-d229bdaacd97_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c576d40c-b20e-43ca-bf25-9a73903c9000_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9f4576e-fa3c-4652-b84e-76926308f897_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_bed793df-dc55-493c-8363-eb39d8d625a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b9130a47-85d0-4558-9dd4-b0c9c5df59c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e5f7b73f-1b93-4451-bdf7-b89c7939c8ed_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_55205544-117b-404e-a1bf-4e0732e49ca3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6ac8e642-462d-4412-9b9d-87eda5513493_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ece2e187-b0aa-4cb0-b05a-bd7f1fa099c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_92b27f3a-4e92-41e0-8d68-d7e047622412_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_79ff2f88-2c9d-49ed-85bd-140b7c7c8ebf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d93bb90-5d95-4375-be5d-9416a9bd15aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_SaleOfStockMaximumAggregateOfferingPrice_41b9cd03-74d6-49e0-9319-1babaf977cd6_terseLabel_en-US" xlink:label="lab_absi_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum offering price</link:label>
    <link:label id="lab_absi_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_absi_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_absi_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_absi_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="absi-20250930.xsd#absi_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_absi_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_477550d2-57d0-4b1c-9366-6671dbac03e3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2145cc28-058b-4182-ab52-8bb9be0da123_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_7e42074c-adaa-4b01-b9c6-eb71e008abb3_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5dbdc5e2-a8d6-43d7-8ddc-9bb6d738be0b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d33fb3dc-af0d-4147-8761-4644ab752579_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c4fbff77-4ccb-451c-95c5-7e9660eac8dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_41159752-7249-400d-983c-c1937e3c5fba_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_c0bda1b1-c41a-4447-ac24-873b3a5e29a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5f3c4a72-5f16-4df7-94c2-0690228d08fc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_217fe8fd-e5d9-478d-98ed-7dc847933ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_209d9f21-82f4-4592-92ae-f12c7d000a29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c7e24b62-afbc-4c31-85c1-6989447f4e43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0924e38c-e244-4cb0-9d34-8ed136821ff7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d9986bf3-c059-4259-8826-99453845435e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2f9855e2-b7ad-448c-976c-adb0ea9ae629_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9b7a8710-17d7-44e9-8630-64348214b1e9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_908cca7b-ac3f-41c4-8a4e-401ff96f9490_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_77684049-0100-4aa3-8054-253824ba6d4c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_29e43355-2d2b-4119-af9d-5b3cb3f12968_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4d1e12a4-3ee4-400e-bbe6-034305ad6071_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1a4f2627-b637-4390-9345-5b96e35373c9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ccdf9e32-f83f-47b8-8aeb-4035a903943e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bf7c3f9f-9ff4-477b-8dc6-d28cd733ff5d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b4002561-837d-4a67-bd3a-707e79e8a005_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_861e920b-c12b-42ac-b21a-8d272816f780_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_7cea5012-57f9-4cd2-864e-0baf4bac467b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ca76a63f-bc10-4e23-ad3e-654e26fdb9f4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fdc890b6-f887-4dbd-b7fa-5bb610c99ee7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7c45bf19-c01d-4dd0-a858-0e236575ea6e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e9d764f0-390e-4cce-854e-26c8656e0ede_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_DrugCreationAndPlatformMember_cd0f74f5-3e62-4e2f-9bf5-4876e384eda9_terseLabel_en-US" xlink:label="lab_absi_DrugCreationAndPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug creation program and platform</link:label>
    <link:label id="lab_absi_DrugCreationAndPlatformMember_label_en-US" xlink:label="lab_absi_DrugCreationAndPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Creation And Platform [Member]</link:label>
    <link:label id="lab_absi_DrugCreationAndPlatformMember_documentation_en-US" xlink:label="lab_absi_DrugCreationAndPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug Creation And Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_DrugCreationAndPlatformMember" xlink:href="absi-20250930.xsd#absi_DrugCreationAndPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_DrugCreationAndPlatformMember" xlink:to="lab_absi_DrugCreationAndPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05306c2a-b9a4-41a4-9ac1-32199f057174_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75479c5a-5528-4ced-a577-b05651489b64_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6b03d8d-39b5-4d48-a7f7-260cc9fec9d7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner program revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_eb8cc006-ec54-437a-b60a-4f717e72cc81_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_26385351-24b0-4fe2-8d07-1477467193e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial commitment 2028</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e3197196-6fbe-4be3-b50f-61cb754c95d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1799f192-42c7-49fd-8d0c-f7069e6916a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_19049544-2a60-4858-91dc-196093802b4e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_f29256cd-8d74-4a48-9674-c7e0644e216c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial commitment 2025</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c78352a9-6fa0-4294-818f-171c4d598b29_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3da400a2-d4f7-46d0-b2ca-578d50f2a9b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9686d939-33b9-4406-a271-2f9d58833350_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fe93a3c2-a1fa-47f1-86b7-ed50f8877729_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ac90928-7f00-4887-9ae3-77ef013a6c68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonvested, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d85d52e8-fcf6-43b4-acb9-863ff06e2cc9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9e3264e-d64a-4d82-9393-605b336835cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash - Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98c0d08d-2e7e-473c-8a7f-b34ab075c726_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash - End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_04d47062-8bc7-46fe-9f72-9a8b534fdef9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f83d2674-2f70-4910-b4c9-d5fd12fc46f5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_586cf559-1ba0-4170-83ff-1cf44857a976_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b9f6e097-d96f-4eba-9f52-0909bc582b05_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_becd5bad-aa52-4358-bd5f-669ea474c3da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2a85bb7a-5778-43a5-8893-2c576b19b18f_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_945c8974-6c6f-4545-994a-38f61310e9eb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_728a1287-1f25-4199-bc3a-c3aa1dfe911f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_680095d0-b8b4-4ac9-9bc8-13a7ebe0e873_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e58ba41-54a4-4d68-be72-a62bb62a6f26_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_96887ba0-ce91-4604-9fa3-e70b6a587237_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General &amp; administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6afdc626-6961-4f30-b4f8-4c7c94b3c0eb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_967fd4ea-7796-45f3-ae9d-2ea33b770a59_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense not yet recognized, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_91eb5032-e077-4665-8f17-33891fb3b25c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c584b8e1-100e-43ae-913b-ec152f8a148e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_d0e92827-46c4-400d-8f3f-8a454d002f28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair market value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_053e61f0-d14a-48d5-a886-d0ff21accd2d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_6e1972e1-fa23-47c4-9783-7f316403b454_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b8163837-4ebe-4d8b-84c5-3d29e8213e24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4ffce613-78ab-4b86-83a3-4376d8a004da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Determination of Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_501a3091-f722-48a4-a634-f41904e982db_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e105be6b-cc31-4458-8d50-445b9409bcf7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7b71b56d-a25a-482a-a4fe-bc18ce912d02_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b45ac12a-1fbd-45b9-81a6-0530cef8dc09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_ceafed2d-875e-40dd-880b-3362843248f3_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_b764c3f4-2338-45d1-8e3e-b52a1f665e97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial commitment 2026</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_fe7c6997-db0d-437c-82d7-1ab725612a3f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fc4c9b83-db0d-48f9-926c-73c4d118c5c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9a88f22d-f63b-456e-9c4a-30232c8ff469_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions and Methodology</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_62075b54-5f3b-4f8c-ab46-3ff0ca16ec88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bf5c96b0-9248-4395-8ff2-be5b75df7480_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_e6c0be4c-334c-42cf-bce7-4e185b8e4d24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6b69373-2795-4f1c-b5a4-4bd09aec22da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9da4ad6b-5905-4808-8f0c-3fc36894c4eb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_4b0f84ef-c39d-4b90-b1a7-35761d777af7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_2323451f-99d4-4542-8f30-c6fde30ce8eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0aee6e0b-e2c0-43dd-b9e4-43caaf566b19_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_27a1da9e-2183-4739-b844-9976145bc6e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7af87b8f-04b4-4aa5-93c9-e2be257b1afa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_adc5205e-ce98-4062-b44d-80c119587d70_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_07966a2c-1b85-4342-acce-fe4d95ae4c26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ba810007-569d-4523-a85e-f5f09c3bd83f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_155c8960-8b6a-4434-b0d0-8d7e4cc03f1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d5a721c2-3560-4d23-804c-0e8c94241d63_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_489262ac-5005-4fc5-9553-1f59ea4b5e08_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0d2d275d-620a-47fc-a320-4423815df81b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense not yet recognized, recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6bca034-ad34-43a3-9c58-f78d219b8561_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bae3d2ea-4ddb-46d0-8c83-558cb9b3714d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_f8420a56-5ded-4437-8cf2-35145a93d03b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ec6726e1-f35e-43da-b38e-3b7438bfaebb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_85909415-6f34-4bf4-b871-ebe4ae6b2e07_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a88ab271-8ea0-42ba-a43c-7291f16effac_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_91bcf474-5292-4dcc-80c4-6c6d07ab2d7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_c871bd61-b31d-408a-8d67-0d721e22a6e7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d5e393ca-e4eb-415b-a24e-d8c4f535c12a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0267c742-7d92-4a9a-87bb-3c6a4caf80aa_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9d230b88-543c-4fb0-9721-1fab7b84c565_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d6fdeb63-89de-4be0-9faf-dd6c4f1f53ee_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bc5a5c87-9aa5-4d27-a9a0-56915927fbaa_netLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_ContingentConsiderationFairValue_db76ce6b-dd04-4c2e-80de-af8592ebe560_terseLabel_en-US" xlink:label="lab_absi_ContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_absi_ContingentConsiderationFairValue_label_en-US" xlink:label="lab_absi_ContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Fair Value</link:label>
    <link:label id="lab_absi_ContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_absi_ContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ContingentConsiderationFairValue" xlink:href="absi-20250930.xsd#absi_ContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_ContingentConsiderationFairValue" xlink:to="lab_absi_ContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_27976824-ed82-4c6d-9986-af942db5feaf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_311e27d1-592a-425b-85cf-00c9b9713aee_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5e8ce19a-bf81-48de-a341-be1252d0f721_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from company offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9bc3d63a-dd98-4629-9ae1-3eddc8671a84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c9df386a-c18b-445e-84bc-8a5d596ac4f1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_aeaea7b4-25a2-40a2-a95f-2d48dbafbccc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_947ab260-aaf4-48b3-9e3c-e3369bf2c788_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_A2023InducementPlanMember_e13e8763-31e4-43c1-b8d9-818881542835_terseLabel_en-US" xlink:label="lab_absi_A2023InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Inducement Plan</link:label>
    <link:label id="lab_absi_A2023InducementPlanMember_label_en-US" xlink:label="lab_absi_A2023InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Inducement Plan [Member]</link:label>
    <link:label id="lab_absi_A2023InducementPlanMember_documentation_en-US" xlink:label="lab_absi_A2023InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2023InducementPlanMember" xlink:href="absi-20250930.xsd#absi_A2023InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_A2023InducementPlanMember" xlink:to="lab_absi_A2023InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5fc14382-5bdb-4d7a-a3c0-d4c7a5bc7032_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6fec76d4-e960-4e96-b22f-f56b743c6245_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_70f2064f-dcbf-46fc-a1a4-a394915f5952_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense not yet recognized other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_ec54bf0d-ae7f-42c5-9ce0-5f9a5c008d74_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_5bfa6dc0-d1bd-4ad4-aaec-aafaf8282fae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_a585997f-7850-4c0f-a714-f0f5cb232139_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_ExternalPreClinicalAndClinicalDevelopmentMember_790a3abf-766c-41eb-b114-85bea3f28ae8_terseLabel_en-US" xlink:label="lab_absi_ExternalPreClinicalAndClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External preclinical and clinical development</link:label>
    <link:label id="lab_absi_ExternalPreClinicalAndClinicalDevelopmentMember_label_en-US" xlink:label="lab_absi_ExternalPreClinicalAndClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">External Pre-Clinical And Clinical Development [Member]</link:label>
    <link:label id="lab_absi_ExternalPreClinicalAndClinicalDevelopmentMember_documentation_en-US" xlink:label="lab_absi_ExternalPreClinicalAndClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External Pre-Clinical And Clinical Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ExternalPreClinicalAndClinicalDevelopmentMember" xlink:href="absi-20250930.xsd#absi_ExternalPreClinicalAndClinicalDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_ExternalPreClinicalAndClinicalDevelopmentMember" xlink:to="lab_absi_ExternalPreClinicalAndClinicalDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_92b99305-6f8a-4c08-ab36-669383e30bbd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_240627dc-014f-4c89-aed7-c806c08624f3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9fd1008a-e6ef-4fd2-a0c0-b1dfca295ecd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_77e93657-bca6-499f-9fc3-2bb2d3f7531c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_SegmentOneMember_1a2ffeb4-0af2-4dbe-a063-3a624e83c48e_terseLabel_en-US" xlink:label="lab_absi_SegmentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment One</link:label>
    <link:label id="lab_absi_SegmentOneMember_label_en-US" xlink:label="lab_absi_SegmentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment One [Member]</link:label>
    <link:label id="lab_absi_SegmentOneMember_documentation_en-US" xlink:label="lab_absi_SegmentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SegmentOneMember" xlink:href="absi-20250930.xsd#absi_SegmentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_SegmentOneMember" xlink:to="lab_absi_SegmentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b32ddf93-cd96-4ec6-baeb-2244399b731f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4006f94f-76d8-4db4-9ac1-7f25983a4a41_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Street</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_927037bb-8737-44ce-9162-accf0fee158b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_568bc3c6-0511-41ce-beed-27d4a7f513c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_86fc8dbb-ad4e-4f96-a4eb-f67b8f9170a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c56f2085-29af-4117-a57c-d80121393cab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease obligations, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e44f85a9-b4b2-42a3-8f2c-7bf8ac433978_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6fb71282-0be9-4e54-a212-2c7211c333c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_fadf63e6-ba0a-44f7-a8cd-fa3bd077b4d6_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8c0c413c-4599-4984-93f2-8aff1e979596_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8ada89be-0d83-4bcc-9f43-6a9227230a7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a9051fa7-aa44-42e5-aa9a-2c6e8a8222ae_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_631d4775-dfb7-4b47-ac7c-207c55f7240a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a570fa93-fa2a-45e5-b8fa-798d56c41618_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d4b5ab36-39c3-451d-a309-9a3931c09960_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_670e8a00-c664-489b-8020-503a0709e08c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93791982-7d73-434c-b2cb-ef1fd331126a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3e7b21fc-8122-43cf-bd4d-47cf7a2efa79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value, shares outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_07c68254-aa8f-4c24-aeca-ad91fdc99fa7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1df407c2-5e6a-4e63-b5cc-696642c7ba55_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83eb55c8-2af0-408f-8796-55720a3921f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_8f77e457-0760-4197-8538-9228ffa62282_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_TechnologyDevelopmentRevenueMember_e9f46991-b62a-40e4-93ec-dc9d4e00feaa_terseLabel_en-US" xlink:label="lab_absi_TechnologyDevelopmentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner program revenue</link:label>
    <link:label id="lab_absi_TechnologyDevelopmentRevenueMember_label_en-US" xlink:label="lab_absi_TechnologyDevelopmentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Development Revenue [Member]</link:label>
    <link:label id="lab_absi_TechnologyDevelopmentRevenueMember_documentation_en-US" xlink:label="lab_absi_TechnologyDevelopmentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Development Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_TechnologyDevelopmentRevenueMember" xlink:href="absi-20250930.xsd#absi_TechnologyDevelopmentRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_TechnologyDevelopmentRevenueMember" xlink:to="lab_absi_TechnologyDevelopmentRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e545d21-500e-444a-8110-339f3f279009_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend Yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e34cfd49-79a0-4175-830e-6fa693287381_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from customer contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6e11f294-43f6-4735-972d-65a289da2571_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance unvested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3bebf4a0-d3ca-4dff-b88b-6d103931f394_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance unvested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_cc716ec0-c960-4976-9996-ba2c41fc142b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, long-term</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_A2020StockOptionAndGrantPlanMember_906e58bc-e13f-47ca-b2af-6c6d61c6c108_terseLabel_en-US" xlink:label="lab_absi_A2020StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_absi_A2020StockOptionAndGrantPlanMember_label_en-US" xlink:label="lab_absi_A2020StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Stock Option and Grant Plan [Member]</link:label>
    <link:label id="lab_absi_A2020StockOptionAndGrantPlanMember_documentation_en-US" xlink:label="lab_absi_A2020StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Stock Option and Grant Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2020StockOptionAndGrantPlanMember" xlink:href="absi-20250930.xsd#absi_A2020StockOptionAndGrantPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_A2020StockOptionAndGrantPlanMember" xlink:to="lab_absi_A2020StockOptionAndGrantPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_614c51ec-da9a-4629-b6c8-83ce4073e795_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9462c1d0-2504-4041-951e-3a807bdf48af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_54c39a16-6075-4292-bb6d-9b0e5e432139_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53dada5f-cbcf-4ac2-8a8d-209d81d0ae5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50261e21-d959-457e-8560-b1d7b0288503_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_9c97fae6-ec8d-42f1-89d1-8c6b249f30ba_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7f703c56-31a4-47d7-ae4d-68f68f80e03e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18c555a6-26ec-4adc-a3cf-442f2d4aa161_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_beb7971d-ea7f-487f-af9d-cd4f22512a3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d629b728-44b5-4fa8-a799-7ceae1d9a3da_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b05e0b8c-4054-4b6c-af1d-27c59b7d5437_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a7ef30f1-1165-4659-ae65-16d1f8a9e771_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c390d90e-9479-47f6-93d5-5463447fdddd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_cd00b029-73ac-4fe3-9a4f-71ae4358b91f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock through employee equity plans, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0b70648f-c7f1-4e69-aed8-5fb8cf9609c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e43d7aaa-dd4e-4542-87da-c4922c8355ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81bae9a8-5939-465b-8ad5-fa236dde94a8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding: diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f55867d3-bbe6-438e-a668-18a409127d11_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments (See Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_86e6c7fa-83f2-473e-95e1-8086cb725e3a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_22dce3fb-55b8-419b-a106-fb28aba085e3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_5aad5c83-3979-4b3b-8cbd-f62f76a06282_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Non-vested Share Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d7c18645-84b1-40ea-9bef-12791cd0d1f0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction_22d796f7-b4cc-47ea-9dde-fd422bc9bb44_terseLabel_en-US" xlink:label="lab_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction_label_en-US" xlink:label="lab_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Authorized For Issuances In Transaction</link:label>
    <link:label id="lab_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction_documentation_en-US" xlink:label="lab_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Authorized For Issuances In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" xlink:href="absi-20250930.xsd#absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" xlink:to="lab_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_07a859a5-7351-4b35-bba7-4cf9060f839f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities_90ca5fcb-1e3f-4497-8a76-306a073c6ca8_terseLabel_en-US" xlink:label="lab_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities</link:label>
    <link:label id="lab_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities_label_en-US" xlink:label="lab_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Operating Lease Right-Of-Use Assets And Liabilities</link:label>
    <link:label id="lab_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities_documentation_en-US" xlink:label="lab_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Operating Lease Right-Of-Use Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:href="absi-20250930.xsd#absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="lab_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c5ce2be3-3837-470e-b334-cb652202974a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_18df4379-b0e7-4cf6-a4c0-17cc8353e86a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_99aef2a9-d6d8-41b3-a916-bcbf266229b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled/Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_95a05087-738d-413f-b881-6d0b9fcc61c2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability for a payment</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2bb31aee-e458-4667-84bf-55237ab5c8c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8cd8676d-23b5-49b5-8ea1-05a52ae6aea5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_30f68d1a-a15c-4d87-bf07-ad040fc6aea4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ef23ce13-f345-4ccf-bf34-ee555a562e15_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_538f77a5-671a-42e0-9755-cca05ece481c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9d8af750-1d7d-41a1-8226-2bd033aa434e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_8c119ad2-c240-41e1-b415-d373c83927f7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_ShelfRegistrationMember_c4c851a8-5a4b-4fe7-be07-6619d2ef0e38_terseLabel_en-US" xlink:label="lab_absi_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf Registration</link:label>
    <link:label id="lab_absi_ShelfRegistrationMember_label_en-US" xlink:label="lab_absi_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration [Member]</link:label>
    <link:label id="lab_absi_ShelfRegistrationMember_documentation_en-US" xlink:label="lab_absi_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ShelfRegistrationMember" xlink:href="absi-20250930.xsd#absi_ShelfRegistrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_ShelfRegistrationMember" xlink:to="lab_absi_ShelfRegistrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45d9d833-d6dc-4020-8491-078c2a17e948_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f1e53164-4cf0-4c0c-8d11-78a8d9c1e771_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c8000dc3-b1f7-4751-b715-d39a6ab74970_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_CowenAndCompanyLLCMember_d8900bef-e75a-4615-b6dd-a506f5df6440_terseLabel_en-US" xlink:label="lab_absi_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cowen and Company L L C</link:label>
    <link:label id="lab_absi_CowenAndCompanyLLCMember_label_en-US" xlink:label="lab_absi_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cowen And Company L L C [Member]</link:label>
    <link:label id="lab_absi_CowenAndCompanyLLCMember_documentation_en-US" xlink:label="lab_absi_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cowen And Company L L C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_CowenAndCompanyLLCMember" xlink:href="absi-20250930.xsd#absi_CowenAndCompanyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_CowenAndCompanyLLCMember" xlink:to="lab_absi_CowenAndCompanyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2e9046cc-0dad-44b4-8661-e2479cce306a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled/Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd7b719e-0e26-42df-9c90-a75d58d2bc3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_b71b41bd-4c4a-4e2e-b7d9-2c72e8188446_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_016b9f0a-4de6-4544-9e75-fb1043df6ca0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_ProceedsFromCollaborativeArrangement_eac8ddb9-2635-4a31-9860-6883fe16c3db_terseLabel_en-US" xlink:label="lab_absi_ProceedsFromCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaborative arrangements</link:label>
    <link:label id="lab_absi_ProceedsFromCollaborativeArrangement_label_en-US" xlink:label="lab_absi_ProceedsFromCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Collaborative Arrangement</link:label>
    <link:label id="lab_absi_ProceedsFromCollaborativeArrangement_documentation_en-US" xlink:label="lab_absi_ProceedsFromCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ProceedsFromCollaborativeArrangement" xlink:href="absi-20250930.xsd#absi_ProceedsFromCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_ProceedsFromCollaborativeArrangement" xlink:to="lab_absi_ProceedsFromCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9745f4ba-7b1b-4860-b739-ee434f5102ba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1c792b83-5159-495f-97b6-4c20c94082ab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_e2784757-a0db-4952-af81-89ed52d28948_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_AdvancedMicroDevicesIncMember_046c37ac-d7f0-4d7c-96c6-f311c55cfc5b_terseLabel_en-US" xlink:label="lab_absi_AdvancedMicroDevicesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced Micro Devices, Inc</link:label>
    <link:label id="lab_absi_AdvancedMicroDevicesIncMember_label_en-US" xlink:label="lab_absi_AdvancedMicroDevicesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Micro Devices, Inc [Member]</link:label>
    <link:label id="lab_absi_AdvancedMicroDevicesIncMember_documentation_en-US" xlink:label="lab_absi_AdvancedMicroDevicesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advanced Micro Devices, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AdvancedMicroDevicesIncMember" xlink:href="absi-20250930.xsd#absi_AdvancedMicroDevicesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_AdvancedMicroDevicesIncMember" xlink:to="lab_absi_AdvancedMicroDevicesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_93673d7c-a4c2-4f42-be93-b3cdcd425e0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d0fffdc9-46eb-4af3-8797-fd51c24a11de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3da1dd3b-8ea9-442b-99d2-756fb8a81161_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6effcc10-99af-4558-9b7b-3f8d48329f33_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share: diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_SaleOfStockSalesAgentCommissionPercentage_d7756aaf-9f06-4575-8446-0b450823c4b6_terseLabel_en-US" xlink:label="lab_absi_SaleOfStockSalesAgentCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, commission (as a percent)</link:label>
    <link:label id="lab_absi_SaleOfStockSalesAgentCommissionPercentage_label_en-US" xlink:label="lab_absi_SaleOfStockSalesAgentCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Sales Agent Commission Percentage</link:label>
    <link:label id="lab_absi_SaleOfStockSalesAgentCommissionPercentage_documentation_en-US" xlink:label="lab_absi_SaleOfStockSalesAgentCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Sales Agent Commission Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockSalesAgentCommissionPercentage" xlink:href="absi-20250930.xsd#absi_SaleOfStockSalesAgentCommissionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_SaleOfStockSalesAgentCommissionPercentage" xlink:to="lab_absi_SaleOfStockSalesAgentCommissionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2349e072-f0c4-4e38-93e3-64a6b15994e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5b9f3b41-2275-4e92-b9c5-4a4fbc126948_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_558872a7-1697-4f20-b210-f04fc16b24d4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b6b04386-db4c-45b7-bdac-0edaeb19e9bb_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c68d4078-0c8f-4891-bc1d-b40d8ffd731f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued and sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_TDSecuritiesUSALLCMember_cfa552b7-e2e0-4016-a1e7-999835c0b46f_terseLabel_en-US" xlink:label="lab_absi_TDSecuritiesUSALLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TD Securities (USA) LLC</link:label>
    <link:label id="lab_absi_TDSecuritiesUSALLCMember_label_en-US" xlink:label="lab_absi_TDSecuritiesUSALLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TD Securities (USA) LLC [Member]</link:label>
    <link:label id="lab_absi_TDSecuritiesUSALLCMember_documentation_en-US" xlink:label="lab_absi_TDSecuritiesUSALLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TD Securities (USA) LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_TDSecuritiesUSALLCMember" xlink:href="absi-20250930.xsd#absi_TDSecuritiesUSALLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_TDSecuritiesUSALLCMember" xlink:to="lab_absi_TDSecuritiesUSALLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7374b36e-1127-47a7-bb0f-40020605850f_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aed11281-55f0-4387-a4dc-d160df34a653_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_aebb2d7e-495a-4acb-9849-fb48f8e7b73a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_3b14aaef-84b0-4cb1-b3ad-0f7c30fce745_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_NumberOfPartners_c8d2649a-6a17-4a8a-bf4f-49257c498189_terseLabel_en-US" xlink:label="lab_absi_NumberOfPartners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of partners (partner)</link:label>
    <link:label id="lab_absi_NumberOfPartners_label_en-US" xlink:label="lab_absi_NumberOfPartners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Partners</link:label>
    <link:label id="lab_absi_NumberOfPartners_documentation_en-US" xlink:label="lab_absi_NumberOfPartners" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_NumberOfPartners" xlink:href="absi-20250930.xsd#absi_NumberOfPartners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_NumberOfPartners" xlink:to="lab_absi_NumberOfPartners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c99fc422-12a7-4bdf-8c2c-bef41760bd16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_df6f4866-e2c2-46ad-acea-7f6c6ef77f94_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20a73759-a440-47b9-b421-3ba1c1207ef8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ca20bd15-b597-404b-9c75-eb90208a11eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e763d8b9-d5fb-4048-b7f3-5230d95840cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ab5b8a1c-c387-410f-b4e2-a2d1f012e771_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f5341bc6-423f-433a-9dca-70560e9b8a57_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_38328093-98ea-469b-be63-79306812639b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8492fcdc-50fc-4874-8aed-2fa3cf9b8feb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_24c5235f-e296-4268-a15d-6ea01854eca9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f355dd76-d2b5-4069-bb48-9b9139ec0827_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_368d4611-06dd-4d64-927b-1794d6430f2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b887ffbf-bb8b-4339-90b5-6286b983e46f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8799e2c4-3fe9-4952-9986-8c06f1400c2c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_f3ecbcf6-c92e-4090-b41d-6a9031da3d63_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_08f5286e-2617-46bc-8ab3-8d5161d5c841_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_307e78ca-2184-47d6-9484-8c27d4d002fa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Debt and Equity Instruments and Cash and Cash Equivalent [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e230af76-8e05-447c-aad3-4415ea74df16_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_A2021StockOptionAndGrantPlanMember_0b95f9c6-8889-4367-bff1-d5cf2c21d077_terseLabel_en-US" xlink:label="lab_absi_A2021StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_absi_A2021StockOptionAndGrantPlanMember_label_en-US" xlink:label="lab_absi_A2021StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Stock Option and Grant Plan [Member]</link:label>
    <link:label id="lab_absi_A2021StockOptionAndGrantPlanMember_documentation_en-US" xlink:label="lab_absi_A2021StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Stock Option and Grant Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2021StockOptionAndGrantPlanMember" xlink:href="absi-20250930.xsd#absi_A2021StockOptionAndGrantPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_A2021StockOptionAndGrantPlanMember" xlink:to="lab_absi_A2021StockOptionAndGrantPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_eabf5c7a-8200-43e0-a0b0-78056bf4c455_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalUnitLineItems_7c75458c-2448-4c8e-8e55-dbf8ee754ea4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalUnitLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Unit</link:label>
    <link:label id="lab_us-gaap_CapitalUnitLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalUnitLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Unit [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitLineItems" xlink:to="lab_us-gaap_CapitalUnitLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_18e898c5-c9c5-4c64-9d41-e66c13cdde71_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b4467dbd-bd9b-4b26-8254-a9ced004db9a_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b8a9f0b6-934e-452c-b47b-e04a72c70752_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_69ae5679-ea86-4b8f-a26d-d9ac5e152ef2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_71e0f1fe-089a-4906-b532-a91b241b3ac9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_AtTheMarketOfferingProgramMember_708033c5-03f2-4833-83f1-325531ff9232_terseLabel_en-US" xlink:label="lab_absi_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Offering Program</link:label>
    <link:label id="lab_absi_AtTheMarketOfferingProgramMember_label_en-US" xlink:label="lab_absi_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Program [Member]</link:label>
    <link:label id="lab_absi_AtTheMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_absi_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AtTheMarketOfferingProgramMember" xlink:href="absi-20250930.xsd#absi_AtTheMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_AtTheMarketOfferingProgramMember" xlink:to="lab_absi_AtTheMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_738f52d5-96d3-4866-9bbd-ba6bd36fbf11_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d635cc34-3dcf-48c2-bb72-9962d405a1af_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a1a077fd-39ae-469c-86f7-47666462bd3c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cb3bbb94-8e03-4fbd-b68a-95c46c13a6f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afb4a26-6c4a-4ab6-af41-5278e8e569c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3db819f4-b451-4259-ae2d-a1333d19c9bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_591f24f7-b18d-42f8-8524-ee8ca6d7af94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_45441cba-1492-48e0-895b-ae869d52c627_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08c1e5b-02d8-4af8-a5b9-f48163631f5d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_13d7487d-a2a9-4140-992a-a5888f296244_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_54a68d41-2294-4cac-a2f1-3102b05ea26a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_69f4d769-5b0c-4bbb-a1cd-3c9d32b1c142_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_448c8a3f-e358-424f-ac86-f56a83e7e6cb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and nature of operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37942450-4c27-494d-8896-f5db15a976f2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b1b8b6c6-fc0b-4b20-b4a3-a8b1e005103e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5dc9c96f-69fb-4f11-a75e-c2932e1b2004_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for employee (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_30eb6a2b-5e2d-4553-ae0b-458ac97e5a4d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e9119a87-569e-4ef4-bb3d-c47edb2a2748_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_8a7373b6-705b-4aa6-8e4a-800aa588a54b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3461ba04-45f2-4fa9-bd4a-80fd4301011f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding: basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_201e7a74-040c-4bc4-8593-898c9507ed32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d90b1f8f-9e30-4065-b19a-742518d9dc77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_66bf98d2-7d82-43ed-8d18-3d46d295dbd1_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d554c806-4623-472d-9205-fb0cfe5d57c8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_439e0660-a81f-4c84-abd7-693cf0e9ef51_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9322c781-8c02-45e9-9816-260140a4dcff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5549ffe-d9cd-415b-9e79-a5a4e902bab5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_945db754-5f22-498d-8158-d61b417399bb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_79b18647-5ac9-41cd-944b-5c303a4a184d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures_e1df69fd-8043-4085-8e2f-03bc242875e3_terseLabel_en-US" xlink:label="lab_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares under stock plans, net of shares withheld for tax payments</link:label>
    <link:label id="lab_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures_label_en-US" xlink:label="lab_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures</link:label>
    <link:label id="lab_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures_documentation_en-US" xlink:label="lab_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" xlink:href="absi-20250930.xsd#absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" xlink:to="lab_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_327232b1-cd95-4ffd-970c-0928578cef7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2123d902-4062-4f46-af17-f857d8e48126_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_10cce758-b66e-4b60-b8c8-102c83d41cb9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dc6981b8-a89c-4c30-ad53-d003e630e03d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_53aa6ba4-5316-4a80-b3a7-e4fdf3efee6f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_9202cf29-728f-44ad-bf4c-8822c628cd10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ccc6e3b5-3f5f-4706-b3b4-9827a9e5ffc0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a8230aa-b902-49ae-9ecc-29021840214f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7968028a-84e1-469c-a33d-76e0ecf9625c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c0b1c320-1806-4d38-aaba-6ad065a18eb1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalUnitsTable_13b9936a-0704-40c2-983c-87288e4e5a63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalUnitsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, Capital Unit or Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalUnitsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalUnitsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Capital Unit or Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCapitalUnitsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable" xlink:to="lab_us-gaap_ScheduleOfCapitalUnitsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_84a518bd-79af-403d-8c2d-299de85946a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_87854521-a099-4aa9-8ba2-ab142cbed191_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2f595025-a678-4676-b208-42c9aab307e5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e8283706-fd97-4943-9b84-f6009c52cccf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_663113ee-f80a-41a5-954e-858a4a89da3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e24487a8-3df3-428e-b564-4e1d58015157_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1f9438f9-3652-430f-abb6-cf8367c44c9d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_459ee973-cffc-4f9e-be0c-c7d18e2a00ed_verboseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87d16664-6e84-4087-8379-c56cf90dd9a7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_09b1603d-8819-4e69-9a0b-fef11b5a8f80_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash Equivalent, period increase (decrease), including exchange rate effect and discontinued operation</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_bd3a17a8-ffa5-4258-9441-bb46c757bb04_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>absi-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a3e69f22-3845-4b88-95f7-36018340f30a,g:dbd2b148-ca4f-47a0-84c9-32244e24e6c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.absci.com/role/Cover" xlink:type="simple" xlink:href="absi-20250930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9bf06518-ddb4-4eaf-ad9c-f427ee34e304" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_DocumentType_9bf06518-ddb4-4eaf-ad9c-f427ee34e304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4c0138b7-77be-4869-9060-c444ece85343" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_DocumentQuarterlyReport_4c0138b7-77be-4869-9060-c444ece85343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6c9c04fc-1222-4e9e-807f-eb6f11213e88" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_DocumentPeriodEndDate_6c9c04fc-1222-4e9e-807f-eb6f11213e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1f746afd-8cbe-4bbe-9e31-a0a3dd190e6b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_DocumentTransitionReport_1f746afd-8cbe-4bbe-9e31-a0a3dd190e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_32936038-8051-43b2-a3c1-c90fa274750b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityFileNumber_32936038-8051-43b2-a3c1-c90fa274750b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_94309820-ceb4-4839-9209-18903aab11b2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityRegistrantName_94309820-ceb4-4839-9209-18903aab11b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_82999d59-cae4-481e-9bdd-3bbff71cadb5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_82999d59-cae4-481e-9bdd-3bbff71cadb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_739e8f7d-4d4b-42aa-9c99-ceddc691b8eb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityTaxIdentificationNumber_739e8f7d-4d4b-42aa-9c99-ceddc691b8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_896f531b-6716-40d6-9229-f2661b2b7261" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityAddressAddressLine1_896f531b-6716-40d6-9229-f2661b2b7261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_66a453cd-112d-4b02-b79b-4ae9b5db8522" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityAddressCityOrTown_66a453cd-112d-4b02-b79b-4ae9b5db8522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4206f8a3-c435-4562-80b2-b5795a7a7000" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityAddressStateOrProvince_4206f8a3-c435-4562-80b2-b5795a7a7000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ad85adc9-bff2-4b14-a9c9-0a812114809b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityAddressPostalZipCode_ad85adc9-bff2-4b14-a9c9-0a812114809b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f511625a-5cf7-41c0-a3d2-43f1f3066ef2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_CityAreaCode_f511625a-5cf7-41c0-a3d2-43f1f3066ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a5fbd9bb-1ff5-49ca-87cd-28215ef98f53" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_LocalPhoneNumber_a5fbd9bb-1ff5-49ca-87cd-28215ef98f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_06c73ec2-9658-4fcb-8e06-9b8dee61e3a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_Security12bTitle_06c73ec2-9658-4fcb-8e06-9b8dee61e3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9199985e-5089-4e60-a5e7-06d124a10a07" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_TradingSymbol_9199985e-5089-4e60-a5e7-06d124a10a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4f0395a9-8732-49e2-9daf-99755a867778" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_SecurityExchangeName_4f0395a9-8732-49e2-9daf-99755a867778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f0d8afd3-012b-4cc0-88f5-5d0620cbbd9d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityCurrentReportingStatus_f0d8afd3-012b-4cc0-88f5-5d0620cbbd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1935533f-a800-45c2-9a77-65ad21f154ba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityInteractiveDataCurrent_1935533f-a800-45c2-9a77-65ad21f154ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6b084f4a-5a8a-4f5f-86a4-a04010ac136b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityFilerCategory_6b084f4a-5a8a-4f5f-86a4-a04010ac136b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bcaf6357-f4e1-4916-bb22-ff234dec141e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntitySmallBusiness_bcaf6357-f4e1-4916-bb22-ff234dec141e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ee39cf6d-8508-490e-b296-cd3058e9188b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityEmergingGrowthCompany_ee39cf6d-8508-490e-b296-cd3058e9188b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_90f9e345-446e-458f-a69e-e11cff9613c6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityExTransitionPeriod_90f9e345-446e-458f-a69e-e11cff9613c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_77d65ed9-5659-4e0a-b610-6b163ad6f5f4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityShellCompany_77d65ed9-5659-4e0a-b610-6b163ad6f5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_123a3d1d-fdff-4727-8a35-1dab0f98e140" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_123a3d1d-fdff-4727-8a35-1dab0f98e140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_852b9783-2b76-46fa-871b-36fd237040f7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_AmendmentFlag_852b9783-2b76-46fa-871b-36fd237040f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_87f7bb48-a518-4cfb-be64-cf1af22a5db1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_CurrentFiscalYearEndDate_87f7bb48-a518-4cfb-be64-cf1af22a5db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_af432dc1-c872-4ad0-8ed9-f9260f25dfd6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_DocumentFiscalYearFocus_af432dc1-c872-4ad0-8ed9-f9260f25dfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_53452fb6-361f-4dc9-bbf1-2115cafab9e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_53452fb6-361f-4dc9-bbf1-2115cafab9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f7f75518-9ca2-4aa9-8de4-c9079224c5b0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b34f9980-2c06-4480-a184-325ec77f5bb4" xlink:to="loc_dei_EntityCentralIndexKey_f7f75518-9ca2-4aa9-8de4-c9079224c5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_650821c6-2ef6-4d56-903b-cd87a6a45ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_650821c6-2ef6-4d56-903b-cd87a6a45ac3" xlink:to="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ca2b675-3f43-41bc-98ce-958cd1c7cb80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ca2b675-3f43-41bc-98ce-958cd1c7cb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f57be29c-3a30-43cf-87a9-78fdcdb841ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:to="loc_us-gaap_RestrictedCash_f57be29c-3a30-43cf-87a9-78fdcdb841ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_61f68cdf-87ed-46e4-88a2-9d6f46e56876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_61f68cdf-87ed-46e4-88a2-9d6f46e56876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d085edd7-abc9-4dc2-86f7-0a3246a56698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d085edd7-abc9-4dc2-86f7-0a3246a56698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4657cb42-a405-46ab-8e38-28ee3d5b8bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4657cb42-a405-46ab-8e38-28ee3d5b8bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c52a1948-7bce-458f-bb76-3a07ab6848b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a60584d-45ea-4eb5-992d-9399dc13654c" xlink:to="loc_us-gaap_AssetsCurrent_c52a1948-7bce-458f-bb76-3a07ab6848b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f6624ef-3ad3-499c-95b7-2b7a9c0d303d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f6624ef-3ad3-499c-95b7-2b7a9c0d303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_55366bea-c769-4a6a-a511-6c12256501a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_55366bea-c769-4a6a-a511-6c12256501a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a997fd6a-ee55-415c-9d16-ad09e6a9f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a997fd6a-ee55-415c-9d16-ad09e6a9f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_80fa0e07-908e-4397-8ca5-8d1a4e8fe9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_80fa0e07-908e-4397-8ca5-8d1a4e8fe9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_78d1948d-c24e-4472-a11b-4423c57f8034" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_78d1948d-c24e-4472-a11b-4423c57f8034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_058b2806-81d1-4db2-b527-2f4e65acf8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0770fdbc-a7b7-4857-b398-d574c0e30092" xlink:to="loc_us-gaap_Assets_058b2806-81d1-4db2-b527-2f4e65acf8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_650821c6-2ef6-4d56-903b-cd87a6a45ac3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2a034849-6d33-406c-aa5a-08e6aaec9d36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_AccountsPayableCurrent_2a034849-6d33-406c-aa5a-08e6aaec9d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_729da2ae-2529-4066-9c8e-1df56b0cf3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_729da2ae-2529-4066-9c8e-1df56b0cf3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_568e56c6-1426-41f8-b719-d0468affce58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_568e56c6-1426-41f8-b719-d0468affce58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_a4b5751d-cd1a-47fa-b07f-8313535ec590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_NotesPayableCurrent_a4b5751d-cd1a-47fa-b07f-8313535ec590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f9a98b7-f2ed-4cb0-8af6-871eaa2c5d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f9a98b7-f2ed-4cb0-8af6-871eaa2c5d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_309134de-5586-4f26-92b0-84eb14533790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_309134de-5586-4f26-92b0-84eb14533790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5ad48491-58ee-4150-a1a0-48f1798c9d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5ad48491-58ee-4150-a1a0-48f1798c9d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_18e413e9-1f6c-437d-aa93-b44f476ff1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_93e36028-4261-4bc6-bebe-fe2fa2c8b7c7" xlink:to="loc_us-gaap_LiabilitiesCurrent_18e413e9-1f6c-437d-aa93-b44f476ff1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_fd1c8d7d-4086-46e5-a5f2-593365215ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_LongTermNotesPayable_fd1c8d7d-4086-46e5-a5f2-593365215ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbb477cc-86f4-494b-a1d4-673fa4a583cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbb477cc-86f4-494b-a1d4-673fa4a583cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_532ceb65-3432-4cb8-83ec-5a21c2c8c9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_532ceb65-3432-4cb8-83ec-5a21c2c8c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9c672070-f172-4fe6-a2e6-0d9cb98bb0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_Liabilities_9c672070-f172-4fe6-a2e6-0d9cb98bb0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_89382f4e-b7bb-4543-8942-e4323d10c516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_CommitmentsAndContingencies_89382f4e-b7bb-4543-8942-e4323d10c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_dc989f57-afc7-4c4a-b720-fe24d97c8482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:to="loc_us-gaap_PreferredStockValue_dc989f57-afc7-4c4a-b720-fe24d97c8482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2e8e4ae0-75a0-4b03-a132-34c6899ecb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:to="loc_us-gaap_CommonStockValue_2e8e4ae0-75a0-4b03-a132-34c6899ecb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5158050c-b1b4-4784-976a-281544d684c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5158050c-b1b4-4784-976a-281544d684c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4482a483-c6eb-431f-985b-79bc57492899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4482a483-c6eb-431f-985b-79bc57492899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7271ab0a-5494-44a3-a695-61a1c208e1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7271ab0a-5494-44a3-a695-61a1c208e1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c2919a2-5c96-49d7-9b9a-b98954f8f1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce785912-c837-499c-b2c9-6bafb543c072" xlink:to="loc_us-gaap_StockholdersEquity_3c2919a2-5c96-49d7-9b9a-b98954f8f1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dec47dd7-84b6-414c-a7b8-7c6c675c9c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9968353a-7199-4124-a5e9-a47178582110" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dec47dd7-84b6-414c-a7b8-7c6c675c9c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b7067565-5907-4966-b1e8-25de17134772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_RevenuesAbstract_b7067565-5907-4966-b1e8-25de17134772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5863e84c-4c02-4aa5-b1ba-f450954e6abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b7067565-5907-4966-b1e8-25de17134772" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5863e84c-4c02-4aa5-b1ba-f450954e6abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f03a41f3-a625-4b84-ab00-09787ead06bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f03a41f3-a625-4b84-ab00-09787ead06bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_aa6544e4-3b9a-45ff-95ec-8c8dc6d6f649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f03a41f3-a625-4b84-ab00-09787ead06bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_aa6544e4-3b9a-45ff-95ec-8c8dc6d6f649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_26d18db5-b5f1-446a-a33b-d699349887b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f03a41f3-a625-4b84-ab00-09787ead06bd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_26d18db5-b5f1-446a-a33b-d699349887b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d2828831-0374-4457-a06f-14055c81cc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f03a41f3-a625-4b84-ab00-09787ead06bd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d2828831-0374-4457-a06f-14055c81cc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_444379f9-a00a-4380-b729-743b74a5d398" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f03a41f3-a625-4b84-ab00-09787ead06bd" xlink:to="loc_us-gaap_OperatingExpenses_444379f9-a00a-4380-b729-743b74a5d398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0a262083-d9bb-44e5-85d9-d8962594895f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_0a262083-d9bb-44e5-85d9-d8962594895f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7ea5e84e-7333-4504-a47f-7e7a4e5ea7db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7ea5e84e-7333-4504-a47f-7e7a4e5ea7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b1ded848-c27b-4abb-bd84-63c908b2bc36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7ea5e84e-7333-4504-a47f-7e7a4e5ea7db" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b1ded848-c27b-4abb-bd84-63c908b2bc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fd1ef363-a5ec-4a92-a310-354329265141" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7ea5e84e-7333-4504-a47f-7e7a4e5ea7db" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fd1ef363-a5ec-4a92-a310-354329265141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5798ae84-03a4-4e07-ae46-7a4f5f0cbdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7ea5e84e-7333-4504-a47f-7e7a4e5ea7db" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5798ae84-03a4-4e07-ae46-7a4f5f0cbdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2ad58581-2265-462b-93a6-d7a55b72f2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2ad58581-2265-462b-93a6-d7a55b72f2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cffcfe17-9148-4713-bc15-04b254b5c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cffcfe17-9148-4713-bc15-04b254b5c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c1ec4cd-64ec-4b2f-a065-0c03df23a611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_NetIncomeLoss_8c1ec4cd-64ec-4b2f-a065-0c03df23a611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8951442c-e155-43a4-beaa-e5689debe696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_EarningsPerShareBasic_8951442c-e155-43a4-beaa-e5689debe696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_056765fe-bb12-442c-b557-3e38329a7dad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_EarningsPerShareDiluted_056765fe-bb12-442c-b557-3e38329a7dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88ea3c50-a46f-41d5-9220-4f17006657e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88ea3c50-a46f-41d5-9220-4f17006657e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f0e367a-75fc-4c19-baf3-95f864a47848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f0e367a-75fc-4c19-baf3-95f864a47848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_38ab8852-4223-473a-ad9b-cc89dc271900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_38ab8852-4223-473a-ad9b-cc89dc271900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c49f7865-2d69-4c5d-9019-58623a84e75b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_38ab8852-4223-473a-ad9b-cc89dc271900" xlink:to="loc_us-gaap_NetIncomeLoss_c49f7865-2d69-4c5d-9019-58623a84e75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_cfaafb58-9438-4e56-99ed-5d5cf4dbad29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_38ab8852-4223-473a-ad9b-cc89dc271900" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_cfaafb58-9438-4e56-99ed-5d5cf4dbad29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dcc6f259-5a8c-4b3b-8286-51213d8cea78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_38ab8852-4223-473a-ad9b-cc89dc271900" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dcc6f259-5a8c-4b3b-8286-51213d8cea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0b1061e5-254c-42a5-b8a5-06d58e9dc4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_38ab8852-4223-473a-ad9b-cc89dc271900" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0b1061e5-254c-42a5-b8a5-06d58e9dc4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_2f203738-b8dc-4c91-a5be-d073f3ad8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09ed234e-5ca2-4289-8de7-779f913d48ac" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_2f203738-b8dc-4c91-a5be-d073f3ad8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0448d4e5-91ee-4723-87ff-98a2a577ed01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9b0aa124-6540-46b1-9b06-dc279daa51c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0448d4e5-91ee-4723-87ff-98a2a577ed01" xlink:to="loc_us-gaap_StatementTable_9b0aa124-6540-46b1-9b06-dc279daa51c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fd67adc-d3da-47fc-b500-1bf102df55fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9b0aa124-6540-46b1-9b06-dc279daa51c2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fd67adc-d3da-47fc-b500-1bf102df55fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fd67adc-d3da-47fc-b500-1bf102df55fe" xlink:to="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_38b243e9-12e0-4d12-b11c-506605bcbcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_CommonStockMember_38b243e9-12e0-4d12-b11c-506605bcbcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3fd7f887-d108-4ffa-a7d8-f7ceb684b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3fd7f887-d108-4ffa-a7d8-f7ceb684b7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_87ae5977-f44a-4b81-9d67-fd996054afe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_RetainedEarningsMember_87ae5977-f44a-4b81-9d67-fd996054afe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1ddbeb94-2e8b-4171-95ff-d60f024d90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbc03527-84df-4c42-8a8b-32100633e642" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1ddbeb94-2e8b-4171-95ff-d60f024d90e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e6419b30-1046-488f-a286-1531b283e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9b0aa124-6540-46b1-9b06-dc279daa51c2" xlink:to="loc_us-gaap_StatementLineItems_e6419b30-1046-488f-a286-1531b283e0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e6419b30-1046-488f-a286-1531b283e0aa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_24425bad-6a4d-4056-a938-07831de0e3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_24425bad-6a4d-4056-a938-07831de0e3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fef92bb-55b6-4df4-98de-ec4000b380d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockholdersEquity_9fef92bb-55b6-4df4-98de-ec4000b380d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d58002ee-baa9-4613-a92c-ea42d297775d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d58002ee-baa9-4613-a92c-ea42d297775d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a19dbcc1-e025-45d9-9832-57217f548aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a19dbcc1-e025-45d9-9832-57217f548aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6a55307d-dd33-4799-ab5c-e7b0d45937e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6a55307d-dd33-4799-ab5c-e7b0d45937e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures_87b3b631-feb1-4b4c-82ad-fad8e35f4af8" xlink:href="absi-20250930.xsd#absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures_87b3b631-feb1-4b4c-82ad-fad8e35f4af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acae3637-887f-4f6d-bbff-4bd5d1890cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acae3637-887f-4f6d-bbff-4bd5d1890cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4fa0809-f133-4eb3-b91b-20c92022af3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b4fa0809-f133-4eb3-b91b-20c92022af3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_31c89a5a-8ed5-4676-8eca-f15ecdf06111" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_31c89a5a-8ed5-4676-8eca-f15ecdf06111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_110460d4-e890-4275-8d1f-e8da1bc730e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_110460d4-e890-4275-8d1f-e8da1bc730e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_09002622-cfda-4def-85cf-74101f8a62f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_09002622-cfda-4def-85cf-74101f8a62f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_972ffd66-082b-4c83-a936-fa15faecd4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_NetIncomeLoss_972ffd66-082b-4c83-a936-fa15faecd4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6db64b48-5bf3-47aa-8215-a1b1371088e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6db64b48-5bf3-47aa-8215-a1b1371088e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e92aabbb-3fc6-4b25-ad01-1f946fdb4c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e65c8dc7-0e7f-4572-905a-ce43046faa4e" xlink:to="loc_us-gaap_StockholdersEquity_e92aabbb-3fc6-4b25-ad01-1f946fdb4c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_488a67e9-f90b-43e9-aaba-c0980199b7af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_59ceb06c-8051-4f6a-9d06-2cf5976832f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_488a67e9-f90b-43e9-aaba-c0980199b7af" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_59ceb06c-8051-4f6a-9d06-2cf5976832f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f3ed7fd-d8f7-4ade-b27b-fd3d0876da76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_488a67e9-f90b-43e9-aaba-c0980199b7af" xlink:to="loc_us-gaap_NetIncomeLoss_0f3ed7fd-d8f7-4ade-b27b-fd3d0876da76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="absi-20250930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c088ca36-c0d2-473f-89cf-24a24bc63f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c088ca36-c0d2-473f-89cf-24a24bc63f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1add6272-14ff-4855-be73-14903a23e32e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c088ca36-c0d2-473f-89cf-24a24bc63f4d" xlink:to="loc_us-gaap_NetIncomeLoss_1add6272-14ff-4855-be73-14903a23e32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0cc58f73-f7a1-49d4-b155-f58e8ce636b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c088ca36-c0d2-473f-89cf-24a24bc63f4d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0cc58f73-f7a1-49d4-b155-f58e8ce636b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2a88e371-64ad-4df7-9386-9a2b53f48c46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0cc58f73-f7a1-49d4-b155-f58e8ce636b2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2a88e371-64ad-4df7-9386-9a2b53f48c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a6245ffb-9ddb-4b91-b846-edd57c49b519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0cc58f73-f7a1-49d4-b155-f58e8ce636b2" xlink:to="loc_us-gaap_ShareBasedCompensation_a6245ffb-9ddb-4b91-b846-edd57c49b519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_eb9e9a37-7075-49b9-a180-c067ca4520f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0cc58f73-f7a1-49d4-b155-f58e8ce636b2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_eb9e9a37-7075-49b9-a180-c067ca4520f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_13a0545b-0fe1-4286-9548-39cf45e22613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0cc58f73-f7a1-49d4-b155-f58e8ce636b2" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_13a0545b-0fe1-4286-9548-39cf45e22613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0cc58f73-f7a1-49d4-b155-f58e8ce636b2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ae9c414d-78b7-4459-8032-a36c325e0879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ae9c414d-78b7-4459-8032-a36c325e0879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9ff3898b-22da-4034-8f4b-25466839cf94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9ff3898b-22da-4034-8f4b-25466839cf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities_792c8570-1a90-416b-aece-1b9154da69b4" xlink:href="absi-20250930.xsd#absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:to="loc_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities_792c8570-1a90-416b-aece-1b9154da69b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d3235c67-1328-43a6-90cf-ce60c2989bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d3235c67-1328-43a6-90cf-ce60c2989bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_da691246-3d8c-477a-862b-6880b380dd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_da691246-3d8c-477a-862b-6880b380dd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_b1ac708d-a5f2-4826-9357-4b21ef12f3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_b1ac708d-a5f2-4826-9357-4b21ef12f3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1e253fe4-13ca-4b16-a71d-347096ae1bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_520c13b7-5c58-488f-aa62-ad7c57f52c3c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1e253fe4-13ca-4b16-a71d-347096ae1bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54e917a3-0e61-4932-90db-cd073bb63696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c088ca36-c0d2-473f-89cf-24a24bc63f4d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54e917a3-0e61-4932-90db-cd073bb63696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ef2fc546-b9e1-40ed-9143-fe533d32b141" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ef2fc546-b9e1-40ed-9143-fe533d32b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17f3bcd6-2789-4784-82e2-392b8f43d6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ef2fc546-b9e1-40ed-9143-fe533d32b141" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17f3bcd6-2789-4784-82e2-392b8f43d6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_db87ba95-37d2-4b97-8273-6a573ef67737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ef2fc546-b9e1-40ed-9143-fe533d32b141" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_db87ba95-37d2-4b97-8273-6a573ef67737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_97c503c5-b8ca-4b18-8091-b05f0c10b9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ef2fc546-b9e1-40ed-9143-fe533d32b141" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_97c503c5-b8ca-4b18-8091-b05f0c10b9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ea66b69a-6281-48c7-bb7e-0b06f80dd73d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ef2fc546-b9e1-40ed-9143-fe533d32b141" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ea66b69a-6281-48c7-bb7e-0b06f80dd73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e901ca8a-b3e1-4157-b870-ab9a9bb713a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ef2fc546-b9e1-40ed-9143-fe533d32b141" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e901ca8a-b3e1-4157-b870-ab9a9bb713a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e60a0549-1345-4066-871b-d6920b8ed261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e60a0549-1345-4066-871b-d6920b8ed261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5514287d-04f5-436b-bfc1-051b227535b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e60a0549-1345-4066-871b-d6920b8ed261" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5514287d-04f5-436b-bfc1-051b227535b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0aad0ad4-3466-47c1-9d0a-74bbc55064dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e60a0549-1345-4066-871b-d6920b8ed261" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0aad0ad4-3466-47c1-9d0a-74bbc55064dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_59b1194d-4808-4c48-ace3-9b25ac2645ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e60a0549-1345-4066-871b-d6920b8ed261" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_59b1194d-4808-4c48-ace3-9b25ac2645ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b6257a87-1b98-4a43-850f-be8905664e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e60a0549-1345-4066-871b-d6920b8ed261" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b6257a87-1b98-4a43-850f-be8905664e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2d0bf879-19ed-4b86-8ea6-9ff2dfa6512d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e60a0549-1345-4066-871b-d6920b8ed261" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2d0bf879-19ed-4b86-8ea6-9ff2dfa6512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b6bc012-ecca-4f92-bddb-16e116d8fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b6bc012-ecca-4f92-bddb-16e116d8fbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e985e91-5166-46ab-a41a-0a03b0fff31a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e985e91-5166-46ab-a41a-0a03b0fff31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ee1e908-300b-4754-a153-804e3d8855d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ee1e908-300b-4754-a153-804e3d8855d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6dd6ce35-c126-4ae9-b0ed-b2f3ec7b42c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2dfc9a8e-789e-4b9e-a742-5afb997c6922" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6dd6ce35-c126-4ae9-b0ed-b2f3ec7b42c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_71e19c8f-a7fb-4309-887d-f72579bc2735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6dd6ce35-c126-4ae9-b0ed-b2f3ec7b42c9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_71e19c8f-a7fb-4309-887d-f72579bc2735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Organizationandnatureofoperations" xlink:type="simple" xlink:href="absi-20250930.xsd#Organizationandnatureofoperations"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Organizationandnatureofoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e61bb075-16e5-4e02-8360-9c88bcce0533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4e84b1b4-4c35-48dd-99bd-7bd76f503a07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e61bb075-16e5-4e02-8360-9c88bcce0533" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4e84b1b4-4c35-48dd-99bd-7bd76f503a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Revenuerecognition" xlink:type="simple" xlink:href="absi-20250930.xsd#Revenuerecognition"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Revenuerecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fccd358-7ebf-4f51-b56a-8f2311de47c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_16acde8a-b1c7-41c3-b960-53881f3f7eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fccd358-7ebf-4f51-b56a-8f2311de47c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_16acde8a-b1c7-41c3-b960-53881f3f7eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Collaborativearrangements" xlink:type="simple" xlink:href="absi-20250930.xsd#Collaborativearrangements"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Collaborativearrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee91c009-66d0-4e89-b871-7a299f60cc24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c05356f7-507d-4c2b-b22e-4515804c06cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee91c009-66d0-4e89-b871-7a299f60cc24" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c05356f7-507d-4c2b-b22e-4515804c06cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Investments" xlink:type="simple" xlink:href="absi-20250930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_ff69b641-ab2c-4f87-9dce-934e99e3075e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_01e5d064-7dc5-49e2-aa29-6b862ee30e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ff69b641-ab2c-4f87-9dce-934e99e3075e" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_01e5d064-7dc5-49e2-aa29-6b862ee30e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="absi-20250930.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_32bfdfa1-05ce-40d2-8519-4eda471efe88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_72bfd858-fa18-4376-91bf-224b71f88d02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_32bfdfa1-05ce-40d2-8519-4eda471efe88" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_72bfd858-fa18-4376-91bf-224b71f88d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="absi-20250930.xsd#Commitmentsandcontingencies"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Commitmentsandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b31ae0a9-6a64-4b0d-84bf-2fbe11e58661" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c79fdac3-c5da-48da-b796-6d578b61934a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b31ae0a9-6a64-4b0d-84bf-2fbe11e58661" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c79fdac3-c5da-48da-b796-6d578b61934a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Commonstock" xlink:type="simple" xlink:href="absi-20250930.xsd#Commonstock"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Commonstock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a0c572ce-a816-401b-9d65-98dab1e79566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_73aa58e5-43ae-4ce9-a23f-560add75846b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a0c572ce-a816-401b-9d65-98dab1e79566" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_73aa58e5-43ae-4ce9-a23f-560add75846b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="absi-20250930.xsd#Stockbasedcompensation"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Stockbasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bbcb10f-8ff0-4e8e-a230-9608c9adbc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_105070a7-78cf-4adb-a48f-42bc725f88da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bbcb10f-8ff0-4e8e-a230-9608c9adbc1c" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_105070a7-78cf-4adb-a48f-42bc725f88da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Netlosspershare" xlink:type="simple" xlink:href="absi-20250930.xsd#Netlosspershare"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Netlosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92c51156-1bc9-47ee-8137-8c703afaa956" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8fe3c6cb-b43a-4145-92bf-d3b4ec3cd674" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92c51156-1bc9-47ee-8137-8c703afaa956" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8fe3c6cb-b43a-4145-92bf-d3b4ec3cd674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Segmentreporting" xlink:type="simple" xlink:href="absi-20250930.xsd#Segmentreporting"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Segmentreporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_efba5421-73a6-47fd-a320-bdf3520b8fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_9fe30781-fe62-4dd8-b3ce-0f68f40b3add" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_efba5421-73a6-47fd-a320-bdf3520b8fa2" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_9fe30781-fe62-4dd8-b3ce-0f68f40b3add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/Subsequentevents" xlink:type="simple" xlink:href="absi-20250930.xsd#Subsequentevents"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/Subsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f63e1554-e48f-4415-8529-49afcd3409d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_147b39b0-0a5c-4758-af1c-37cc825681f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f63e1554-e48f-4415-8529-49afcd3409d7" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_147b39b0-0a5c-4758-af1c-37cc825681f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/InvestmentsTables" xlink:type="simple" xlink:href="absi-20250930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_e311a360-bcc6-415e-b523-0537cd31db7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_9716a70b-9ce3-4b48-b823-0788f1509a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_e311a360-bcc6-415e-b523-0537cd31db7b" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_9716a70b-9ce3-4b48-b823-0788f1509a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="absi-20250930.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be79872f-1ad1-4a49-b38c-e5df747eca7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_70179451-08e0-41a2-881b-8ce302f51770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be79872f-1ad1-4a49-b38c-e5df747eca7d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_70179451-08e0-41a2-881b-8ce302f51770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationTables" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationTables"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/StockbasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4873690-f352-4407-847e-ea51437cfb85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1de952c4-e41b-4600-8372-aee17b6237fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4873690-f352-4407-847e-ea51437cfb85" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1de952c4-e41b-4600-8372-aee17b6237fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ba1d5953-4177-4dfe-a047-b8cd286c369b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4873690-f352-4407-847e-ea51437cfb85" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ba1d5953-4177-4dfe-a047-b8cd286c369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3158cdc3-9ba9-4e93-85fa-870a3c58004a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4873690-f352-4407-847e-ea51437cfb85" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3158cdc3-9ba9-4e93-85fa-870a3c58004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_ac820b27-1d5e-4ee5-89a3-4ff220a6b8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4873690-f352-4407-847e-ea51437cfb85" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_ac820b27-1d5e-4ee5-89a3-4ff220a6b8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="absi-20250930.xsd#NetlosspershareTables"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/NetlosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cf68305d-19a9-4473-8e6c-0de5aae97447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b6fdd108-1dbe-40a6-aa38-81003a01d735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cf68305d-19a9-4473-8e6c-0de5aae97447" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b6fdd108-1dbe-40a6-aa38-81003a01d735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/SegmentreportingTables" xlink:type="simple" xlink:href="absi-20250930.xsd#SegmentreportingTables"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/SegmentreportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9a67804f-27f0-42d7-b23b-06db40713ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_08b56582-2932-4b92-bcaf-fec8bc35c73e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9a67804f-27f0-42d7-b23b-06db40713ec1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_08b56582-2932-4b92-bcaf-fec8bc35c73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/RevenuerecognitionDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#RevenuerecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/RevenuerecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f47c5f97-d51d-45c3-8263-32c7fb7935df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f47c5f97-d51d-45c3-8263-32c7fb7935df" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3d3f604-f030-4a82-8b4b-74c942363453" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:to="loc_srt_ProductOrServiceAxis_d3d3f604-f030-4a82-8b4b-74c942363453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ceffb6e-c2b0-47db-8fca-af73edbb7702" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d3d3f604-f030-4a82-8b4b-74c942363453" xlink:to="loc_srt_ProductsAndServicesDomain_7ceffb6e-c2b0-47db-8fca-af73edbb7702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_TechnologyDevelopmentRevenueMember_27cb5605-a366-416b-bcad-67baecb370ea" xlink:href="absi-20250930.xsd#absi_TechnologyDevelopmentRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ceffb6e-c2b0-47db-8fca-af73edbb7702" xlink:to="loc_absi_TechnologyDevelopmentRevenueMember_27cb5605-a366-416b-bcad-67baecb370ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f8de441-6ecb-42b5-80a4-f9e9db8dc261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f8de441-6ecb-42b5-80a4-f9e9db8dc261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c9a2e6c-81ea-4375-a343-f98b0db0449a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f8de441-6ecb-42b5-80a4-f9e9db8dc261" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c9a2e6c-81ea-4375-a343-f98b0db0449a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7f739cad-f75e-480e-8136-80362954f765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c9a2e6c-81ea-4375-a343-f98b0db0449a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7f739cad-f75e-480e-8136-80362954f765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d97ba9c9-f355-4953-afdb-4459c846f85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b4e26270-0fcb-4b55-b8ae-fb3a99bc41a5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d97ba9c9-f355-4953-afdb-4459c846f85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f9b3ba98-1f34-44aa-a570-82ab80ff2d82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d97ba9c9-f355-4953-afdb-4459c846f85b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f9b3ba98-1f34-44aa-a570-82ab80ff2d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd414923-70f4-4503-8f43-4136aa294910" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9deb89e4-3a67-4b5c-a30c-28ef9bb6a548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9deb89e4-3a67-4b5c-a30c-28ef9bb6a548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cb1a2763-3e4a-4438-95b3-311be9e6821f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cb1a2763-3e4a-4438-95b3-311be9e6821f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_NumberOfPartners_fb1cb6ab-7d40-4256-8397-ec881bcdb05c" xlink:href="absi-20250930.xsd#absi_NumberOfPartners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_absi_NumberOfPartners_fb1cb6ab-7d40-4256-8397-ec881bcdb05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f51bde1d-12e1-4048-ace6-a7ffbed2ba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52a848fc-ff2a-4d82-b3eb-643f09587b93" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f51bde1d-12e1-4048-ace6-a7ffbed2ba1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/CollaborativearrangementsDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#CollaborativearrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/CollaborativearrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e6872f4-5483-4db6-ae03-51ac31c37a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ProceedsFromCollaborativeArrangement_999f61a5-300a-486d-9f60-ef689aeb3810" xlink:href="absi-20250930.xsd#absi_ProceedsFromCollaborativeArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e6872f4-5483-4db6-ae03-51ac31c37a68" xlink:to="loc_absi_ProceedsFromCollaborativeArrangement_999f61a5-300a-486d-9f60-ef689aeb3810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#InvestmentsAmortizedandFairValueofourInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_c2b8aaa6-b60d-4da9-8aa2-6a0dbb3f4d02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c2b8aaa6-b60d-4da9-8aa2-6a0dbb3f4d02" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_29b8ad27-c588-4f37-ac15-960e613c5a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:to="loc_us-gaap_FinancialInstrumentAxis_29b8ad27-c588-4f37-ac15-960e613c5a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_29b8ad27-c588-4f37-ac15-960e613c5a74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_93ef39f4-5d04-4c6c-bdb3-75496aff7c06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_93ef39f4-5d04-4c6c-bdb3-75496aff7c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_334ba361-6c43-4d94-8c85-4d8335aee695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_624328b1-1b68-4457-9fd4-7bef0664024e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_334ba361-6c43-4d94-8c85-4d8335aee695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_248d3933-ce6e-4fba-80d8-8efac1877087" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_248d3933-ce6e-4fba-80d8-8efac1877087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_248d3933-ce6e-4fba-80d8-8efac1877087" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_9e648a06-1c44-440c-809c-df70e28d5de5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:to="loc_us-gaap_CashEquivalentsMember_9e648a06-1c44-440c-809c-df70e28d5de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_92a7f438-f37e-45a0-882f-ae87cb392b26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ffcf70c-c200-4bb4-a93f-6ec66b1db07a" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_92a7f438-f37e-45a0-882f-ae87cb392b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ec1fd4ca-90be-4166-bebf-8cf1488d7350" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6cc5c98c-53cf-4534-b59b-0935326a228d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6cc5c98c-53cf-4534-b59b-0935326a228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa1c8e5d-5c24-42e6-a72c-9af1c5ac1307" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa1c8e5d-5c24-42e6-a72c-9af1c5ac1307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_52c550f8-5117-4bf3-a31e-c24969a386dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_52c550f8-5117-4bf3-a31e-c24969a386dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d3a52f7-789d-4636-b3b1-b9a90ffdd25b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6e82e701-6a6a-49f5-b270-46e28d241175" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d3a52f7-789d-4636-b3b1-b9a90ffdd25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/InvestmentsNarrativesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#InvestmentsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/InvestmentsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d54064be-3a4a-493c-9335-9f2161b6ebba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e758db3b-d35a-47ee-b3f0-9384a6a1dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d54064be-3a4a-493c-9335-9f2161b6ebba" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e758db3b-d35a-47ee-b3f0-9384a6a1dca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38555f66-a2e1-4d78-b56e-7eb3e5668cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e758db3b-d35a-47ee-b3f0-9384a6a1dca6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38555f66-a2e1-4d78-b56e-7eb3e5668cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b566bf8e-d166-4fb3-9200-5ed683790c59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38555f66-a2e1-4d78-b56e-7eb3e5668cd8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b566bf8e-d166-4fb3-9200-5ed683790c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_aa26660b-ae17-4ca3-868e-aebc482c5428" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b566bf8e-d166-4fb3-9200-5ed683790c59" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_aa26660b-ae17-4ca3-868e-aebc482c5428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e758db3b-d35a-47ee-b3f0-9384a6a1dca6" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_15a471ae-d9ff-4b4f-8b61-963bac78946d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_15a471ae-d9ff-4b4f-8b61-963bac78946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_9d848b22-c6e6-4692-9b30-9eb33f2170f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_9d848b22-c6e6-4692-9b30-9eb33f2170f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_0f242a15-7602-49a4-a086-e1af3c2d4978" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d29b3e49-b460-4493-bcd9-9e97257db5a7" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_0f242a15-7602-49a4-a086-e1af3c2d4978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71413fe1-0984-49d0-ae15-6950ccf5f48f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71413fe1-0984-49d0-ae15-6950ccf5f48f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54ca4a07-607e-43b4-8187-5c0e2c7ee9ed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ae336d1e-bb5c-49da-9c4e-2a91c921c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ae336d1e-bb5c-49da-9c4e-2a91c921c00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d3da3ec1-9875-4513-afa2-1e4a9d2acb66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d3da3ec1-9875-4513-afa2-1e4a9d2acb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_726abf1b-b6a5-468d-b57d-82d98b3ce9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7ea3596-09ad-458b-ad5c-a9a215b29782" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_726abf1b-b6a5-468d-b57d-82d98b3ce9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b7f9efb4-04ae-469c-8236-ee6210888688" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b7f9efb4-04ae-469c-8236-ee6210888688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbdfa7ff-6548-4648-9ce6-05ef2721450d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b7f9efb4-04ae-469c-8236-ee6210888688" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbdfa7ff-6548-4648-9ce6-05ef2721450d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_71d44cc5-83de-4721-9093-8bd2954c4110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bbdfa7ff-6548-4648-9ce6-05ef2721450d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_71d44cc5-83de-4721-9093-8bd2954c4110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2b795c6d-112a-4cdc-a9c6-8b41ef1e3b8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ff8e4a25-2dd7-46eb-abad-7281bbb26196" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ff8e4a25-2dd7-46eb-abad-7281bbb26196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a31daefd-073f-4af5-ad09-7e4099006995" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebb44c61-9d46-4256-99bd-4f9a2358cbf7" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a31daefd-073f-4af5-ad09-7e4099006995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69c0bde2-2226-4428-9cc6-bdc6e9bb700c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_2648e512-19ea-4f09-966e-cf8ccdc903a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_2648e512-19ea-4f09-966e-cf8ccdc903a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a51ceb83-9bbc-4657-a48f-ec1894b0f653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b44b47c8-0ab9-4d87-9361-7ae335e3c1c8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a51ceb83-9bbc-4657-a48f-ec1894b0f653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54efef92-228b-4df0-ba5f-c2d56d88b134" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ContingentConsiderationFairValue_c977aa55-a26b-46c9-a6f5-809afa8f9350" xlink:href="absi-20250930.xsd#absi_ContingentConsiderationFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:to="loc_absi_ContingentConsiderationFairValue_c977aa55-a26b-46c9-a6f5-809afa8f9350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_867596e1-1cd1-476f-9606-8ed51229fe1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_3af4369e-2791-4b6f-9b49-e0353681b2ac" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_867596e1-1cd1-476f-9606-8ed51229fe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/FairvaluemeasurementsNarrativesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#FairvaluemeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/FairvaluemeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7568263e-c761-4bb3-b61e-6397089a8ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_75253d94-9467-4dbb-a8bc-18ba440b21f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7568263e-c761-4bb3-b61e-6397089a8ab7" xlink:to="loc_us-gaap_EscrowDeposit_75253d94-9467-4dbb-a8bc-18ba440b21f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/CommitmentsandcontingenciesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#CommitmentsandcontingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/CommitmentsandcontingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ee9e5b3-74b7-4da2-b4eb-29e382ffad82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_f74408d2-a720-479e-b001-aa00d6754197" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ee9e5b3-74b7-4da2-b4eb-29e382ffad82" xlink:to="loc_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_f74408d2-a720-479e-b001-aa00d6754197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_a2b9cb1f-02eb-4e14-a734-1d9cb11ad4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ee9e5b3-74b7-4da2-b4eb-29e382ffad82" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_a2b9cb1f-02eb-4e14-a734-1d9cb11ad4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_388c8a3a-b10d-4ccd-b424-d34ab1477aab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ee9e5b3-74b7-4da2-b4eb-29e382ffad82" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_388c8a3a-b10d-4ccd-b424-d34ab1477aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_7e31476e-7698-42d5-b49e-a76364f69ead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ee9e5b3-74b7-4da2-b4eb-29e382ffad82" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_7e31476e-7698-42d5-b49e-a76364f69ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/CommonstockDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#CommonstockDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/CommonstockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_53dc4eb3-4e9d-4b21-bed7-c8dd73ba2648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCapitalUnitsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_53dc4eb3-4e9d-4b21-bed7-c8dd73ba2648" xlink:to="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:to="loc_srt_RangeAxis_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4fa31b0e-490b-44e9-949b-dedffaf8d661" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d4b2b4b-64a9-44e1-b60e-8ab04783be3d" xlink:to="loc_srt_RangeMember_4fa31b0e-490b-44e9-949b-dedffaf8d661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_927bab20-0316-48f5-935f-8a8e0f4474e5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4fa31b0e-490b-44e9-949b-dedffaf8d661" xlink:to="loc_srt_MaximumMember_927bab20-0316-48f5-935f-8a8e0f4474e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:to="loc_srt_CounterpartyNameAxis_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b2c9b720-e4b9-40e4-8ecc-cd6fbaa8bac1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_CowenAndCompanyLLCMember_7fa108ff-59aa-4481-b5cd-de6c37b4cd9c" xlink:href="absi-20250930.xsd#absi_CowenAndCompanyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:to="loc_absi_CowenAndCompanyLLCMember_7fa108ff-59aa-4481-b5cd-de6c37b4cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AdvancedMicroDevicesIncMember_c7744076-c748-4449-af09-190869b447fa" xlink:href="absi-20250930.xsd#absi_AdvancedMicroDevicesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:to="loc_absi_AdvancedMicroDevicesIncMember_c7744076-c748-4449-af09-190869b447fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_TDSecuritiesUSALLCMember_f7266482-3c90-4317-af9b-427d6ca0848a" xlink:href="absi-20250930.xsd#absi_TDSecuritiesUSALLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2c7581f-35fd-4ce0-b34e-d53361ce789f" xlink:to="loc_absi_TDSecuritiesUSALLCMember_f7266482-3c90-4317-af9b-427d6ca0848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_226a1bcf-5270-4649-8398-2163c8ed1504" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_226a1bcf-5270-4649-8398-2163c8ed1504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_226a1bcf-5270-4649-8398-2163c8ed1504" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ShelfRegistrationMember_1100d8cf-d626-460c-bcfc-b18dd96ccd18" xlink:href="absi-20250930.xsd#absi_ShelfRegistrationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:to="loc_absi_ShelfRegistrationMember_1100d8cf-d626-460c-bcfc-b18dd96ccd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AtTheMarketOfferingProgramMember_290b0b43-a5d5-4f15-8fc6-2bf41ee2b70f" xlink:href="absi-20250930.xsd#absi_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:to="loc_absi_AtTheMarketOfferingProgramMember_290b0b43-a5d5-4f15-8fc6-2bf41ee2b70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_eb5c2ad4-6bb9-4a9b-b2dd-29c25792f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_282c7b4e-c4e7-4b02-9333-31630a9f82ba" xlink:to="loc_us-gaap_PrivatePlacementMember_eb5c2ad4-6bb9-4a9b-b2dd-29c25792f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_4c7809ae-abdb-49ba-a2c9-7b868eb0498e" xlink:to="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction_8eaa5517-c38b-470d-bd40-bc26a19cedb2" xlink:href="absi-20250930.xsd#absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction_8eaa5517-c38b-470d-bd40-bc26a19cedb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0194d2ab-8576-4b38-af32-beffe9315836" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0194d2ab-8576-4b38-af32-beffe9315836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99d8ee75-1b85-4257-9a9e-1c011b7b1851" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99d8ee75-1b85-4257-9a9e-1c011b7b1851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e579c27c-f023-4763-9497-8a5b0aee2a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_SharePrice_e579c27c-f023-4763-9497-8a5b0aee2a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockMaximumAggregateOfferingPrice_3604b00a-84ae-4654-b913-186821be3d5c" xlink:href="absi-20250930.xsd#absi_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_SaleOfStockMaximumAggregateOfferingPrice_3604b00a-84ae-4654-b913-186821be3d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SaleOfStockSalesAgentCommissionPercentage_7cb2d907-6e26-4a97-a3df-c132868ead59" xlink:href="absi-20250930.xsd#absi_SaleOfStockSalesAgentCommissionPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_SaleOfStockSalesAgentCommissionPercentage_7cb2d907-6e26-4a97-a3df-c132868ead59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_414f01b9-f8e1-4e62-bca4-f81ae80708f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_414f01b9-f8e1-4e62-bca4-f81ae80708f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_AmortizationOfEquityIssuanceDiscountPremium_2033b8c7-5f88-43fd-92cb-a21eedf11b6f" xlink:href="absi-20250930.xsd#absi_AmortizationOfEquityIssuanceDiscountPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_b87d331c-9ec5-4a8d-be84-42afea185ef4" xlink:to="loc_absi_AmortizationOfEquityIssuanceDiscountPremium_2033b8c7-5f88-43fd-92cb-a21eedf11b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationNarrativesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/StockbasedcompensationNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03eab8d7-f7a0-48fd-9565-96a6094e745b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03eab8d7-f7a0-48fd-9565-96a6094e745b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_61247106-49e7-4c19-b9cc-cb27662d9d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:to="loc_us-gaap_PlanNameAxis_61247106-49e7-4c19-b9cc-cb27662d9d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_61247106-49e7-4c19-b9cc-cb27662d9d67" xlink:to="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2021StockOptionAndGrantPlanMember_db715a69-3450-440c-b70b-d3a095b4efb7" xlink:href="absi-20250930.xsd#absi_A2021StockOptionAndGrantPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:to="loc_absi_A2021StockOptionAndGrantPlanMember_db715a69-3450-440c-b70b-d3a095b4efb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2023InducementPlanMember_620d7fc2-e55a-473a-95ac-9b4c80cfccbe" xlink:href="absi-20250930.xsd#absi_A2023InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:to="loc_absi_A2023InducementPlanMember_620d7fc2-e55a-473a-95ac-9b4c80cfccbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_A2020StockOptionAndGrantPlanMember_f2b1120a-9656-4f31-a928-7102df2ef4d3" xlink:href="absi-20250930.xsd#absi_A2020StockOptionAndGrantPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_00f9b079-418e-4a12-a6c7-be08c6f352f0" xlink:to="loc_absi_A2020StockOptionAndGrantPlanMember_f2b1120a-9656-4f31-a928-7102df2ef4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c644151-fe65-46c0-86c5-135df633f2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:to="loc_us-gaap_AwardTypeAxis_7c644151-fe65-46c0-86c5-135df633f2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c644151-fe65-46c0-86c5-135df633f2fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_95ab9ed6-53e4-4cd5-aacc-6e3fd99749f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:to="loc_us-gaap_EmployeeStockOptionMember_95ab9ed6-53e4-4cd5-aacc-6e3fd99749f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_45f9ef25-b1c9-4df9-8626-78d96c977604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7cf612-3dd8-44c3-98c4-feeb893ee465" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_45f9ef25-b1c9-4df9-8626-78d96c977604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9e66bf7-2571-4e6c-94a5-2f61d81375fb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:to="loc_srt_RangeAxis_f9e66bf7-2571-4e6c-94a5-2f61d81375fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f9e66bf7-2571-4e6c-94a5-2f61d81375fb" xlink:to="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b072d89-9696-456f-b205-f01ffb0400b6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:to="loc_srt_MinimumMember_9b072d89-9696-456f-b205-f01ffb0400b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5d37135-fe1d-458e-80c3-6bb044e2618f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a94add51-3a34-470e-a9cb-eeb2cf426218" xlink:to="loc_srt_MaximumMember_f5d37135-fe1d-458e-80c3-6bb044e2618f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_559278f4-4971-4d2d-bd76-b69435a609b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d1971794-1c91-46d9-85c2-4ed30be76aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d1971794-1c91-46d9-85c2-4ed30be76aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b40a1101-47ca-4ebc-9964-4bd8661f8c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b40a1101-47ca-4ebc-9964-4bd8661f8c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c57b3d1-ee59-4101-92c7-0583ca407453" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c57b3d1-ee59-4101-92c7-0583ca407453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_817852d2-d60c-49ea-86bf-61df19e5be01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_817852d2-d60c-49ea-86bf-61df19e5be01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b38135d-3e33-4dc6-8355-54d8e46d8642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b38135d-3e33-4dc6-8355-54d8e46d8642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d8ff2a7b-b7a1-41e6-9ff8-f78cc37d0635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d8ff2a7b-b7a1-41e6-9ff8-f78cc37d0635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e661a71e-dde2-4657-9b21-0128177a97e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e661a71e-dde2-4657-9b21-0128177a97e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9b48f84-ae28-41ae-905d-33c3fe6f6878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9e334d4-c0ff-4b18-9087-9237ceec14a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9b48f84-ae28-41ae-905d-33c3fe6f6878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ded7ee96-0adb-4de5-8f58-1e67f385258d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b8c6c192-573d-4a03-95bc-006465a81712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ded7ee96-0adb-4de5-8f58-1e67f385258d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b8c6c192-573d-4a03-95bc-006465a81712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4acb91b2-2024-42de-936b-e36c1378f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b8c6c192-573d-4a03-95bc-006465a81712" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4acb91b2-2024-42de-936b-e36c1378f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4acb91b2-2024-42de-936b-e36c1378f6ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_41b5ba0c-3232-477c-af55-e0e39613df10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_41b5ba0c-3232-477c-af55-e0e39613df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f1154a80-3853-4f96-91f9-192501449268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_872fa72d-54f9-4aed-a34b-26a2754f03e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f1154a80-3853-4f96-91f9-192501449268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_48076e43-aae4-4d4c-99dc-d55c00780ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b8c6c192-573d-4a03-95bc-006465a81712" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_48076e43-aae4-4d4c-99dc-d55c00780ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f32a40a4-e2c2-4b9c-9e28-f69c90a9d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_48076e43-aae4-4d4c-99dc-d55c00780ffa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f32a40a4-e2c2-4b9c-9e28-f69c90a9d64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationStockOptionRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7dbe1fce-1cdf-45a0-a48f-4b0a069916ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7dbe1fce-1cdf-45a0-a48f-4b0a069916ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bacd93ef-167e-444c-8a11-f0aeea64f8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bacd93ef-167e-444c-8a11-f0aeea64f8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_214d3578-c6ec-4d85-9f68-bae5f45fc217" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_214d3578-c6ec-4d85-9f68-bae5f45fc217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3833e193-5b20-463d-a4ab-49481a061498" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3833e193-5b20-463d-a4ab-49481a061498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4e36af0d-bbd3-4ace-8b2b-c5d53b6b5361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4e36af0d-bbd3-4ace-8b2b-c5d53b6b5361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c0c6c5da-ebfd-49dd-a005-35c20b5ab66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b1d8571-80ee-4a7b-adbd-f3a554664e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c0c6c5da-ebfd-49dd-a005-35c20b5ab66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e5edfeaf-1dfd-42cb-bb99-d067afa43697" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e5edfeaf-1dfd-42cb-bb99-d067afa43697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c75e6b0-b9f1-467e-9fda-e529e5ae0552" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c75e6b0-b9f1-467e-9fda-e529e5ae0552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_92f30ca4-ef05-469d-818e-a60e599ae073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_92f30ca4-ef05-469d-818e-a60e599ae073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27bca6c3-019e-436b-b076-22e87f981bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27bca6c3-019e-436b-b076-22e87f981bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_32a8f160-cbb6-4a17-94b6-8618f8579509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_32a8f160-cbb6-4a17-94b6-8618f8579509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5d6b24ec-a2a9-4b51-9048-85dfeed7b48a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5d6b24ec-a2a9-4b51-9048-85dfeed7b48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1bfd0d48-510e-41be-8b6b-f02c7ef71902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6fcde446-c52a-4718-a471-5adb17e4276c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1bfd0d48-510e-41be-8b6b-f02c7ef71902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_af0383fa-f25b-437e-a910-e856987f5731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_af0383fa-f25b-437e-a910-e856987f5731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9f331fd5-0cbc-414a-9c62-0f6c984a298e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9f331fd5-0cbc-414a-9c62-0f6c984a298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b7fbdaa3-2133-44db-bddd-5ea3f805b6de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b7fbdaa3-2133-44db-bddd-5ea3f805b6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1ba7ec32-be36-46c0-848e-0429dcb89d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1ba7ec32-be36-46c0-848e-0429dcb89d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c1f5bcbf-1103-4411-abba-5d176ddeefd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c1f5bcbf-1103-4411-abba-5d176ddeefd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7dfc0c3d-4e3e-4805-ac14-7431077a54aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a81a907-67f4-431f-9df4-e8decc2a6068" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7dfc0c3d-4e3e-4805-ac14-7431077a54aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationDeterminationofFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed04be03-c1f2-4b54-b17d-3947faa93a14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fdc9950-0205-4521-a123-646deb9c3088" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed04be03-c1f2-4b54-b17d-3947faa93a14" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fdc9950-0205-4521-a123-646deb9c3088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7298065-ff72-4d8b-9da2-60f508a4459d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fdc9950-0205-4521-a123-646deb9c3088" xlink:to="loc_srt_RangeAxis_e7298065-ff72-4d8b-9da2-60f508a4459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e7298065-ff72-4d8b-9da2-60f508a4459d" xlink:to="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ccbda978-829a-489b-a9e8-7ea1865a0bf0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:to="loc_srt_MinimumMember_ccbda978-829a-489b-a9e8-7ea1865a0bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be3fac38-b5dd-408d-a37c-5265fc7c1ad7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c8b67813-c132-444f-9a49-eb6eb7d77ab1" xlink:to="loc_srt_MaximumMember_be3fac38-b5dd-408d-a37c-5265fc7c1ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eae1412-c80d-402e-a562-9ce66b931aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fdc9950-0205-4521-a123-646deb9c3088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eae1412-c80d-402e-a562-9ce66b931aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eae1412-c80d-402e-a562-9ce66b931aa0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92317b3c-8321-4757-bc8a-fe802013e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92317b3c-8321-4757-bc8a-fe802013e56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1af57e54-6c77-463b-a793-69e975ffe1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1af57e54-6c77-463b-a793-69e975ffe1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_aa3c7cb9-9331-43a9-b306-4079cb4da3af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_aa3c7cb9-9331-43a9-b306-4079cb4da3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_89fafd7d-d028-4850-9a3d-419f325f1d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_89fafd7d-d028-4850-9a3d-419f325f1d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3363a508-ecaa-482c-85a0-b9e5ae066a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_36a4e860-d37b-415a-aa8d-868053fa6c80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3363a508-ecaa-482c-85a0-b9e5ae066a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#StockbasedcompensationRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfda9d66-1ee2-4051-902d-3b5c39c5266e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb35aa83-4074-471f-bed8-4610ecda9651" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfda9d66-1ee2-4051-902d-3b5c39c5266e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb35aa83-4074-471f-bed8-4610ecda9651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac05ac56-ec10-4c2e-a245-1ef4d8008818" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb35aa83-4074-471f-bed8-4610ecda9651" xlink:to="loc_us-gaap_AwardTypeAxis_ac05ac56-ec10-4c2e-a245-1ef4d8008818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c319ced9-7061-4b95-94a2-11c955bb630f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac05ac56-ec10-4c2e-a245-1ef4d8008818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c319ced9-7061-4b95-94a2-11c955bb630f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_27ffc012-3707-40fe-8f9f-13b5114a1068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c319ced9-7061-4b95-94a2-11c955bb630f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_27ffc012-3707-40fe-8f9f-13b5114a1068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb35aa83-4074-471f-bed8-4610ecda9651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c41832fd-7371-4e81-8822-1bc6fb867a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c41832fd-7371-4e81-8822-1bc6fb867a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c2ececd5-5588-4da4-9b62-1aa7c9b68b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c2ececd5-5588-4da4-9b62-1aa7c9b68b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d82a6d82-74d9-454f-b7c2-8ebd31d72155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d82a6d82-74d9-454f-b7c2-8ebd31d72155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4bf1627-e073-4e7d-ab24-4ffc01ae8084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4bf1627-e073-4e7d-ab24-4ffc01ae8084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_479dc7b1-400d-4e3f-b4ed-071d581a1500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fc0b455a-a4d3-42f1-b4f1-0af6bcbb7324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_479dc7b1-400d-4e3f-b4ed-071d581a1500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76813fbd-4b21-4844-9af8-8b1db332eae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef37900-ce5d-4def-8192-cc2c26178e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef37900-ce5d-4def-8192-cc2c26178e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4ed159da-14ab-4f8e-a69c-727251d9fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4ed159da-14ab-4f8e-a69c-727251d9fd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0c37afd4-07e5-4dc1-b777-d7c787b70ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0c37afd4-07e5-4dc1-b777-d7c787b70ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72241d62-82ec-49dd-a18e-8ee36543ba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72241d62-82ec-49dd-a18e-8ee36543ba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_294a670f-6da8-4003-97fb-43b341dd204a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea962157-6487-4805-9ca6-855d0c4b2a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_294a670f-6da8-4003-97fb-43b341dd204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#NetlosspershareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30b17013-38e0-402d-beca-61020f1a478a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc59d41a-60db-4745-823f-6be449b2dc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30b17013-38e0-402d-beca-61020f1a478a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc59d41a-60db-4745-823f-6be449b2dc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c322f2f-adf7-493f-83ff-0e32f489a3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc59d41a-60db-4745-823f-6be449b2dc5d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c322f2f-adf7-493f-83ff-0e32f489a3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c322f2f-adf7-493f-83ff-0e32f489a3c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf109cbd-d6ba-4852-8dbd-afc912e3f22b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf109cbd-d6ba-4852-8dbd-afc912e3f22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2676f861-335e-4063-8e6f-51a6bc3992a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2676f861-335e-4063-8e6f-51a6bc3992a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_beda3ed1-3dec-45df-acb4-9e5ce70fd1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85e83bf8-6aea-499f-aa08-34e67e2bbe7d" xlink:to="loc_us-gaap_RestrictedStockMember_beda3ed1-3dec-45df-acb4-9e5ce70fd1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91ae3295-4545-424d-acb1-c31da7d21a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc59d41a-60db-4745-823f-6be449b2dc5d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91ae3295-4545-424d-acb1-c31da7d21a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6aa0b159-e58f-4c69-9ea1-f229852bfa56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91ae3295-4545-424d-acb1-c31da7d21a6c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6aa0b159-e58f-4c69-9ea1-f229852bfa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/SegmentreportingNarrativeDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#SegmentreportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/SegmentreportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f5bd8268-6b6d-4e04-b741-dbbf777d83d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_94a3ffc6-57ca-44a1-961d-812ab0678dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f5bd8268-6b6d-4e04-b741-dbbf777d83d5" xlink:to="loc_us-gaap_NumberOfReportableSegments_94a3ffc6-57ca-44a1-961d-812ab0678dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/SegmentreportingSegmentExpensesDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#SegmentreportingSegmentExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/SegmentreportingSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4f5ac11c-d15a-46c4-a9eb-a0e9be1f20a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4f5ac11c-d15a-46c4-a9eb-a0e9be1f20a5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60fb9f62-4c30-4e8a-a163-6c8c59424146" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:to="loc_srt_ProductOrServiceAxis_60fb9f62-4c30-4e8a-a163-6c8c59424146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_60fb9f62-4c30-4e8a-a163-6c8c59424146" xlink:to="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_DrugCreationAndPlatformMember_add2e83d-9bfc-4506-81e2-1e5e253b60b9" xlink:href="absi-20250930.xsd#absi_DrugCreationAndPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:to="loc_absi_DrugCreationAndPlatformMember_add2e83d-9bfc-4506-81e2-1e5e253b60b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_ExternalPreClinicalAndClinicalDevelopmentMember_c2f776d2-3f20-4109-8f53-ac54b5efb375" xlink:href="absi-20250930.xsd#absi_ExternalPreClinicalAndClinicalDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_291b7181-5d0d-4b09-bbf7-e0bf1679fe0a" xlink:to="loc_absi_ExternalPreClinicalAndClinicalDevelopmentMember_c2f776d2-3f20-4109-8f53-ac54b5efb375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4e973121-f2a1-4aaa-b908-a9606704e65f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c8f46d1c-d1dc-4363-9dcb-61fc84ea2a26" xlink:to="loc_us-gaap_SegmentDomain_4e973121-f2a1-4aaa-b908-a9606704e65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_absi_SegmentOneMember_bd521cff-f43b-46ef-87e3-d40c549e6ab3" xlink:href="absi-20250930.xsd#absi_SegmentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4e973121-f2a1-4aaa-b908-a9606704e65f" xlink:to="loc_absi_SegmentOneMember_bd521cff-f43b-46ef-87e3-d40c549e6ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_01de8467-04d4-41ab-9a87-d61e6d2577ef" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_def5f57b-0c63-4d6f-accf-40563f96b86c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_def5f57b-0c63-4d6f-accf-40563f96b86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_49ffa246-ccca-4303-bf11-0f26be7064f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_LaborAndRelatedExpense_49ffa246-ccca-4303-bf11-0f26be7064f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0d44d028-8a4c-4aa4-a870-e6c853368b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0d44d028-8a4c-4aa4-a870-e6c853368b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fed4647d-082e-4080-9e8f-98ba88df527a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fed4647d-082e-4080-9e8f-98ba88df527a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f7c7d944-6968-4c91-8b27-377e9243733c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f7c7d944-6968-4c91-8b27-377e9243733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_55324c7e-7f5e-4ce0-a937-53d63ca142ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_OperatingExpenses_55324c7e-7f5e-4ce0-a937-53d63ca142ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5ecae61b-9b2d-4863-9898-bb8243d98073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_55649f31-a1fd-41f3-b709-5b16487dee58" xlink:to="loc_us-gaap_AssetImpairmentCharges_5ecae61b-9b2d-4863-9898-bb8243d98073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.absci.com/role/SubsequenteventsDetails" xlink:type="simple" xlink:href="absi-20250930.xsd#SubsequenteventsDetails"/>
  <link:presentationLink xlink:role="http://www.absci.com/role/SubsequenteventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3986ac72-8a5e-4c4d-9421-b68dd6c9fb37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6a29e891-eb9b-485b-8a01-1ced33ffad23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3986ac72-8a5e-4c4d-9421-b68dd6c9fb37" xlink:to="loc_us-gaap_SubsequentEventTable_6a29e891-eb9b-485b-8a01-1ced33ffad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e83a7048-38f7-4cda-b558-7e7f46d6864b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6a29e891-eb9b-485b-8a01-1ced33ffad23" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e83a7048-38f7-4cda-b558-7e7f46d6864b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ce0ef8d9-397a-415f-9f9e-762c4f4880f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e83a7048-38f7-4cda-b558-7e7f46d6864b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ce0ef8d9-397a-415f-9f9e-762c4f4880f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2f7ad705-4619-4072-97e5-a6479be8de53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ce0ef8d9-397a-415f-9f9e-762c4f4880f0" xlink:to="loc_us-gaap_SubsequentEventMember_2f7ad705-4619-4072-97e5-a6479be8de53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6a29e891-eb9b-485b-8a01-1ced33ffad23" xlink:to="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7fe4e5c7-7296-49e1-ad9e-54c60dfbf154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7fe4e5c7-7296-49e1-ad9e-54c60dfbf154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81b06c5c-860b-4cec-aa17-fd77899ed011" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_72631c56-519d-4835-982f-f8fbcee10e6b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81b06c5c-860b-4cec-aa17-fd77899ed011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>absi-20250930_g1.jpg
<TEXT>
begin 644 absi-20250930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /."1 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!#3;_]^)O_ (BC_AI+X;?]#3;_ /?B;_XBCZWAO^?D?O0?V1F7_0-/_P
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M (!+_(],HKS/_AI+X;?]#3;_ /?B;_XBC_AI+X;?]#3;_P#?B;_XBCZWAO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.Y3@9)P!UZG.:V?&?Q#F^)O[*^H:O>6L-OJ2ZI%;WDD";%GD4QXDQZE"@/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?F!XM\-W7A#Q-J>BWL9CN;*=H6!YR >"#W!&"#W!%?I_7(^-_A-X3^(NQM
M?T:&]G12J7"LT4JC_?0@D>QR*\7-,OECH1Y'9Q[^9]OPMQ!#(JU3VT'*$TKV
MW35[;[[OJC\UZ*^]?^&3OAM_T"+G_P #I?\ XJC_ (9.^&W_ $"+G_P.E_\
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M2ZZ(****]H^)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?Z_Y5_)/[E_\D?!5%?>O_#)WPV_Z!%S_ .!TO_Q5'_#)WPV_Z!%S_P"!TO\
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MI^'<X628WZS*/-%IQ:6]G9Z?-(_,"BOO9_V3_ALSL1HTZ G(47TV![<M2?\
M#)WPV_Z!%S_X'2__ !5?)_V#BN\?O?\ D?KG^O\ E7\D_N7_ ,D?!5%?>O\
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M_P +WGBCXM^'$M(7E2QNXM0N&3'[N.)U8L<]L[1_P*OK'_AD[X;?] BY_P#
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M"21V+,[7+DL3U))/)KGZ* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
MA//$7_0:O_\ P(?_ !K!HH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\
M"'_QK!HH WO^$\\1?]!J_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A
M//$7_0:O_P#P(?\ QH_X3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "
M'_QH_P"$\\1?]!J__P# A_\ &L&B@#>_X3SQ%_T&K_\ \"'_ ,:/^$\\1?\
M0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\ A//$7_0:O_\ P(?_ !K!
MHH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\"'_QK!HH WO^$\\1?]!J
M_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A//$7_0:O_P#P(?\ QH_X
M3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
MA//$7_0:O_\ P(?_ !K!HH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\
M"'_QK!HH WO^$\\1?]!J_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A
M//$7_0:O_P#P(?\ QH_X3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "
M'_QH_P"$\\1?]!J__P# A_\ &L&B@#>_X3SQ%_T&K_\ \"'_ ,:/^$\\1?\
M0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\ A//$7_0:O_\ P(?_ !K!
MHH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\"'_QK!HH WO^$\\1?]!J
M_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A//$7_0:O_P#P(?\ QH_X
M3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
MA//$7_0:O_\ P(?_ !K!HH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\
M"'_QK!HH WO^$\\1?]!J_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A
M//$7_0:O_P#P(?\ QH_X3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "
M'_QH_P"$\\1?]!J__P# A_\ &L&B@#>_X3SQ%_T&K_\ \"'_ ,:/^$\\1?\
M0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\ A//$7_0:O_\ P(?_ !K!
MHH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\"'_QK!HH WO^$\\1?]!J
M_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A//$7_0:O_P#P(?\ QH_X
M3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
MA//$7_0:O_\ P(?_ !K!HH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\
M"'_QK!HH WO^$\\1?]!J_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A
M//$7_0:O_P#P(?\ QH_X3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "
M'_QH_P"$\\1?]!J__P# A_\ &L&B@#>_X3SQ%_T&K_\ \"'_ ,:/^$\\1?\
M0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\ A//$7_0:O_\ P(?_ !K!
MHH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\"'_QK!HH WO^$\\1?]!J
M_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A//$7_0:O_P#P(?\ QH_X
M3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
MA//$7_0:O_\ P(?_ !K!HH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\
M"'_QK!HH WO^$\\1?]!J_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A
M//$7_0:O_P#P(?\ QH_X3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "
M'_QH_P"$\\1?]!J__P# A_\ &L&B@#>_X3SQ%_T&K_\ \"'_ ,:/^$\\1?\
M0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\ A//$7_0:O_\ P(?_ !K!
MHH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\"'_QK!HH WO^$\\1?]!J
M_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A//$7_0:O_P#P(?\ QH_X
M3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
MA//$7_0:O_\ P(?_ !K!HH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\
M"'_QK!HH WO^$\\1?]!J_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A
M//$7_0:O_P#P(?\ QH_X3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "
M'_QH_P"$\\1?]!J__P# A_\ &L&B@#>_X3SQ%_T&K_\ \"'_ ,:/^$\\1?\
M0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\ A//$7_0:O_\ P(?_ !K!
MHH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\"'_QK!HH WO^$\\1?]!J
M_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A//$7_0:O_P#P(?\ QH_X
M3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
MA//$7_0:O_\ P(?_ !K!HH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\
M"'_QK!HH WO^$\\1?]!J_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A
M//$7_0:O_P#P(?\ QH_X3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "
M'_QH_P"$\\1?]!J__P# A_\ &L&B@#>_X3SQ%_T&K_\ \"'_ ,:/^$\\1?\
M0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\ A//$7_0:O_\ P(?_ !K!
MHH WO^$\\1?]!J__ / A_P#&C_A//$7_ $&K_P#\"'_QK!HH WO^$\\1?]!J
M_P#_  (?_&C_ (3SQ%_T&K__ ,"'_P :P:* -[_A//$7_0:O_P#P(?\ QH_X
M3SQ%_P!!J_\ _ A_\:P:* -[_A//$7_0:O\ _P "'_QH_P"$\\1?]!J__P#
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MK_\ \"'_ ,:/^$\\1?\ 0:O_ /P(?_&L&B@#>_X3SQ%_T&K_ /\  A_\:/\
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M110 4444 %%%% !1110 4444 %?EG_P7'_X\_@Y_W&?YV%?J97Y9_P#!<?\
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MWVG?$;PE!&9IKW0=WGPQ 9:5H3G*#'+(SX&2< $U\=4 %%%% !1110 4444
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M_9U\"? ?P;\#+SP;I4NG7?B70'O=5EENY9S<3".V(;#L0G,K\* .>G KXZH
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MP_=?M4^$K7Q' VQ](N[&WAN4<@$*T9O]ZG!!^[W% 'YST5]:?M*?\$U_B?\
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MC(Y!!K@?C=_P2U\7_#_X=W7COP#XQT;XL^&+.)Y[F71E\NX6)<EY$17D215
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M?@__ -CCH_\ Z6PU]A_M<?\ *+C]FW_K]C_])[FOCS]E3_DZ'X/_ /8XZ/\
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MFG_@ME_R</X)_P"Q63_TKN:=_P %AXV.N_!2<*3#)X794D'W6(9"<'Z,/S%
M'$?LW_L]_#+XL?LP_M(_$"^\/3OJ/AF.YN/#CR7TR&Q00221AE5]LA&%SOW9
MQ6?^Q'^Q+X?^,/A#7_BQ\6-=E\+?";P\Y$LJ-Y;W[H,R /R5C7**2JEG9MJX
M()'I7["/_*/W]JS_ +!TW_I%)6[%X>U#XF_\$9M(LO!,;W=WX?UB:YU^RM,M
M(Z1WD\C[@.3M2:WF([*OM0!2\/\ B'_@GG\0M=B\$1>#/$GA07#_ &>V\67M
MU<10^83@.7-U(5!..98M@SR% KY<_;7_ &3KW]D;XM#PX=1_MG0-1M_M^D:B
MP"RR0EBI251P)$88)'!!5AC.T>$:5I5[KNIVFG:=:37^H7<JP6]K;1F22:1B
M J*HY))(  ]:]7_:8_9Z^)?[/OBO3;+XFA'U35+1;FVN!J2WC21+A<$[BR[3
M\OS #Y3MR!F@#BOA-X,TWXA_$CP]X;U?Q+8>#]+U*[6"YUS4R1;V:'DNWY8&
M2!DC+*,L/O/X@+^PI^S+K"^"KSP?KWQ@URV14U+6[+4V>)'(Y0,EQ%&7'7$:
M_+G!;(('R5^QM\!;7]I3]HGPKX$U&\EL=(O&EN+^>#'F^1#$TC*F>C-M" \X
MW9P<8KZP^+W[3?[.G[./Q#U[X=>$OV7_  YXJ3PY=R:7<ZMXED2226>)BDF!
M+#,[#<& <N,]< 8H Y#]JC]E'X2:M^S;8_M!_ *ZU"V\)I<I::MH.I2M(UF6
MD$0(+EG5UD9%92SAA(K*<#YO2?@#^R!^SOJG["_@OXS_ !2CO-(-O<7=WK6H
M6M[<;K^..]N;:*U6,,0NXB 910QV_>&XL/1_B7XRA^(7_!)[XC^)+3X4:7\(
M--U*[M9K+1M)C2.&[A^W60%WM6./&\AE&5Y$:D$@BO%_B9<20_\ !%SX3(CE
M5F\3SHX'\2_;M3;'YJ#^% 'BO[5OB+]F?QIH'A2P_9\\"ZUHOB:>_:.]-[+<
MNSQ;0L4:QR3RJS.[ @KR-F#]ZO>;G]ES]G#]B?P'H%]^T4VJ^.OB+K4"WB^$
M]%F9!:KW&(Y8P55B5,CR .5.Q3M:OB/]FW5-+T/]H?X8:CK;1IH]IXGTV>[>
M4X1(ENHRS-[  D^PK]3/^"@'QJ^$?PA^,EK'\3/V>4\=W=_I\;V7B6>Y5$N8
MU)#1#*G!C8X(SG#*>C"@#QG0OV</V8/VZ/">O0_ :#5/AG\2]*MFNTT+6)G>
M*Z4< LK2RCRRQ"[XW!0E2R'(!^>/V-?V:_AU\3/'7BR/XS>.[7P+IGA)'DO-
M$FN5MKV[:,L)0K.,!8RA#!=SG(  ZU]8?LS?M4_#K6/&E_JGP3_9$O9?$FDV
M,D]S=:)?1+)#;MPPR4 );H$&6;!V@XKA_P!G_P"$?PR^-.I?M!?M-_%3PSJ$
MWA?1=:O;R/P<'82"<G[1*)MI0LP,B*%.U<LV[@8 !0T_XE?\$_?$'B2'PL_P
MJ\3:-I4DPMX_%4M]<JJ$\><X^ULX3ORAQGE!V\ _;N_91B_9+^,,.A:7J,VK
M^%]7LUU+2;NY*F81EF5HI"H 9E*_>  (93@'('MFC?MR?"KQ#XALM \)_L8^
M!]3N;R=;:QM)(X+BZG=CA1_QYDDGCC)QZUU/_!:=77Q?\(1)9)IL@T*X#6<;
M!E@/F1YC!  (7ID#'% 'YMT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5ZK^R=_P G3_!O_L<]&_\ 2Z&O*J]5_9._
MY.G^#?\ V.>C?^ET- 'M7_!6#_D]KQ?_ ->6G?\ I)'7#?L4? 7P!\>?B5>V
M7Q'\?V/@CP[I=J;V2&>Y2WN-1 R6CADD^10JJ68G+8QA3RR]S_P5@_Y/:\7_
M /7EIW_I)'6E_P $[OV8_ 7Q:T_XD_$CXH076I^#? -@+R31[1F5KQA'+,Y8
MHP8A$A.$!&XN.< @@'=S_$[_ ()^6_B$^%Q\*?%$^CI+Y!\5I>76&(.//"_:
MA)L[_<!_Z9]J\8_;[_9'TK]ESQSX>NO"6K2ZSX"\6V;7^C7%PZR2)MV>9&74
M .H$L3*^!D2 ')!)]0C_ &\/@W-JT6E>%_V./!6H1S3""TCO$@N+NX9CA!M%
MHQW$X^4%N3U->B_\%B%G7X9_LY"YT&'PM<BPOQ+H5L5,6G-Y-AFV0J I6,_(
M, #"\ 4 >@?M%_LK_L9?LD:II?B'QWHFL3VFI6_V73_"EA?74[3RQL6FNB3,
MK<"2)<&14&.%8L<?("? CP!^V%^UU:>#OV>])N_"7@(V$5S?7E^9IS;(@!N+
MC9+(S#YI$B5-^"V.0&R/6/\ @MI<2-\?O L!<F)/# =5[!FNIP3^.U?RI?\
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M>:.=1N4EA>S6W\L01[%PK(&BW(3N3 # $U>_;=C:3_@G9^RS,BEHDMHT9QR
MQM!@9]?E;\C0!\.?%S4?!VK_ !)\0WGP^TJ\T3P7+=%M*T_4)"\\,&  ')=^
M<Y/WVZ]:^Q?^",7_ "=AK/\ V*=Y_P"E-I7P97WG_P $8O\ D[#6?^Q3O/\
MTIM* +O_  3"_P"4@GB3_KTUC_T<M?''QX_Y+C\1/^QCU'_TIDK['_X)A?\
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ML3?LE:1HND^)+;4?CQXNO;5+J>\T?4,VT2,,AL13I&BL#E4)D?&"2 03W?\
MP4H^$VJ?$?XF?LI?#G4-2":MJL3Z/>:D1OVNS6:338)&XCYFQGGIWKF/C_\
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M>X@"]RN*\ _;J_8X;]E[XQZ5HGANYNM>\,^)X1<Z$\@#W!;?L:W)7[[*63#
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MO^(/V4KOQ%92:#9^-O"'B)?^)IH6H2^7YK[2N]9"KX)5BK!E8,.HX!KYKHH
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MM-^/_@9\7)?B-X>U<R^(;N6634?MP,D6I"5]\J3KD;@S?-D$$$ @@C->544
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KV#]CV&2;]JCX1K&C2,/%FDL0HR<"]A)/T !/X5X_7V]
M_P $HOV?M3^)?[1FF>,)[.1?#/A'=J$]V\9\N2YVE;>%6Z;]["7_ '8CTR*
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M[;44 ?B3_P .;/CA_P _WA3_ ,&<O_QBC_AS9\</^?[PI_X,Y?\ XQ7[;44
M?B3_ ,.;/CA_S_>%/_!G+_\ &*/^'-GQP_Y_O"G_ (,Y?_C%?MM10!^)/_#F
MSXX?\_WA3_P9R_\ QBC_ (<V?'#_ )_O"G_@SE_^,5^VU% 'XD_\.;/CA_S_
M 'A3_P &<O\ \8H_X<V?'#_G^\*?^#.7_P",5^VU% 'XD_\ #FSXX?\ /]X4
M_P#!G+_\8H_X<V?'#_G^\*?^#.7_ .,5^VU% 'XD_P##FSXX?\_WA3_P9R__
M !BC_AS9\</^?[PI_P"#.7_XQ7[;44 ?B3_PYL^.'_/]X4_\&<O_ ,8H_P"'
M-GQP_P"?[PI_X,Y?_C%?MM10!^)/_#FSXX?\_P!X4_\ !G+_ /&*/^'-GQP_
MY_O"G_@SE_\ C%?MM10!^)/_  YL^.'_ #_>%/\ P9R__&*/^'-GQP_Y_O"G
M_@SE_P#C%?MM10!^)/\ PYL^.'_/]X4_\&<O_P 8H_X<V?'#_G^\*?\ @SE_
M^,5^VU% 'XD_\.;/CA_S_>%/_!G+_P#&*/\ AS9\</\ G^\*?^#.7_XQ7[;4
M4 ?B3_PYL^.'_/\ >%/_  9R_P#QBC_AS9\</^?[PI_X,Y?_ (Q7[;44 ?B3
M_P .;/CA_P _WA3_ ,&<O_QBC_AS9\</^?[PI_X,Y?\ XQ7[;44 ?B3_ ,.;
M/CA_S_>%/_!G+_\ &*/^'-GQP_Y_O"G_ (,Y?_C%?MM10!^)/_#FSXX?\_WA
M3_P9R_\ QBC_ (<V?'#_ )_O"G_@SE_^,5^VU% 'XD_\.;/CA_S_ 'A3_P &
M<O\ \8H_X<V?'#_G^\*?^#.7_P",5^VU% 'XD_\ #FSXX?\ /]X4_P#!G+_\
M8H_X<V?'#_G^\*?^#.7_ .,5^VU% 'XD_P##FSXX?\_WA3_P9R__ !BC_AS9
M\</^?[PI_P"#.7_XQ7[;44 ?B3_PYL^.'_/]X4_\&<O_ ,8H_P"'-GQP_P"?
M[PI_X,Y?_C%?MM10!^)/_#FSXX?\_P!X4_\ !G+_ /&*/^'-GQP_Y_O"G_@S
ME_\ C%?MM10!^)/_  YL^.'_ #_>%/\ P9R__&*/^'-GQP_Y_O"G_@SE_P#C
M%?MM10!^)/\ PYL^.'_/]X4_\&<O_P 8H_X<V?'#_G^\*?\ @SE_^,5^VU%
M'XD_\.;/CA_S_>%/_!G+_P#&*/\ AS9\</\ G^\*?^#.7_XQ7[;44 ?B3_PY
ML^.'_/\ >%/_  9R_P#QBC_AS9\</^?[PI_X,Y?_ (Q7[;44 ?B3_P .;/CA
M_P _WA3_ ,&<O_QBC_AS9\</^?[PI_X,Y?\ XQ7[;44 ?B3_ ,.;/CA_S_>%
M/_!G+_\ &*/^'-GQP_Y_O"G_ (,Y?_C%?MM10!^)/_#FSXX?\_WA3_P9R_\
MQBC_ (<V?'#_ )_O"G_@SE_^,5^VU% 'XD_\.;/CA_S_ 'A3_P &<O\ \8H_
MX<V?'#_G^\*?^#.7_P",5^VU% 'XD_\ #FSXX?\ /]X4_P#!G+_\8K@_A-_P
M31^*GQC_ .$R_L.Z\/Q_\(KXDO?"]]]KOW3==VVSS"F(CE/WBX)P3SP*_?*O
MEK]@VTGM/^&B?/ADA\WXQ^(I$\Q"N]#]GPPSU!]: /SN_P"'-GQP_P"?[PI_
MX,Y?_C%'_#FSXX?\_P!X4_\ !G+_ /&*_;:B@#\2?^'-GQP_Y_O"G_@SE_\
MC%'_  YL^.'_ #_>%/\ P9R__&*_;:B@#\2?^'-GQP_Y_O"G_@SE_P#C%'_#
MFSXX?\_WA3_P9R__ !BOVVHH _$G_AS9\</^?[PI_P"#.7_XQ1_PYL^.'_/]
MX4_\&<O_ ,8K]MJ* /Q)_P"'-GQP_P"?[PI_X,Y?_C%'_#FSXX?\_P!X4_\
M!G+_ /&*_;:B@#\2?^'-GQP_Y_O"G_@SE_\ C%'_  YL^.'_ #_>%/\ P9R_
M_&*_;:B@#\2?^'-GQP_Y_O"G_@SE_P#C%'_#FSXX?\_WA3_P9R__ !BOVVHH
M _$G_AS9\</^?[PI_P"#.7_XQ1_PYL^.'_/]X4_\&<O_ ,8K]MJ* /Q)_P"'
M-GQP_P"?[PI_X,Y?_C%'_#FSXX?\_P!X4_\ !G+_ /&*_;:B@#\2?^'-GQP_
MY_O"G_@SE_\ C%'_  YL^.'_ #_>%/\ P9R__&*_;:B@#\2?^'-GQP_Y_O"G
M_@SE_P#C%'_#FSXX?\_WA3_P9R__ !BOVVHH _$G_AS9\</^?[PI_P"#.7_X
MQ1_PYL^.'_/]X4_\&<O_ ,8K]MJ* /Q)_P"'-GQP_P"?[PI_X,Y?_C%'_#FS
MXX?\_P!X4_\ !G+_ /&*_;:B@#\2?^'-GQP_Y_O"G_@SE_\ C%'_  YL^.'_
M #_>%/\ P9R__&*_;:B@#\2?^'-GQP_Y_O"G_@SE_P#C%'_#FSXX?\_WA3_P
M9R__ !BOVVHH _$G_AS9\</^?[PI_P"#.7_XQ1_PYL^.'_/]X4_\&<O_ ,8K
M]MJ* /Q)_P"'-GQP_P"?[PI_X,Y?_C%'_#FSXX?\_P!X4_\ !G+_ /&*_;:B
M@#\2?^'-GQP_Y_O"G_@SE_\ C%'_  YL^.'_ #_>%/\ P9R__&*_;:B@#\2?
M^'-GQP_Y_O"G_@SE_P#C%'_#FSXX?\_WA3_P9R__ !BOVVHH _$G_AS9\</^
M?[PI_P"#.7_XQ1_PYL^.'_/]X4_\&<O_ ,8K]MJ* /Q)_P"'-GQP_P"?[PI_
MX,Y?_C%'_#FSXX?\_P!X4_\ !G+_ /&*_;:B@#\#?@7_ ,$T?BI^T#\*]$\?
M>&[KP_%HNK^?]G2^OWCF'E3R0MN41,!\T38Y/&*[S_AS9\</^?[PI_X,Y?\
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M* /Q)_X<V?'#_G^\*?\ @SE_^,4?\.;/CA_S_>%/_!G+_P#&*_;:B@#\2?\
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MV?'#_G^\*?\ @SE_^,4?\.;/CA_S_>%/_!G+_P#&*_;:B@#\2?\ AS9\</\
MG^\*?^#.7_XQ1_PYL^.'_/\ >%/_  9R_P#QBOVVHH _$G_AS9\</^?[PI_X
M,Y?_ (Q1_P .;/CA_P _WA3_ ,&<O_QBOVVHH _$G_AS9\</^?[PI_X,Y?\
MXQ1_PYL^.'_/]X4_\&<O_P 8K]MJ* /Q)_X<V?'#_G^\*?\ @SE_^,4?\.;/
MCA_S_>%/_!G+_P#&*_;:B@#\2?\ AS9\</\ G^\*?^#.7_XQ1_PYL^.'_/\
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M^?[PI_X,Y?\ XQ1_PYL^.'_/]X4_\&<O_P 8K]MJ* /Q)_X<V?'#_G^\*?\
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MR_\ QBOVVHH _$G_ (<V?'#_ )_O"G_@SE_^,4?\.;/CA_S_ 'A3_P &<O\
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M_P#!G+_\8K]MJ* /Q)_X<V?'#_G^\*?^#.7_ .,4?\.;/CA_S_>%/_!G+_\
M&*_;:B@#\2?^'-GQP_Y_O"G_ (,Y?_C%'_#FSXX?\_WA3_P9R_\ QBOVVHH
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M)&ZN['DL>OTP*ZZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBOAW_@J[^TUK/P(^#FA:'X1UJYT/Q;XFO_ -W>6,ICG@M(,/*RL.5+.T*>
MX9Q0!]Q45^:'_!(_]K;Q3\5=;\:> ?'WB>_\2:NL2:QI5UJEP9I?+4B*XB#-
MS@%H6"^\A]:^EO\ @H_XZ\0_#?\ 9 \9^(/"VLWF@:W;36"PZAI\QBFC#WL*
M-M8<C*L0?8F@#Z9HK\1_@5HG[;'[1O@<^+?!/Q(\07NBBZDL_,N?$Y@?S4"E
MAM9LX^8<UT?@W]L[]I']CGX\Z1X,^.5]=:UH]PT#7MEJTD-Q(+21B@N;>Y3)
M."&."Q!*,I /( /V5HK\X?\ @II^W/XW^$GC72OA+\+YFTWQ!?6D=S?ZM!&L
MMRIF8K%;P @[7(7<6P3\Z;2#DU\_>,?@[^WK\'O#\OCV[\8^*[^"TA^VWMO:
M>*&OVM5 R?,M6<JX4=0BN  3T!- '[/T5\N_\$^/CO\ %#X^_!@:Y\3?"YTJ
M>-T33]=6,0)K4)!S*(.J$$#YP C[OE P17U%0 445YE\>/VD?A_^S5X<M-:^
M(&M/H]I>RM;VBQ6DUQ)<2A2Q15C5L' ZM@>] 'IM%?BKX0_;M^(?QO\ V]_"
MT^B^+/$6B?#_ %OQ;86UOX;-ZRP"S\R.+;)$IV@NJEG49&YVY/4_4_\ P4X_
M;QU_]GV;2_AW\.KF&U\8:I:F[U#4S&)9-/MV.V)8@<KYKE7.6!VJ 0,L" #]
M Z*_$;Q/HO[=_P 'O!;?%36O$?C2UTB)$NKE+G7%NS:QG!#363.P1>?F!3Y>
M=P'-?H+^Q)^W%8?M"?L_^(/%OC&6TT?7/!D<C^)&MHW\I;=8VE6[5!N8*R1R
M949.Z)\#&!0!]:45^/7[??\ P4U_X3[4_#VC? GQ;KVD:=IYEFU#7+(RV'VU
MV"A(T5MK[4 8DL!DL,#C)_2;]D'Q)JGC#]F#X8ZWK>H7&JZO?Z%;3W5[=2%Y
M9I&3)9F/))]: /7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\T^"/QOL?C;_ ,)]]ATRXTW_ (1'Q;J'A.?[0ZM]HEM?+W3+CHK>
M8, \\5Z77RK^P+_S<;_V6;Q'_P"V] 'U51110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'FG[.'QOL?VCO@QX=^(FFZ9<:/9:S]H\NRNG
M5Y(_)N98#DKP<F(GZ$5Z77RK_P $N/\ DQ/X9?\ <3_].EW7U50 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>=>-_ACX2\5?&#X:>,-8U"2W\4
M^%/[3_L*T6Z2-;C[3;K%<[HR-TFV-01M(V]3FO1:^5?VA_\ D^S]D;_N;O\
MTUQT ?55%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YO^TK
MHE_XE_9R^*FD:59S:AJFH>%-5M+2SMT+R3S26<JI&BCDLS$ #N37I%<?\9/'
M$_PR^$/CCQA:VT=[<^'M"OM6BMIF*I*\%N\H1B.0"4 )'K0!C_LU:)?^&OV<
MOA7I&JV<VGZII_A32K2[L[A"DD$T=G$KQNIY#*P(([$5Z17'_!OQQ/\ $WX0
M^!_&%U;1V5SXAT*QU:6VA8LD3SVZ2E%)Y(!<@$^E=A0 4444 %%%% !1110
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MW_!6?X->*_AO^T!H'QU\-6EPVFSK9O/J4$1=;#4;5E$1D(X4,JP[2>I1AZ9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKSKX,ZY\.=<_X3G_ (5U'9Q_8_%-]:>(_L=E);;M:39]K,F]%\Q^8\R+N5N,
M,<5Z+7RK^P+_ ,W&_P#99O$?_MO0!]54444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!YU^SUKGPY\2?!_0-1^$L=G#\/IOM']F)864EG
M",7$BS;871&7]\)<Y49.3R#FO1:^5?\ @EQ_R8G\,O\ N)_^G2[KZJH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ/\ A8GA3_H9M&_\#XO_ (JOS*HH_P!8:G_/M?>'_$.\/_T$/_P%?YGZ:_\
M"Q/"G_0S:-_X'Q?_ !5'_"Q/"G_0S:-_X'Q?_%5^95%'^L-3_GVOO#_B'>'_
M .@A_P#@*_S/TU_X6)X4_P"AFT;_ ,#XO_BJ/^%B>%/^AFT;_P #XO\ XJOS
M*HH_UAJ?\^U]X?\ $.\/_P!!#_\  5_F?IK_ ,+$\*?]#-HW_@?%_P#%4?\
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M!\7_ ,57YE44?ZPU/^?:^\/^(=X?_H(?_@*_S/TU_P"%B>%/^AFT;_P/B_\
MBJ/^%B>%/^AFT;_P/B_^*K\RJ*/]8:G_ #[7WA_Q#O#_ /00_P#P%?YGZ:_\
M+$\*?]#-HW_@?%_\51_PL3PI_P!#-HW_ ('Q?_%5^95%'^L-3_GVOO#_ (AW
MA_\ H(?_ ("O\S]-?^%B>%/^AFT;_P #XO\ XJC_ (6)X4_Z&;1O_ ^+_P"*
MK\RJ*/\ 6&I_S[7WA_Q#O#_]!#_\!7^9^FO_  L3PI_T,VC?^!\7_P 51_PL
M3PI_T,VC?^!\7_Q5?F511_K#4_Y]K[P_XAWA_P#H(?\ X"O\S]-?^%B>%/\
MH9M&_P# ^+_XJC_A8GA3_H9M&_\  ^+_ .*K\RJ*/]8:G_/M?>'_ !#O#_\
M00__  %?YGZ:_P#"Q/"G_0S:-_X'Q?\ Q5'_  L3PI_T,VC?^!\7_P 57YE4
M4?ZPU/\ GVOO#_B'>'_Z"'_X"O\ ,_37_A8GA3_H9M&_\#XO_BJ/^%B>%/\
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ME%=>[5_(_7+_ (6)X4_Z&;1O_ ^+_P"*H_X6)X4_Z&;1O_ ^+_XJOS*HK/\
MUAJ?\^U]YT_\0[P__00__ 5_F?IK_P +$\*?]#-HW_@?%_\ %4?\+$\*?]#-
MHW_@?%_\57YE44?ZPU/^?:^\/^(=X?\ Z"'_ . K_,_37_A8GA3_ *&;1O\
MP/B_^*H_X6)X4_Z&;1O_  /B_P#BJ_,JBC_6&I_S[7WA_P 0[P__ $$/_P !
M7^9^FO\ PL3PI_T,VC?^!\7_ ,51_P +$\*?]#-HW_@?%_\ %5^95%'^L-3_
M )]K[P_XAWA_^@A_^ K_ #/TU_X6)X4_Z&;1O_ ^+_XJC_A8GA3_ *&;1O\
MP/B_^*K\RJ*/]8:G_/M?>'_$.\/_ -!#_P# 5_F?IK_PL3PI_P!#-HW_ ('Q
M?_%4?\+$\*?]#-HW_@?%_P#%5^95%'^L-3_GVOO#_B'>'_Z"'_X"O\S]-?\
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MO_ ^+_XJC_A8GA3_ *&;1O\ P/B_^*K\RJ*/]8:G_/M?>'_$.\/_ -!#_P#
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M $,VC?\ @?%_\51_PL3PI_T,VC?^!\7_ ,57YE44O]8:G_/M?>7_ ,0[P_\
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M-B. \+AH*<\1*S<8Z16\I**Z]VK^1^N7_"Q/"G_0S:-_X'Q?_%4?\+$\*?\
M0S:-_P"!\7_Q5?F516?^L-3_ )]K[SI_XAWA_P#H(?\ X"O\S]-?^%B>%/\
MH9M&_P# ^+_XJC_A8GA3_H9M&_\  ^+_ .*K\RJ*/]8:G_/M?>'_ !#O#_\
M00__  %?YGZ:_P#"Q/"G_0S:-_X'Q?\ Q5'_  L3PI_T,VC?^!\7_P 57YE4
M4?ZPU/\ GVOO#_B'>'_Z"'_X"O\ ,_37_A8GA3_H9M&_\#XO_BJ/^%B>%/\
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M[K_-=5\^H^BBBO2/F@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6NXN*6JOL[W1\W4445X)]Z%%%% !1110 4444 %%%% !1110 4444 %%%%
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M/^O;;2OYJROZHP:***\@^O"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNOPC_P"XO_Z2K7JE<[K?C#3M&\8>&M"N;>:34-:^T_9)D12D7DQAWW$D$9!
M& <]\5TX>3C-N*OI+\8O7Y;GFYA3A5HQC.7*N>F[^:J1:7S:2^9T5%%%<QZ0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<K\6/^26>,O^P->?\
MHAZZJLGQ?H;>)_">M:,LPMVU&QGM!,5W!#)&R;L=\9SBM:34:D9/9-'-BH2J
M8>I"*U::_ R_A/\ \DL\&_\ 8&L__1"5U59/A#0V\,>$]%T9IA<-IUC!:&8+
MM#F.-4W8[9QG%:U%5J52375L6%A*GAZ<)+5))_<%%%%9'4%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %>5_$/_DNOPC_[B_\ Z2K7JE<[K?C#3M&\8>&M
M"N;>:34-:^T_9)D12D7DQAWW$D$9! & <]\5TX>3C-N*OI+\8O7Y;GFYA3A5
MHQC.7*N>F[^:J1:7S:2^9T5%%%<QZ04444 %%%% !1110 4444 %%%% !111
M0 4444 /BE>"5)8G:.1&#*Z'!4CH0>QK[F_9O^.R?$K1QH^LW"+XGLUY) 7[
M7&/^6BC^\/X@ .Q'!./A:KFCZO>:!JEKJ6GW#VE]:R"6&:/JC \'_P"L>#7I
M8'&SP57G6J>Z_KJ?-9]D='/,+[*>DUK&79_Y/K]_0_4JBN*^#OCJZ^(WP_TS
M6[W3Y=/NY5V2JZ[4E9< R1_[#'D9Z<CG&3VM?IM.I&K!3CL]3^7\10GA:TZ%
M7XHMI^J"BBBM#G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\J:*
M**_'#^S0HHHH **** "BBB@ HHHH ][^!?\ R1#XO?\ 7E'_ .@2UJ_"GPUJ
M7B_]E/QGI.CVC7NHW&LIY4", 6VFU8\D@<!2?PKY^L=>U/3+&\LK/4;NTL[P
M!;FW@G9(YP,X#J#AL9/7UJWHGC;Q%X9MGMM'U_5-*MW?S&AL;R2%&; &XA6
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MO=?;#<_:F!\W=NW "XP.>@' J']J73K+Q;IOA?XDZ,C?V?K%N+:?< &21<E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M117Z/&*A%1BK)'\UU:DZTY5*CO)N[?=L****HS"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^2?^&'+_P#Z&VV_\ 6_^+H_X8<O_P#H;;;_
M , 6_P#BZN?\-2?';_HU'Q!_X5-A_A1_PU)\=O\ HU'Q!_X5-A_A7B_V-@OY
M/Q?^9]O_ *YYW_S^_P#)8_Y%/_AAR_\ ^AMMO_ %O_BZ/^&'+_\ Z&VV_P#
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MV_Z-1\0?^%38?X4?\-2?';_HU'Q!_P"%38?X4?V-@OY/Q?\ F'^N>=_\_O\
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M\ 6_^+H_X8<O_P#H;;;_ , 6_P#BZN?\-2?';_HU'Q!_X5-A_A1_PU)\=O\
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MZYYW_P _O_)8_P"13_X8<O\ _H;;;_P!;_XNC_AAR_\ ^AMMO_ %O_BZN?\
M#4GQV_Z-1\0?^%38?X4?\-2?';_HU'Q!_P"%38?X4?V-@OY/Q?\ F'^N>=_\
M_O\ R6/^13_X8<O_ /H;;;_P!;_XNC_AAR__ .AMMO\ P!;_ .+JY_PU)\=O
M^C4?$'_A4V'^%'_#4GQV_P"C4?$'_A4V'^%']C8+^3\7_F'^N>=_\_O_ "6/
M^13_ .&'+_\ Z&VV_P# %O\ XNC_ (8<O_\ H;;;_P  6_\ BZN?\-2?';_H
MU'Q!_P"%38?X4?\ #4GQV_Z-1\0?^%38?X4?V-@OY/Q?^8?ZYYW_ ,_O_)8_
MY%/_ (8<O_\ H;;;_P  6_\ BZ/^&'+_ /Z&VV_\ 6_^+JY_PU)\=O\ HU'Q
M!_X5-A_A1_PU)\=O^C4?$'_A4V'^%']C8+^3\7_F'^N>=_\ /[_R6/\ D4_^
M&'+_ /Z&VV_\ 6_^+H_X8<O_ /H;;;_P!;_XNKG_  U)\=O^C4?$'_A4V'^%
M'_#4GQV_Z-1\0?\ A4V'^%']C8+^3\7_ )A_KGG?_/[_ ,EC_D4_^&'+_P#Z
M&VV_\ 6_^+H_X8<O_P#H;;;_ , 6_P#BZN?\-2?';_HU'Q!_X5-A_A1_PU)\
M=O\ HU'Q!_X5-A_A1_8V"_D_%_YA_KGG?_/[_P EC_D4_P#AAR__ .AMMO\
MP!;_ .+H_P"&'+__ *&VV_\  %O_ (NKG_#4GQV_Z-1\0?\ A4V'^%'_  U)
M\=O^C4?$'_A4V'^%']C8+^3\7_F'^N>=_P#/[_R6/^13_P"&'+__ *&VV_\
M %O_ (NC_AAR_P#^AMMO_ %O_BZN?\-2?';_ *-1\0?^%38?X4?\-2?';_HU
M'Q!_X5-A_A1_8V"_D_%_YA_KGG?_ #^_\EC_ )%/_AAR_P#^AMMO_ %O_BZ/
M^&'+_P#Z&VV_\ 6_^+JY_P -2?';_HU'Q!_X5-A_A1_PU)\=O^C4?$'_ (5-
MA_A1_8V"_D_%_P"8?ZYYW_S^_P#)8_Y%/_AAR_\ ^AMMO_ %O_BZ/^&'+_\
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M7\GXO_,W_P!<\[_Y_?\ DL?\BG_PPY?_ /0VVW_@"W_Q='_##E__ -#;;?\
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MH^(/_"IL/\*/^&I/CM_T:CX@_P#"IL/\*/[&P7\GXO\ S#_7/._^?W_DL?\
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MH_X:D^.W_1J/B#_PJ;#_  H_L;!?R?B_\P_USSO_ )_?^2Q_R*?_  PY?_\
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MP_PH_L;!?R?B_P#,/]<\[_Y_?^2Q_P BG_PPY?\ _0VVW_@"W_Q='_##E_\
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M_%U<_P"&I/CM_P!&H^(/_"IL/\*/^&I/CM_T:CX@_P#"IL/\*/[&P7\GXO\
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M%_YA_KGG?_/[_P EC_D4_P#AAR__ .AMMO\ P!;_ .+H_P"&'+__ *&VV_\
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M_P"C4?$'_A4V'^%']C8+^3\7_F'^N>=_\_O_ "6/^13_ .&'+_\ Z&VV_P#
M%O\ XNC_ (8<O_\ H;;;_P  6_\ BZN?\-2?';_HU'Q!_P"%38?X4?\ #4GQ
MV_Z-1\0?^%38?X4?V-@OY/Q?^8?ZYYW_ ,_O_)8_Y%/_ (8<O_\ H;;;_P
M6_\ BZ/^&'+_ /Z&VV_\ 6_^+JY_PU)\=O\ HU'Q!_X5-A_A1_PU)\=O^C4?
M$'_A4V'^%']C8+^3\7_F'^N>=_\ /[_R6/\ D4_^&'+_ /Z&VV_\ 6_^+H_X
M8<O_ /H;;;_P!;_XNKG_  U)\=O^C4?$'_A4V'^%'_#4GQV_Z-1\0?\ A4V'
M^%']C8+^3\7_ )A_KGG?_/[_ ,EC_D4_^&'+_P#Z&VV_\ 6_^+H_X8<O_P#H
M;;;_ , 6_P#BZN?\-2?';_HU'Q!_X5-A_A1_PU)\=O\ HU'Q!_X5-A_A1_8V
M"_D_%_YA_KGG?_/[_P EC_D4_P#AAR__ .AMMO\ P!;_ .+H_P"&'+__ *&V
MV_\  %O_ (NKG_#4GQV_Z-1\0?\ A4V'^%'_  U)\=O^C4?$'_A4V'^%']C8
M+^3\7_F'^N>=_P#/[_R6/^13_P"&'+__ *&VV_\  %O_ (NC_AAR_P#^AMMO
M_ %O_BZN?\-2?';_ *-1\0?^%38?X4?\-2?';_HU'Q!_X5-A_A1_8V"_D_%_
MYA_KGG?_ #^_\EC_ )%/_AAR_P#^AMMO_ %O_BZ/^&'+_P#Z&VV_\ 6_^+JY
M_P -2?';_HU'Q!_X5-A_A1_PU)\=O^C4?$'_ (5-A_A1_8V"_D_%_P"8?ZYY
MW_S^_P#)8_Y%/_AAR_\ ^AMMO_ %O_BZ/^&'+_\ Z&VV_P# %O\ XNKG_#4G
MQV_Z-1\0?^%38?X4?\-2?';_ *-1\0?^%38?X4?V-@OY/Q?^8?ZYYW_S^_\
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M  J/[&P7\GXO_,W_ -<\[_Y_?^2Q_P BG_PPY?\ _0VVW_@"W_Q='_##E_\
M]#;;?^ +?_%U<_X:D^.W_1J/B#_PJ;#_  H_X:D^.W_1J/B#_P *FP_PH_L;
M!?R?B_\ ,/\ 7/._^?W_ )+'_(I_\,.7_P#T-MM_X M_\71_PPY?_P#0VVW_
M ( M_P#%U<_X:D^.W_1J/B#_ ,*FP_PH_P"&I/CM_P!&H^(/_"IL/\*/[&P7
M\GXO_,/]<\[_ .?W_DL?\BG_ ,,.7_\ T-MM_P" +?\ Q='_  PY?_\ 0VVW
M_@"W_P 75S_AJ3X[?]&H^(/_  J;#_"C_AJ3X[?]&H^(/_"IL/\ "C^QL%_)
M^+_S#_7/._\ G]_Y+'_(I_\ ##E__P!#;;?^ +?_ !='_##E_P#]#;;?^ +?
M_%U<_P"&I/CM_P!&H^(/_"IL/\*/^&I/CM_T:CX@_P#"IL/\*/[&P7\GXO\
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M^2Q_R*?_  PY?_\ 0VVW_@"W_P 71_PPY?\ _0VVW_@"W_Q=7/\ AJ3X[?\
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MH^(/_"IL/\*/[&P7\GXO_,/]<\[_ .?W_DL?\BG_ ,,.7_\ T-MM_P" +?\
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M=O\ HU'Q!_X5-A_A1_8V"_D_%_Y@N,\[7_+[_P EC_D4_P#AAR__ .AMMO\
MP!;_ .+H_P"&'+__ *&VV_\  %O_ (NKG_#4GQV_Z-1\0?\ A4V'^%'_  U)
M\=O^C4?$'_A4V'^%']C8+^3\7_F/_7/._P#G]_Y+'_(I_P###E__ -#;;?\
M@"W_ ,71_P ,.7__ $-MM_X M_\ %U<_X:D^.W_1J/B#_P *FP_PH_X:D^.W
M_1J/B#_PJ;#_  H_L;!?R?B_\P_USSO_ )_?^2Q_R*?_  PY?_\ 0VVW_@"W
M_P 71_PPY?\ _0VVW_@"W_Q=7/\ AJ3X[?\ 1J/B#_PJ;#_"C_AJ3X[?]&H^
M(/\ PJ;#_"C^QL%_)^+_ ,P_USSO_G]_Y+'_ "*?_##E_P#]#;;?^ +?_%T?
M\,.7_P#T-MM_X M_\75S_AJ3X[?]&H^(/_"IL/\ "C_AJ3X[?]&H^(/_  J;
M#_"C^QL%_)^+_P P_P!<\[_Y_?\ DL?\BG_PPY?_ /0VVW_@"W_Q='_##E__
M -#;;?\ @"W_ ,75S_AJ3X[?]&H^(/\ PJ;#_"C_ (:D^.W_ $:CX@_\*FP_
MPH_L;!?R?B_\P_USSO\ Y_?^2Q_R*?\ PPY?_P#0VVW_ ( M_P#%T?\ ##E_
M_P!#;;?^ +?_ !=7/^&I/CM_T:CX@_\ "IL/\*/^&I/CM_T:CX@_\*FP_P *
M/[&P7\GXO_,/]<\[_P"?W_DL?\BG_P ,.7__ $-MM_X M_\ %T?\,.7_ /T-
MMM_X M_\75S_ (:D^.W_ $:CX@_\*FP_PH_X:D^.W_1J/B#_ ,*FP_PH_L;!
M?R?B_P#,/]<\[_Y_?^2Q_P BG_PPY?\ _0VVW_@"W_Q='_##E_\ ]#;;?^ +
M?_%U<_X:D^.W_1J/B#_PJ;#_  H_X:D^.W_1J/B#_P *FP_PH_L;!?R?B_\
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MM_T:CX@_\*FP_P */[&P7\GXO_,/]<\[_P"?W_DL?\BG_P ,.7__ $-MM_X
MM_\ %T?\,.7_ /T-MM_X M_\75S_ (:D^.W_ $:CX@_\*FP_PH_X:D^.W_1J
M/B#_ ,*FP_PH_L;!?R?B_P#,/]<\[_Y_?^2Q_P BG_PPY?\ _0VVW_@"W_Q=
M>!?&/]E6[T']JW]GCPXWB*&9]?\ ^$BVW M2!#Y%BDAR-W.<XZC%?1/_  U)
M\=O^C4?$'_A4V'^%>4?$7QC\=_'OQX^$/Q''[->OV*^ ?[8SIIU^QD-]]NM5
M@_UFX>7LV[ONMNSCCK5PRG!TW>,.ZW?56?7L85N+<XQ$5"I5NDT_ACO%J2Z=
MTCTO_AAR_P#^AMMO_ %O_BZ/^&'+_P#Z&VV_\ 6_^+JY_P -2?';_HU'Q!_X
M5-A_A1_PU)\=O^C4?$'_ (5-A_A4?V-@OY/Q?^9O_KGG?_/[_P EC_D4_P#A
MAR__ .AMMO\ P!;_ .+H_P"&'+__ *&VV_\  %O_ (NKG_#4GQV_Z-1\0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#G$:@*P'_/N: /U4_9_^/_A/]I7X<P>-/!LMR^E27$MJ\5[$(YX98SAE=0S
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M1.,GHJJ 6=CV502>PKJ:^8/VX_V*$_;&\-Z-;)XRO_#.H:(99+.#RUFL)7<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSWKU"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_)K'P;_ .Q,T;_TAAKU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9?@+_GAK/_@*G_QRC_ALOP%_SPUG_P !4_\ CE?#]%']N8OR^X/]1,H_O?\
M@7_ /N#_ (;+\!?\\-9_\!4_^.4?\-E^ O\ GAK/_@*G_P <KX?HH_MS%^7W
M!_J)E'][_P "_P" ?<'_  V7X"_YX:S_ . J?_'*/^&R_ 7_ #PUG_P%3_XY
M7P_11_;F+\ON#_43*/[W_@7_  #[@_X;+\!?\\-9_P# 5/\ XY1_PV7X"_YX
M:S_X"I_\<KX?HH_MS%^7W!_J)E'][_P+_@'W!_PV7X"_YX:S_P" J?\ QRC_
M (;+\!?\\-9_\!4_^.5\/T4?VYB_+[@_U$RC^]_X%_P#[@_X;+\!?\\-9_\
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MH_X;+\!?\\-9_P# 5/\ XY7P_11_;F+\ON#_ %$RC^]_X%_P#[@_X;+\!?\
M/#6?_ 5/_CE'_#9?@+_GAK/_ ("I_P#'*^'Z*/[<Q?E]P?ZB91_>_P# O^ ?
M<'_#9?@+_GAK/_@*G_QRC_ALOP%_SPUG_P !4_\ CE?#]%']N8OR^X/]1,H_
MO?\ @7_ /N#_ (;+\!?\\-9_\!4_^.4?\-E^ O\ GAK/_@*G_P <KX?HH_MS
M%^7W!_J)E'][_P "_P" ?<'_  V7X"_YX:S_ . J?_'*/^&R_ 7_ #PUG_P%
M3_XY7P_11_;F+\ON#_43*/[W_@7_  #[@_X;+\!?\\-9_P# 5/\ XY1_PV7X
M"_YX:S_X"I_\<KX?HH_MS%^7W!_J)E'][_P+_@'W!_PV7X"_YX:S_P" J?\
MQRC_ (;+\!?\\-9_\!4_^.5\/T4?VYB_+[@_U$RC^]_X%_P#[@_X;+\!?\\-
M9_\  5/_ (Y7CO[-_P"W5!K_ /PM+_A-K[4M4^Q>.]4L]$\FP@C^S:6GE?9X
M6V;=S+E\LVYCGEC7@->=?!K0-1T#_A.?[0M)+3[;XIOKVW\P?ZV%]FQQ['!_
M*NB&=8ETYR;5U:VAP5N"<MAB*5."ERRYKZ]EITT/TE_X;+\!?\\-9_\  5/_
M (Y1_P -E^ O^>&L_P#@*G_QROA^BN?^W,7Y?<=_^HF4?WO_  +_ (!]P?\
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M9?@+_GAK/_@*G_QRC_ALOP%_SPUG_P !4_\ CE?#]%']N8OR^X/]1,H_O?\
M@7_ /N#_ (;+\!?\\-9_\!4_^.4?\-E^ O\ GAK/_@*G_P <KX?HH_MS%^7W
M!_J)E'][_P "_P" ?<'_  V7X"_YX:S_ . J?_'*/^&R_ 7_ #PUG_P%3_XY
M7P_11_;F+\ON#_43*/[W_@7_  #[@_X;+\!?\\-9_P# 5/\ XY1_PV7X"_YX
M:S_X"I_\<KX?HH_MS%^7W!_J)E'][_P+_@'W!_PV7X"_YX:S_P" J?\ QRC_
M (;+\!?\\-9_\!4_^.5\/T4?VYB_+[@_U$RC^]_X%_P#[@_X;+\!?\\-9_\
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M_ 7_ #PUG_P%3_XY1_PV7X"_YX:S_P" J?\ QROA^BC^W,7Y?<'^HF4?WO\
MP+_@'W!_PV7X"_YX:S_X"I_\<H_X;+\!?\\-9_\  5/_ (Y7P_11_;F+\ON#
M_43*/[W_ (%_P#[@_P"&R_ 7_/#6?_ 5/_CE'_#9?@+_ )X:S_X"I_\ '*^'
MZ*/[<Q?E]P?ZB91_>_\  O\ @'W!_P -E^ O^>&L_P#@*G_QRC_ALOP%_P \
M-9_\!4_^.5\/T4?VYB_+[@_U$RC^]_X%_P  ^X/^&R_ 7_/#6?\ P%3_ ..4
M?\-E^ O^>&L_^ J?_'*^'Z*/[<Q?E]P?ZB91_>_\"_X!]P?\-E^ O^>&L_\
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M #PUG_P%3_XY7P_11_;F+\ON#_43*/[W_@7_  #[@_X;+\!?\\-9_P# 5/\
MXY1_PV7X"_YX:S_X"I_\<KX?HH_MS%^7W!_J)E'][_P+_@'W!_PV7X"_YX:S
M_P" J?\ QRC_ (;+\!?\\-9_\!4_^.5\/T4?VYB_+[@_U$RC^]_X%_P#[@_X
M;+\!?\\-9_\  5/_ (Y1_P -E^ O^>&L_P#@*G_QROA^BC^W,7Y?<'^HF4?W
MO_ O^ ?<'_#9?@+_ )X:S_X"I_\ '*/^&R_ 7_/#6?\ P%3_ ..5\/T4?VYB
M_+[@_P!1,H_O?^!?\ ^X/^&R_ 7_ #PUG_P%3_XY1_PV7X"_YX:S_P" J?\
MQROA^BC^W,7Y?<'^HF4?WO\ P+_@'W!_PV7X"_YX:S_X"I_\<H_X;+\!?\\-
M9_\  5/_ (Y7P_11_;F+\ON#_43*/[W_ (%_P#[@_P"&R_ 7_/#6?_ 5/_CE
M'_#9?@+_ )X:S_X"I_\ '*^'Z*/[<Q?E]P?ZB91_>_\  O\ @'W!_P -E^ O
M^>&L_P#@*G_QRC_ALOP%_P \-9_\!4_^.5\/T4?VYB_+[@_U$RC^]_X%_P
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M/4O_ &G753C%TJDFM5;\SR\15G#%T*<7I+FOYV6AZI1117*>H%%%% !1110
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M<'*NOB?*O)]_EI]Y\1GN-QD*T:6!>M*/M9^:3LH_]O+F^X^4:.M=EXV\&2>
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M0^AP.+K8E3CB*+IRB[;W3ZWC*RNN_9[EO2M,N-:U2ST^SC,MW=S)!"@_B=B
MH_,U[?\ 'W]G;3_A;X6TW5]&O+N_43"VU#[0Z,$=E!5E"J-HR&X.?O+^-/\
M94\,6]SXQU#Q7J0":3X:M'NY)&&0)"K;?R42-]5%=9\'?%[_ !I3XC^#]8D"
MR>(!)J=D)#D12@@8'^[B$@>B&O3PN&I3H\M1>_4OR^5O\WH?+YMF6*I8WVF'
ME^ZP_*ZB[\[M;_MV/O?,\1^$VFVNL?$SPQ8WL"75I<:A#'+#(,JZE@""/2KW
MQQTBRT'XK^)-/TZVCL[*"X"Q00KM5!L4X _&CX06DUA\9O"UM<1M%/#J\,<D
M;=582 $'Z$5[-%\.])\;?M'^/=0\0C?H.A#[;=1'.V0^6-JMCG& S'UVX[UC
M1H.OAU"*]YSM^#.S'9A' YBZ]1MPC1;LNKYTE9;7=[+U/E^BOH>3]KZ[MM2:
MTL?".BQ^%0VP:<T1$C1].6!V D?[! Z<]:S/COX#T'2]4\(>+?"\ M=#\2!9
MA:*N%ADRC'"_P@A_NC@%3CC K*>$IN$IT:G-R[Z6WTNNZ.JCFV(C7A0QN']G
M[1/E?,I)M*[3LE9V]5YGA=%?8WQZ^+VF_![Q8D/ASP]IDWBBZMTDN=0NH21#
M'R$10"#DX)X('3(.>.>T'7M+_:G\*:]INKZ-9:?XUTZV-U:7]DA7S0.@.<G&
M=JLI)'S9&"..F>7P51T(U;S72VC\K]_ZN>=1XBKSPT,?5PKC0E:\N9-I/2_+
M;X;];WMK8^6J*^A?V<_AW9'P?KGCV^T&3Q3=V,OV;3=(2/?YDH"DN5Y!Y=>2
M#M"L<$XKN= \>_$;7]7@TKQ=\+X[GPM<R"&2"/37'V="<;AN)! SD\#IP144
MLOYX1E.37-M:+?WOI^)MB^(51K5:5"FI*GI)N<8N]KM13WM\E?0^0:*^A)?V
M>K _M(#PDAD7P\8_[3V;B7%OCF/=U^_\F<YQSUJUK_[4Y\(:U-H_@GPUHUKX
M<LW,"B:!MURJD@M\K+@'J,@GN3SBL_J2IIO$3Y4FUM>[6_;3S.AYY+$RA#+J
M/M7**F[M123VN[/5V>ENA\^Z/]B_M>Q_M'S/[/\ /3[3Y7W_ "MPW[??&<5V
MGQID\"2>*+?_ (5^DBZ2+51,6\T*9LMG;YOS?=VY[9KH/BYX@\!^,M1\-ZYX
M6MSIFKW17^U-,CM]D,;9'.< %LY'RC!&"<'.>H_:)&B:9^T-IIU;2I=0T<6M
MN9[&Q(C>7)? &!SSCC@GID9S5>P4:52*E%J\=;=[]>GFK&2Q\JN*H5)4YQDX
M5'R7MK%Q5FMI/7W7=+[]/G>BOK^?Q]\4VN1%X4^&,&F^%D($-C>60CDDC_VQ
MO4*3UP!QGJ>M>;_M6>"]/T#5/#6N66E+H<VN6C2W>G( %BF4(6X' /[P XX)
M7/<TZV ]G2E5A)M1M>\6M]-+[_@+!9_]9Q5/"U::BYWMRSC-JRO:25N5V]5T
M/"****\@^O"BBB@ HHHH **** "K_P"S(^E_'GXDS>'[J*[L+*TU>]TB=XI%
M$CM;PE]ZD@@ G'4'O5"D_P""<7_)==?_ .QTUK_TF->G@:4*LUSJ^L?Q=F?,
MYYBZV%HOV,K7A4?SC!M?<SZ#U;P+\"-%UR^TB]\3>)K:[L[B2UF)165'1BK<
MK <C(/2N4^+_ ,$8_ >CZ?XDT#5T\0>%-0;9#>*!OC8Y(5L<'.#R,<@@@'&:
M_P 2OAKXMU3XG^*Y;/POK-S#/J]V\4L5A*R.IF<A@VW!!'.>E>B>-M'N/A9^
MR[;>&=?=(]<U;4/M$-D7#- @96;IQP%&?>3%=LJ<:L:JG245%-IJZU6RWL[G
MA0KU,)/"2HXN5251Q4H2<9:-7;5DFN7?MT9G:7\)/AEH_P ,?#/B;Q?K.N64
M^L(V%LRC)N!.<#RF(& .IIUC\$OAM\2+6ZMOA_XOOI-?AB,J6.KH%$H'8'RT
M_,;L=Q6WXF^''B+XC?L]_#:W\.Z<=1FMEDDE431Q[5.0#\[#//I4'P3^!6O_
M  W\6P^,O&;V_AO2=(225C-=1LTA9&0#Y&( ^;N<G@ '/'2J%ZD*?L$X-1O*
MS6Z5W>]M#S)8_EP];$/'M5XRGRPO%WM)J,>2W,[Z+\3S[X%?"&S^(?Q%U3PU
MXB:]L#86DTDB6KJDBRI*B%265A@;F[=J\I-?3G[-.OQ>*OVC?&.L6Z&.WOK6
M[N(E88(1KF(KGWP1GWKYC/6O(Q%.$*%.4.KEKW2M8^QR_$UZV/Q%.L[)0I.W
M9R4N;\OP.S^#?@NR^(?Q)T;P_J,L\-E>&7S'MF"R#;"[C!((ZJ.U>GZMX&^
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MKSA'9-K[F>;EE>>)P-"O5=Y2A%OU<4V%%%%<QZ04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5S6O>%=*U;QGX7UJ[NY(=3TC[5]AMUE15F\V,))N4C+84
M C:1COFNEKROXA_\EU^$?_<7_P#25:Z</%RFTG;27X1?Y['FYA4C3HQE./,N
M>FK>;J12?R;O\CU2BBBN8](**** "BBB@ HHHH **** "BBB@ HHHH ****
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MTDY0B[+1*Z3LEV[!1117,>D%%%% !1110 4444 %%%% !1110 4444 %%%%
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M)M6U88:*A0IQB[I):]]-PHHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7.^#-!T30?[=_L2=9_MNJSWE]MG
M$NRZ?;YBG'W2,#Y>U=%7E?P"_P":C?\ 8YZE_P"TZZ:<6Z4Y7VM\]3S:]2,<
M50@XIM\VO5673U/5****YCT@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .=^'N@Z)X8\'Z?IGAR=;G1H/,\B5)Q,&W2,S?..#\Q8?I715Y7
M^RY_R0KPS_V]?^E4M>J5TXF+A7G%N[3>O?4\W+*D:V!H58145*$6DME=+1>2
MV"BBBN8](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7Q=X0U'6?BCX
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M** /FC_AA_1?^AGO_P#P'3_&C_AA_1?^AGO_ /P'3_&OI>BO)_LK!?\ /O\
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M+_T,]_\ ^ Z?XU]+T4?V5@O^??Y_YA_K9G7_ $$/[H_Y'S1_PP_HO_0SW_\
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M-\/3C1I5VHQ225EHEHNA\T?\,/Z+_P!#/?\ _@.G^-'_  P_HO\ T,]__P"
MZ?XU]+T5']E8+_GW^?\ F;?ZV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP
M_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW
M_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'
MS1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?Z
MV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5
M@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^
M Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP
M_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW
M_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'
MS1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?Z
MV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5
M@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^
M Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP
M_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW
M_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'
MS1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?Z
MV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5
M@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^
M Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C1_PP
M_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'S1_PP_HO_0SW
M_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?ZV9U_T$/[H_Y'
MS1_PP_HO_0SW_P#X#I_C1_PP_HO_ $,]_P#^ Z?XU]+T4?V5@O\ GW^?^8?Z
MV9U_T$/[H_Y'S1_PP_HO_0SW_P#X#I_C7B'Q8_8KN(?VFO@-!ILFMZEX?F_M
M[^UM8AT\O#IF+)#!YKJ"J>8^57>1DC R:_0:O'_B9\;[[P)^T+\%_AW!IEO=
M67CS^VOM-[(["2U^Q6B3IL X.XM@YZ#I5QRW"0=XP[KKU5GU[&-7B;-ZT5&I
M7;5T]EO%IKIT:3.(_P"&']%_Z&>__P# =/\ &C_AA_1?^AGO_P#P'3_&OI>B
MH_LK!?\ /O\ /_,V_P!;,Z_Z"']T?\CYH_X8?T7_ *&>_P#_  '3_&C_ (8?
MT7_H9[__ ,!T_P :^EZ*/[*P7_/O\_\ ,/\ 6S.O^@A_='_(^:/^&']%_P"A
MGO\ _P !T_QH_P"&']%_Z&>__P# =/\ &OI>BC^RL%_S[_/_ ##_ %LSK_H(
M?W1_R/FC_AA_1?\ H9[_ /\  =/\:/\ AA_1?^AGO_\ P'3_ !KZ7HH_LK!?
M\^_S_P P_P!;,Z_Z"']T?\CYH_X8?T7_ *&>_P#_  '3_&C_ (8?T7_H9[__
M ,!T_P :^EZ*/[*P7_/O\_\ ,/\ 6S.O^@A_='_(^:/^&']%_P"AGO\ _P !
MT_QH_P"&']%_Z&>__P# =/\ &OI>BC^RL%_S[_/_ ##_ %LSK_H(?W1_R/FC
M_AA_1?\ H9[_ /\  =/\:/\ AA_1?^AGO_\ P'3_ !KZ7HH_LK!?\^_S_P P
M_P!;,Z_Z"']T?\CYH_X8?T7_ *&>_P#_  '3_&C_ (8?T7_H9[__ ,!T_P :
M^EZ*/[*P7_/O\_\ ,/\ 6S.O^@A_='_(^:/^&']%_P"AGO\ _P !T_QH_P"&
M']%_Z&>__P# =/\ &OI>BC^RL%_S[_/_ ##_ %LSK_H(?W1_R/FC_AA_1?\
MH9[_ /\  =/\:/\ AA_1?^AGO_\ P'3_ !KZ7HH_LK!?\^_S_P P_P!;,Z_Z
M"']T?\CYH_X8?T7_ *&>_P#_  '3_&C_ (8?T7_H9[__ ,!T_P :^EZ*/[*P
M7_/O\_\ ,/\ 6S.O^@A_='_(^:/^&']%_P"AGO\ _P !T_QH_P"&']%_Z&>_
M_P# =/\ &OI>BC^RL%_S[_/_ ##_ %LSK_H(?W1_R/FC_AA_1?\ H9[_ /\
M =/\:/\ AA_1?^AGO_\ P'3_ !KZ7HH_LK!?\^_S_P P_P!;,Z_Z"']T?\CY
MH_X8?T7_ *&>_P#_  '3_&C_ (8?T7_H9[__ ,!T_P :^EZ*/[*P7_/O\_\
M,/\ 6S.O^@A_='_(^:/^&']%_P"AGO\ _P !T_QH_P"&']%_Z&>__P# =/\
M&OI>BC^RL%_S[_/_ ##_ %LSK_H(?W1_R/FC_AA_1?\ H9[_ /\  =/\:/\
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MYM_;6-_F_!']*?ZE9+_SZ?\ X%+_ #/KW_AM[1?^A9O_ /P(3_"C_AM[1?\
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M_H6;_P#\"$_PKY"HH_MK&_S?@@_U*R7_ )]/_P "E_F?7O\ PV]HO_0LW_\
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M_P#0LW__ ($)_A7R%11_;6-_F_!!_J5DO_/I_P#@4O\ ,^O?^&WM%_Z%F_\
M_ A/\*/^&WM%_P"A9O\ _P "$_PKY"HH_MK&_P WX(/]2LE_Y]/_ ,"E_F?7
MO_#;VB_]"S?_ /@0G^%'_#;VB_\ 0LW_ /X$)_A7R%11_;6-_F_!!_J5DO\
MSZ?_ (%+_,^O?^&WM%_Z%F__ / A/\*/^&WM%_Z%F_\ _ A/\*^0J*/[:QO\
MWX(/]2LE_P"?3_\  I?YGU[_ ,-O:+_T+-__ .!"?X4?\-O:+_T+-_\ ^!"?
MX5\A44?VUC?YOP0?ZE9+_P ^G_X%+_,^O?\ AM[1?^A9O_\ P(3_  H_X;>T
M7_H6;_\ \"$_PKY"HH_MK&_S?@@_U*R7_GT__ I?YGU[_P -O:+_ -"S?_\
M@0G^%'_#;VB_]"S?_P#@0G^%?(5%']M8W^;\$'^I62_\^G_X%+_,^O?^&WM%
M_P"A9O\ _P "$_PH_P"&WM%_Z%F__P# A/\ "OD*BC^VL;_-^"#_ %*R7_GT
M_P#P*7^9]>_\-O:+_P!"S?\ _@0G^%'_  V]HO\ T+-__P"!"?X5\A44?VUC
M?YOP0?ZE9+_SZ?\ X%+_ #/KW_AM[1?^A9O_ /P(3_"C_AM[1?\ H6;_ /\
M A/\*^0J*/[:QO\ -^"#_4K)?^?3_P# I?YGU[_PV]HO_0LW_P#X$)_A1_PV
M]HO_ $+-_P#^!"?X5\A44?VUC?YOP0?ZE9+_ ,^G_P"!2_S/KW_AM[1?^A9O
M_P#P(3_"C_AM[1?^A9O_ /P(3_"OD*BC^VL;_-^"#_4K)?\ GT__  *7^9]>
M_P##;VB_]"S?_P#@0G^%'_#;VB_]"S?_ /@0G^%?(5%']M8W^;\$'^I62_\
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M6-_F_!!_J5DO_/I_^!2_S/KW_AM[1?\ H6;_ /\  A/\*/\ AM[1?^A9O_\
MP(3_  KY"HH_MK&_S?@@_P!2LE_Y]/\ \"E_F?7O_#;VB_\ 0LW_ /X$)_A1
M_P -O:+_ -"S?_\ @0G^%?(5%']M8W^;\$'^I62_\^G_ .!2_P SZ]_X;>T7
M_H6;_P#\"$_PH_X;>T7_ *%F_P#_  (3_"OD*BC^VL;_ #?@@_U*R7_GT_\
MP*7^9]>_\-O:+_T+-_\ ^!"?X4?\-O:+_P!"S?\ _@0G^%?(5%']M8W^;\$'
M^I62_P#/I_\ @4O\SZ]_X;>T7_H6;_\ \"$_PH_X;>T7_H6;_P#\"$_PKY"H
MH_MK&_S?@@_U*R7_ )]/_P "E_F?7O\ PV]HO_0LW_\ X$)_A1_PV]HO_0LW
M_P#X$)_A7R%11_;6-_F_!!_J5DO_ #Z?_@4O\SZ]_P"&WM%_Z%F__P# A/\
M"C_AM[1?^A9O_P#P(3_"OD*BC^VL;_-^"#_4K)?^?3_\"E_F?7O_  V]HO\
MT+-__P"!"?X4?\-O:+_T+-__ .!"?X5\A44?VUC?YOP0?ZE9+_SZ?_@4O\SZ
M]_X;>T7_ *%F_P#_  (3_"C_ (;>T7_H6;__ ,"$_P *^0J*/[:QO\WX(/\
M4K)?^?3_ / I?YGU[_PV]HO_ $+-_P#^!"?X4?\ #;VB_P#0LW__ ($)_A7R
M%11_;6-_F_!!_J5DO_/I_P#@4O\ ,^O?^&WM%_Z%F_\ _ A/\*/^&WM%_P"A
M9O\ _P "$_PKY"HH_MK&_P WX(/]2LE_Y]/_ ,"E_F?7O_#;VB_]"S?_ /@0
MG^%'_#;VB_\ 0LW_ /X$)_A7R%11_;6-_F_!!_J5DO\ SZ?_ (%+_,^O?^&W
MM%_Z%F__ / A/\*/^&WM%_Z%F_\ _ A/\*^0J*/[:QO\WX(/]2LE_P"?3_\
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M .!"?X4?\-O:+_T+-_\ ^!"?X5\A44?VUC?YOP0?ZE9+_P ^G_X%+_,^O?\
MAM[1?^A9O_\ P(3_  H_X;>T7_H6;_\ \"$_PKY"HH_MK&_S?@@_U*R7_GT_
M_ I?YGU[_P -O:+_ -"S?_\ @0G^%'_#;VB_]"S?_P#@0G^%?(5%']M8W^;\
M$'^I62_\^G_X%+_,^O?^&WM%_P"A9O\ _P "$_PH_P"&WM%_Z%F__P# A/\
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M_P#^!"?X4?\ #;VB_P#0LW__ ($)_A7R%11_;6-_F_!!_J5DO_/I_P#@4O\
M,^O?^&WM%_Z%F_\ _ A/\*/^&WM%_P"A9O\ _P "$_PKY"HH_MK&_P WX(/]
M2LE_Y]/_ ,"E_F?7O_#;VB_]"S?_ /@0G^%'_#;VB_\ 0LW_ /X$)_A7R%11
M_;6-_F_!!_J5DO\ SZ?_ (%+_,^O?^&WM%_Z%F__ / A/\*/^&WM%_Z%F_\
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MO_0LW_\ X$)_A7R%11_;6-_F_!!_J5DO_/I_^!2_S/KW_AM[1?\ H6;_ /\
M A/\*/\ AM[1?^A9O_\ P(3_  KY"HH_MK&_S?@@_P!2LE_Y]/\ \"E_F?7O
M_#;VB_\ 0LW_ /X$)_A1_P -O:+_ -"S?_\ @0G^%?(5%']M8W^;\$'^I62_
M\^G_ .!2_P SZ]_X;>T7_H6;_P#\"$_PH_X;>T7_ *%F_P#_  (3_"OD*BC^
MVL;_ #?@@_U*R7_GT_\ P*7^9]>_\-O:+_T+-_\ ^!"?X4?\-O:+_P!"S?\
M_@0G^%?(5%']M8W^;\$'^I62_P#/I_\ @4O\SZ]_X;>T7_H6;_\ \"$_PH_X
M;>T7_H6;_P#\"$_PKY"HH_MK&_S?@@_U*R7_ )]/_P "E_F?7O\ PV]HO_0L
MW_\ X$)_A1_PV]HO_0LW_P#X$)_A7R%11_;6-_F_!!_J5DO_ #Z?_@4O\SZ]
M_P"&WM%_Z%F__P# A/\ "C_AM[1?^A9O_P#P(3_"OD*BC^VL;_-^"#_4K)?^
M?3_\"E_F?7O_  V]HO\ T+-__P"!"?X4?\-O:+_T+-__ .!"?X5\A44?VUC?
MYOP0?ZE9+_SZ?_@4O\SZ]_X;>T7_ *%F_P#_  (3_"C_ (;>T7_H6;__ ,"$
M_P *^0J*/[:QO\WX(/\ 4K)?^?3_ / I?YGU[_PV]HO_ $+-_P#^!"?X4?\
M#;VB_P#0LW__ ($)_A7R%11_;6-_F_!!_J5DO_/I_P#@4O\ ,^O?^&WM%_Z%
MF_\ _ A/\*/^&WM%_P"A9O\ _P "$_PKY"HH_MK&_P WX(/]2LE_Y]/_ ,"E
M_F?7O_#;VB_]"S?_ /@0G^%'_#;VB_\ 0LW_ /X$)_A7R%11_;6-_F_!!_J5
MDO\ SZ?_ (%+_,^O?^&WM%_Z%F__ / A/\*/^&WM%_Z%F_\ _ A/\*^0J*/[
M:QO\WX(/]2LE_P"?3_\  I?YGU[_ ,-O:+_T+-__ .!"?X4?\-O:+_T+-_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _*RBBBOQH_LT**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KSKX,Z!J.@?\ "=?VA:26GVWQ5?7MOY@_UL+[-CCV
M.#^5>BUQGPT\;W?C;_A*OM4$,']D:]=Z3%Y.?GCBV[6;)/S'<<XXKIIN7LII
M+32_WGFUU2>*H.;?-[UNSTUN=G1117,>D%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N:^)UW/8?#;Q9=6LTEM<P:3=R130N5>-Q"Y#*1R"" 0172UA>/='N/$/@7Q
M'I5F%:[OM-N;:$.V 7>)E7)[#)%:TFE4BWM='+BE*6'J*&]G;[BO\,;N>_\
MAMX3NKJ:2YN9])M))9IG+/(YA0EF)Y)))))KI:PO 6CW'A[P+X<TJ\"K=V.F
MVUM,$;(#I$JM@]QD&MVBJTZDFMKL,(I1P]-3WY5?UL%%%%9'4%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\1M&P<'))P.V001GJ:X[X/ZMJ'PG^.-S\.X(;.[T^?4G!NKB$FX""(LA5@0
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MDVD<L,R%7C<0H"K \@@@@@UTM%5)5));7881R>'IN>_*K^M@HHHK(Z@HHHH
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M5Y<&+EC@M@GKW[UY9/\ '+79_B?:>._L6F1ZM;1^6END+BWQY;1\KOW='/\
M%UKBM?UF?Q'KNI:M=*BW-_<R74JQ A [L68 $D@9)[T0QGU:A[*B[OF;U2VL
MN]^PJN3O,<;]:QL+)TU&RF])<TF]5:ZL]WIY'O7[7]SK,^IZ!+'=I/X+N;99
MM+2V0+$K[0&R1U.""IZ!6P!US\[5V]Y\7-9U'X:6_@B\M[*[TRVE$MM<S1N;
MF AB0%;=C&"R\J>&(],<17-C:T<16=6+WMOT?;T['IY)@ZN7X-86JDN1M)K[
M2OI)^;Z^>H4445PGNA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'E7[+?_ "0GPS_V]?\ I5+7
MJM<Y\/+[PYJ7@_3[GPDL*>'W\S[*MO T*#$C!\(P!'SANWO71UTXF7/7J3:M
M=O1[K4\W+*2H8&A24E)1A%76SLDKKR>Z"BBBN8](**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5RGPF_Y)7X-_[ ME_P"B$KJZ*J4:DDN[#"3E4P].<G=N*?X!11161U!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%?5'[-/[.F[[%XQ\3P<?+/INGN.O=9I!^
M15?Q/:NS"82IC*BIT_F^QXV;9MA\GPSQ&(?HNK?9?Y]#HOV:/V?8_"]E:^*_
M$5L'UJ=1)9VL@_X]$(R&8'I(<]/X1[YQSW[0_P#R?9^R-_W-W_IKCKZJKR3X
MD? Z?QY\??@[\1H]7CLX? /]L^;I[0%VO/MUJL VON 385W'(.<XXK]/PV&I
MX2FJ5-:?GYG\P9GF6(S7$RQ.(=V]ET2Z)>7_  YZW11174>4%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!^5E%%%?C1_9H4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7E7P!_YJ/_ -CGJ7_M.O5:YSP9H&B:#_;O]B3K/]MU6>\OMLXE
MV73[?,4X^Z1@?+VKIIS4:4X][?F>;7HRGBJ%5-6CS>NJZ'1T445S'I!1110
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MBV\0^'=+U6SC>&TOK6*ZACD4*RHZ!E! ) (!' )%:-<I\)O^25^#?^P+9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M / F>@?\,A?#W_GAJ/\ X&'_  H_X9"^'O\ SPU'_P ##_A7G_\ PV#\3_\
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M&'_"C_AD+X>_\\-1_P# P_X5Y_\ \-@_$_\ Z-<^('_@3:__ !5'_#8/Q/\
M^C7/B!_X$VO_ ,51_9^$_P"?2^X/]8,V_P"@F?\ X$ST#_AD+X>_\\-1_P#
MP_X4?\,A?#W_ )X:C_X&'_"O/_\ AL'XG_\ 1KGQ _\  FU_^*H_X;!^)_\
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M0OA[_P \-1_\##_A7G__  V#\3_^C7/B!_X$VO\ \51_PV#\3_\ HUSX@?\
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M17K?V7\5M>TRW\NY*XAC\C8#QR?F/->H?\-@_$__ *-<^('_ ($VO_Q5>5?
M+XG?$_X'?\+'_P",=_B!K?\ PF'C/4O%WW;6W^R?:_+_ -'_ -:^_9Y?W_ES
MG[HQ5+ X5)I4U9^1G+/,SE)3>(G=;:O2^Y]*_P##(7P]_P">&H_^!A_PH_X9
M"^'O_/#4?_ P_P"%>?\ _#8/Q/\ ^C7/B!_X$VO_ ,51_P -@_$__HUSX@?^
M!-K_ /%5/]GX3_GTON-/]8,V_P"@F?\ X$ST#_AD+X>_\\-1_P# P_X4?\,A
M?#W_ )X:C_X&'_"O/_\ AL'XG_\ 1KGQ _\  FU_^*H_X;!^)_\ T:Y\0/\
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MV?A/^?2^X/\ 6#-O^@F?_@3/0/\ AD+X>_\ /#4?_ P_X4?\,A?#W_GAJ/\
MX&'_  KS_P#X;!^)_P#T:Y\0/_ FU_\ BJ/^&P?B?_T:Y\0/_ FU_P#BJ/[/
MPG_/I?<'^L&;?]!,_P#P)GH'_#(7P]_YX:C_ .!A_P */^&0OA[_ ,\-1_\
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M / F>@?\,A?#W_GAJ/\ X&'_  H_X9"^'O\ SPU'_P ##_A7G_\ PV#\3_\
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M$ST#_AD+X>_\\-1_\##_ (4?\,A?#W_GAJ/_ (&'_"O/_P#AL'XG_P#1KGQ
M_P# FU_^*H_X;!^)_P#T:Y\0/_ FU_\ BJ/[/PG_ #Z7W!_K!FW_ $$S_P#
MF>@?\,A?#W_GAJ/_ (&'_"C_ (9"^'O_ #PU'_P,/^%>?_\ #8/Q/_Z-<^('
M_@3:_P#Q5'_#8/Q/_P"C7/B!_P"!-K_\51_9^$_Y]+[@_P!8,V_Z"9_^!,]
M_P"&0OA[_P \-1_\##_A1_PR%\/?^>&H_P#@8?\ "O/_ /AL'XG_ /1KGQ _
M\";7_P"*H_X;!^)__1KGQ _\";7_ .*H_L_"?\^E]P?ZP9M_T$S_ / F>@?\
M,A?#W_GAJ/\ X&'_  H_X9"^'O\ SPU'_P ##_A7G_\ PV#\3_\ HUSX@?\
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M/^&P?B?_ -&N?$#_ ,";7_XJC^S\)_SZ7W!_K!FW_03/_P "9Z!_PR%\/?\
MGAJ/_@8?\*/^&0OA[_SPU'_P,/\ A7G_ /PV#\3_ /HUSX@?^!-K_P#%4?\
M#8/Q/_Z-<^('_@3:_P#Q5']GX3_GTON#_6#-O^@F?_@3/0/^&0OA[_SPU'_P
M,/\ A1_PR%\/?^>&H_\ @8?\*\__ .&P?B?_ -&N?$#_ ,";7_XJC_AL'XG_
M /1KGQ _\";7_P"*H_L_"?\ /I?<'^L&;?\ 03/_ ,"9Z!_PR%\/?^>&H_\
M@8?\*/\ AD+X>_\ /#4?_ P_X5Y__P -@_$__HUSX@?^!-K_ /%4?\-@_$__
M *-<^('_ ($VO_Q5']GX3_GTON#_ %@S;_H)G_X$ST#_ (9"^'O_ #PU'_P,
M/^%'_#(7P]_YX:C_ .!A_P *\_\ ^&P?B?\ ]&N?$#_P)M?_ (JC_AL'XG_]
M&N?$#_P)M?\ XJC^S\)_SZ7W!_K!FW_03/\ \"9Z!_PR%\/?^>&H_P#@8?\
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M?#W_ )X:C_X&'_"O/_\ AL'XG_\ 1KGQ _\  FU_^*H_X;!^)_\ T:Y\0/\
MP)M?_BJ/[/PG_/I?<'^L&;?]!,__  )GH'_#(7P]_P">&H_^!A_PKPGXO?!_
MP_X._:D_9_\  VFBZ3P_XR_X2#^UHY)=TC_9+%)H-CXRF'8YQU'%=M_PV#\3
M_P#HUSX@?^!-K_\ %5XK\5?C+\5_&/[2?P,\<Q_LV?$"WM_!O]N^;:>7'+]I
M^UV:0K^]7*1;2N?WA&[HN31_9^$_Y]+[@?$&;/\ YBI_^!,^JO\ AD+X>_\
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M .*H_L_"?\^E]P?ZP9M_T$S_ / F>@?\,A?#W_GAJ/\ X&'_  H_X9"^'O\
MSPU'_P ##_A7G_\ PV#\3_\ HUSX@?\ @3:__%4?\-@_$_\ Z-<^('_@3:__
M !5']GX3_GTON#_6#-O^@F?_ ($ST#_AD+X>_P#/#4?_  ,/^%'_  R%\/?^
M>&H_^!A_PKS_ /X;!^)__1KGQ _\";7_ .*H_P"&P?B?_P!&N?$#_P ";7_X
MJC^S\)_SZ7W!_K!FW_03/_P)GH'_  R%\/?^>&H_^!A_PH_X9"^'O_/#4?\
MP,/^%>?_ /#8/Q/_ .C7/B!_X$VO_P 51_PV#\3_ /HUSX@?^!-K_P#%4?V?
MA/\ GTON#_6#-O\ H)G_ .!,] _X9"^'O_/#4?\ P,/^%'_#(7P]_P">&H_^
M!A_PKS__ (;!^)__ $:Y\0/_  )M?_BJ/^&P?B?_ -&N?$#_ ,";7_XJC^S\
M)_SZ7W!_K!FW_03/_P "9Z!_PR%\/?\ GAJ/_@8?\*/^&0OA[_SPU'_P,/\
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M %@S;_H)G_X$ST#_ (9"^'O_ #PU'_P,/^%'_#(7P]_YX:C_ .!A_P *\_\
M^&P?B?\ ]&N?$#_P)M?_ (JC_AL'XG_]&N?$#_P)M?\ XJC^S\)_SZ7W!_K!
MFW_03/\ \"9Z!_PR%\/?^>&H_P#@8?\ "C_AD+X>_P#/#4?_  ,/^%>?_P##
M8/Q/_P"C7/B!_P"!-K_\51_PV#\3_P#HUSX@?^!-K_\ %4?V?A/^?2^X/]8,
MV_Z"9_\ @3/0/^&0OA[_ ,\-1_\  P_X4?\ #(7P]_YX:C_X&'_"O/\ _AL'
MXG_]&N?$#_P)M?\ XJC_ (;!^)__ $:Y\0/_  )M?_BJ/[/PG_/I?<'^L&;?
M]!,__ F>@?\ #(7P]_YX:C_X&'_"C_AD+X>_\\-1_P# P_X5Y_\ \-@_$_\
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M4/ 81ZNFON!9_FL598F=O\3/0/\ AD+X>_\ /#4?_ P_X4?\,A?#W_GAJ/\
MX&'_  KS_P#X;!^)_P#T:Y\0/_ FU_\ BJ/^&P?B?_T:Y\0/_ FU_P#BJ7]G
MX3_GTON'_K!FW_03/_P)GH'_  R%\/?^>&H_^!A_PH_X9"^'O_/#4?\ P,/^
M%>?_ /#8/Q/_ .C7/B!_X$VO_P 51_PV#\3_ /HUSX@?^!-K_P#%4?V?A/\
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M('_@3:__ !5'_#8/Q/\ ^C7/B!_X$VO_ ,51_9^$_P"?2^X/]8,V_P"@F?\
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M7P]_YX:C_P"!A_PH_P"&0OA[_P \-1_\##_A7G__  V#\3_^C7/B!_X$VO\
M\51_PV#\3_\ HUSX@?\ @3:__%4?V?A/^?2^X/\ 6#-O^@F?_@3/0/\ AD+X
M>_\ /#4?_ P_X4?\,A?#W_GAJ/\ X&'_  KS_P#X;!^)_P#T:Y\0/_ FU_\
MBJ/^&P?B?_T:Y\0/_ FU_P#BJ/[/PG_/I?<'^L&;?]!,_P#P)GH'_#(7P]_Y
MX:C_ .!A_P */^&0OA[_ ,\-1_\  P_X5Y__ ,-@_$__ *-<^('_ ($VO_Q5
M'_#8/Q/_ .C7/B!_X$VO_P 51_9^$_Y]+[@_U@S;_H)G_P"!,] _X9"^'O\
MSPU'_P ##_A1_P ,A?#W_GAJ/_@8?\*\_P#^&P?B?_T:Y\0/_ FU_P#BJ/\
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M'XG_ /1KGQ _\";7_P"*H_X;!^)__1KGQ _\";7_ .*H ^JZ*^5/^&P?B?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OE_P#84U:^U;_AH7[=>7%Y]F^,'B&V@^T2M)Y4
M2_9]L:Y/RJ,G"C@9KZ@KP_\ 9;^#>O\ P<_X6[_;SV;_ /"5?$/5_%%A]CE,
MF+.Y\KRA)E1M?]VV5&0..30![A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'R__P $S=6OM<_8B^&]]J5Y<:A>R_VEYES=2M+(^-2N
M@,LQ).  /H!7U!7A_P"Q3\&]?_9^_9D\&^ ?$[V<FN:1]M^T-82F6$^;>SS)
MM8JI/R2KG@<YKW"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\
M?^)GQOOO G[0OP7^'<&F6]U9>//[:^TWLCL)+7[%:).FP#@[BV#GH.E>P5\J
M_M#_ /)]G[(W_<W?^FN.@#ZJHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N9^)OA72O'?PV\6>&M=NY-/T36=)N].O[N&5(G@MYH7CD=7<%
M5*JS$%@0,9((KIJ\J_:Q_P"36/C)_P!B9K/_ *0S4 =?\,O"NE>!/AMX3\-:
M%=R:AHFC:3::=87<TJ2O/;PPI'&[.@"L655)*@ YR !735Y5^R=_R:Q\&_\
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M(?\ @KEXACC541?$GBA551@  7F !0!^TE%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?/_P"R'\4O$_Q0_P"%U?\ "3ZG_:?_  CO
MQ-UOP]I?^CQ1?9["W\GR8?W:KNV[V^9LL<\DU] 5\Z_L:> /$7@'_A>?_"0Z
M3<:3_;7Q3UW6=.^T #[393>1Y4ZX/W6VMCZ4 ?15%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?/_[!7Q2\3_&G]D[P-XR\9:G_ &SX
MDU+[=]KO?L\4'F>7?W$2?)$JH,)&@X49QD\DFOH"OG7_ ()Z^ /$7PN_8_\
M /ACQ7I-QH>OV/\ :'VFPN@!)%OU"YD3(!/5'5OH17T50 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>=>-_C!X<\&?&#X:>!-2TZ\N?$'C3^T_
M[(O(8(WAMOL=NLT_FNSADW(P"[%;)X.!S7HM?*O[0_\ R?9^R-_W-W_IKCH
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M:?\ 9%Y#!&\-M]CMUFG\UV<,FY& 78K9/!P.:]%KY5_:'_Y/L_9&_P"YN_\
M37'0!]54444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\<_\ !57XV'X2
M_LJZKI-G/Y6L^,9AH< 4_,(&!:Y;Z&)3&?>85\4_LH_\$H5_:$^"&A^/]<\<
M7?A:766EDMM/BTQ9_P#1UD*)(6,B_>*LP&/NE3WK],?^&O?A[_SWU'_P#/\
MC1_PU[\/?^>^H_\ @&?\:\_^T,)_S]7WGT'^K^;?] T__ 6?E)^V[_P36;]D
M[X8Z=XUTCQ=<^++%]12QOHYM/6W-L'1C')D2-D%EVGIRR^M>B?MG_&P_'[_@
MFG\%_%%Q/Y^KQ^(H=-U1F.6^UP6=U&[-[N%63Z2"OT7_ .&O?A[_ ,]]1_\
M ,_XT?\ #7OP]_Y[ZC_X!G_&C^T,)_S]7WA_J_FW_0-/_P !9^5_P"_X*O\
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MK%-&LCH>4=C<.P4\@*I."<#Z?M_VJ/A?:7,EQ!%<PW$GWY8]/"NWU(Y-6_\
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MWX>_\]]1_P# ,_XT?VAA/^?J^\/]7\V_Z!I_^ L]KHKQ3_AKWX>_\]]1_P#
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M3_GZOO#_ %?S;_H&G_X"SVNBO%/^&O?A[_SWU'_P#/\ C1_PU[\/?^>^H_\
M@&?\:/[0PG_/U?>'^K^;?] T_P#P%GM=%>*?\->_#W_GOJ/_ (!G_&C_ (:]
M^'O_ #WU'_P#/^-']H83_GZOO#_5_-O^@:?_ ("SVNBO%/\ AKWX>_\ /?4?
M_ ,_XT?\->_#W_GOJ/\ X!G_ !H_M#"?\_5]X?ZOYM_T#3_\!9[77C7[-7QM
MU7XU_P#"U/[4L+.Q_P"$2\>ZKX3M?L>_]];VOE;))-Q/SGS#G&!P, 5#_P -
M>_#W_GOJ/_@&?\:^;_V+/VCO!OA'_A>_]H2WJ_VI\5M>U.W\NV+9AD\C83SP
M?E/%4L=A6FU45EYF<LCS.,E!X>=WMH];;GWW17BG_#7OP]_Y[ZC_ . 9_P :
M/^&O?A[_ ,]]1_\  ,_XU/\ :&$_Y^K[S3_5_-O^@:?_ ("SVNBO%/\ AKWX
M>_\ /?4?_ ,_XT?\->_#W_GOJ/\ X!G_ !H_M#"?\_5]X?ZOYM_T#3_\!9[7
M17BG_#7OP]_Y[ZC_ . 9_P :/^&O?A[_ ,]]1_\  ,_XT?VAA/\ GZOO#_5_
M-O\ H&G_ . L]KHKQ3_AKWX>_P#/?4?_  #/^-'_  U[\/?^>^H_^ 9_QH_M
M#"?\_5]X?ZOYM_T#3_\  6>UT5XI_P ->_#W_GOJ/_@&?\:/^&O?A[_SWU'_
M , S_C1_:&$_Y^K[P_U?S;_H&G_X"SVNBO%/^&O?A[_SWU'_ , S_C1_PU[\
M/?\ GOJ/_@&?\:/[0PG_ #]7WA_J_FW_ $#3_P# 6>UT5XI_PU[\/?\ GOJ/
M_@&?\:/^&O?A[_SWU'_P#/\ C1_:&$_Y^K[P_P!7\V_Z!I_^ L]KHKQ3_AKW
MX>_\]]1_\ S_ (T?\->_#W_GOJ/_ (!G_&C^T,)_S]7WA_J_FW_0-/\ \!9[
M717BG_#7OP]_Y[ZC_P" 9_QH_P"&O?A[_P ]]1_\ S_C1_:&$_Y^K[P_U?S;
M_H&G_P" L]KHKQ3_ (:]^'O_ #WU'_P#/^-'_#7OP]_Y[ZC_ . 9_P :/[0P
MG_/U?>'^K^;?] T__ 6>UT5XI_PU[\/?^>^H_P#@&?\ &C_AKWX>_P#/?4?_
M  #/^-']H83_ )^K[P_U?S;_ *!I_P#@+/:Z*\4_X:]^'O\ SWU'_P  S_C1
M_P ->_#W_GOJ/_@&?\:/[0PG_/U?>'^K^;?] T__  %GM=%>*?\ #7OP]_Y[
MZC_X!G_&C_AKWX>_\]]1_P# ,_XT?VAA/^?J^\/]7\V_Z!I_^ L]KHKQ3_AK
MWX>_\]]1_P# ,_XT?\->_#W_ )[ZC_X!G_&C^T,)_P _5]X?ZOYM_P! T_\
MP%GM=%>*?\->_#W_ )[ZC_X!G_&C_AKWX>_\]]1_\ S_ (T?VAA/^?J^\/\
M5_-O^@:?_@+/:Z*\4_X:]^'O_/?4?_ ,_P"-'_#7OP]_Y[ZC_P" 9_QH_M#"
M?\_5]X?ZOYM_T#3_ / 6>UT5XI_PU[\/?^>^H_\ @&?\:/\ AKWX>_\ /?4?
M_ ,_XT?VAA/^?J^\/]7\V_Z!I_\ @+/:Z*\4_P"&O?A[_P ]]1_\ S_C1_PU
M[\/?^>^H_P#@&?\ &C^T,)_S]7WA_J_FW_0-/_P%GM=%>*?\->_#W_GOJ/\
MX!G_ !H_X:]^'O\ SWU'_P  S_C1_:&$_P"?J^\/]7\V_P"@:?\ X"SVNBO%
M/^&O?A[_ ,]]1_\  ,_XT?\ #7OP]_Y[ZC_X!G_&C^T,)_S]7WA_J_FW_0-/
M_P !9[717BG_  U[\/?^>^H_^ 9_QH_X:]^'O_/?4?\ P#/^-']H83_GZOO#
M_5_-O^@:?_@+)OV/?C;JO[1G[.?A+XAZW86>F:GK/VOSK6PW^2GE7DT"[=Y)
MY6($Y/4FO9:^!/\ @G9^T=X-\!?L<?#_ $+59;U;^T_M#S!%;%U^;4+EQ@YY
MX85](?\ #7OP]_Y[ZC_X!G_&JECL+"3C*HDUYF=/(\SK0C4IX>;BU=-)ZI[,
M]KHKQ3_AKWX>_P#/?4?_  #/^-'_  U[\/?^>^H_^ 9_QJ?[0PG_ #]7WFG^
MK^;?] T__ 6>UT5XI_PU[\/?^>^H_P#@&?\ &C_AKWX>_P#/?4?_  #/^-']
MH83_ )^K[P_U?S;_ *!I_P#@+/:Z*\4_X:]^'O\ SWU'_P  S_C1_P ->_#W
M_GOJ/_@&?\:/[0PG_/U?>'^K^;?] T__  %GM=%>*?\ #7OP]_Y[ZC_X!G_&
MC_AKWX>_\]]1_P# ,_XT?VAA/^?J^\/]7\V_Z!I_^ L]KHKQ3_AKWX>_\]]1
M_P# ,_XT?\->_#W_ )[ZC_X!G_&C^T,)_P _5]X?ZOYM_P! T_\ P%GM=%<9
M\.OB[X:^*45VVA7;22VK 2V\Z>7* >C;>Z]L^HKLZ[*=2%6*G!W3/'KX>KA:
MCI5XN,ENFK,****T.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\Z\;W/PYB^,'PTA\2BS/Q!E_M/_A$3-'(TPQ;
MJ;[RF VK^YV[MQ&1TYKT6OE7]H?_ )/L_9&_[F[_ --<= 'U51110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<)\>O"&H_$'X&?$7PMI"QOJV
MN>'-1TRS69]B&::VDCC#-V&YAD]J[NN"^/\ XLU+P%\!_B1XFT:9;?6-%\-:
MEJ5E,Z!U2>&UDDC8J<A@&4'!X- #O@+X0U'X?? SX=>%M76--6T/PYIVF7BP
MOO030VT<<@5NXW*<'O7=UP7P \6:EX]^ _PW\3:S,MQK&M>&M-U*]F1 BO/-
M:QR2,%& H+,3@<"N]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O.O&]S\.8OC!\-(?$HLS\09?[3_ .$1,T<C3#%NIOO*8#:O[G;NW$9'3FO1
M:^5?VA_^3[/V1O\ N;O_ $UQT ?55%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?E91117XT?V:%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SG@S
MQO:^-O[=^RP30?V1JL^DR^=CYY(MNYEP3\IW#&>:Z.O*O@#_ ,U'_P"QSU+_
M -IUTTX1E2G-[JWYGFUZ\Z>*H4H[2YK_ "5T>JT445S'I!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _*RBBBOQH_LT**** "BBB@ HHHH ****
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M&T>=B,[R["571KUE&2Z:^IX/176?$CX<WOPRUJWTR^O]/U"6:W%R)=.E:2,
MLRX)*KS\IXQT(KDZY9PE3DX35FCU:%>GB:<:U)WB]F%%%%0;!1110 4444 %
M%%;MKX)UB[\)7OB9+0C1+29;>2Z9@ 9&(PJCJ3R,XZ9JHQE+X5<SJ584DG.2
M5VDK]WLO5F%1114F@4444 %%%% !1110!SGP\OO#FI>#]/N?"2PIX??S/LJV
M\#0H,2,'PC $?.&[>]='7E7[+?\ R0GPS_V]?^E4M>JUTXF'LZ]2"=[-K7?<
M\W+*SQ&!H5FDG*$79:)72=DNW8****YCT@HHHH **** "BBB@ HHHH ****
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M6C5[.UCU<33K93B*]'+W+6C*:3;E[R=KKF;=[/;JTC,UWXH_"WP!J\N@:/\
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M(^ ?@G1-1\3Z$GBWQ;K$(N4L+AAY,"'!P000, @$E6)8'& #65IG_)GFK_\
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M7AZ=>I3;2Y7)K1<KVNDUMY7.M8_$8&AB(1E/VJ@I:S56*7-9S3WTO>SLM-C
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MDDFKWMY^>Q-3,:^*6$HT93<)1D[N<82E*,N6SFM';^[JU9W/)O'OPK\)Z_\
M#R;QW\.Y[I+"TD$>H:3>'=);Y(&0<D\;E)&6!!R#P12_#SX2^%=)^'J^/?B'
M=7":5<.8['3;0XDN3R <@YR2K8&1P,DXKN/%7BSQO;?!36M1O?!_ASPMI&H
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M &)FC?\ I##7JM<Y\-Y?#DWP[\+2>#A"/"+Z5:MHPMU98_L1A7R-@;D+Y>S
M/..M='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%?%WX0^(O
M&7[47P \=:;';MH'@S_A(/[6>28+(OVNR2&#8O\ %EU.?05[K7@OQA^+'B3P
MA^U3^SUX)TR\CA\.^,/^$A_MBW:!':;[)8I-!M<C<FUV).TC/0T >]4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!^5E%%%?C1_9H4444 %%%% !111
M0 4444 7['7M3TRQO+*SU&[M+.\ 6YMX)V2.<#. Z@X;J>OK0NOZFFCOI*ZC
M=KI3R>:UB)V$#/Q\Q3.TG@<X[50HJN:6US-TJ;=W%;WVZ]_4NZ1K6H:!>K>:
M7?W.FW:@JMQ:3-%( >" RD'FJDDCS2-)(S/(Y+,S'))/4DTVBE=VL5RQ4N:V
MII7?B;6-0FLIKK5;ZYEL55+62:Y=VMU4Y41DGY0,#&,8J#5=7O\ 7;Z2]U*]
MN-0O),;[BZE:61L  99B2<  ?A52BFY2>[)C2IP:<8I6\B_-K^IW&CP:3+J-
MW)I4#F6*Q>=C!&YSEE3.T'YFY [GUI-'U[4_#MV;K2M1N],N60QF:SG:%RIQ
ME=RD'' X]JHT4<TKWN'LJ;BX\JL]]-R:SO;C3[J.YM9Y;:YB;='-"Y1T/J".
M0:Z#4OB=XNUB*".]\3ZM=) ZRQK)>2':ZG*L.?O @$'J#7,T4XU)Q346TB9T
M*522G.";6S:3L:R>+=<CUQM:76=076&ZZ@+J07!^7;_K,[ON\=>G%9D\\ES-
M)--(TLLC%WD<DLS$Y))/4FF44G)O=EQIP@[Q26EODNGH7[[7]3U2RL[.\U&[
MN[.S4K;6\\[/' #C(12<*.!T]!5OP_XU\0>$Q(-%UJ_TM9#EUM+EXU8^I .#
M6+134Y)\R>I$J%*4/9RBG'M96^XOZSK^I^([O[5JNHW>IW.-OG7DS2N!Z98D
MX]JH445+;D[LTC&,$HQ5D@K4T'Q1K'A:Y:XT?5+S2YF&&>SG:(L/0[2,CZUE
MT4*3B[Q=F*<(U(N$U=/HS6U_Q9K?BJ5)-9U>^U5TSL-Y</+LSUQN)Q^%06^O
MZI::3<Z7!J5W#IERP>>RCG9896&,%D!PQ&!U'8>E4**;G)OF;U)5&G&*@HJR
MV5M$36=[<:==PW5I/+:W4+B2*:%RCQL#D,K#D$'N*?J6IWFLWTM[J%W/?7DI
M!DN+F1I)'.,<LQ)/  JM12N[6Z%\L>;GMKW.ETKXF>+M#L%LM/\ $VK65FHP
MD$%[(J(/]D \?A7/W5W/?7,EQ<S27%Q(VYY96+.Y]23R345%5*<I)*3ND9PH
M4J<G.$$F]VDE?U-KP_XU\0>$Q(-%UJ_TM9#EUM+EXU8^I .#536=?U/Q'=_:
MM5U&[U.YQM\Z\F:5P/3+$G'M5"BASDX\K>G8%0I*;JJ*YGULK_>7EU[4TT=]
M)74;M=*>3SFL1.WD%^/F*9VYX'.,\5-H/BC6/"URUQH^J7FES,,,]G.T18>A
MVD9'UK+HI*<DTT]4-TJ<HN+BK/=6W]36U_Q9K?BJ5)-9U>^U5TSL-Y</+LSU
MQN)Q^%=?\%;3P1J&NW5MXROKS2VEBVV%]!+Y<=O+S\[,.01QM)^7KGM7G5%:
M4ZKA4522YO7J<U?"1JX>6'IR=-/9QT:]#ZF?P(QPOBKXY0:CX40YDMX]3+27
M48YV$>8>H]-Q]!7'^+O'7@?XP?& S>(;Z[T?PE9V/V&QFMXCN<J259A@E1EV
M(^4\*H..:\)HKOGC^9*,8*UTW=MWMLM7MY'A4,A]G-U:E=N5FHN,8PY;[M)*
MW,[;L]^\3^./!/PS^&.I^$_ .ISZWJ.N-B_U22,Q[8>FSE1U!*@#/WW).<"O
M :**XZ^(E7:NDDE9);(]C 8"G@(R49.4I.\I2U;>VMDEHM$DK(****YCTPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3P!X%_X0;_A(_\ 3OMO]L:U
M<ZO_ *KR_)\W;^[^\=V-OWN,YZ"NKKS+X&ZC=:A_PL#[5<S7/D>+M0@B\Z0O
MY<:^7M1<]%&3@#BNFFI.E-IZ:7^\\VO*DL50C*-Y/FL^VFOK<^E/#W[1'Q"\
M,:;'867B*5K6)=L:W,,<Y0=@&=2<#L,X%<IXM\;Z[X[U$7VO:G/J5R!M4RD!
M4'HJC"J/H!6'14SQ%:<>2<VUVN[%TLOP="JZU*C&,WU44G]]KF]<>.M<NO!U
MKX5EOM^@VTYN8K3RD&V0[OFW[=Q^^W!..:@\*^+-5\$ZY!K&BW7V+48 PCF\
MM)-H92K?*X(/!(Y%9%%1[2=U+F=UMY6VL;_5Z/)*GR+EE>ZLK.^]UUOUON:2
M>(]3BU]M;BO98-6:=KDW<!\MQ(Q)+#;C&23TXYKO[K]IKXD7>F-9/XB949=A
MFBMHDE(_WPH(/N,'WKRZBKAB*U*ZA-J^]FS"OE^#Q+BZ]&,N7:\4[>ET=#XA
M^(&O^*K71K?5=1:\BT>(0V(:-%,2 *,9 !;[B\MD\59U7XI>*M9\60>)KK6)
MO[=@54CO(42%E49P,( ,<G/'.>:Y6BI]M4>O,^G7MM]W0T6#PR22I1LDULMI
M:R7H^O?J>J7G[3_Q)O;%K5O$)C5E*M+#:PI(1[,$R#[C!KS.+4+J"^6]CN9H
M[Q9/-6X5R) ^<[@W7.><U7HJJE>K6LZDV[=W<C#X#"81-8>E&">]DE?UL>IP
M_M/?$F"P%JOB(LH7:)7M86DQ_O%,D^YY]ZX.#Q9K$'B:+Q"+^:76HIUN5O)R
M)7\P'(8[L@]!P<BLBBG/$5JEN>;=MKMDT<NP>'YO8T8QYM[12OZV6IIZWXFU
M/Q%K]QK>H7;3:I/()I+E0(V+C&" H &,#H!7?6G[37Q)LM/6S3Q&[HJ[5EEM
MH9)0/]]D))]SDUY=12AB*U-N4)M-[V;U'6R_!XB,85J,9*.R<4TO330NZQK-
M_P"(-2GU#4KN:^O9VW23SN69C]3_ "[5Z!H7[2/Q#\/:;'86WB!I+>)=D?VF
M".9D Z?,RDG'N37F5%*%>K2DY0DTWV95? X7%05.O2C**V32:7IV-CQ5XOUG
MQOJSZGKNH3:C>L-OF2X 5?[JJ,!1R>  .374^$/CWXZ\#Z:FGZ7KL@L8QB.W
MN8DF6,>B[P2H]@<5Y]11&O5A-U(R:;ZWU"K@<+6I*A4I1<%LFE9>BV1T_C;X
ME^)OB+<12^(-6FU#RO\ 5Q$*D:>X10%!]\9J/P7\1?$?P\O)+GP_JLVGO( )
M$4!XY,=-R,"I^I&1FN<HI>VJ<_M.9\W>^OWE?4\,J/U;V<?9_P ME;[MCTG6
M?VBOB#KEU93W'B!T-G*)XDA@B1-XZ%E"X?Z-D>U<)K>M7OB/5[S5-1F^TWUW
M*TTTNT+O<G).  !] *HT4ZE>K5_B2;]63A\#A<)_N]*,.FB2T^05O7_CK7-3
M\)Z=X9N;XRZ'I\C36UKY2#RW8L2=P7<?OMU)ZU@T5FI2C=1=KG3.E3J.+G%/
ME=U=;/:Z[/7<M:9JEWHNH6]]87,MG>6[AXIX6*NC#N"*]'O?VFOB1?Z<UG)X
MB9$==K2PVT4<I'^^J@@^XP:\NHK6G7JTDU3FTGV=CEQ&!PF+E&>(I1FULVD[
M?>=/J?Q+\2ZROA\7NIM<?V!C^S2T,8,&-A'(7+_ZM/O9Z?6L[Q5XJU3QKKMS
MK.M77VS4KC:)9O+2/=M4*ORJ !PH' [5DT5$JM2:M*3?S[:+\#6GA:%%J5.F
MDU=*R2LF[M?-ZON]3UW]GGPO!XBUB_:R\92>%O%447_$LC0;5G;N&)X9>,%.
MO.><$5[;%X8^,>JR^1XV\66&C^%H3NO[JV>*)YH@?F 944J".,DJ,'D'I7QK
M4T][<7**DUQ+*B?=5W+ ?3->GA\="C34'%_*32?JO\K'S689'5QN(=:-2-G:
MW-3C*4?\,KJW?6]GJ>B?M#>/[3XB_$V]U#3G,NG6\:6=O*?^6BIDEA[%F8CV
MQ3/#'[0WC[PCID>GV&O.UG$NV..ZACF\L=@&=20!V&<"O.**XWBJSJRK1DU)
M]M#V(95@UA:>#J4U.$$DN9)[==>IT/C+X@>(?B#?)=^(-4FU&6,$1J^%2,'K
MM10%7\!SBK7@7XI>)_AM)<-X>U1[%;C'G1&-)(WQT)5P1GW'-<I16*K5%/VB
MD^;O?7[SK>#PTJ'U9TX^S_ELN7[MC:\7>,=8\=ZS)JNN7K7]^ZA#*R*F%'0!
M5  'T%8M%%1*3FW*3NV;TZ<*4%3IQ2BM$EHEZ(****DT"BBB@ HHHH Y3X6^
M!?\ A6O@33/#?V[^T?L7F_Z3Y7E;]\KR?=W-C&_'4]*ZNO,OV:M1NM5^"GAR
MZO;F:\NI/M.^:XD+NV+F4#+'D\ #\*]-KIQ*E&O44W=W=WW=SS<LE2G@:$J,
M>6#A&RWLK*ROUL@HHHKF/2"BBB@ HHHH **** "BBB@ HHK7\)^$]4\;Z]:Z
M/H]JUW?7#851T4=V8]E'4FG&+FU&*NV14J0I0=2H[):MO9&C\./AUJWQ/\30
MZ-I,8WD;YKA_N01@@%V_,<=R0*_0/X<?#O2OACX8M]&TJ/*I\\UPX DN)#U=
MB/R [  =JS?@_P#"K3_A+X4CTRV(GOIB);V\(YFEQCCT0=%';D]22>ZK]&RO
M+8X.'//XW^'E_F?SCQ1Q)/.*SH47:C%Z?WGW?Z+]0HHHKWCX,**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_L7&_P OXH/]=<E_Y^O_ ,!E_D?(5%?7O_#$.B_]#-?_ /@.G^-'_#$.B_\
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M'1?^AFO_ /P'3_&C_AB'1?\ H9K_ /\  =/\:/[%QO\ +^*#_77)?^?K_P#
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M *&:_P#_  '3_&C^Q<;_ "_B@_UUR7_GZ_\ P&7^1\A45]>_\,0Z+_T,U_\
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M . Z?XT?\,0Z+_T,U_\ ^ Z?XT?V+C?Y?Q0?ZZY+_P _7_X#+_(^0J*^O?\
MAB'1?^AFO_\ P'3_ !H_X8AT7_H9K_\ \!T_QH_L7&_R_B@_UUR7_GZ__ 9?
MY'R%17U[_P ,0Z+_ -#-?_\ @.G^-'_#$.B_]#-?_P#@.G^-']BXW^7\4'^N
MN2_\_7_X#+_(^0J*^O?^&(=%_P"AFO\ _P !T_QH_P"&(=%_Z&:__P# =/\
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M1?\ H9K_ /\  =/\:/\ AB'1?^AFO_\ P'3_ !H_L7&_R_B@_P!=<E_Y^O\
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M_P O^"?FG%7%/]K?[)@VU16[V<G_ )+MWU[!1117TA^;!1110 4444 %%%%
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MPKO]K[_HKGP__P#":D_^*H_X5W^U]_T5SX?_ /A-2?\ Q5?5=% 'RI_PKO\
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M /A-2?\ Q5?5=% 'RI_PKO\ :^_Z*Y\/_P#PFI/_ (JC_A7?[7W_ $5SX?\
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MPKO]K[_HKGP__P#":D_^*H_X5W^U]_T5SX?_ /A-2?\ Q5?5=% 'RI_PKO\
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M_HKGP_\ _":D_P#BJ/\ A7?[7W_17/A__P"$U)_\57U710!\J?\ "N_VOO\
MHKGP_P#_  FI/_BJ/^%=_M??]%<^'_\ X34G_P 57U710!\J?\*[_:^_Z*Y\
M/_\ PFI/_BJ/^%=_M??]%<^'_P#X34G_ ,57U710!\J?\*[_ &OO^BN?#_\
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MI_PKO]K[_HKGP_\ _":D_P#BJ/\ A7?[7W_17/A__P"$U)_\57U710!\J?\
M"N_VOO\ HKGP_P#_  FI/_BJ/^%=_M??]%<^'_\ X34G_P 57U710!\J?\*[
M_:^_Z*Y\/_\ PFI/_BJ/^%=_M??]%<^'_P#X34G_ ,57U710!\J?\*[_ &OO
M^BN?#_\ \)J3_P"*H_X5W^U]_P!%<^'_ /X34G_Q5?5=% 'RI_PKO]K[_HKG
MP_\ _":D_P#BJ/\ A7?[7W_17/A__P"$U)_\57U710!\J?\ "N_VOO\ HKGP
M_P#_  FI/_BJ/^%=_M??]%<^'_\ X34G_P 57U710!\J?\*[_:^_Z*Y\/_\
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M /PFI/\ XJOJNB@#Y4_X5W^U]_T5SX?_ /A-2?\ Q5'_  KO]K[_ **Y\/\
M_P )J3_XJOJNB@#Y4_X5W^U]_P!%<^'_ /X34G_Q5'_"N_VOO^BN?#__ ,)J
M3_XJOJNB@#Y4_P"%=_M??]%<^'__ (34G_Q5'_"N_P!K[_HKGP__ /":D_\
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M ^5/^%=_M??]%<^'_P#X34G_ ,51_P *[_:^_P"BN?#_ /\ ":D_^*KZKHH
M^5/^%=_M??\ 17/A_P#^$U)_\51_PKO]K[_HKGP__P#":D_^*KZKHH ^5/\
MA7?[7W_17/A__P"$U)_\51_PKO\ :^_Z*Y\/_P#PFI/_ (JOJNB@#Y4_X5W^
MU]_T5SX?_P#A-2?_ !5'_"N_VOO^BN?#_P#\)J3_ .*KZKHH ^5/^%=_M??]
M%<^'_P#X34G_ ,51_P *[_:^_P"BN?#_ /\ ":D_^*KZKHH ^5/^%=_M??\
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M)J3_ .*KZKHH ^5/^%=_M??]%<^'_P#X34G_ ,51_P *[_:^_P"BN?#_ /\
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M /A-2?\ Q5?5=% 'RI_PKO\ :^_Z*Y\/_P#PFI/_ (JC_A7?[7W_ $5SX?\
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MPKO]K[_HKGP__P#":D_^*H_X5W^U]_T5SX?_ /A-2?\ Q5?5=% 'RI_PKO\
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M@1X2\?7/Q#U+1[O7+9YVLXM.CE2$B5TP&+@G[F>W6O/OV=6\4_L8?\%$=/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^S;\*-,U.RN-.U*R\):3;75G=Q-%-!*EG$KQNC %65@05(!!!!KTN@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *^5?VA_^3[/V1O\ N;O_ $UQ
MU]55YUXW^#_ASQG\8/AIX[U+4;RV\0>"_P"T_P"R+.&>-(;G[9;K#/YJ,A9]
MJ*"NQEP>3D<4 >BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E>*O$
MVG^"_#&K^(-6G%KI6E6<U]=SGI'#$A=V_!5-?AO^R1\:O!'B?]N75OC+\8?$
M=MX>M$FO-:M5NXY9E>[D;RX(1L1L"))"5)QCREK](O\ @I_J?CB?]FFZ\)>
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M,VVHZZ]]%IJ7<MT9!97%V4$-]&X.V3(DYW#(#L?E9:['X2_'K]MCX,_#G1?
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M47*C/2@#[;^!'_!0]=?_ &(M=^,OC/1VO=6\(WL6DZO::251KN1Y;>-)D5B
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MCXR?]B9K/_I#-0!U'PA\<R?$_P"$W@KQC+:+I\OB'1++5VM$D\P0&>!)2@;
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M%#^1_A_F'_$/<?\ \_H?^3?Y'Z*T5^=7_"^_B%_T-FH_]]C_  H_X7W\0O\
MH;-1_P"^Q_A1_K!0_D?X?YA_Q#W'_P#/Z'_DW^1^BM%?G5_POOXA?]#9J/\
MWV/\*/\ A??Q"_Z&S4?^^Q_A1_K!0_D?X?YA_P 0]Q__ #^A_P"3?Y'Z*T5^
M=7_"^_B%_P!#9J/_ 'V/\*/^%]_$+_H;-1_[['^%'^L%#^1_A_F'_$/<?_S^
MA_Y-_D?HK17YU?\ "^_B%_T-FH_]]C_"C_A??Q"_Z&S4?^^Q_A1_K!0_D?X?
MYA_Q#W'_ //Z'_DW^1^BM%?G5_POOXA?]#9J/_?8_P */^%]_$+_ *&S4?\
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M[4^R:*9#-'<1)+$ZRQ.H9'0Y5@>00>XI]?2'YOL%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]LBY\N6,G!..S '(/7CT)%>B?%;X9:39_M-Z3I#6^W2=>GM[F2WC)0 2.4D
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MY9$/$EP_&0#R0,LHX&23@8Q77>']$^!_Q2OAX>T>SUCPMJ\P*6EY<R%EF?'
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MB2^R^Z\G^'IM[-1117U1^4A1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5I_L!>*=4\4?'2_\ [3NOM/\ 9WBC5M/M?W:IY<$=LVQ/E SC
M)Y.2>YK,K-_8UU1_@[\2/$7B#Q%I]Y'9'Q5JE[%'"BF2:&6'9&Z L 02>Y'
M->I@94X2YYVTE'\]3Y?/:=>M2=*BF^:%5675N&E^F^USZE\<_'KPOH_C;Q!8
M7'PI\/:C/:ZA<027DR1;YV61E,C9A)RQ&3R>O6ME_'>F>//V</'USI?A;3_"
ML4$D4;P:>%"RG?&=QVHO/;I7S;XWUN#Q+XTU_5[5)([;4-0N+N))@ ZH\C,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KSKQO\8/#G@SXP?#3P)J6G7ESX@\:?VG_9%Y#!
M&\-M]CMUFG\UV<,FY& 78K9/!P.:]%KY5_:'_P"3[/V1O^YN_P#37'0!]544
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\5_MJ_\E3TK_L#1?\ H^>O
M *]__;5_Y*GI7_8&B_\ 1\]> 5^6YG_OE3U/ZGX9_P"1/AO\(4445YA],%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UM>7%FQ,$
M\D!/!,;E<_E43,6))))/))I**+BLKW"BBB@84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<9\-/&]WXV_P"$J^U00P?V1KUWI,7DY^>.+;M9LD_,=QSCBNSKRKX _P#-
M1_\ L<]2_P#:==5.$71J2:U5OS/+Q%6<,70IQ>DN:_G9:'JM%%%<IZ@4444
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M>,O$\ Q@3:=I\B@]1E9G!_-1]#Z5SG[-'[/TGBJ]MO%?B*V*Z' PDL[:4?\
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M_P#Y\P_\F_S/SJ_X4)\0O^A3U'_O@?XT?\*$^(7_ $*>H_\ ? _QK]%:*/\
M5^A_._P_R#_B(6/_ .?,/_)O\S\ZO^%"?$+_ *%/4?\ O@?XT?\ "A/B%_T*
M>H_]\#_&OT5HH_U?H?SO\/\ (/\ B(6/_P"?,/\ R;_,_.K_ (4)\0O^A3U'
M_O@?XT?\*$^(7_0IZC_WP/\ &OT5HH_U?H?SO\/\@_XB%C_^?,/_ ";_ #/S
MJ_X4)\0O^A3U'_O@?XT?\*$^(7_0IZC_ -\#_&OT5HH_U?H?SO\ #_(/^(A8
M_P#Y\P_\F_S/SJ_X4)\0O^A3U'_O@?XT?\*$^(7_ $*>H_\ ? _QK]%:*/\
M5^A_._P_R#_B(6/_ .?,/_)O\S\ZO^%"?$+_ *%/4?\ O@?XT?\ "A/B%_T*
M>H_]\#_&OT5HH_U?H?SO\/\ (/\ B(6/_P"?,/\ R;_,_.K_ (4)\0O^A3U'
M_O@?XT?\*$^(7_0IZC_WP/\ &OT5HH_U?H?SO\/\@_XB%C_^?,/_ ";_ #/S
MJ_X4)\0O^A3U'_O@?XT?\*$^(7_0IZC_ -\#_&OT5HH_U?H?SO\ #_(/^(A8
M_P#Y\P_\F_S/SJ_X4)\0O^A3U'_O@?XT?\*$^(7_ $*>H_\ ? _QK]%:*/\
M5^A_._P_R#_B(6/_ .?,/_)O\S\ZO^%"?$+_ *%/4?\ O@?XT?\ "A/B%_T*
M>H_]\#_&OT5HH_U?H?SO\/\ (/\ B(6/_P"?,/\ R;_,_.K_ (4)\0O^A3U'
M_O@?XT?\*$^(7_0IZC_WP/\ &OT5HH_U?H?SO\/\@_XB%C_^?,/_ ";_ #/S
MJ_X4)\0O^A3U'_O@?XT?\*$^(7_0IZC_ -\#_&OT5HH_U?H?SO\ #_(/^(A8
M_P#Y\P_\F_S/SJ_X4)\0O^A3U'_O@?XT?\*$^(7_ $*>H_\ ? _QK]%:*/\
M5^A_._P_R#_B(6/_ .?,/_)O\S\ZO^%"?$+_ *%/4?\ O@?XT?\ "A/B%_T*
M>H_]\#_&OT5HH_U?H?SO\/\ (/\ B(6/_P"?,/\ R;_,_.K_ (4)\0O^A3U'
M_O@?XT?\*$^(7_0IZC_WP/\ &OT5HH_U?H?SO\/\@_XB%C_^?,/_ ";_ #/S
MJ_X4)\0O^A3U'_O@?XT?\*$^(7_0IZC_ -\#_&OT5HH_U?H?SO\ #_(/^(A8
M_P#Y\P_\F_S/SJ_X4)\0O^A3U'_O@?XT?\*$^(7_ $*>H_\ ? _QK]%:*/\
M5^A_._P_R#_B(6/_ .?,/_)O\S\ZO^%"?$+_ *%/4?\ O@?XT?\ "A/B%_T*
M>H_]\#_&OT5HH_U?H?SO\/\ (/\ B(6/_P"?,/\ R;_,_.K_ (4)\0O^A3U'
M_O@?XT?\*$^(7_0IZC_WP/\ &OT5HH_U?H?SO\/\@_XB%C_^?,/_ ";_ #/S
MJ_X4)\0O^A3U'_O@?XT?\*$^(7_0IZC_ -\#_&OT5HH_U?H?SO\ #_(/^(A8
M_P#Y\P_\F_S/SJ_X4)\0O^A3U'_O@?XT?\*$^(7_ $*>H_\ ? _QK]%:*/\
M5^A_._P_R#_B(6/_ .?,/_)O\S\ZO^%"?$+_ *%/4?\ O@?XT?\ "A/B%_T*
M>H_]\#_&OT5HH_U?H?SO\/\ (/\ B(6/_P"?,/\ R;_,_.K_ (4)\0O^A3U'
M_O@?XT?\*$^(7_0IZC_WP/\ &OT5HH_U?H?SO\/\@_XB%C_^?,/_ ";_ #/S
MJ_X4)\0O^A3U'_O@?XT?\*$^(7_0IZC_ -\#_&OT5HH_U?H?SO\ #_(/^(A8
M_P#Y\P_\F_S/SJ_X4)\0O^A3U'_O@?XT?\*$^(7_ $*>H_\ ? _QK]%:*/\
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M3XA?]"GJ/_? _P :/^%"?$+_ *%/4?\ O@?XU^BM%'^K]#^=_A_D'_$0L?\
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MH3XA?]"GJ/\ WP/\:/\ A0GQ"_Z%/4?^^!_C7Z*T4?ZOT/YW^'^0?\1"Q_\
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M!7C&6T73Y?$.B66KM:))Y@@,\"2E V!N"[\9P,XZ5UM !1110 4444 %%%%
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M% 'RK_P[R\,?]%7^,'_A92__ !%'_#O+PQ_T5?XP?^%E+_\ $5]544 ?*O\
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M?XP?^%E+_P#$4?\ #O+PQ_T5?XP?^%E+_P#$5]544 ?*O_#O+PQ_T5?XP?\
MA92__$4?\.\O#'_15_C!_P"%E+_\17U510!\J_\ #O+PQ_T5?XP?^%E+_P#$
M4?\ #O+PQ_T5?XP?^%E+_P#$5]544 ?*O_#O+PQ_T5?XP?\ A92__$4?\.\O
M#'_15_C!_P"%E+_\17U510!\J_\ #O+PQ_T5?XP?^%E+_P#$4?\ #O+PQ_T5
M?XP?^%E+_P#$5]544 ?*O_#O+PQ_T5?XP?\ A92__$4?\.\O#'_15_C!_P"%
ME+_\17U510!\J_\ #O+PQ_T5?XP?^%E+_P#$4?\ #O+PQ_T5?XP?^%E+_P#$
M5]544 ?*O_#O+PQ_T5?XP?\ A92__$4?\.\O#'_15_C!_P"%E+_\17U510!\
MJ_\ #O+PQ_T5?XP?^%E+_P#$4?\ #O+PQ_T5?XP?^%E+_P#$5]544 ?*O_#O
M+PQ_T5?XP?\ A92__$4?\.\O#'_15_C!_P"%E+_\17U510!\J_\ #O+PQ_T5
M?XP?^%E+_P#$4?\ #O+PQ_T5?XP?^%E+_P#$5]544 ?*O_#O+PQ_T5?XP?\
MA92__$4?\.\O#'_15_C!_P"%E+_\17U510!\J_\ #O+PQ_T5?XP?^%E+_P#$
M4?\ #O+PQ_T5?XP?^%E+_P#$5]544 ?*O_#O+PQ_T5?XP?\ A92__$4?\.\O
M#'_15_C!_P"%E+_\17U510!\J_\ #O+PQ_T5?XP?^%E+_P#$5Q_B;_@F)I&L
M?$+P7KEM\6/B(-/T;[;]K%_K\L]^?.B")]DN,#[/R/WGRMO7"\8S7VU7S5\=
MO%FN:/\ MG?LNZ)8:SJ%EHNL?\)3_:6G6]T\=O?>5IT;P^=&"%DV,2R[@=I.
M1@T 97_#O+PQ_P!%7^,'_A92_P#Q%'_#O+PQ_P!%7^,'_A92_P#Q%?55% 'R
MK_P[R\,?]%7^,'_A92__ !%'_#O+PQ_T5?XP?^%E+_\ $5]544 ?*O\ P[R\
M,?\ 15_C!_X64O\ \11_P[R\,?\ 15_C!_X64O\ \17U510!\J_\.\O#'_15
M_C!_X64O_P 11_P[R\,?]%7^,'_A92__ !%?55% 'RK_ ,.\O#'_ $5?XP?^
M%E+_ /$4?\.\O#'_ $5?XP?^%E+_ /$5]544 ?*O_#O+PQ_T5?XP?^%E+_\
M$4?\.\O#'_15_C!_X64O_P 17U510!\J_P##O+PQ_P!%7^,'_A92_P#Q%'_#
MO+PQ_P!%7^,'_A92_P#Q%?55% 'RK_P[R\,?]%7^,'_A92__ !%'_#O+PQ_T
M5?XP?^%E+_\ $5]544 ?*O\ P[R\,?\ 15_C!_X64O\ \11_P[R\,?\ 15_C
M!_X64O\ \17U510!\J_\.\O#'_15_C!_X64O_P 11_P[R\,?]%7^,'_A92__
M !%?55% 'RK_ ,.\O#'_ $5?XP?^%E+_ /$4?\.\O#'_ $5?XP?^%E+_ /$5
M]544 ?*O_#O+PQ_T5?XP?^%E+_\ $4?\.\O#'_15_C!_X64O_P 17U510!\J
M_P##O+PQ_P!%7^,'_A92_P#Q%'_#O+PQ_P!%7^,'_A92_P#Q%?55% 'RK_P[
MR\,?]%7^,'_A92__ !%'_#O+PQ_T5?XP?^%E+_\ $5]544 ?*O\ P[R\,?\
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MX<\7_ +X::[/\3/BI83:IX9TR]>TT[Q9)#;0M):QN4BC"81%+85>P %>@?\
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MR\,?]%7^,'_A92__ !%'_#O+PQ_T5?XP?^%E+_\ $5]544 ?*O\ P[R\,?\
M15_C!_X64O\ \11_P[R\,?\ 15_C!_X64O\ \17U510!\J_\.\O#'_15_C!_
MX64O_P 11_P[R\,?]%7^,'_A92__ !%?55% 'RK_ ,.\O#'_ $5?XP?^%E+_
M /$4?\.\O#'_ $5?XP?^%E+_ /$5]544 ?*O_#O+PQ_T5?XP?^%E+_\ $4?\
M.\O#'_15_C!_X64O_P 17U510!\J_P##O+PQ_P!%7^,'_A92_P#Q%'_#O+PQ
M_P!%7^,'_A92_P#Q%?55% 'RK_P[R\,?]%7^,'_A92__ !%'_#O+PQ_T5?XP
M?^%E+_\ $5]544 ?*O\ P[R\,?\ 15_C!_X64O\ \11_P[R\,?\ 15_C!_X6
M4O\ \17U510!\J_\.\O#'_15_C!_X64O_P 11_P[R\,?]%7^,'_A92__ !%?
M55% 'RK_ ,.\O#'_ $5?XP?^%E+_ /$4?\.\O#'_ $5?XP?^%E+_ /$5]544
M ?*O_#O+PQ_T5?XP?^%E+_\ $4?\.\O#'_15_C!_X64O_P 17U510!\J_P##
MO+PQ_P!%7^,'_A92_P#Q%'_#O+PQ_P!%7^,'_A92_P#Q%?55% 'RK_P[R\,?
M]%7^,'_A92__ !%'_#O+PQ_T5?XP?^%E+_\ $5]544 ?*O\ P[R\,?\ 15_C
M!_X64O\ \17'^)O^"8FD:Q\0O!>N6WQ8^(@T_1OMOVL7^ORSWY\Z((GV2XP/
ML_(_>?*V]<+QC-?;5?-7QV\6:YH_[9W[+NB6&LZA9:+K'_"4_P!I:=;W3QV]
M]Y6G1O#YT8(638Q++N!VDY&#0!E?\.\O#'_15_C!_P"%E+_\11_P[R\,?]%7
M^,'_ (64O_Q%?55% 'RK_P .\O#'_15_C!_X64O_ ,11_P .\O#'_15_C!_X
M64O_ ,17U510!\J_\.\O#'_15_C!_P"%E+_\11_P[R\,?]%7^,'_ (64O_Q%
M?55% 'RK_P .\O#'_15_C!_X64O_ ,11_P .\O#'_15_C!_X64O_ ,17U510
M!\J_\.\O#'_15_C!_P"%E+_\11_P[R\,?]%7^,'_ (64O_Q%?55% 'RK_P .
M\O#'_15_C!_X64O_ ,11_P .\O#'_15_C!_X64O_ ,17U510!\J_\.\O#'_1
M5_C!_P"%E+_\11_P[R\,?]%7^,'_ (64O_Q%?55% 'RK_P .\O#'_15_C!_X
M64O_ ,11_P .\O#'_15_C!_X64O_ ,17U510!\J_\.\O#'_15_C!_P"%E+_\
M11_P[R\,?]%7^,'_ (64O_Q%?55% 'RK_P .\O#'_15_C!_X64O_ ,11_P .
M\O#'_15_C!_X64O_ ,17U510!\J_\.\O#'_15_C!_P"%E+_\11_P[R\,?]%7
M^,'_ (64O_Q%?55% 'RK_P .\O#'_15_C!_X64O_ ,11_P .\O#'_15_C!_X
M64O_ ,17U510!\J_\.\O#'_15_C!_P"%E+_\11_P[R\,?]%7^,'_ (64O_Q%
M?55% 'RK_P .\O#'_15_C!_X64O_ ,11_P .\O#'_15_C!_X64O_ ,17U510
M!\J_\.\O#'_15_C!_P"%E+_\11_P[R\,?]%7^,'_ (64O_Q%?55% 'RK_P .
M\O#'_15_C!_X64O_ ,11_P .\O#'_15_C!_X64O_ ,17U510!\J_\.\O#'_1
M5_C!_P"%E+_\11_P[R\,?]%7^,'_ (64O_Q%?55% 'RK_P .\O#'_15_C!_X
M64O_ ,11_P .\O#'_15_C!_X64O_ ,17U510!\J_\.\O#'_15_C!_P"%E+_\
M11_P[R\,?]%7^,'_ (64O_Q%?55% 'RK_P .\O#'_15_C!_X64O_ ,17:_"'
M]D?1O@WXRC\1Z=X_^(FNS)#) ;'Q%XC>]M)%<=6B90"00"#G@BO=:* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKD?'WCF3P7
M]AV6BW7VGS,[I-NW;M]C_>_2N2_X7E/_ - B/_O^?_B: /6Z*\D_X7E/_P!
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MNBO)/^%Y3_\ 0(C_ ._Y_P#B:/\ A>4__0(C_P"_Y_\ B: /6Z*\D_X7E/\
M] B/_O\ G_XFC_A>4_\ T"(_^_Y_^)H ];HKR3_A>4__ $"(_P#O^?\ XFC_
M (7E/_T"(_\ O^?_ (F@#UNBO)/^%Y3_ /0(C_[_ )_^)H_X7E/_ - B/_O^
M?_B: /6Z*\D_X7E/_P! B/\ [_G_ .)H_P"%Y3_] B/_ +_G_P")H ];HKR3
M_A>4_P#T"(_^_P"?_B:/^%Y3_P#0(C_[_G_XF@#UNBO)/^%Y3_\ 0(C_ ._Y
M_P#B:/\ A>4__0(C_P"_Y_\ B: /6Z*\D_X7E/\ ] B/_O\ G_XFC_A>4_\
MT"(_^_Y_^)H ];HKR3_A>4__ $"(_P#O^?\ XFC_ (7E/_T"(_\ O^?_ (F@
M#UNBO)/^%Y3_ /0(C_[_ )_^)H_X7E/_ - B/_O^?_B: /6Z*\D_X7E/_P!
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MNBO)/^%Y3_\ 0(C_ ._Y_P#B:/\ A>4__0(C_P"_Y_\ B: /6Z*\D_X7E/\
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MH ];HKR3_A>4_P#T"(_^_P"?_B:/^%Y3_P#0(C_[_G_XF@#UNBO)/^%Y3_\
M0(C_ ._Y_P#B:/\ A>4__0(C_P"_Y_\ B: /6Z*\D_X7E/\ ] B/_O\ G_XF
MC_A>4_\ T"(_^_Y_^)H ];HKR3_A>4__ $"(_P#O^?\ XFC_ (7E/_T"(_\
MO^?_ (F@#UNBO)/^%Y3_ /0(C_[_ )_^)H_X7E/_ - B/_O^?_B: /6Z*\D_
MX7E/_P! B/\ [_G_ .)H_P"%Y3_] B/_ +_G_P")H ];HKR3_A>4_P#T"(_^
M_P"?_B:/^%Y3_P#0(C_[_G_XF@#UNBO)4^.4N]=VD)MSSB<YQ_WS7INCZO:Z
M[IT-[9R"2&09'JI[@^A% %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#RGXZ?\P3_ +;_ /M.O*J]5^.G_,$_
M[;_^TZ\JH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_ .$/PH_X55_P
MFO\ Q-/[4_X23Q->^(_^/?R?L_VC9^Y^\V_;L^_QG/W17H%>&?LJZSJ&L?\
M"X/M]]<WWV7XBZQ:V_VF9I/)A7R=L:9)VH,G"C@9H ]SHHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KRK]K'_DUCXR?]B9K/_I#-7JM<Y\2/!^G?$+X=
M^*?"NL7$UGI&N:5=:9>7%NZI)%!-"T<C(S JK!6)!((!'(- '&_LG?\ )K'P
M;_[$S1O_ $AAKU6N<^&_@_3OA[\._"WA71[B:\TC0]*M=,L[BX=7DE@AA6.-
MG90%9BJ@D@ $G@"NCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ-\9?#/A/XC>'/ UY/<2>)-?1I+.UMX#)A%SEW(^ZOROR?[C>E '<T45^?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** /#_V*?@WK_P"S]^S)X-\
M^)WLY-<TC[;]H:PE,L)\V]GF3:Q52?DE7/ YS7N%?/\ ^P5\4O$_QI_9.\#>
M,O&6I_VSXDU+[=]KO?L\4'F>7?W$2?)$JH,)&@X49QD\DFOH"@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?\ "BOVK_ 'Q1B_<:#XH7_A&]><<*'.!%(Y^@1OI;FI;J/_ (7]^V[#$?\
M2/"WPMM1(W>-]3E.1^*D#\;8^M>R_M'?!Y/CI\(=;\*(\$&H3*L]A<7&0D-R
MAW(20"0#RI(!.US@&L7]E;X%7OP)^'MS8ZY>P:KXJU6^EU#5=0@D>59I&.%P
M[JK-A0"20/F9_7- 'S=\0/$GB/4_VZ/$]Q:_#J3XG3>%M.MXM,TB74([9+$-
M%$YN0'5@QW2MCC@N#U"XZ#XZZ[\5?CO\/=0\,ZM^S?<032KNL]1.OP2R64PP
M5D0>6#VP0"-PR">:]9^.7[.6N>*?'FG?$CX;^(X_"7Q LH/LLDERA>TOX>R3
M  XP.,[6R O *@CAO$7P5_:&^-T,6@?$#QCX=\->$3(C7L7AA)#<W04Y RRC
M )YY; (!VG&* .&_:9T37]2_9;^"&B>-8)K777U^QT_4(YG#2C$4T668$Y8J
M 2<]37V_H_AW2_#]A966F:=;6%I91^3;0V\2HL*8 VJ .!P*\=_:$^ FK?$W
MPCX T3P[?6T*^&];L[^236+F5GD@AC9"-X5V>0Y'+8SR2:]NN[N#3[2:ZNIH
M[>V@1I)9I6"I&@&2S$\   DDT ?)/ALK^SE^VGJVBR$6O@_XF0&_M"QVQPZ@
MA)=<]!EC)P/^>T0[59_9@MS\:_CK\1/C7=*9=+CF/A_PX7' MX\;Y5!Z9&TY
M'>605D?\% M4\+^/?AMX-L-$U"#6/&-_J\!\/)I<Z222"0;78%3PARG(_B">
MAKZ6^#?PVM/A%\,/#OA*SVLNFVJQRRH,"68_-+)_P)V8_C0!V=?GS^SQ\;?$
M'PN\0?%:RT?X8^(_'4-SXKNYGNM%C9HX&WD;&PC<X&?QK]!J\5_9J^"FN?!N
M7Q^VM76GW0\0>()]5M?L$COLB?HK[D7#>PR/>@#QSQ=HWQ4_;(UG0=#U[P-<
M?#7X:V%ZE_J!U2;-Y>E<@(JE5(X+#&W SDL<!:U/V[/#UGXK\8? C0[^,2:?
MJ/BA+.XCZ!HG>!67\02*^N:\8^/GP7UOXI^-/A3J^DW5A;VWA37X]5O4O)'5
MY(E>)B(@J,"V$/#%1TYH ]$\2B'P?X+U6^TG3[>*;2],G:T@@A5 H2,LL:@#
M 7*C@<=*^>_^"?'A#1_^%-+XX=4U#Q=XAO;N74]4G >XW"=E$9<\@$*'([E\
MGMCZF90RD$ @\$'O7R8/V:?BG\$/$VKW?P0\4:1#X8U6<W4OAGQ"C&*VD/\
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MY<>);N0#SK@CECZ#T KHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH *\T_:;U:^T#]FWXKZGIE[<:=J5EX2U:YM;RTE:*:"5+.5DD1U(*LK
M$,""" 17I=<)\>O"&H_$'X&?$7PMI"QOJVN>'-1TRS69]B&::VDCC#-V&YAD
M]J ,_P#9DU:^U_\ 9M^%&IZG>W&HZE>^$M)N;J\NY6EFGE>SB9Y'=B2S,Q)+
M$DDDDUZ77"? 7PAJ/P^^!GPZ\+:NL::MH?AS3M,O%A?>@FAMHXY K=QN4X/>
MN[H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE7]H?_D^S]D;_
M +F[_P!-<=?55>=>-[GX<Q?&#X:0^)19GX@R_P!I_P#"(F:.1IABW4WWE,!M
M7]SMW;B,CIS0!Z+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E/QT_
MY@G_ &W_ /:=>55ZK\=/^8)_VW_]IUY50 4444 %%%% !1110 4444 %%%%
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MR"2#3-;U0O;# X# #=_WRR^G2OI2TM(+"TAM;:%+>V@18XH8E"HB 8"@#@
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MKC/T%5_^$>TK_H&6?_@.G^% 'S)17TW_ ,(]I7_0,L__  '3_"C_ (1[2O\
MH&6?_@.G^% 'S)17TW_PCVE?] RS_P# =/\ "C_A'M*_Z!EG_P" Z?X4 ?,E
M%?3?_"/:5_T#+/\ \!T_PH_X1[2O^@99_P#@.G^% 'S)17TW_P (]I7_ $#+
M/_P'3_"C_A'M*_Z!EG_X#I_A0!\R45]-_P#"/:5_T#+/_P !T_PH_P"$>TK_
M *!EG_X#I_A0!\R45]-_\(]I7_0,L_\ P'3_  H_X1[2O^@99_\ @.G^% 'S
M)17TW_PCVE?] RS_ / =/\*/^$>TK_H&6?\ X#I_A0!\R45]-_\ "/:5_P!
MRS_\!T_PH_X1[2O^@99_^ Z?X4 ?,E%?3?\ PCVE?] RS_\  =/\*/\ A'M*
M_P"@99_^ Z?X4 ?,E%?3?_"/:5_T#+/_ ,!T_P */^$>TK_H&6?_ (#I_A0!
M\R45]-_\(]I7_0,L_P#P'3_"C_A'M*_Z!EG_ . Z?X4 ?,E%?3?_  CVE?\
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M_P! RS_\!T_PH_X1[2O^@99_^ Z?X4 ?,E%?3?\ PCVE?] RS_\  =/\*/\
MA'M*_P"@99_^ Z?X4 ?,E%?3?_"/:5_T#+/_ ,!T_P */^$>TK_H&6?_ (#I
M_A0!\R45]-_\(]I7_0,L_P#P'3_"C_A'M*_Z!EG_ . Z?X4 ?,E%?3?_  CV
ME?\ 0,L__ =/\*/^$>TK_H&6?_@.G^% 'S)17TW_ ,(]I7_0,L__  '3_"C_
M (1[2O\ H&6?_@.G^% 'S)17TW_PCVE?] RS_P# =/\ "C_A'M*_Z!EG_P"
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M?_CU'_#[3X6?]"+XP_[YM?\ X]0!^BM%?G5_P^T^%G_0B^,/^^;7_P"/4?\
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MB^,/^^;7_P"/4 ?HK17YU?\ #[3X6?\ 0B^,/^^;7_X]1_P^T^%G_0B^,/\
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M ,>H_P"';W[-O_1+=/\ _ V[_P#CU?2M% 'S5_P[>_9M_P"B6Z?_ .!MW_\
M'J/^';W[-O\ T2W3_P#P-N__ (]7TK10!\U?\.WOV;?^B6Z?_P"!MW_\>H_X
M=O?LV_\ 1+=/_P# V[_^/5]*T4 ?-7_#M[]FW_HENG_^!MW_ /'J/^';W[-O
M_1+=/_\  V[_ /CU?2M% 'S5_P .WOV;?^B6Z?\ ^!MW_P#'J/\ AV]^S;_T
M2W3_ /P-N_\ X]7TK10!\U?\.WOV;?\ HENG_P#@;=__ !ZC_AV]^S;_ -$M
MT_\ \#;O_P"/5]*T4 ?-7_#M[]FW_HENG_\ @;=__'J/^';W[-O_ $2W3_\
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M ,#;O_X]7TK10!\U?\.WOV;?^B6Z?_X&W?\ \>H_X=O?LV_]$MT__P #;O\
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MO_1+=/\ _ V[_P#CU?2M% 'S5_P[>_9M_P"B6Z?_ .!MW_\ 'J/^';W[-O\
MT2W3_P#P-N__ (]7TK10!\U?\.WOV;?^B6Z?_P"!MW_\>H_X=O?LV_\ 1+=/
M_P# V[_^/5]*T4 ?-7_#M[]FW_HENG_^!MW_ /'J/^';W[-O_1+=/_\  V[_
M /CU?2M% 'S5_P .WOV;?^B6Z?\ ^!MW_P#'J/\ AV]^S;_T2W3_ /P-N_\
MX]7TK10!\U?\.WOV;?\ HENG_P#@;=__ !ZC_AV]^S;_ -$MT_\ \#;O_P"/
M5]*T4 ?-7_#M[]FW_HENG_\ @;=__'J/^';W[-O_ $2W3_\ P-N__CU?2M%
M'S5_P[>_9M_Z);I__@;=_P#QZC_AV]^S;_T2W3__  -N_P#X]7TK10!\U?\
M#M[]FW_HENG_ /@;=_\ QZC_ (=O?LV_]$MT_P#\#;O_ ./5]*T4 ?-7_#M[
M]FW_ *);I_\ X&W?_P >H_X=O?LV_P#1+=/_ / V[_\ CU?2M% 'S5_P[>_9
MM_Z);I__ (&W?_QZC_AV]^S;_P!$MT__ ,#;O_X]7TK10!\U?\.WOV;?^B6Z
M?_X&W?\ \>H_X=O?LV_]$MT__P #;O\ ^/5]*T4 ?-7_  [>_9M_Z);I_P#X
M&W?_ ,>H_P"';W[-O_1+=/\ _ V[_P#CU?2M% 'S5_P[>_9M_P"B6Z?_ .!M
MW_\ 'J/^';W[-O\ T2W3_P#P-N__ (]7TK10!\U?\.WOV;?^B6Z?_P"!MW_\
M>H_X=O?LV_\ 1+=/_P# V[_^/5]*T4 ?-7_#M[]FW_HENG_^!MW_ /'J/^';
MW[-O_1+=/_\  V[_ /CU?2M% 'S5_P .WOV;?^B6Z?\ ^!MW_P#'J/\ AV]^
MS;_T2W3_ /P-N_\ X]7TK10!\U?\.WOV;?\ HENG_P#@;=__ !ZC_AV]^S;_
M -$MT_\ \#;O_P"/5]*T4 ?-7_#M[]FW_HENG_\ @;=__'J/^';W[-O_ $2W
M3_\ P-N__CU?2M% 'S5_P[>_9M_Z);I__@;=_P#QZC_AV]^S;_T2W3__  -N
M_P#X]7TK10!\U?\ #M[]FW_HENG_ /@;=_\ QZC_ (=O?LV_]$MT_P#\#;O_
M ./5]*T4 ?-7_#M[]FW_ *);I_\ X&W?_P >H_X=O?LV_P#1+=/_ / V[_\
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MNG_^!MW_ /'J/^';W[-O_1+=/_\  V[_ /CU?2M% 'S5_P .WOV;?^B6Z?\
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M /@;=_\ QZC_ (=O?LV_]$MT_P#\#;O_ ./5]*T4 ?-7_#M[]FW_ *);I_\
MX&W?_P >H_X=O?LV_P#1+=/_ / V[_\ CU?2M% 'S5_P[>_9M_Z);I__ (&W
M?_QZC_AV]^S;_P!$MT__ ,#;O_X]7TK10!\U?\.WOV;?^B6Z?_X&W?\ \>H_
MX=O?LV_]$MT__P #;O\ ^/5]*T4 ?-7_  [>_9M_Z);I_P#X&W?_ ,>H_P"'
M;W[-O_1+=/\ _ V[_P#CU?2M% 'S5_P[>_9M_P"B6Z?_ .!MW_\ 'J/^';W[
M-O\ T2W3_P#P-N__ (]7TK10!\U?\.WOV;?^B6Z?_P"!MW_\>H_X=O?LV_\
M1+=/_P# V[_^/5]*T4 ?-7_#M[]FW_HENG_^!MW_ /'J/^';W[-O_1+=/_\
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M/^';W[-O_1+=/_\  V[_ /CU?2M% 'S5_P .WOV;?^B6Z?\ ^!MW_P#'J/\
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M7TK10!\U?\.WOV;?^B6Z?_X&W?\ \>H_X=O?LV_]$MT__P #;O\ ^/5]*T4
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M_P#@;=__ !ZC_AV]^S;_ -$MT_\ \#;O_P"/5]*T4 ?-7_#M[]FW_HENG_\
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M_P #;O\ ^/5]*T4 ?-7_  [>_9M_Z);I_P#X&W?_ ,>H_P"';W[-O_1+=/\
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ML=-TG2K9KJ^U*Z:U0K!;PKR[D*3R0 !DD"@#G_\ AV]^S;_T2W3_ /P-N_\
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M[I]Q);W/B+1(;6*RE>,E9!:FXGB:ZVL"I,:E20<,: ,G_AV]^S;_ -$MT_\
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M3.?,\S9G?GG=G/O78:MX?TO7VL3J>FV>HFQN4O;0W<"2_9[A00DL>X'8X#,
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MI52.."!CI6CJ^C:?K^DW>EZI8VVI:9=Q-;W%E=PK+#-&PPR.C AE(."",$4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABSCI CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-3383487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street</a></td>
<td class="text">18105 SE Mill Plain Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Vancouver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">949-1041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock. $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">ABSI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,371,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001672688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,476<span></span>
</td>
<td class="nump">$ 41,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">16,342<span></span>
</td>
<td class="nump">15,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">142,999<span></span>
</td>
<td class="nump">71,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,177<span></span>
</td>
<td class="nump">5,459<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">174,994<span></span>
</td>
<td class="nump">133,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,190<span></span>
</td>
<td class="nump">3,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">23,016<span></span>
</td>
<td class="nump">29,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">42,356<span></span>
</td>
<td class="nump">44,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, long-term</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">244,992<span></span>
</td>
<td class="nump">213,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,586<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,229<span></span>
</td>
<td class="nump">6,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Long-term debt</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligations</a></td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease obligations</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">29,708<span></span>
</td>
<td class="nump">28,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term debt, net of current portion</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="nump">3,093<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,786<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">34,652<span></span>
</td>
<td class="nump">34,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (See Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">805,047<span></span>
</td>
<td class="nump">688,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(595,222)<span></span>
</td>
<td class="num">(509,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">500<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">210,340<span></span>
</td>
<td class="nump">179,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 244,992<span></span>
</td>
<td class="nump">$ 213,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Partner program revenue</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 1,701<span></span>
</td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="nump">$ 3,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">19,249<span></span>
</td>
<td class="nump">17,985<span></span>
</td>
<td class="nump">56,071<span></span>
</td>
<td class="nump">45,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">8,441<span></span>
</td>
<td class="nump">9,256<span></span>
</td>
<td class="nump">26,441<span></span>
</td>
<td class="nump">27,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
<td class="nump">8,914<span></span>
</td>
<td class="nump">10,155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,532<span></span>
</td>
<td class="nump">30,596<span></span>
</td>
<td class="nump">91,426<span></span>
</td>
<td class="nump">82,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(30,154)<span></span>
</td>
<td class="num">(28,895)<span></span>
</td>
<td class="num">(89,276)<span></span>
</td>
<td class="num">(79,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
<td class="nump">5,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
<td class="nump">5,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(28,602)<span></span>
</td>
<td class="num">(27,361)<span></span>
</td>
<td class="num">(85,390)<span></span>
</td>
<td class="num">(74,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,706)<span></span>
</td>
<td class="num">$ (27,398)<span></span>
</td>
<td class="num">$ (85,621)<span></span>
</td>
<td class="num">$ (74,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share: basic (in usd per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share: diluted (in usd per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic (in shares)</a></td>
<td class="nump">143,769,552<span></span>
</td>
<td class="nump">113,613,488<span></span>
</td>
<td class="nump">132,114,850<span></span>
</td>
<td class="nump">108,665,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted (in shares)</a></td>
<td class="nump">143,769,552<span></span>
</td>
<td class="nump">113,613,488<span></span>
</td>
<td class="nump">132,114,850<span></span>
</td>
<td class="nump">108,665,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,706)<span></span>
</td>
<td class="num">$ (27,398)<span></span>
</td>
<td class="num">$ (85,621)<span></span>
</td>
<td class="num">$ (74,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (28,517)<span></span>
</td>
<td class="num">$ (27,033)<span></span>
</td>
<td class="num">$ (85,117)<span></span>
</td>
<td class="num">$ (73,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License and Service [Member]<span></span>
</td>
<td class="text">License and Service [Member]<span></span>
</td>
<td class="text">License and Service [Member]<span></span>
</td>
<td class="text">License and Service [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,087,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 176,176<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 582,699<span></span>
</td>
<td class="num">$ (406,495)<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance costs</a></td>
<td class="nump">80,827<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">80,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures', window );">Issuance of shares under stock plans, net of shares withheld for tax payments</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,998,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">240,107<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">668,698<span></span>
</td>
<td class="num">(428,470)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,087,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">176,176<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">582,699<span></span>
</td>
<td class="num">(406,495)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,190,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">201,335<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">681,691<span></span>
</td>
<td class="num">(480,618)<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,998,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">240,107<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">668,698<span></span>
</td>
<td class="num">(428,470)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures', window );">Issuance of shares under stock plans, net of shares withheld for tax payments</a></td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Forfeiture of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,444,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">221,488<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">674,811<span></span>
</td>
<td class="num">(453,220)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures', window );">Issuance of shares under stock plans, net of shares withheld for tax payments</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27,398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,190,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">201,335<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">681,691<span></span>
</td>
<td class="num">(480,618)<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,362,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">179,133<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">688,726<span></span>
</td>
<td class="num">(509,601)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,983,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance costs</a></td>
<td class="nump">39,159<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">39,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures', window );">Issuance of shares under stock plans, net of shares withheld for tax payments</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,540,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">198,796<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">734,711<span></span>
</td>
<td class="num">(535,947)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,362,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">179,133<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">688,726<span></span>
</td>
<td class="num">(509,601)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(85,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,746,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">210,340<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">805,047<span></span>
</td>
<td class="num">(595,222)<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,540,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">198,796<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">734,711<span></span>
</td>
<td class="num">(535,947)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures', window );">Issuance of shares under stock plans, net of shares withheld for tax payments</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,677,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">173,373<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">739,565<span></span>
</td>
<td class="num">(566,516)<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,778,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance costs</a></td>
<td class="nump">60,649<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">60,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures', window );">Issuance of shares under stock plans, net of shares withheld for tax payments</a></td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,746,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">$ 210,340<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 805,047<span></span>
</td>
<td class="num">$ (595,222)<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 3,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,706)<span></span>
</td>
<td class="num">$ (30,569)<span></span>
</td>
<td class="num">$ (26,346)<span></span>
</td>
<td class="num">$ (27,398)<span></span>
</td>
<td class="num">$ (24,750)<span></span>
</td>
<td class="num">$ (21,975)<span></span>
</td>
<td class="num">$ (85,621)<span></span>
</td>
<td class="num">$ (74,123)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,621)<span></span>
</td>
<td class="num">$ (74,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,914<span></span>
</td>
<td class="nump">10,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,064<span></span>
</td>
<td class="nump">14,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on marketable securities</a></td>
<td class="num">(2,016)<span></span>
</td>
<td class="num">(2,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(308)<span></span>
</td>
<td class="nump">1,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="num">(412)<span></span>
</td>
<td class="num">(635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">249<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">460<span></span>
</td>
<td class="num">(2,359)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(63,743)<span></span>
</td>
<td class="num">(55,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,210)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Investment in marketable securities</a></td>
<td class="num">(134,871)<span></span>
</td>
<td class="num">(159,483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">65,191<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(69,707)<span></span>
</td>
<td class="num">(60,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(2,619)<span></span>
</td>
<td class="num">(2,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligations</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">102,336<span></span>
</td>
<td class="nump">84,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock through employee equity plans, net</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">102,107<span></span>
</td>
<td class="nump">81,540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(31,343)<span></span>
</td>
<td class="num">(34,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - Beginning of period</a></td>
<td class="nump">58,214<span></span>
</td>
<td class="nump">89,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - End of period</a></td>
<td class="nump">26,871<span></span>
</td>
<td class="nump">55,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Operating Lease Right-Of-Use Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, classified as other, in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and nature of operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and nature of operations</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Organization and nature of operations</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absci Corporation (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company advancing potential breakthrough antibody therapeutics with generative AI. The Company&#8217;s Integrated Drug Creation platform comprises, in part, cutting edge AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was organized in the State of Oregon in August 2011 as a limited liability company and converted to a limited liability company (&#8220;LLC&#8221;) in Delaware in April 2016. In October 2020, the Company converted from a Delaware LLC to a Delaware corporation. The Company&#8217;s headquarters are located in Vancouver, Washington.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its interim condensed consolidated financial statements that accompany these notes in conformity with accounting principles generally accepted in the United States, consistent in all material respects with those applied in its Annual Report on Form 10-K for the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made estimates and judgments affecting the amounts reported in its condensed consolidated financial statements and the accompanying notes. The actual results that the Company experiences may differ materially from its estimates. The interim financial information is unaudited and reflects all normal adjustments that are, in the Company&#8217;s opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the consolidated financial statements in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Revenue recognition</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of the satisfaction of performance obligations. As of September&#160;30, 2025 and December&#160;31, 2024, contract liabilities were $1.6 million and $1.1&#160;million, respectively. During the three and nine months ended September 30, 2025, the Company recognized $0.2 million and $0.8 million, respectively, as revenue that had been included in deferred revenue at the beginning of the period. During the three and nine months ended September 30, 2024, the Company recognized $0.8 million and $3.0 million, respectively, as revenue that had been included in deferred revenue at the beginning of the period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2025, two partners represented approximately 93% and three partners represented 98% of total partner program revenue, respectively. During the three and nine months ended September 30, 2024, two partners represented 100% of total partner program revenue.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative arrangements</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Collaborative arrangements</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company has collaborative arrangements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin that involve joint research and development activities and for which the parties are exposed to significant risks and rewards dependent on the commercial success of such activities. The Company performs drug creation activities to co-develop product candidates. These arrangements include rights for the parties to share in the potential value created by the programs, as well as cost sharing which may result in payments and/or credits between the parties. The Company&#8217;s accounting policy is to present cost sharing payments to and from the Company&#8217;s collaborators within research and development expense on the condensed consolidated statements of operations and comprehensive loss. The Company received $0.8 million of cost sharing payments and credits related to collaborative arrangements during the three and nine months ended September 30, 2025. The Company did not have cost sharing payments related to collaborative arrangements during the three or nine months ended September 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Investments</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities are classified as available-for-sale and are recorded at fair value on the condensed consolidated balance sheets, with any unrealized gains and losses reported in accumulated </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive loss, which is reflected as a separate component of stockholders&#8217; equity on the Company&#8217;s condensed consolidated balance sheets, until realized. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company considers all marketable securities to be current assets as they are available for use in current operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of investments are as follows (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair market value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair market value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities of available-for-sale securities were $39.0 million and $65.2&#160;million for the three and nine months ended September 30, 2025, respectively. Proceeds from maturities of available-for-sale securities were $43.0 million and $132.1&#160;million for the three and nine months ended September 30, 2024, respectively. As of September&#160;30, 2025, the Company held $32.6 million of marketable securities with a remaining maturity of greater than one year. There were no realized gains or losses on securities for the three and nine months ended September 30, 2025 and 2024. Unrealized gains and losses on securities were primarily due to changes in interest rates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalent, investment in debt and equity securities, equity method investment, investment in joint venture, and investment classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Fair value measurements</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value to establish a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices in active markets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation hierarchy.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2 inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews trading activity and pricing for its available-for-sale securities as of the measurement date.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change to the value of liabilities measured at fair value using significant unobservable inputs (Level 3) for the nine months ended September 30, 2025. The contingent consideration liability is related to the acquisition of Totient, Inc. and is included in contingent consideration on the condensed consolidated balance sheet as of September&#160;30, 2025 and December&#160;31, 2024. The fair value estimate is based on a probability-weighted approach on conditions that existed as of September 30, 2025 (See Note 11: Subsequent events) . The contingent consideration of $15.0&#160;million held in escrow shall be paid upon the achievement of the milestone of either entering into agreements meeting certain financial criteria with third parties using, or relating to, Totient technology or the first commercial sale of a Totient product. The contingent consideration </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held in escrow is included in restricted cash on the condensed consolidated balance sheets as of September&#160;30, 2025 and December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of long-term debt approximates fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Commitments and contingencies</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to compute capacity and other services through an agreement with Oracle Cloud Infrastructure (OCI) through early 2028. The remaining financial commitments for the years 2025, 2026, 2027, and 2028 are $0.7 million, $4.6 million, $8.3 million, and $2.3 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common stock</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Common stock</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement on Form S-3</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company filed a shelf registration statement on Form S-3 (the Prior Shelf Registration Statement) with the SEC relating to the registration of up to an aggregate of $250.0&#160;million in shares of the Company&#8217;s common stock, preferred stock, debt securities, warrants and units or any combination thereof. In July 2025, the Company has issued 16,670,000 shares and received $46.7 million in net proceeds from the sale of securities pursuant to the Prior Shelf Registration Statement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement) with the SEC relating to the registration of up to an aggregate of $400.0&#160;million in shares of the Company&#8217;s common stock, preferred stock, debt securities, warrants and units or any combination thereof.  During the nine months ended September 30, 2025, the Company has not issued any shares pursuant to the Shelf Registration Statement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-market offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company entered into a Sales Agreement with Cowen and Company, LLC, as Sales Agent (the &#8220;Prior Sales Agreement&#8221;), with respect to an &#8220;at the market offering&#8221; program under which the Company had the ability to offer and sell, from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $100.0&#160;million through the Sales Agent. The Company agreed to pay the Sales Agent a commission up to 3.0% of the gross sales proceeds of any shares sold under the Prior Sales Agreement. During the nine months ended September 30, 2025, the Company has issued 10,377,752 shares and received $35.7 million in net proceeds from the sale of securities pursuant to the Prior Sales Agreement. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company entered into a Sales Agreement with TD Securities (USA) LLC, as Sales Agent (the &#8220;Sales Agreement&#8221;), with respect to an &#8220;at the market offering&#8221; program under which the Company may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0&#160;million through the Sales Agent. The Company has agreed to pay the Sales Agent a commission of up to 3.0% of the gross proceeds of any shares sold under the Sales Agreement. Upon execution, the Sales Agreement terminated and superseded the Prior Sales Agreement in its entirety. During the nine months ended September 30, 2025, the Company did not issue any shares of common stock under the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private investment in public equity</span></div><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2025, the Company entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD) and sold an aggregate of 5,714,285 shares of the Company&#8217;s common stock to AMD for net proceeds of $20.0 million through a private investment in public equity (PIPE). This strategic collaboration with AMD has a goal to optimize the performance of AMD Instinct</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> accelerators and ROCm</span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">software to support the Company&#8217;s AI drug creation, including its de novo antibody design models. The issuance of stock to AMD was at a premium of approximately $2.5 million over the market price on the issuance date. The premium was recorded to accrued expenses and other long-term liabilities on the condensed consolidated balance sheet and will be recognized as a credit to research and development expense over the collaboration term. The amortization of the premium was $0.2 million and $0.5 million for the three and nine months ended September 30, 2025, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Stock-based compensation</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options, restricted stock units, and stock appreciation rights (&#8220;SARs&#8221;) under the 2021 Stock Option and Incentive Plan (&#8220;2021 Plan&#8221;) and the 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;). On January 1, 2025, the number of shares of common stock reserved for future issuance under the 2021 Plan was increased by 5,768,113 shares pursuant to an automatic annual increase. As of September&#160;30, 2025, 5,483,484 <span id="id6b2bc6cd52b4e3e8449d294cd04927c_1482"></span>shares were available for future grant under the 2021 Plan. As of September&#160;30, 2025, 1,724,200 shares were available for future grant under the 2023 Inducement Plan.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to all of the Company&#8217;s stock-based awards was recorded in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options is shown below:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Contractual Term (in years)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands $)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,177,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,512,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(864,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,738</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,293,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(626,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,905,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,804&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,105,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, total unrecognized stock-based compensation related to stock options was $22.0 million, which the Company expects to recognize over a remaining weighted average period of 2.1 years. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determination of fair value</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant-date fair value of all the Company&#8217;s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.132%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.8-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.5-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.5-6.1</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91%-91%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82%-84%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90%-92%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81%-84%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8%-4.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7%-4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8%-4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7%-4.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for restricted stock units is shown below:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,711,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,667,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(469,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(489,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,420,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, there was $5.9&#160;million of unrecognized compensation expense related to the outstanding restricted stock units expected to be recognized over a remaining weighted-average period of 1.9 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt">Net loss per share</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities, presented based on amounts outstanding at period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would be anti-dilutive:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:65.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.784%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,905,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,565,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,420,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,348,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,325,776</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,012,997</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment reporting</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.7pt">Segment reporting</span><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one reportable segment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating performance. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses by expense category and the CODM makes decisions using this information on a consolidated basis. There are no other measures of profitability used by the CODM, other than those disclosed in these condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the significant segment expenses (in thousands) provided to the Company&#8217;s CODM on a regular basis:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.401%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Drug creation programs and platform </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">External preclinical and clinical development </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Personnel </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General &amp; administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asset and goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#8220;Drug creation programs and platform&#8221; consists of research and development costs incurred related to the Company&#8217;s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company&#8217;s Integrated Drug Creation platform.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) &#8220;External preclinical and clinical development&#8221; expense consists of external costs incurred following the Company&#8217;s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) &#8220;Personnel&#8221; expense consists of all employee wages, taxes, benefits, other employee related costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.7pt">Subsequent events</span>In October 2025, the Company entered into an agreement with the selling stockholders of Totient to settle the contingent consideration liability for a payment of approximately $7.6&#160;million and to release the remaining $8.7&#160;million, held as restricted cash on the condensed consolidated balance sheets, from escrow to the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Amortized and Fair Value of Our Investments</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of investments are as follows (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair market value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair market value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocation of Share-based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to all of the Company&#8217;s stock-based awards was recorded in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options is shown below:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Contractual Term (in years)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands $)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,177,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,512,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(864,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,738</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,293,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(626,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,905,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,804&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,105,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Determination of Fair Value</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant-date fair value of all the Company&#8217;s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.132%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.8-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.5-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.5-6.1</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91%-91%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82%-84%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90%-92%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81%-84%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8%-4.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7%-4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8%-4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7%-4.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Non-vested Share Activity</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for restricted stock units is shown below:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,711,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,667,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(469,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(489,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,420,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities, presented based on amounts outstanding at period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would be anti-dilutive:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:65.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.784%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,905,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,565,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,420,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,348,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,325,776</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,012,997</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the significant segment expenses (in thousands) provided to the Company&#8217;s CODM on a regular basis:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.401%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Drug creation programs and platform </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">External preclinical and clinical development </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Personnel </span><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General &amp; administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asset and goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#8220;Drug creation programs and platform&#8221; consists of research and development costs incurred related to the Company&#8217;s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company&#8217;s Integrated Drug Creation platform.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) &#8220;External preclinical and clinical development&#8221; expense consists of external costs incurred following the Company&#8217;s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) &#8220;Personnel&#8221; expense consists of all employee wages, taxes, benefits, other employee related costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>partner</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>partner</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>partner</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>partner</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from customer contract liability</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=absi_TechnologyDevelopmentRevenueMember', window );">Partner program revenue | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_NumberOfPartners', window );">Number of partners (partner) | partner</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_NumberOfPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Partners</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_NumberOfPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=absi_TechnologyDevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=absi_TechnologyDevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ProceedsFromCollaborativeArrangement', window );">Proceeds from collaborative arrangements</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_ProceedsFromCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_ProceedsFromCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Amortized and Fair Value of our Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">$ 143,041<span></span>
</td>
<td class="nump">$ 73,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair market value</a></td>
<td class="nump">143,191<span></span>
</td>
<td class="nump">73,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair market value</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair market value</a></td>
<td class="nump">142,999<span></span>
</td>
<td class="nump">71,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair market value</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">142,849<span></span>
</td>
<td class="nump">71,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair market value</a></td>
<td class="nump">$ 142,999<span></span>
</td>
<td class="nump">$ 71,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narratives (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of debt securities</a></td>
<td class="nump">$ 39,000,000.0<span></span>
</td>
<td class="nump">$ 43,000,000.0<span></span>
</td>
<td class="nump">$ 65,200,000<span></span>
</td>
<td class="nump">$ 132,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">32,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Realized gain (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">$ 143,191<span></span>
</td>
<td class="nump">$ 73,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">142,999<span></span>
</td>
<td class="nump">71,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">143,191<span></span>
</td>
<td class="nump">73,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ContingentConsiderationFairValue', window );">Contingent consideration</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">142,999<span></span>
</td>
<td class="nump">71,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">19,848<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ContingentConsiderationFairValue', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">19,656<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">123,343<span></span>
</td>
<td class="nump">71,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ContingentConsiderationFairValue', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">123,343<span></span>
</td>
<td class="nump">71,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_ContingentConsiderationFairValue', window );">Contingent consideration</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt Securities:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_ContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_ContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Narratives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear', window );">Financial commitment 2025</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">Financial commitment 2026</a></td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">Financial commitment 2027</a></td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">Financial commitment 2028</a></td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,710,000<span></span>
</td>
<td class="nump">$ 744,000<span></span>
</td>
<td class="nump">$ 411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=absi_ShelfRegistrationMember', window );">Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from company offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=absi_CowenAndCompanyLLCMember', window );">Cowen and Company L L C | ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,377,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from company offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_SaleOfStockMaximumAggregateOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_SaleOfStockSalesAgentCommissionPercentage', window );">Sale of stock, commission (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=absi_AdvancedMicroDevicesIncMember', window );">Advanced Micro Devices, Inc | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,714,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from company offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_AmortizationOfEquityIssuanceDiscountPremium', window );">Amortization of the premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=absi_TDSecuritiesUSALLCMember', window );">TD Securities (USA) LLC | ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_SaleOfStockMaximumAggregateOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_SaleOfStockSalesAgentCommissionPercentage', window );">Sale of stock, commission (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction', window );">Shares authorized (in shares)</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_AmortizationOfEquityIssuanceDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Equity Issuance Discount (Premium)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_AmortizationOfEquityIssuanceDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Authorized For Issuances In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_absi_SaleOfStockSalesAgentCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Sales Agent Commission Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">absi_SaleOfStockSalesAgentCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>absi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=absi_ShelfRegistrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=absi_ShelfRegistrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=absi_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=absi_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=absi_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=absi_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=absi_AdvancedMicroDevicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=absi_AdvancedMicroDevicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=absi_TDSecuritiesUSALLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=absi_TDSecuritiesUSALLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Narratives (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation expense not yet recognized, recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share based compensation expense not yet recognized other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=absi_A2021StockOptionAndGrantPlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized for issuance (in shares)</a></td>
<td class="nump">5,768,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=absi_A2023InducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=absi_A2020StockOptionAndGrantPlanMember', window );">2020 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share based compensation expense not yet recognized, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation expense not yet recognized, recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=absi_A2021StockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=absi_A2021StockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=absi_A2023InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=absi_A2023InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=absi_A2020StockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=absi_A2020StockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Allocated Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 5,508<span></span>
</td>
<td class="nump">$ 14,093<span></span>
</td>
<td class="nump">$ 14,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">6,020<span></span>
</td>
<td class="nump">5,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,414<span></span>
</td>
<td class="nump">$ 3,498<span></span>
</td>
<td class="nump">$ 8,073<span></span>
</td>
<td class="nump">$ 8,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock Option Rollforward (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">19,177,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">6,512,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(864,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled/Forfeited (in shares)</a></td>
<td class="num">(2,293,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(626,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">21,905,416<span></span>
</td>
<td class="nump">19,177,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">10,105,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share)</a></td>
<td class="nump">$ 3.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled/Forfeited (in usd per share)</a></td>
<td class="nump">3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share)</a></td>
<td class="nump">7.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share)</a></td>
<td class="nump">3.29<span></span>
</td>
<td class="nump">$ 3.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average price (in usd per share)</a></td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, shares outstanding</a></td>
<td class="nump">$ 9,804<span></span>
</td>
<td class="nump">$ 7,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 6,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Determination of Fair Value (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Restricted Stock (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Nonvested, Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, unvested (in shares) | shares</a></td>
<td class="nump">3,711,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,667,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(469,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeitures (in shares) | shares</a></td>
<td class="num">(489,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, unvested (in shares) | shares</a></td>
<td class="nump">4,420,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance unvested (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">3.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">3.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures (in usd per share) | $ / shares</a></td>
<td class="nump">2.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance unvested (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">26,325,776<span></span>
</td>
<td class="nump">24,012,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">21,905,416<span></span>
</td>
<td class="nump">19,565,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">4,420,360<span></span>
</td>
<td class="nump">4,348,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting - Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 19,249<span></span>
</td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="nump">$ 56,071<span></span>
</td>
<td class="nump">$ 45,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">4,396<span></span>
</td>
<td class="nump">5,508<span></span>
</td>
<td class="nump">14,093<span></span>
</td>
<td class="nump">14,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
<td class="nump">8,914<span></span>
</td>
<td class="nump">10,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,532<span></span>
</td>
<td class="nump">30,596<span></span>
</td>
<td class="nump">91,426<span></span>
</td>
<td class="nump">82,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=absi_SegmentOneMember', window );">Segment One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel</a></td>
<td class="nump">10,488<span></span>
</td>
<td class="nump">9,813<span></span>
</td>
<td class="nump">30,638<span></span>
</td>
<td class="nump">29,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">4,396<span></span>
</td>
<td class="nump">5,508<span></span>
</td>
<td class="nump">14,093<span></span>
</td>
<td class="nump">14,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General &amp; administrative</a></td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">3,799<span></span>
</td>
<td class="nump">11,158<span></span>
</td>
<td class="nump">11,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
<td class="nump">8,914<span></span>
</td>
<td class="nump">10,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,532<span></span>
</td>
<td class="nump">30,596<span></span>
</td>
<td class="nump">91,426<span></span>
</td>
<td class="nump">82,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=absi_DrugCreationAndPlatformMember', window );">Drug creation program and platform | Segment One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">5,669<span></span>
</td>
<td class="nump">4,144<span></span>
</td>
<td class="nump">14,963<span></span>
</td>
<td class="nump">11,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=absi_ExternalPreClinicalAndClinicalDevelopmentMember', window );">External preclinical and clinical development | Segment One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 3,606<span></span>
</td>
<td class="nump">$ 2,852<span></span>
</td>
<td class="nump">$ 11,660<span></span>
</td>
<td class="nump">$ 5,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=absi_SegmentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=absi_SegmentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=absi_DrugCreationAndPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=absi_DrugCreationAndPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=absi_ExternalPreClinicalAndClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=absi_ExternalPreClinicalAndClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Restricted cash Equivalent, period increase (decrease), including exchange rate effect and discontinued operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,343)<span></span>
</td>
<td class="num">$ (34,518)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liability for a payment</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Restricted cash Equivalent, period increase (decrease), including exchange rate effect and discontinued operation</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>169</ContextCount>
  <ElementCount>208</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization and nature of operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Organizationandnatureofoperations</Role>
      <ShortName>Organization and nature of operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Revenuerecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Collaborative arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Collaborativearrangements</Role>
      <ShortName>Collaborative arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Common stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Commonstock</Role>
      <ShortName>Common stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Stockbasedcompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Netlosspershare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Segment reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Segmentreporting</Role>
      <ShortName>Segment reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/Subsequentevents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.absci.com/role/Investments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.absci.com/role/Fairvaluemeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/StockbasedcompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.absci.com/role/Stockbasedcompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/NetlosspershareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.absci.com/role/Netlosspershare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Segment reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/SegmentreportingTables</Role>
      <ShortName>Segment reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.absci.com/role/Segmentreporting</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Revenue recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/RevenuerecognitionDetails</Role>
      <ShortName>Revenue recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.absci.com/role/Revenuerecognition</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Collaborative arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/CollaborativearrangementsDetails</Role>
      <ShortName>Collaborative arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.absci.com/role/Collaborativearrangements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Investments - Amortized and Fair Value of our Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails</Role>
      <ShortName>Investments - Amortized and Fair Value of our Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Investments - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/InvestmentsNarrativesDetails</Role>
      <ShortName>Investments - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Fair value measurements - Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair value measurements - Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Fair value measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/FairvaluemeasurementsNarrativesDetails</Role>
      <ShortName>Fair value measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/CommitmentsandcontingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.absci.com/role/Commitmentsandcontingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/CommonstockDetails</Role>
      <ShortName>Common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.absci.com/role/Commonstock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Stock-based compensation - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/StockbasedcompensationNarrativesDetails</Role>
      <ShortName>Stock-based compensation - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Stock-based compensation - Allocated Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based compensation - Allocated Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Stock-based compensation - Stock Option Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails</Role>
      <ShortName>Stock-based compensation - Stock Option Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Stock-based compensation - Determination of Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails</Role>
      <ShortName>Stock-based compensation - Determination of Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Stock-based compensation - Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails</Role>
      <ShortName>Stock-based compensation - Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Net loss per share - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net loss per share - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Segment reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/SegmentreportingNarrativeDetails</Role>
      <ShortName>Segment reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Segment reporting - Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/SegmentreportingSegmentExpensesDetails</Role>
      <ShortName>Segment reporting - Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="absi-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.absci.com/role/SubsequenteventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.absci.com/role/Subsequentevents</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="absi-20250930.htm">absi-20250930.htm</File>
    <File>absi-20250930.xsd</File>
    <File>absi-20250930_cal.xml</File>
    <File>absi-20250930_def.xml</File>
    <File>absi-20250930_lab.xml</File>
    <File>absi-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>absi-20250930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="555">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "absi-20250930.htm": {
   "nsprefix": "absi",
   "nsuri": "http://www.absci.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "absi-20250930.htm"
     ]
    },
    "schema": {
     "local": [
      "absi-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "absi-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "absi-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "absi-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "absi-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 199,
   "keyCustom": 9,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 12,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 169,
   "entityCount": 1,
   "segmentCount": 38,
   "elementCount": 437,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 555,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.absci.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "9952152 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "longName": "9952153 - Statement - UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "shortName": "UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "longName": "9952154 - Statement - UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "shortName": "UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.absci.com/role/Organizationandnatureofoperations",
     "longName": "9952156 - Disclosure - Organization and nature of operations",
     "shortName": "Organization and nature of operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.absci.com/role/Revenuerecognition",
     "longName": "9952157 - Disclosure - Revenue recognition",
     "shortName": "Revenue recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.absci.com/role/Collaborativearrangements",
     "longName": "9952158 - Disclosure - Collaborative arrangements",
     "shortName": "Collaborative arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.absci.com/role/Investments",
     "longName": "9952159 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.absci.com/role/Fairvaluemeasurements",
     "longName": "9952160 - Disclosure - Fair value measurements",
     "shortName": "Fair value measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.absci.com/role/Commitmentsandcontingencies",
     "longName": "9952161 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.absci.com/role/Commonstock",
     "longName": "9952162 - Disclosure - Common stock",
     "shortName": "Common stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.absci.com/role/Stockbasedcompensation",
     "longName": "9952163 - Disclosure - Stock-based compensation",
     "shortName": "Stock-based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.absci.com/role/Netlosspershare",
     "longName": "9952164 - Disclosure - Net loss per share",
     "shortName": "Net loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.absci.com/role/Segmentreporting",
     "longName": "9952165 - Disclosure - Segment reporting",
     "shortName": "Segment reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.absci.com/role/Subsequentevents",
     "longName": "9952166 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.absci.com/role/InvestmentsTables",
     "longName": "9955511 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.absci.com/role/FairvaluemeasurementsTables",
     "longName": "9955512 - Disclosure - Fair value measurements (Tables)",
     "shortName": "Fair value measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.absci.com/role/StockbasedcompensationTables",
     "longName": "9955513 - Disclosure - Stock-based compensation (Tables)",
     "shortName": "Stock-based compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.absci.com/role/NetlosspershareTables",
     "longName": "9955514 - Disclosure - Net loss per share (Tables)",
     "shortName": "Net loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.absci.com/role/SegmentreportingTables",
     "longName": "9955515 - Disclosure - Segment reporting (Tables)",
     "shortName": "Segment reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.absci.com/role/RevenuerecognitionDetails",
     "longName": "9955516 - Disclosure - Revenue recognition (Details)",
     "shortName": "Revenue recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.absci.com/role/CollaborativearrangementsDetails",
     "longName": "9955517 - Disclosure - Collaborative arrangements (Details)",
     "shortName": "Collaborative arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "absi:ProceedsFromCollaborativeArrangement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "absi:ProceedsFromCollaborativeArrangement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails",
     "longName": "9955518 - Disclosure - Investments - Amortized and Fair Value of our Investments (Details)",
     "shortName": "Investments - Amortized and Fair Value of our Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.absci.com/role/InvestmentsNarrativesDetails",
     "longName": "9955519 - Disclosure - Investments - Narratives (Details)",
     "shortName": "Investments - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9955520 - Disclosure - Fair value measurements - Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Fair value measurements - Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.absci.com/role/FairvaluemeasurementsNarrativesDetails",
     "longName": "9955521 - Disclosure - Fair value measurements - Narratives (Details)",
     "shortName": "Fair value measurements - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EscrowDeposit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EscrowDeposit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.absci.com/role/CommitmentsandcontingenciesDetails",
     "longName": "9955522 - Disclosure - Commitments and contingencies (Details)",
     "shortName": "Commitments and contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.absci.com/role/CommonstockDetails",
     "longName": "9955523 - Disclosure - Common stock (Details)",
     "shortName": "Common stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
     "longName": "9955524 - Disclosure - Stock-based compensation - Narratives (Details)",
     "shortName": "Stock-based compensation - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails",
     "longName": "9955525 - Disclosure - Stock-based compensation - Allocated Share-based Compensation Expense (Details)",
     "shortName": "Stock-based compensation - Allocated Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails",
     "longName": "9955526 - Disclosure - Stock-based compensation - Stock Option Rollforward (Details)",
     "shortName": "Stock-based compensation - Stock Option Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails",
     "longName": "9955527 - Disclosure - Stock-based compensation - Determination of Fair Value (Details)",
     "shortName": "Stock-based compensation - Determination of Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails",
     "longName": "9955528 - Disclosure - Stock-based compensation - Restricted Stock (Details)",
     "shortName": "Stock-based compensation - Restricted Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails",
     "longName": "9955529 - Disclosure - Net loss per share - Anti-dilutive Securities (Details)",
     "shortName": "Net loss per share - Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.absci.com/role/SegmentreportingNarrativeDetails",
     "longName": "9955530 - Disclosure - Segment reporting - Narrative (Details)",
     "shortName": "Segment reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails",
     "longName": "9955531 - Disclosure - Segment reporting - Segment Expenses (Details)",
     "shortName": "Segment reporting - Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-165",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.absci.com/role/SubsequenteventsDetails",
     "longName": "9955532 - Disclosure - Subsequent events (Details)",
     "shortName": "Subsequent events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-169",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "absi-20250930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "absi_A2020StockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "A2020StockOptionAndGrantPlanMember",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan",
        "label": "2020 Stock Option and Grant Plan [Member]",
        "documentation": "2020 Stock Option and Grant Plan"
       }
      }
     },
     "auth_ref": []
    },
    "absi_A2021StockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "A2021StockOptionAndGrantPlanMember",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "2021 Stock Option and Grant Plan [Member]",
        "documentation": "2021 Stock Option and Grant Plan"
       }
      }
     },
     "auth_ref": []
    },
    "absi_A2023InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "A2023InducementPlanMember",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Inducement Plan",
        "label": "2023 Inducement Plan [Member]",
        "documentation": "2023 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r675"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accretion of discount on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r41",
      "r91",
      "r487",
      "r525",
      "r526",
      "r939"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r13",
      "r376",
      "r379",
      "r434",
      "r521",
      "r522",
      "r807",
      "r808",
      "r809",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r863",
      "r864",
      "r865",
      "r866",
      "r940",
      "r1000"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "absi_AdvancedMicroDevicesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "AdvancedMicroDevicesIncMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advanced Micro Devices, Inc",
        "label": "Advanced Micro Devices, Inc [Member]",
        "documentation": "Advanced Micro Devices, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r716",
      "r726",
      "r758"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r719",
      "r729",
      "r761"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r754",
      "r762",
      "r766",
      "r774"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails",
      "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r345",
      "r346"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "absi_AmortizationOfEquityIssuanceDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "AmortizationOfEquityIssuanceDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of the premium",
        "label": "Amortization of Equity Issuance Discount (Premium)",
        "documentation": "Amortization of Equity Issuance Discount (Premium)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Impairment Charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r23",
      "r677",
      "r678"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r72",
      "r90",
      "r107",
      "r108",
      "r109",
      "r141",
      "r149",
      "r167",
      "r171",
      "r210",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r366",
      "r368",
      "r416",
      "r478",
      "r479",
      "r483",
      "r561",
      "r634",
      "r635",
      "r644",
      "r675",
      "r684",
      "r685",
      "r697",
      "r895",
      "r896",
      "r955"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r92",
      "r107",
      "r108",
      "r109",
      "r210",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r366",
      "r368",
      "r416",
      "r675",
      "r895",
      "r896",
      "r955"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r663"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "absi_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Offering Program",
        "label": "At The Market Offering Program [Member]",
        "documentation": "At The Market Offering Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934"
     ]
    },
    "us-gaap_CapitalUnitLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitLineItems",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Unit",
        "label": "Capital Unit [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r88",
      "r615"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails",
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash - Beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash - End of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r50",
      "r106"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.absci.com/role/SubsequenteventsDetails",
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash",
        "terseLabel": "Restricted cash Equivalent, period increase (decrease), including exchange rate effect and discontinued operation",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r50"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.absci.com/role/Collaborativearrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r363",
      "r364"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments (See Note 6)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r65",
      "r484",
      "r548"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.absci.com/role/Commitmentsandcontingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r239",
      "r240",
      "r607",
      "r890",
      "r892"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r691",
      "r692",
      "r693",
      "r694",
      "r863",
      "r864",
      "r866",
      "r940",
      "r998",
      "r1000"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35",
      "r549",
      "r567",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r260",
      "r266",
      "r486",
      "r675"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r96",
      "r100",
      "r476",
      "r494",
      "r495"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r177",
      "r528",
      "r529",
      "r606",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r177",
      "r528",
      "r529",
      "r606",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r177",
      "r528",
      "r529",
      "r606",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk (as a percent)",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r177",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r177",
      "r528",
      "r529",
      "r606",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "absi_ContingentConsiderationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "ContingentConsiderationFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Contingent Consideration, Fair Value",
        "documentation": "Contingent Consideration, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r286",
      "r297"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r286",
      "r297"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from customer contract liability",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r111",
      "r112",
      "r254",
      "r270",
      "r435",
      "r455",
      "r482",
      "r616",
      "r617",
      "r618",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "absi_CowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "CowenAndCompanyLLCMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cowen and Company L L C",
        "label": "Cowen And Company L L C [Member]",
        "documentation": "Cowen And Company L L C"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r870"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value",
        "verboseLabel": "Debt Securities:",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain (loss)",
        "label": "Debt Securities, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r811",
      "r812"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails",
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization",
        "netLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r102",
      "r141",
      "r154",
      "r171",
      "r619",
      "r634",
      "r635"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "absi_DrugCreationAndPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "DrugCreationAndPlatformMember",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug creation program and platform",
        "label": "Drug Creation And Platform [Member]",
        "documentation": "Drug Creation And Platform"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share: basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r101",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r130",
      "r132",
      "r134",
      "r135",
      "r136",
      "r140",
      "r258",
      "r344",
      "r357",
      "r362",
      "r388",
      "r389",
      "r477",
      "r496",
      "r627"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share: diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r101",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r132",
      "r134",
      "r135",
      "r136",
      "r140",
      "r258",
      "r344",
      "r357",
      "r362",
      "r388",
      "r389",
      "r477",
      "r496",
      "r627"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.absci.com/role/Netlosspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r137",
      "r138",
      "r139"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense not yet recognized, recognition period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense not yet recognized other than options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense not yet recognized, options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Street",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Incorporation, State",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r78",
      "r79",
      "r80",
      "r97",
      "r98",
      "r99",
      "r113",
      "r114",
      "r115",
      "r117",
      "r124",
      "r126",
      "r128",
      "r142",
      "r211",
      "r212",
      "r232",
      "r257",
      "r282",
      "r344",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r361",
      "r362",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r434",
      "r492",
      "r521",
      "r522",
      "r523",
      "r536",
      "r586"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r716",
      "r726",
      "r758"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow deposit",
        "label": "Escrow Deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r608"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "absi_ExternalPreClinicalAndClinicalDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "ExternalPreClinicalAndClinicalDevelopmentMember",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External preclinical and clinical development",
        "label": "External Pre-Clinical And Clinical Development [Member]",
        "documentation": "External Pre-Clinical And Clinical Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r405",
      "r663"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r405",
      "r663"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r942",
      "r943",
      "r948"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r406",
      "r612",
      "r664",
      "r673"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r406",
      "r612",
      "r664",
      "r673"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r404",
      "r405",
      "r407",
      "r414",
      "r442",
      "r443",
      "r444",
      "r612",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r663",
      "r666",
      "r673"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r395",
      "r663",
      "r945",
      "r949"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.absci.com/role/Fairvaluemeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r400",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r474",
      "r663",
      "r667"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r301",
      "r306",
      "r307",
      "r392",
      "r405",
      "r414",
      "r442",
      "r612",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r663",
      "r673"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r301",
      "r306",
      "r307",
      "r309",
      "r392",
      "r393",
      "r405",
      "r414",
      "r443",
      "r612",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r663",
      "r673"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r392",
      "r393",
      "r394",
      "r395",
      "r405",
      "r414",
      "r444",
      "r612",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r663",
      "r666",
      "r673"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r395",
      "r663",
      "r945",
      "r949"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r404",
      "r405",
      "r407",
      "r414",
      "r442",
      "r443",
      "r444",
      "r612",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r663",
      "r666",
      "r673"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r949"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease obligations",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails",
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instrument [Axis]",
        "terseLabel": "Investment Type [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r256",
      "r280",
      "r374",
      "r385",
      "r412",
      "r415",
      "r418",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r481",
      "r493",
      "r640",
      "r663",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r676",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r881",
      "r882",
      "r883",
      "r884",
      "r941",
      "r944",
      "r945",
      "r946",
      "r947",
      "r949",
      "r950",
      "r951"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r943",
      "r947",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r762"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r762"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r762"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r762"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r762"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General &amp; administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r570"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r67",
      "r71",
      "r478",
      "r480",
      "r490",
      "r621",
      "r623",
      "r624",
      "r629",
      "r634",
      "r868",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r370",
      "r371",
      "r372",
      "r373",
      "r397",
      "r401",
      "r406",
      "r417",
      "r418",
      "r419",
      "r518",
      "r520",
      "r571",
      "r611",
      "r612",
      "r656",
      "r657",
      "r661",
      "r662",
      "r665",
      "r673",
      "r931",
      "r932",
      "r969"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r370",
      "r371",
      "r372",
      "r373",
      "r397",
      "r401",
      "r406",
      "r417",
      "r418",
      "r419",
      "r518",
      "r520",
      "r571",
      "r611",
      "r612",
      "r656",
      "r657",
      "r661",
      "r662",
      "r665",
      "r673",
      "r931",
      "r932",
      "r969"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r75",
      "r107",
      "r127",
      "r128",
      "r141",
      "r157",
      "r171",
      "r349",
      "r350",
      "r353",
      "r498",
      "r621",
      "r623",
      "r624",
      "r655"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r856"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "absi_IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets and liabilities",
        "label": "Increase (Decrease) Operating Lease Right-Of-Use Assets And Liabilities",
        "documentation": "Increase (Decrease) Operating Lease Right-Of-Use Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r754",
      "r762",
      "r766",
      "r774"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r778"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r778"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r778"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r887",
      "r888"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r621",
      "r624",
      "r813"
     ]
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "presentation": [
      "http://www.absci.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment in Debt and Equity Instruments and Cash and Cash Equivalent [Text Block]",
        "documentation": "The entire disclosure for cash, cash equivalent, investment in debt and equity securities, equity method investment, investment in joint venture, and investment classified as other."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r623",
      "r810"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r107",
      "r108",
      "r109",
      "r210",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r367",
      "r368",
      "r369",
      "r416",
      "r547",
      "r628",
      "r644",
      "r697",
      "r895",
      "r955",
      "r956"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r66",
      "r489",
      "r675",
      "r684",
      "r685",
      "r858",
      "r861",
      "r885",
      "r954"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r87",
      "r107",
      "r108",
      "r109",
      "r210",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r367",
      "r368",
      "r369",
      "r416",
      "r675",
      "r895",
      "r955",
      "r956"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net of current portion",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, noncurrent",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails",
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r241",
      "r242",
      "r243",
      "r244",
      "r310",
      "r337",
      "r338",
      "r339",
      "r347",
      "r395",
      "r471",
      "r517",
      "r519",
      "r527",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r602",
      "r603",
      "r604",
      "r605",
      "r609",
      "r610",
      "r639",
      "r645",
      "r653",
      "r656",
      "r658",
      "r659",
      "r666",
      "r667",
      "r671",
      "r672",
      "r680",
      "r897",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r241",
      "r242",
      "r243",
      "r244",
      "r310",
      "r337",
      "r338",
      "r339",
      "r347",
      "r395",
      "r471",
      "r517",
      "r519",
      "r527",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r602",
      "r603",
      "r604",
      "r605",
      "r609",
      "r610",
      "r639",
      "r645",
      "r653",
      "r656",
      "r658",
      "r659",
      "r666",
      "r667",
      "r671",
      "r680",
      "r897",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r900"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Operating Activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "netLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r52",
      "r68",
      "r80",
      "r85",
      "r93",
      "r95",
      "r99",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r127",
      "r128",
      "r133",
      "r210",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r258",
      "r261",
      "r263",
      "r267",
      "r344",
      "r357",
      "r362",
      "r389",
      "r416",
      "r491",
      "r568",
      "r584",
      "r585",
      "r621",
      "r623",
      "r624",
      "r695",
      "r895"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r720",
      "r730",
      "r754",
      "r762"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "absi_NumberOfPartners": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "NumberOfPartners",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of partners (partner)",
        "label": "Number Of Partners",
        "documentation": "Number Of Partners"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r638",
      "r874"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails",
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r621",
      "r624",
      "r629",
      "r868",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease obligations",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease obligations, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.absci.com/role/Organizationandnatureofoperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and nature of operations",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r81",
      "r82",
      "r83",
      "r530",
      "r531"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/CommitmentsandcontingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial commitment 2026",
        "label": "Other Commitment, to be Paid, Year One",
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r862",
      "r965"
     ]
    },
    "us-gaap_OtherCommitmentDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/CommitmentsandcontingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial commitment 2027",
        "label": "Other Commitment, to be Paid, Year Two",
        "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r862",
      "r965"
     ]
    },
    "us-gaap_OtherCommitmentDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/CommitmentsandcontingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial commitment 2028",
        "label": "Other Commitment, to be Paid, Year Three",
        "documentation": "Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r862",
      "r965"
     ]
    },
    "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/CommitmentsandcontingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial commitment 2025",
        "label": "Other Commitment, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on investments",
        "verboseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r62"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustments",
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r62"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r660"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item",
        "documentation": "Amount of cash inflow (outflow) from operating activity, classified as other, in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r718",
      "r728",
      "r760"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r721",
      "r731",
      "r763"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r721",
      "r731",
      "r763"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/SubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability for a payment",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails",
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment in marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r103",
      "r179"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r260",
      "r265",
      "r485",
      "r675"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "absi_ProceedsFromCollaborativeArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "ProceedsFromCollaborativeArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/CollaborativearrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaborative arrangements",
        "label": "Proceeds From Collaborative Arrangement",
        "documentation": "Proceeds From Collaborative Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of debt securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r880"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities",
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r880"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock through employee equity plans, net",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails",
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r473",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r613",
      "r620",
      "r623",
      "r624",
      "r646",
      "r647",
      "r679",
      "r680",
      "r681",
      "r683",
      "r686",
      "r785",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r852",
      "r853",
      "r854",
      "r855",
      "r893",
      "r894",
      "r968",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails",
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r473",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r613",
      "r620",
      "r623",
      "r624",
      "r646",
      "r647",
      "r679",
      "r680",
      "r681",
      "r683",
      "r686",
      "r785",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r852",
      "r853",
      "r854",
      "r855",
      "r893",
      "r894",
      "r968",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r889"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails",
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r241",
      "r242",
      "r243",
      "r244",
      "r300",
      "r310",
      "r337",
      "r338",
      "r339",
      "r343",
      "r347",
      "r395",
      "r445",
      "r454",
      "r471",
      "r517",
      "r519",
      "r527",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r602",
      "r603",
      "r604",
      "r605",
      "r609",
      "r610",
      "r639",
      "r645",
      "r653",
      "r656",
      "r658",
      "r659",
      "r666",
      "r667",
      "r671",
      "r672",
      "r680",
      "r689",
      "r891",
      "r897",
      "r945",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails",
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r241",
      "r242",
      "r243",
      "r244",
      "r300",
      "r310",
      "r337",
      "r338",
      "r339",
      "r343",
      "r347",
      "r395",
      "r445",
      "r454",
      "r471",
      "r517",
      "r519",
      "r527",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r602",
      "r603",
      "r604",
      "r605",
      "r609",
      "r610",
      "r639",
      "r645",
      "r653",
      "r656",
      "r658",
      "r659",
      "r666",
      "r667",
      "r671",
      "r672",
      "r680",
      "r689",
      "r891",
      "r897",
      "r945",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r534"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r111",
      "r112",
      "r254",
      "r270",
      "r435",
      "r455",
      "r482",
      "r616",
      "r617",
      "r618",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails",
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r611",
      "r621",
      "r622",
      "r634",
      "r963"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r714",
      "r724",
      "r756"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r757"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r722",
      "r732",
      "r764"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r857",
      "r964",
      "r967"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash, long-term",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r795",
      "r857"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r56",
      "r488",
      "r524",
      "r526",
      "r535",
      "r550",
      "r675"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r113",
      "r114",
      "r115",
      "r117",
      "r124",
      "r126",
      "r128",
      "r211",
      "r212",
      "r232",
      "r257",
      "r344",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r361",
      "r362",
      "r375",
      "r377",
      "r378",
      "r380",
      "r387",
      "r427",
      "r428",
      "r521",
      "r523",
      "r536",
      "r1000"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner program revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r141",
      "r150",
      "r151",
      "r165",
      "r171",
      "r174",
      "r176",
      "r177",
      "r294",
      "r295",
      "r296",
      "r473"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r870",
      "r871"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.absci.com/role/Revenuerecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r299"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r674"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from company offering",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "absi_SaleOfStockMaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum offering price",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "absi_SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Sale Of Stock, Number Of Shares Authorized For Issuances In Transaction",
        "documentation": "Sale Of Stock, Number Of Shares Authorized For Issuances In Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued and sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "absi_SaleOfStockSalesAgentCommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "SaleOfStockSalesAgentCommissionPercentage",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, commission (as a percent)",
        "label": "Sale Of Stock, Sales Agent Commission Percentage",
        "documentation": "Sale Of Stock, Sales Agent Commission Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.absci.com/role/NetlosspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfCapitalUnitsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCapitalUnitsTable",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Capital Unit or Share [Table]",
        "label": "Equity, Capital Unit or Share [Table]",
        "documentation": "Disclosure of information about capital unit or share, including, but not limited to, authorized, outstanding, and value of capital unit or share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails",
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.absci.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortized and Fair Value of Our Investments",
        "label": "Cash, Cash Equivalent, and Investment [Table Text Block]",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of Share-based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-vested Share Activity",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Determination of Fair Value",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of each class",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of each exchange on which registered",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r72",
      "r141",
      "r146",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r177",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r237",
      "r238",
      "r359",
      "r360",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r631",
      "r634",
      "r635",
      "r641",
      "r682",
      "r968",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "absi_SegmentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "SegmentOneMember",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment One",
        "label": "Segment One [Member]",
        "documentation": "Segment One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.absci.com/role/Segmentreporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r161",
      "r163",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r630",
      "r632",
      "r633",
      "r634",
      "r636",
      "r637",
      "r638"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r620",
      "r621",
      "r622",
      "r624",
      "r851"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationAllocatedSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r657"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeitures (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, unvested (in shares)",
        "periodEndLabel": "Ending balance, unvested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested, Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance unvested (in usd per share)",
        "periodEndLabel": "Ending balance unvested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assumptions and Methodology",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Yield (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails",
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for employee (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted average price (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled/Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled/Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "absi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under stock plans, net of shares withheld for tax payments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value, shares outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in usd per share)",
        "periodEndLabel": "Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationNarrativesDetails",
      "http://www.absci.com/role/StockbasedcompensationRestrictedStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance price (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationDeterminationofFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted average remaining contractual term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.absci.com/role/Stockbasedcompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r901"
     ]
    },
    "absi_ShelfRegistrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "ShelfRegistrationMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf Registration",
        "label": "Shelf Registration [Member]",
        "documentation": "Shelf Registration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r614"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.absci.com/role/SegmentreportingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r72",
      "r84",
      "r141",
      "r146",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r177",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r234",
      "r237",
      "r238",
      "r359",
      "r360",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r631",
      "r634",
      "r635",
      "r641",
      "r682",
      "r968",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35",
      "r38",
      "r39",
      "r78",
      "r79",
      "r80",
      "r97",
      "r98",
      "r99",
      "r113",
      "r114",
      "r115",
      "r117",
      "r124",
      "r126",
      "r128",
      "r142",
      "r211",
      "r212",
      "r232",
      "r257",
      "r282",
      "r344",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r361",
      "r362",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r434",
      "r492",
      "r521",
      "r522",
      "r523",
      "r536",
      "r586"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r142",
      "r259",
      "r260",
      "r262",
      "r264",
      "r428",
      "r473",
      "r532",
      "r537",
      "r538",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r623",
      "r624",
      "r690",
      "r999"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r142",
      "r178",
      "r259",
      "r260",
      "r262",
      "r264",
      "r428",
      "r473",
      "r532",
      "r537",
      "r538",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r623",
      "r624",
      "r690",
      "r999"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r717",
      "r727",
      "r759"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r35",
      "r56",
      "r533",
      "r586",
      "r599"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.absci.com/role/StockbasedcompensationStockOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r35",
      "r56",
      "r322"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r35",
      "r56",
      "r536",
      "r586",
      "r599",
      "r696"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeiture of common stock (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r35",
      "r56",
      "r534",
      "r586",
      "r600"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.absci.com/role/UNAUDITEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r53",
      "r551",
      "r567",
      "r587",
      "r588",
      "r675",
      "r697",
      "r858",
      "r860",
      "r861",
      "r885",
      "r954",
      "r1000"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.absci.com/role/Commonstock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r374",
      "r386",
      "r589",
      "r590",
      "r601"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.absci.com/role/SubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r437"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.absci.com/role/SubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r437"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.absci.com/role/SubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r437"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.absci.com/role/SubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r437"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.absci.com/role/SubsequenteventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r437"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.absci.com/role/Subsequentevents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r438"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "absi_TDSecuritiesUSALLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "TDSecuritiesUSALLCMember",
     "presentation": [
      "http://www.absci.com/role/CommonstockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TD Securities (USA) LLC",
        "label": "TD Securities (USA) LLC [Member]",
        "documentation": "TD Securities (USA) LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "absi_TechnologyDevelopmentRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.absci.com/20250930",
     "localname": "TechnologyDevelopmentRevenueMember",
     "presentation": [
      "http://www.absci.com/role/RevenuerecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner program revenue",
        "label": "Technology Development Revenue [Member]",
        "documentation": "Technology Development Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.absci.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol(s)",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails",
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r256",
      "r280",
      "r374",
      "r385",
      "r412",
      "r415",
      "r418",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r481",
      "r493",
      "r663",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r676",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r881",
      "r882",
      "r883",
      "r884",
      "r941",
      "r944",
      "r945",
      "r946",
      "r947",
      "r949",
      "r950",
      "r951"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.absci.com/role/InvestmentsNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasuries",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.absci.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.absci.com/role/InvestmentsAmortizedandFairValueofourInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasuries",
        "verboseLabel": "U.S. treasuries",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r648",
      "r650",
      "r652",
      "r663",
      "r966"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average common shares outstanding: diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r136"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.absci.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average common shares outstanding: basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r136"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001672688-25-000084-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001672688-25-000084-xbrl.zip
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M4L*5/>ZY?P/L %2JE]U,WJ,!5E2N;+WL1N^!#+#"UK_L!O"^#;#"%K[LEJ\
M!EAAM! L(EKDJY4]"7>O!M@!JJ;6RVXA'\P .P2Q2F\MBV" '8)P9;><]V^
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M&&89#&$-WFZLP61IR0O_A7EMS\&BYI;W]O7KQ;X0T8X>>BR)3=UVNPPUB[O
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ME<ZGM5D*YT,X 5H?BJ^%\U8<DM9'RL_"^4..F,:'XF,A/2YW@>_$=G0;=%B
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M&]OL#UDR3O9UFK<R2@L?P2TY\^-G)^E1Q[."1*T>K_>9=#W>?N7$%!N3SU\
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MK1)X-.:E9]WDE,VJ6YTA9\;C;E-\6DD=B+0^F8N5/T>5:.&]1MF "UYJKF#
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MP38K+4V8%J?$%L06*]FBL0.VR)6C E/F):\7'#TCMA$*5L0V8[91#L\V>.1
M5HRB#AP0VQ#;[)QMC,.SC8JMEYIUZI1S$J-H><O0DD=D&3[3L8^]#C$C<G?]
M=NCZ\EU?Z)EGK03\<,]"9@5VCX>!'=BU^_X0TX"I]-!A?5@)5=J><SFFR54B
ML7(K2EC8TY15711-B>"T=]]/D7#".J -V6Q2K=ACA=-*GTB1<#(J+:,NUQI'
MY#4D..7S%10)IWJEI1NRWCS*2L5ET"@[K ]?/LG2$_,8GD1#S=)R!J[GAE'
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MU*BT&K6ZK!960UN D-T)H' SE8]()(*@R.$;L1Y#MV )P9NE?_&#+G.C.-A
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M5GT,F/6C:G7A-<^M_HOU%B(D)U9CX'K9C'0#ICR[:DO7IMO=[=HDJBGHSG[
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M+SRRK?I(>8FO:]7O5F/XL-C<(OUZ.R^R]1BZ<RPWHL-7_'2/S[[M?@>6XR0
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M!WP,3"1BL@U=0VYJ5H>"US[B$<BBL6EQAK>QB"]1I/#/R'H61VA2.0N>":+
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MP8!0,0_]67NLL1!GBP/I+PDJKC$4OG)3&?8@17K']0O+S=_K&2"*FH;6W=D
MO@K,O50468HB=^1ES=-6 VBKO?4 <D57!Z2K=U4@K!F_8YZPFBBTYNCJO2*I
M*I+4X93G8A.\I%)L":78ZU5%*9[+Q<H35ON7=8!.9XSU2B34-_+)3V",]7H[
MW^%8^8J9V6V4* VMWMQZ\'RI,Z]HK$QQK.+8P[DAG9VX(8KOJD=]Y\MWI?RT
M/3'>2C>MNZ6;IEBN>H1WOBQW,.-T9VYL3QB=>J_Z1N?;NTM9T'(UVS;APXZ2
M;!N <,N+L&AOEX-+U=+GL_2Y!)AFNYQLQ(%+S 'UO,JR45DVRTRC;OTP638
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ME%"T%=TT9^GFFB@D^9UX14ID^((;;PS"<,I&W"F)WL9R]*:QN!1;]YX+?_J
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M'"@$@6WV;0=U[ !X^MGSI_%16LP,LRO#47%0T( ^5-%H ."K83$XXO3??1.
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M/Q%3@'MV@V80Z7[S*C[1HQ'58OER)-I?T+[WT^/-';MY^/']X<?UT]W#_6F
M??_P=/O(GA[8G_?7?WZ^>[K]#'NX_WQ[_RC^>GSX>O?Y&C_^<G=_?7]S=_V5
M/3[!!]]N[Y\>B]A]L4EH%)J$C0J;A$)I&!_8'6D*C7ED,U'8 E7E"HVA"=/
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MB21&.&T;#H@D3BR$; >(QG.);;D-'_G 5B&(!N!.VP6N,)]]3H\@*W,\3C8
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MBV.(0%7H[\<11)\_XPYW[:H=V@Z@93_8(9S!8!WS?AG/?]ACF_CU+=(^=VP
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M#B<A]]1O-5<Z>_P%+ 0BG;D$B0CTC3^Q71<3@*=KI@ ('1M$Q+CH$(H8$:4
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MY*_2?\)REM2Z"TITE5!GO^G9\U^@IZ@Y#!ZFM)X3YS%[UC)&($MK\&>F)?S
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MJ-S7I!%LHI,J>F&D=\XRM0N-_^)^,W'S##'-.,I.2"&RED'#N2?&W,2;C_C
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M;=$!#VB38<GJ@ Z:(*VK/LP5/9H#E^6=K&X_]8C1[B<TG[9AN\F$9N5Y'/"
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ME7C0Q&Z<!%_:F 8;&A)2%&_!-F@PYV,Y-1-.=)PB)[5F+6"P"F1 $A,-CL6
MSK^OZIKBG6:&B++NY^.#P1"+6)$'Y +>6@RX!'@K%S9)G.C?Z @$;WS[OM4"
M9K"J]^95;JF9(;GPB&3-.9"9LUE(0+;<$XI,Z*/SAQ%HKJX6%!G3UF7#]W8&
MM(:K*F'^!^,-66]"?%L.HYT$;](M?T 1]Y-'9T^^YL\ CLBKI<0X^7H#;RNX
M9C5Y^K@C[DT/]?6_GUT\_/=;TREX(.<\S=V:X&2U39NR=SY/"SI"\$W)A3./
MG3=1<OAH!?9E>^;>[8RS*H" 9?4QR>S?NS+#-C[F;7R-BD IX3=+!]3.>\IE
MO=3=8PEZ7=UD'-;)KY+9]]^_3N"0ZO?QW0>X+H9P/7KXXIT3P+I_-?KLXL57
M"5_6">.&'/0*,#KY8<H.>V^5Y9?JRXH>Y2#)O@T2IW1J@D=-EV#=[CSD1/1^
MOF:(;HX*2W.5UJR]<R>O-CI($-[-KM/"N1M_HND_%SA<_(L$IH9C!2?O[B4O
M.97%CPQ3LR!;TFVX-H?Q07$^UX9=9B49)J7O1$>)XU479?2^ZK8,S^M,$*['
M=WI\_O#?57U<.N>ED0REUT.: ^#7=C[T4A84OQC=.1<>=;7F@_8K.<7;TI"5
M=%^]>)@\?OX\>?[TD=X?6^/UZ)\>/S4E3!?T(PT<*U ;HYI(<=/5,,.M FTF
MWN-HSNO+[K)SRGJXF/N<V ]OW)[XI7GPC_<OO[KUR![\L")H_DVG\S#G#\)[
MAS/H;S@\AOL=P('(_F-#2#EDW,C''?D295"<.]%*0;7I@(_,<#8GSP)52EL<
MX=9Y%>WV-Y[Q9;ZD7!6=<_MZR-?939M^TWMS-N_H&;SKYNZ+7O(&KWQOWFMW
M.:.<_4 M.!=:[G<.+LEF[WS-+KY)'CU\FKAG,GO<3ZPED49VEZ!]OX%*PI&-
M]=4/57WIOO+>^9-%MIW]?^EZ\\))UCF4EC@>8RX(I3O=?:+E#P?_3T_.GSZT
M]GJ> 4H0/\DR;Q95IS6S<)"YWN8-$[OWX];(WQGW_-KT/<PHA>.B/.3;\(7]
M[LPY9[VH!W [U4/!*&7V[\]AN4VH_MZY6.71UZ:\/2Y4SY)GSQ_>(E2?2Z:2
MV=_/WYW[KP13R9]EM/;\G[09 WOZU3[BYRS P<7OR3/C/_T1Q.^NNKK.KR%Q
M$49(]Y"3-_?FU6X-Z=*R2^MM.%@]UU"K7@OT>!?IO.*<$1^/ES^\85=A[# ^
M39Y?/$D>??UTUUET]\!% "&+!)/Z!A^:'(BZ62G.QFVK/WOP[NV[;[^23DO-
MS<'7MS<%@(-/7YVM\VY-+A4J=+_F:RX[_NF1@;E1AL2XJG)&RS@!B!+HM&#_
M0:L6SZ:K%G?!QCW[MU.M8U^4WFLD>[\KJIO[ \C;*2,XJ0'4TW1KI-C_!:TA
M "7*7#N[^18'KNK<O9;-5W\9O-Q_',= YV?/SB^>WG6&\.\^6_C)^;.O[]W
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MU>=>VCE4U]4"?@R1UU#@1%_@LHRS##SE8\<M/G&]Z<7H?L&IR"C.P0A<'FV
M2TL6@Y,7O364': U2&OGG=6Z).1ONF5[D'\E;A%1^!)QW:2LNKL]R/&#U2HG
M$W=-?-$8-N77:7N'Q;=B'&N,EYB8P*Y7,AG-VED"/ U,^=K# M J\NK?MO3N
M:4KW[X5</.4)%[RZN@*]#3@27^Y]-_]%3L8B<UX*.W!+I<D'[\P.S2X#'VKL
M-<8/RQ78[\E^S=1+XM3$LEM0@EGC#CL^QM9#L1F0$IH0P^X<9)%%0AD0W5>=
M*^?S)6GKUER^7'N_D68R;!LG%$2H*$52BN/KJA JX2 _)B0R:6/5-4\>/GDP
M#QHTK>>I<RW/?OH5?%M0/'A+.@2](PWI,.^*G!ZEOEE^U.B;%!8&?#78I-FK
MRAWXV8-WKU_^Y)0W$O UK< :JL"]_Y878H9#-ZNKUH^+2$&*N"F$+I&U<7_-
M9)W,NH[[TB&FXINI3WRK4Y_,/I;53:EQJ=Q_*K=U)"?F;1AME>@XB+1HP$ E
M/*'-.BV*K#;B) =&J4)CA^CGSFFFBT?SLT<J6]_^*L-<5*KZMF7H%?BCQU=H
MG#..%'JZ^&AS6-' IC!C!;-:)IX9BE+'<:375>['))'N;J#N2O!YL^(;W&E)
MF4A2!R-7EGSWHBN<!=JJJG>FV\43&TT'"A7H=1;!9<YGL+DT8L6]#]X\G7R'
MK=@ZYP71#0I,ZEH2':LD5;!<!.W ,["I5VI]IJ)+.2)E8E,_D6%EAP=?/'P8
M08\,_Y;/0 Q(Q0BH,]\2S@BFL\C)>&/V#RH-?WK^T#*+I9XG?4,4IT1R_?AA
M>T4C2Z"</N?K\4-@&7^?=WOTU+P;)AD/28#??_L:QH4!-2FI2G<5S3J]">)&
M8Y W=28*D&:WK+8JJ^[>2-]05&5]C159^\L<S'%^@$U1D>.6Y?4.@9)K^?08
MYZMXW6"(,&&' 4'D N;1XY':B$67UFBQ<*\JX_'HB;FB4Q#)*O!%<D"B#5VO
MW1[)Z*EHTIRBVVY[B00CE/AGG%7'8\J=L%=\$'V-2Y5X;'"#<2,>Z]C.3IK9
M\]G?JANW:K44?N--E+E QI&G-:/]R8K\,A?6<\+ N0\D23?YNO#GG'@NI2@R
M=QM?EMY(XP$TS?1??E"LLZM-JPO^S\YIJ^ GT_HSYZ1[)O+0;UGJ8TGZ1";.
MRE+?$91C0/M";,CN;1<\65%LX:A@JQU4 6251$;4!V]I&1S(_:6O3]Z]ORA^
M>I[IR;W/,[V% _SX?/9?<&G)I;YF#>K^4.A_&VWZDAR^'UC!_YPW1T+I_*.3
M0"0-<@[*3R6ZN$3W]6>AMGSZ_$1M>;>#]^3<.2X2<.+0O0..9(E)<_?F6$W"
M[2:&&<'I\_5ZX_4O['MN]#WU-;^8Z-^?A;X5"B)F\]8U;9+I8+*973Q.SRZ>
M/LB^HA]=/%W*?YEA!"$!'$6;G E^PIF?-6?G'O1CTJ\2BGHQ<.ZRY(C4Q65X
M6!D!&7('=D+IW$>(C.Y*2\X<U^K8LC7609(M.0M4(FVZ^1K#&\+S1P]-Y4@
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M33F\@Y85M[;1VUM1:NH$^'PA2?@F"]=5L45#R9C X,)&5AD^K/B^-;T,]>Y
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M1!-\$R6 (VP3$4:['TTTA2<,(B,V!DNI DJ=1<ZS;9]^8\=8 @^F(J/<!R.
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M(!@9[GDZU%]N\Q/1_ US.,JN01I04+#QY^F,'LH75"+^E>;>0.OE=T(MN:0
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M?3W(SB_/G:2<9625G8U=PU==5T7F'$:M87\5***H)\.8"S#NS"O/(-G#9:F
M_>RN5M,<CG>1<?)B]#-YB6,"]K:IUE6]<>[@[/MTWLR^1U1%60PGE^\75\Z<
MN)<#M<"(0.)+)ZG\TE*9+E(:OY/T7)-DQ#?Q ZB5->6:,.*H^@"#[<<;Y-=$
M$E/J*" GZ&V=+HEI1,_ JEIT0N7'ZF^=M5?54GK/QXUD< O^^M^/'O8D\F6Q
MN,K6Z;SW9SS%XP]0GLV",(<BO,?AF/ZMN@'VB!#F#?CR%FF3!8_]!@R+% H6
M13JOR$SP^(6.)O=Y:G@7#F^=&;GT\QGV:NG@TIULPM'T7+P59QU.$OC4\ZQ8
M<I)4M&'D MOVJ)T'Y0Z>NW>80W.#O:E^(7CDC,U76!E+?Z-CAVUY-?; N_HV
M9_@$L?X"G;Q>XLSVCPE?(SN-SS]\?_'2@V5":HWBCU61KM?<-#=W^J!004E\
M3^9-RI@I BI*0,*B.(&GB')VT1D(.O:'K%Y\]-/Y?OC/L^>/GCQTWD#E].R?
M?ZYR#,KV'__\WQ_.'E\\O$AF[].R6N5__I!=I_[3#]_^]]F3KY\^?T+OZ;ZS
MV=9A\-_[=__OX<-'XLRBG:WV'_W?]<OY-T\>G;+C]U^"W_W\_<_C$NSVSBDD
M%W,O9BD4U (M4WW1_9O[P(D<QS=^___VP]NSBXNGQY)'^FFT$RDKI ]._7)N
MSP_Q.V68SJXJ!(;-MG&Q(A<,I:N&$BWB'B68C,FP5O>.OG(X&'>G9<9X_G#3
MNKN/#,?+D<_X0+D%$[36,H*1REK9KU=IU[0SRI:+T7'_0?\@1U!GG!F+*)WC
MZ;+:C#YAKTDN$(BM4= L(%JS#(,*F)QV..NFR%?H%2:_;B15JE,C90YW"+LT
M-TK:<=[)-[D'53?);X1]8O1+R=0VR7_Y,8YT+]2'HXMW_EF94%"7>=?+R9@>
MR[%Z28QXM4F=4^.;D)YJF9MDHNO-RZHO^3OLN4L&RS (7KJ;_BOP$A!'LGVN
M0+Q$:=ZTX+PCI<!.2)08B?+-L2-1OK3RC#*I45^J_81IS'^IT \:3\*2<LB,
M!C!(.?$:5.=-CPR=$ZF&T^,O=S Q)__B4_T+FA!<:X7/Z92KW-FD&G.-3NM_
MB/5G<R ^"DU3.*W\059>+?B\E@Z_ZK(,O"5:WL[*3 AG3KMRR%T)?I7WIDX;
M<,@-"$ZV)M<F7=;3#AV8+K:E0=$4#J'U(U>L'.U2-7=1(8KWI]TXJ!E1R(0]
M&;:^QPU>IRTYV $Q,7.B87>S (@$&U%4-Z#TJ9H!TY[9LV-)<T4S@OIL0[O#
M-L/C!(*H2@=9_;/+%Q\YTV0X^]1/C<=R.)%WU_<Y$9/_J/IX(<(=KBOO9RFH
M1S)P4N=B2E0D&I0)MQ0@':7AE'!P\A<\I(*F]X:KV'#T+B4W/*6_2"J0QT9*
M^ S;O$$UT$#5"KPPX8/$CVRN4J2:^A14\?@O@_#*2Y/FP7.&)PA##6JD9B\9
MHZ48T!QS:>N.!HTPGV:ZH0;NN&]T6=T 196E:\4/[M/TJ?F[.O/(J%&J(1D=
MYOL->WQ6)AV[J3-LDAW?%KU6,\O6FZ+:CO-H">7N=56X+>TVJ[I":WJZ96R8
MS<N.O"^Q58VPF6FVD'&S3EA <G>9 G4F28HH17<L*B(&G(\H@84PL,VWP/Y2
M.[!TB?)R,F829&,M<6P@N\RT:)C]4HNO+J0 5_FF47[DFO F0"2<V30F44+@
MC^SJVX3K^>RU(/4"L'A*:34 RV2SCQD21YM.']3M\1+?!E$HI"J,10>R^A:=
M%6=8O<*"]DS=([J##AP#DNA\\?22YNU1&X)(;]1:)/>*,\CTRUA5AGPYW5<U
MD/4HC"I4%#M#V_OB&Z&,57['!I_OC3M6QE<J'E1^;\8!IUIWZH%A(WQK0'O&
M17]29)S[W]3,PMS)MLK#J,*1LQR@SSXKSN!G(>*]E_CG.\+2%1$]@$% K;8Q
MEG>=+B-IB\XQG5SBK$TW^;*/Y67HCZ\6AHVT& T+@'"'5+H/6!*=_4HO95(Z
M:WJ#?V!0_)X("2G)T'92C;)P(<[^H(\C <=\N,IZQZ*W(Z$S?+31 $,; SFP
M591<M8K&+ ZU74S_YM7+LA+]O __9Z1J5/]PD6T,UD.&EPIS4LQDI+\1UX&,
MK]&.LP$-L79O?BXI24:;.Z'>!89G,7:V6=5]]Q)[5A)1D;O'I2'4D_8JMAX,
MOAN]3,(8,K=Y?(;X]'*)]IJ-XABC-M%L>FY,+:I*K9,)IZ6-/;,:TRYKVLS*
M[*9/.U"MYV@Z$J?;'=UJE40S7GFXG//[W9H?RP$;MXD3%+"HJ-MIW[2XS/#-
MM5(*&1.I_A.8(J(E3V22 ^K2A5M;[6*LS=SP5;C@Z ;C3]<YIDA@EBS%LJ:N
MS[7_O/'^B1CR:"O9E-/+&$[@/@VP&0FY)P$Q>_;&XZN(Y[PK-?U$1SJ_JGAM
M9,%]F[:S!=V"67YECFS+<TJGV./]_!,H@+7T[(;M60KY%-;<^9A<*E>_/='Q
MPL[XE3GC#'2S8)4H2"SP>%" /'V8])^8N]*[2_U)\><SF="&&R0T*&+G2UB!
M6F<IW!(G@P"+8(:$'4H/:NV6IX00DI<)V,O08N?A#>*GY>55/L^%QU7$RGVN
M/]E<;1MF&2)%[03 :1EV&U2$@MP(7D1OH6/DS#4".3#467V=Q<^T(H@,Z?Z"
M@>>S15XONG5##[3#)/\QX0E/'I[@"9^[=5.B%#_^PI/AF\'&PUQ$G*)@=YDB
M(CEFS4>P<"W"Z);K*.ENR;?VRRK-,QX\D5/_Z#R-D/=BBS%0$S!Q=S^X4!Q*
M\0W1K61Q6T=BBH?[L\<4@T-NG'$1?Z^MHG8("N#Q?&6%O%M7I^)]MT/4H!I/
MXF]S;U>AG<>/'Z+0%U:"3<#^2\0,_,9U-!Z]R?' 2]1+A:P._DKH'3$B?L J
M$0!,+<39!DEWN)%Q,H!EHI')#*ST"S3%WPS)\$T8@@$BF5/\R+C"FRF*:B&N
MMD0W-.#$7Z\K:=%*1M,V4_F3\CKGS2!K/KRU")(['%Z,KM.BRP8R)(-]QG>5
MYS8@\,)7V$F+OD #&0)"LA-X.0]+X@ L^+-X4]HTL>@^7=-X']<7J&X?RS(R
MW0-K-29$]!K],Z9NW\B")/W9P'6*>2*+E&(PW^L;+2CQ"?B\WSV>/'+WE$Y-
M+R(Q.#OE-H*CCXD#(Z^7/! ABZ@F^@.?=<@GT:@X[YZR9]UPAA;M)\_?B*\M
MR%P_2U1:QU$=H^! !W4D?JA0XX2G66V=)WW)8T.CX4NV3+3.Q=>FN0/++%TR
M>Z%DF&SR./!?(!K*UD1"BZ#MUA:;P> :'P8TU-^)05MV_AAG"WGX+5^ ^3@
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ML;5)IL%R2JK(5VKD"'TLW3>H;=7.I([8- W9)<^X! WFL0BW7VA6C(.M'/,
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M=J^:/7=_H1J;3+' .K_*Z= Y93M[U2V1O'O)O#?N\'V=A" 8Q\K]]>_NML"
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M[>8:JHKN75V1UGKEY#M?S/1/3 ^B P0)E*EX_':[X>!Q@V&G.9J.K]V;+V4
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M8:-*(=F,NTZ:<6GX7)/L'&P"8!0D(B,;$S$6#)6L<$C[80)M&]R"<N06!TX
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M05X[$(4#\5S$+ VL,B$%R+B<%$XY>%*2T%"4E_(@FNM1#M2IW!M#("/6 8/
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MA74B!I*"K]EFIW*F7;S:UY!+)^[YPN@]V7>-ZVK?N*0U6@,V<=)LHKI'L B
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M%9H=I\NS=?%"K(*86U!A]7<A)#)1[=CGW">G:0);0\ZO]XW@]GZ%LW/A S2
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M1-(I]OR\*:E2^GD%G5A-/>SAI1QP\*NOO_EV]I1>TT,O.E^TMZMO\LO.20-
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M;78WR%_1Z#6YFW0'2@-)<XINPH](XK\@1T4@S3L$J/34\E+JTL-.'VNB(5,
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MQKCJK@UA6ZN1+*96,*U@]Z'Y9%V+W"#=KKYDQHXGH?4.G62KW1'!(D$[*A$
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M5"&VFP3N,,LNTFJGR./ 8!A\<6NQNG3EN&*6M+Z=+^O\\MH<+^.TB5KD/&I
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M0^L0GJ,+'!X<,_S;NKQKPSS7&W;IH+%,$(H(]ID&D:MP76ECE6HV"B^\E%P
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MT19!Y 76&&?'(B<Z25=+HMHYUZ2^&(&UOM/3^GT&<#_-!*2&,-VE]E ,%&K
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M[-PM>X:213W\2&9OE2PG=WPWB3V6<[.UOVR!!"CAF@04 )3,^]=O?^?1?1H
MJ4?\D!).U<S$% GTX_3I\_R^'*>%&'R%$\Y3P6WUWY>)@'3:DVQ30SK];5FP
MFD'7"P"3<\!V6 TWXA1*@NP6[R/H$"X0/R9WE_>Z,;==7#NXW>:O$*"@]!LU
M%[DK:^&C4\[\_&<^C;)1(2Q/N[DL";RJ]@@("/>'&(:6NVB>C)*#VQW^$CL\
M=0;G66ZJIGTUU=QM;>..I!#,:@J"VP&,D6-^0L5-*$*.<K1;#^,+[".?F8!9
MJQ2I7%W4H&5OR5W[$8A'7[$R_=X:I"4MQ"<@8_HFVY.,LJ MH42SL7![GX5$
M/@+169VBM\<.SP/].ST_T(^ZU0%?0G;0*I%R;\.R#&" +%*$"AH)3VAH'1(=
M:!$G/A? U$RG^9)3^"IP<8\I5]ZA]:$)DH ZDXJ"88L\*]*M"'R%:T 2U(0/
M[^]UK<WPE8?;K?DB-A@U",[AX5 SCP ]D1GV&[5'"LCB=CN^Q'8 "J09+-J(
M7!7Z","3$J(+V%;;;?HB08.:J5.!2K 8+++9[L.7V <ANS#P)!:'1& 9../9
M1P/J(^G'1!\+X!/5@R6'$8#<QL+ [47VI32G"1$%#H0>5T(5*4^SW=M=^F*I
M*F(OI-QE5 (^K8LF[^'$G+SYQ^M7.^,7"9(;^0+,X9UNV>W.?8F=DWY$YY+C
MS%!S '!EIE59N4T)I04-L]MNM^0+V.Z,\72I@'=2D3OB(EUWOKC(/J6^PVX%
M[D/IPNMRLHLY+#ZDNX1%,$.OZL]IDZ6_)7^;5Q,GI:<Y&O701$0P>&76+=J/
M&'EB1%H;C>H"TA+&?+[0"G-"%V%K,"J=H>@F_;::N0N(.W+ TLY%]U(^!SO&
MV2?HU*M*Z<#&5$*)3M\_:_(PV-WD95VEF0?[HYHM"<)IG39U?TH,+6 ^M3<H
M&.]"SY(Q).5'0P/T'=(7:=..;.1M.D\!5<BVDC&UT#IIU@>0746[; TA==B7
M63472H +0OJA(4D]>]&N.D$&/ZE4'A%@3L.XT+@V"+U'7=UA-,KH<AT71;H.
M2->_.Q"R"(,- ])J7\S5+8B-#0=.AX#M'AWQ6_9O_)HG11 A/C_G:>;!:PR6
MLR(^CRR\QE6>?B!@-E^^PB6.JOP8"2DNC@N=LAYS9XCH&F<^*PC=H+0HV[UW
MK^.S3J=.[-R7YYRR8F0 ?OG:<KVJ7K/#]V:#K]/A01U<Y=ZCPA4/2#7N466B
M=M2>"DCEE,!EJ1JQ<"?!++9N8Y9S;>NT"-'%+(<K8"L<^12NEX,A&1#,'J.(
M^CN\FQP/B5Q#-'\RL!5S(T/Y3$S5GAWXB)N ;SBRD3+1,R67!R4-X,$75>,9
MM^AK9NB GT.+<D!RZFI%*>NL M)G&(3_J10+BF0+&"ZW*J(]==HR]WFJXCU)
MFP++-0> SMFYI_WI'RKJ(:)#/W"@_'S+*CE;INBES'.?]?5#$D%9]1_!D0+K
M*G8EZ'92TH&5K^.Q3(8FZ/F2^I*S;FATI_FU=*<1[::0*L*&?B@Z@'2IWQJO
MO3_O#EG D*##C0H>5+RF2TK^#M0-!=.B(ERW%[,Z7>0&\G%">-(^PH#V;\I[
MQ*W#/X2"!]MW>RH!I,.]0XV_GZ;U)'5KLO/FXSQ?43>] 42-2!RB[+G;I:G/
MC'*IA)@S5/!"C_[^Q +7AQ0[L^.P3>1VS"3BAW:*J@M)$@%B'% O.K2%@N:W
M_A[=\J1T"Q+W'WI!XM=<O6'UR@EE!D^\CK5XR ;CLX=V&C![B07#)STT&6?4
M19G?'YU\>\.;$9DL,++I%?,P?8QZPS$@I>.XN5HFI)"F_X/&&LP>Z"(3H%3_
MHI'A<.JA&"O"N$=D%P+%I>:6R>T?,6.<0BA!72$?_9!QPW^-(:='3#XI<-4;
M[A<R_<;?^5N&\%)FR[JD>G.] 2<K2P@C4.M^1TH3&KBY^43.JUJ<8B.2)PZ>
MMZ:A-PG@96/Q\H4K8>A*,DZ"M,"84=_6>MA-7@5PUMS7*T@4J;'.HN)<>@/'
M<H\,#O0NEHR:E<:4,8QXM[1=F[!]3&\;88KJ[8Q&DK7F&+$K7;<)2Z4B+8"L
M*H!$8C/AZ4R<5%>7P;'C8I^L0.OBDFE=/-6(MR^*.CQ1-#KK:*:%8&,HPG:1
M"T"ECY6<6DHAJ#/H+0VTTX6_::C@-KMO+:1B !^V3$+3OJ+?R*_\")0 4]"/
M4P]:&^L^0:SU-/%R4(=F8E4KQ9]N%B 4$Z\/81;9GXSRH]9IL$4?=*"*@U,%
MKARD1<"!Y,5_))?FB@2[*'F;5$I&U%O@2006>5N#_AW]/JQK\C[%BP5;6CB?
MG]3ALK;AUU$0P[8FP'J^&16IT$03W2^6#.7L1<&66_/@/^2FRMX9.(4 V"MT
M )M;,GB]OR,7:T8A^)2(W($5X*\*/S6 /O$]S^_#(W-3($8,O^'546R^2SGN
MU[IAY*[JZH%<X";5H0P3/9]TY!G^(I%CI 4*4QD"=1^<CVU:V2N;:8T S;GQ
MF[&7%"N-3222)_J6>I])5EV53CSR=.$):QE6]I%;)AAB98?FP#-U/?9 W8I0
MR2\9*$4+&)9L>DZ,)A-< \8=!X 9$[D);HD?!/$*DP$H3&)A_9*4BT,5B_'Z
M(6@((&"K*7;:T(LI$O:S4Z!O49GLKK]_D*7YZ.>W_WC,9L]H[:'_RJ?<V6,5
M(<D&N:M* -WYFYBO'<'('1"C+D:()#CT81P[4#>==Z;,SZJ6C _A:=[A,>J*
M[DR8GLB3<CGSA1#GW6= N&>*&T8ZI06?>SI CX5@&9I4ZZC.PL\$TKV1U)='
M>?5R;]F9)9AEEM<DPQZ&[H']YR\@TT9C8JEW4NP:^_$8!3YR[0P;>VE(K$SX
M.B?"YR7!]QESF&HL2FS#G$AY]2'=6P"*7])QQ'RN'=)BTB(:)!$YZIU-84JN
MT:X$@YBS:@@B?LQ.[UN5=+'&FX;Y#K+JPJ8>ALBBASC;%'!%9$IQ5[Y+SI4N
MH3M1.;8,0)L+"9,R,Z:>]7)639?,8;(1[X,)A3R1LAPDPK3.%+>5#!E&V>LN
M GG5 V:-\#D%(RC2=H-V4($4L9-0;W$*"[.?+QL%RM1T#E#0*+:KFI-;Q@JH
M%$8F8_"3A4>X]D70F,6 )SNX4I:%MY.,H"Z%[G2PK.=5Q3!JXLSF21W0]Z['
M8E'WST9<9):>0L0K*)6[XB(GYG(<H; VHN)L^B*B-C<K86@)!XFP9378 U)_
M2Z&?),(L;!E6ZR)"X\]\..PTHD%YN,KUJ8-'?=0]2F:VO^<*].3BAKY/#^Y0
M8EZCBN9BP/A:M*)4HB45@MW'KK@F#C#J]^:ZN*4G] -/E0O8*4W?(/@T75/.
M#H>;JG"I-G=9.U'@@I;PE9Y''"Z K&#M[8TSP)25+37X7"D:BKPVJI4/-+K"
M'=D!BJ2(P?S!%$?]ZCFQN8O2MDF'U=+.9U4?XFS%R4NKVN6^*@E]UD?&(W@@
MCS<!W'RT\4T5^J538A6!ZD-I:<6-TQ%I03Q#-#J?J2,.Y#BZX 8&;B+"2#;5
M1('FD#M5S)\ZY+\$;ZV<.*E$,A3;BO+CE%.-F/^8)YB,_$KX*UC%?8H!C@P1
MIB@#P^]*XLW!,RA&]VNZ]U*B33J%;\S'C.+?2 8.Q*ZV&;4XHW:PS:C=??6\
MOA4SQ</*6.7*MA2,ZR#;K&O/ N#]R) .R"_<8;QTKAW\;^>L%1PKAF92I3V4
MDGD@"OJM2<%@#OM[^V/!5GYSX=7EZQ('A.QHIW631_0M_.=C3PS"B?E_L:7(
M*.)RD5Z(<G8Z '82] ;_!; (A)"!?S@7IG86#:MHR\K M'3XCE _$*-\XW>:
M..>(E"\KW!-H5_D6+:%S4HI^#T[S>_FIS/>M7O)FCM^?OGW[.-;\=!L/VPSP
M&IPZ(2WKQT55,%Q\L"P]"NEU$>N'XI730ISF%VT.K_-__H_QT[WO#O9&6. C
M=C//SA"A:*UCNFD)828HX1-S65X,[1WV:)3X/>*#ZOYYX&05/C1=Y[21D,ZC
MT>'S _>_A_+J47(P&A_LCUX\W?.?X 'CT;/]P]'^7OA4 D-4DLST$4/3N,T4
ML"A^"LY]S1MQ8(7.9MFB8)>,&+F56>!O^'8$E.I+"4FHB6MPZL.K9<5X ?40
M5W!^)$M0PF1JN%(N3]VE_O>T7*(];>PN?M[JH[_PNOTE7JF1VKUM!;ONVD';
M2;L/7^53$J?D8.P-:'>TB<S;F6-S0"O4Q#G%M8NH^W;?[KW&).@EUSJIW%(R
M[;KHBMWDEY+KQ@?_G%!U/F\198MX33J1%GF?9ZRBQ1>[U>\!+2$&/>J;_63Y
MAN+](5<BIB38[!T\#.41=4YH7&OF;EID"=SE -\3N;_S?#Z3\ENIEC4EHB7"
M8XOD=.<@>23M)"B_;R2]6OEJ&%;>P?;MF<^QHC'&.3V#>.1CRYS3"%SZ841-
MXBM*7PM+^+'-..+H>:6HSU8J.II9QH6D13GBT""%+]>L0&.6X+DO4J8G1I=5
M7T5I !4J2A0$7:BL= C8PODDW@:0SXN@7N&!D0]A%R[26>X%C&ODC"[$N"FE
M'FY&PPX\]%9ZOO@3IOI:YB3TK[,Z1WS"F?K>893R;+EBEQ="B\Q)";,1T@Y#
MN0%-XP426.S4#.CF 'JZ/R?J]OG?7H04Q,1N!HB<,UEX/UW>,%-*G3L59CBA
M-8TBU]CZ@J0'8OW^:B/)W12 EK,P.96J<Z>_2](%,T%[,?&#40A&C#CZT.CI
MT="%8E5+N8^8-%$V0O;+# =%>YQ0(OZ/%6=,B1WYW.RDC@@(^TV>\T5$HZ:&
MITC7XN23SRL9L@#,2W._J*OS8E)0Q:X JJ_X\HW>J(2S3BD"Y,AI5K1(P?(F
M.&]%X=4<K>)\4GP!/R!]S18^*U-]K\R5Y$TCQX&L,PS VEJ\2ESD3Y3E Y+-
M=40LUD+-T[F$2?,2!V)?WB,?A0V3HGMR0G5*F5,/#X*\#U9]O"%2!F?U.$&<
M]R.5MN#N"G$J&^"S,<]9,%4DY=;I/\@_HDK,_KPH9TZ[4((;ZZA@!Y:TR?3)
M8VLJIX\>BN9AQ^F-LS&#VS1FMVDD$0QGJC"T&'+"%+[P5BE[*\[XCG:$6>ZF
M'*(3:BXLW<&+OPPKZ?<JZR/)=T:/(W.,Q#ZD+,*FP+P2!"MJB0EA;0W :0UM
M]- .YW6(9C(U+>\Q5]]UPC=FBZ.$Z,#(.R_12D,RY17.R:XEL-H\E">1E=9G
M:5G\*U437.G#A?:.AN&+///Z#%E/V'GTF?-%6A-:7:3_I%K?^J*BO*D)]4HQ
M*88K+4J<.4:H@,# EJ6S:P!"!K,RP(I2<7/E7LBO@0G9>&2/OJ$''BF\8^8L
M)?+SW&U&[%$3)DV 6>7^ TFK,IQ5LZ /5GU%.9]!IJDAB_&/XV&=ZL33J!'X
M1I&8H:6Q&1;(/ODXH=^9JI CPFB%P^3('Y\]XNNBPU*'W-B%K1^5??"I:A-G
M=<Z^6^ ;!I."R6LB=Z%'FFHM;A*,XSS,PAD5=3>'&Z6(C$;,@SX(KGPORT)V
MV?'R;.F.'ZO^J^ !W\#C[=8NA>3Z;$#R;79'JIS2)IA-4=+>#(KJ"+A6 ZD<
M'MY-G%'*LK/;-L3QYCPRQEF,PWO>S]20L[J!O,_&$0Q!K9N,QEL<49"&=FE0
M"UA'44KIT[I&/4 H%835,BT8.U+BW,["]!N.0)C2Z6[(%9!.QF3;.=N:$O[N
M[FXT2RXL/%?Q#VMQ&D(<Z,BSR]N1*8VRJ^WO5J>] KP!/=C:>4LNG["?CQ!2
MD_G+V2_JH>>/^/"M.[@15V>O5Z9W.H=NN?7*^$^:2CS\@Z42)^GTPYG3K&6V
M(PLYH__Y[LN:[-&Y+OJ*.ZHYY08F:-]C?[[H0+]_]961>K[YJ]41CWXY/7Z<
M_/CC2?+(#IEH^;H*R U72*'3Z&AJ$%-YH*7F2I22+Z@EU/,H'COJ1V%'FRYT
M=PL)V>! !-5?W\L+/.S?G)#N[K%KY19R3MEA<S^;F0:G\?Y)W:\2A4+0KC-L
M!D= #Q#FQK,^V-W[BV?"KM%LPR8 =8'EF:^7DT6FL*FY.V*!W4T^M0$I>IZ"
M(I08%2/2^XIXW^CA6(;WQP^XI6=T7'*Q$_FC9,_+5 ?=2*VMMO6Q5!'$S;9Y
M=G_68>-A>M,#K74ZI/1+($VCF_"YG!S^?>GL$R1.?5<94A%*XE!2D;5SW\MI
M)X[<B4C0.NH*JE8;W)(;#(O8TU9:S*6X#E$!'>,EW&K;"\Y[AFVFDUE$=;3(
MU30SUDTAR#WWY3<I<K699\;8-(F9S(*A8GP-:W=(6<Z,SM25J+%?[<3T$XD"
M0O$Y]V'K+"?P=75=>X8FN7&B1#R:27(,;22K*#_Q=6Z;G,2!@L<)UY302H78
M*&7E!A]$,2!D)&F? ^18%0.Z<E.KMH3HDZGO#/DV-L_OSY&]I>IZBY/66-['
M$%QS@@\&2!.Q(_>%+KA7SNZ_@JL%$!36]-Q54T:Q-1@0#2=^@U3IMFB8#H'*
MQ46@,>Q*6YT[KW6:<]ONHKK,H^KT$#:_/YNPN4JLM^04,Y5"<X1W*&L-7Y?"
M]V26P867C<&ZDGDIYN,[_<5)^(48CX]#T\G0*R8K8.<RE(6/DXZ$CKJJPP;Y
MN&RTMQJ4#0K2MZ'/.*2=MOU8LIZ;Q+-#1""PMG;7/9'MW?@AW";B&7]0S%)0
M\XL;[Z)8+E3=%'I<U2"Z""MOL'4H+R5U,87>,Z9@EUXWX7M'X:7357P?</AC
MK8DD8%:3U48M.9A6Z")BQM.@2'2]Y$:&:,L ?/&)SA6C07P@&(&V>YAGU?H'
M+ZCP*+2)#=0+O<Q#:'B@8*AHR&6"R&B0*;VX -N77\'X'6;4;9XN!I:,=QZ[
MA[2EA$;,<EVW6GY]-K[8W6QN$\^$6'-@&%JB!FG[=HN?^V7XQP8D#&UT%/6D
M8T[)TPM/K.E>N%YXN6RIXDR8^;BEL"Z"=)>I,V:G*^Z6X+HYB>I+,8/8<0//
MKC06BRRN%$%D[BGG_K1*TLS_1L/0H@&:6( I-##)R306NYD&R4,L<E^ZTA_+
MEG/KZTDG+'2JS_"!L#K/&5@7+O8)(>R^]O_QFF12_^$^IZ 3U4HR&"_*6<65
M.#NC^!H]<8?*/ZEJQ!9=L"%@L]8(!'3THMS^1A=+.U;*V5H#0;*5K:\F6STS
MC+N[Z;;KE!JI!+C+%L694=7 5/M")HJ&0'$G@R.*^";#3N1<>-3/@&\W_4NP
MJ@[MQ%!A!^K3J2Q]OM(+RAWIHF86W/57U$B^6N2S?GV-X.!:!;#N*=>HFR%3
MC"0S=L!9X6@IAT!0M8SS(-C>$=&$N4*WRNA+*Z/;^[M:RNC,]R7U=D/6+BL+
MRZL%28/B13Y>TY6M15&R>'8%+#;I$)+,"N"B;$7D*]I"'!?4^@>)76CTD3F:
MUE6Y;;?MBW&K"]2?+>SKYI;:!!RA;?+LR&?7Y"A?5%><;4(!HW8]G>=EU-,4
MPBSR*]\O2"@L4H(H<,XYAA#$)7S(\1[OCLM-<WO-%!"#(B7$#[C-'?,G+:\X
M>NCE%5N%<6<2M\@:1?6'YOT$LP=.BM+M1$U\B@W+$?2:,NYH]%@4Q*?CEAY.
M\Q(UO81=H:=22DG6Q%LJL1]S7SO-O!#<&T6(+=P 14W(=O3"IZ"F=F34A@)D
MX4N 81QJ"SD+A0Y'1&@ 0+WDWHXTD7)E;]^ZT7TL<F.@D#DCO_>4#N@=:.:B
MJZ()AI"YA#HEFBW\AB9X;^"3MWQK7^<H:'QX@$Z(Y#SGD!VL6L@%^I?J3',P
M.5*ZP7[UM?JQMV6Z;^?%AWQ>G%=5E@B)R("$XB!H%+SOV[W$H2(ZN*W ?,UX
M80P>P0VIP61B/([:PT9(##NTCI#)1>UCM*_0AEK08^@U ZJ'<*&1+M$:537*
MATSQN/,:Z-8-C]2T*WE0'!I-A/&4.DNR:8MY4'P/).O[4U7G%2'Z323E)6 ?
MP9QDE";-K(_T"V?X61G2!['5JE#O^WL'>A)];OYOPN)X8NS5'].KD"E0ISI-
M)-IS=5YAO>E>S3].!1-N?.1[GJPA'IG?='TA32S=ADR!A']0#'K)-W$J-&X\
M5,2R$7D&FFDK57.9W%PDAR$9''+!4LM&12U3\39N.]I1LF2< HY:([<=QLSK
M5#0BLKF@1B%O.ZV+";%_ 4#J_@C>'?H0[Q2"@6W6A'K!$[?$U$)Z<@YKK?97
MP6DK3_"26#22^7(:I$'LQ@F#).JUIM^S.VOA_#*0,?=Z)?T89GE&(IX5W!4#
MO5*WOD+JEY+:O6A H?/ZNJ%H_0&7NN@K#-P!?,E8D7$107>L:A?VR:334/Z0
M_-,I58K4AI'XQ=##(X58)K"EG8SXDT<!N#\R>6WIX.TED +:LT)$T)_AJ]PW
M24-)U(7:M93"M6%!)"KF!+G9^HT?W5:4K1 Y"SV7WI6^-"W<124]6Z&@!8"M
M9-TK+#[54+>>^7))U1I1MD1/7B;3+F9\+A"P+V:W';Z3+!0YT\4M:.YI8#-W
MMMT'[H;A?AUVA)R$UD4C(,FCZ$>21-!I$)6!HDQ)28J>'SJ9[IIO;=2V-\#=
M9*UP2 R'";'$4[R;(G ?'CNU[^2,;MAU^D R\%6 GR2@ !!YH8I3Z#C869,R
MEIDNC-E0K2>=K3O"(POCX;Y\YHOMTIH;@M9U)#&.T?2\DOHA'KNQ$!3_X +<
M8["RP)3NMPN>9,G9%(S0<$:X<2[;7N7"]UH,BV:HJ$QVZE:$%RW<TM'&-\JI
MJ\ML9>J!J*U?@6,P)^3WP4HL[AG70\PBRK*NX$^4LW+.F=#\"0X"4%)4PJ+"
M2D*5';Y^\(8IG?;Y7(M1W$5R1NA;%GME9,@3@.5N2(V+DL6;0?1]W:=>/B-T
M,0J">IHY[R!JF)NFC:+=4TD8'IS1(6NFYWFVG O<,=5'5R(F))^-  %6;1Z?
M%8K-+&OG^]$178 ,9H=%.K#T:C'?!J''7O"%'(5I NMEN(XGM1Q?DE^ZF#O7
M,9<#ML#\!2R(O[777=/7'74I*[<'/L95'(P=8<OIZ';;B$@9T^B%H$<)-?PO
M:'= 5\S0R)VWI<K2.0RCY=FY0!'D<<:OT@)VL8:)G-Y M(Z&MDY<M::J7BID
ML"%*Y/)(4G("I "+<5F*008(I(;I!'):O50N$V9.5A5&TPYB$#C"Y0NVB,5)
M!\A$-@@1(HMQ9;A:<_VZ:!21$9>U^]-\GCL-28>++W_I%@+.S6[RZSE\U\A+
ML^K1LJ!1]2SM[OI!XO>S5% JG'==@(0F\KL]>(I[)YE+39Y_6"/YS'$@$#+G
MZ.4@_S^3(K2 (MR]+ <6O<XU<-IOXNAL5$ ZYWVBZT:WN-!1\+#LK2&LE2H+
M>2UE;3P 1+96%QKU\._BVA7GY05P*G<FEJ67D;EP6!;K'[U^_G>OZ+[!N)0H
M:AH!#[G'+".^!&$F;YH*Z#IYYE6&*'KRLEEQ!2&/UC5V;0Q4<:^EV.(MW9]+
M_"[^<+@2M!RY1"N0)]4!UY8H+G43Y:"D'Q%/KXL)W01B$ O8T?U9DXV&S2]D
M7IXJHLO!\WV:Z,%S'U-ZK4QS[X0)Y:1BK+GQB^=/V>(0D9=S$R2;U/I918NG
M/0LAIL<&Y4B[79D1@QD19HP B/"4J?I0&H&9@'U#3QWM68 DJ@]ODD>3%8.J
M/8:8XR84-(3P<MA0LIG1U4=(/VE25U+Q'VHD.7PEM4]ADD.F!>2(P_/YC@RZ
M+U+)HY_?_/@8P?MZY0XZ _T%J%[SVXZ</6(OC.KCW<!@<KLO3$'TT#:/!:VQ
M09,=AN!4@GF.*!-WL3%N2/JQ+[@>I\(:C$YW;_/7<?[ZZ4//7W_-U>,Z$ )*
MZB@$W_#LOA 1#AI<U^YO.D2+EO.5.YB+62!V%*Q<_XA'3<40H])QQ%\F>EP%
MUE3PO6K^>#<YMH2RW,4)-$,ZXO$1ZU&5Z 5C#K=3 AT=$ XP'?3.J>U3+QK@
MS=WD5,S;.%7 $1FH"?B6OLW2QP9"#-.',D3O4KI(?QR44&<5<#/(4KCO"&^P
M\X=EZL/L['A5&H@,B*XS\"CUUR7HQG@LL<TR:*B(6!#LX@RPMO?G=KZEQ7)B
MY-UN9W?6(7#L^]GNSYPW:H;WWE7,\G3NTTB_[)[NJHLY$IF$1,PKL/#)X<!9
MX;A"S:'AEG.*'$035B$$:"B+I%'9X-W,@;LCUH80_M)+) C6,X5.T50A92H4
M:\0@W]?$U+1R?A[B+XP H?M&M<D?V3$6H&5584S%>HG@B=,TTAEM8D2/UTDX
M[_5&%H4(ZJ^2YOM#!4K$T-\X5?RR.$M>YJG;T=ER[O[E?#.$^QZ)Z?;FY<N7
MQ[Z_%*!7\ ZU064>THLY^KJ;"(9R&N9/BT1'F%PD5C)8$*>]1!/WDYWX!)03
M*O2!!-'88J&WSBD&D@$$,0SZ**Z0LI&2^,R]K&F+:;"CF&@L\-CPUR4!CEU5
M)TKT)0\KRZEPAU67AP&4WYJ_4EZBJ-N56JSX_O<O7[]_=2ST9& W<Z**O*9^
M95*5RX9[1SUB:AGH$9B>'5$238AR/M5#S+\8!? Q.A0>IU=I5V5*S$S56V=R
MT(4/LL-4BHJEPI0\,AU6-3-40KN@PL1BE6E=Q)2-!I?77 )JJ0J&F8%2T_.=
MU'KRU5/+M*Y! U#FRX(BR<R GM0^=1<"=<!YHF] [Q&+([INT5;LEI[RTR.D
M?%<:C6$9IN6@H ]PN7GO]&\4OT5)S2H"J,"$"*REBR71*K7<Q--1PF_G:!?.
M4TX-#.X_4NJX71#@+Q0B?1)6B(K4O6X913$VVI_EG/"6Y1JF(TKD\77E+OHS
M.H1"=8"/[94:D55[Z'ZQIA0G I4BG=PG#<8F%J1&N&NT"2N3S_.[K6(1RJ,B
M/X2A%]2762<+#@IS\D+YLWDQ&*:]=TW>N]MOZ'[G&J@LGXI"^Y8N+GSKF[]J
M2<>[HOF0_)!2=/G>S.F65@Q \"+Z+,#A-VT-]/!TOD(42YE= 7O4G <=33CY
M_!G@0X3)E0)F(4(?-/J$6@0B"K\N%BE=W@+C(ECV+/> ='2_>2A8R._/;P9'
M0RK=W2@YLZ+!1E%LG.@FK'.8Y KF<,UVZ9[P@@?KTX<(!3:G* TYK\&8NN;Q
MF  S>A@0>/<?3.C<*5Q5#NLT"WAFPRLA!1RDKHDP[RQEYA5#U'A,%^IU Q3>
MT3 F<@UC^@M.^NDO4'!%7\9J@5W[S TX;P8I%&5U2:%]$IF7,E 6[]=# VW,
M4*<Y9?S6+#=E^M-B+A2/>EY9>"JJYN'+J(8%D.4+RFU:?*%PWNAJ\8DP:LP?
M!A >.+14S'C?3NPM%>,O9D/)3G;+=,8@3^Y20/GO--A=S2:7=XBR-%AL=!D/
M&6SW9N&NK2(:''\H+NTN"N>6),ALUU",D&B5F7,X+!RK4T0]G"*X1$Z( %?<
ME"GAY[<&QYC 17J&DS,VZR+G%&3M;G!/O!;V*1397N5HL$8==WQ8(G"J 5+I
MM0!9,".5#A3U/E[&I/&_F'E8KG=D_,Y%B=8^8S5C8Y(2GJ&J09 @H7"\_RM+
M"%-:?[0N1#%9=3VKX126\*Q3I?$Z9ZT*C-?A2TH'?2D+ALNN)/2#B-ZY$UZ,
M^1-XKEY0A+G(+<K<:=IZQ QY"RRGY$ U>=RP=&85QFTN0K&C97'@IN7E95%7
M)9.?L*]1-?;=A/FY;"\(M(=H#5 %H'RM4)%4*]1H7(TC76G3:CX7] 13_!LW
M&@D8-Z5 7Q)'FLB]CPVBX$-,?%DT<#I6#>!X5B+94LW5+"F.F!5-O;S@#"7U
M#"S)_9VG*UV[@FA7A!^E8CCD#L@1B] Y93=8$'$55Y"UR3PM";72G:39+&XH
M' .NLTS<*K9+SE<Z&P<_K/E5_LD$F1K5FY\[O4(Q17YJ3%VDC^ :9ZX!6Y9M
M;<"_)62#]>! DFZ_?(_'3QGW<##]',KX%2&(Y/[C?;U<7'3K;QBUAHJS2BGT
MI_6Q3[?R:]YTX>[/A9.@)5'3X00@--$M9\U3X7^O&7^)C2B03%(\2JL7%:I0
M9RD^J5: <9"'+!HFBQ'S!W)X5G'<!J_#D/K</5>><=V&"4)GZ)7(5'B?8C.%
M6W)>+#12T%7DFZY0B8/<++W])\U\/=MFOCXIB*S$+\QMUI@ )QT;+\$-AYP;
M[X-H56Z#LPDH%@&!HJX&U%%%U<?SXK=ED5%.)LMG*2PHTM9E5>[(+4O5.NY\
MAW>B1*]HET(\4=ON#"[RA$1Z1JH-1JF>4JD"_*?897KTC1VGULWMPHT/PWH]
MCO;)[@T'J@?WJ+M!'H,Q'9(>;N7CA1_>Q]'&7300CQX=54.7ZT51L<LV?<67
M>8PB"85#LEQ0.2NYK[AJ59#5'_U =9A^9%K)1^;TB.]ADSL.&+!1:ECO-[X)
M=JZ0W_4+#J%T-S^LPF[&Y">R)\?,R7LP2DZ=U>U&G_P#97^KY*6S39)'I_]X
MR8D1="F'XND3IPC<QI5%:G)"F-</?J'>FII88HHNJ\O4\I4*^"&36B8_2*C;
M/0YWB/N^EMG9CJ]'/[QZ??(X$6,*1*#N+M:JSS0)9"@R3KJTXQ&V9(=P0FL4
MO?H=,^3ZW!?>1?W74Z'>9(\"D28,L>+4E%LA";LP%<J4<FQ </"W>X$X1)FO
M))5!W0Z(3W@UD1$ ?B*=X-9QFBTA(><YPSPZFP7+0GX4+Y-['<0<K!O.O 'D
MA+;Z</F,(? ;.4GA5G"\2O[:*P&+SU8M1:%D"V&F4:'\X#F4(N,FH>9:2:7I
M;FFEDE_>7@Y=U@])HQ3,<<3M%Q?5^@V7ID*RJOS\F>6O%EQDS73<=3(ANU24
MT2RD=\771T^=,J@6Y%.0]U#DIE%=R0W5IG1V,7?ZP%PUAF(]L!(L 9:MI3<A
M-+OD;-9&3#3T-KY+AZ<G-ZV,;J##2\@% #@]F4O1NG@Z C-@N"*19:.P9DWO
MB882F-N,51^[3ILB'0_E'E3)7*-[@MXAX<?IZRH?:CT75>)4YI)KU3QS1AO:
MA83-8O\HF0B+!3SX*BT%MG/0UJ&H+^MQ?^Z%OX=[<VFH)C9,JF>][419+,E<
M47@%N1Q4*?N6>RDVE7B\DE]U91B-ULZSNJAQF7&0B+ML]5R1,$,G*+D=G:MP
MSY5*8K%FH,1Z[F0S0Q!FOC*_Y% )RMK9[TJ=NZ2E]5+<C:7O\C>U6MI?5LG9
M,G6RWN:FA^OW[#[S>BA^B+]0@O9GG1"; 5K.?FGN.;E02$?1>DW<I4[+M\Z$
M(GN'I["2:RVKP/I+(3\P<J#S(G4:\,%T.D4!&:T="G9:#'JD(6H)O(FB,N;?
MJG$61M,+AU([0HA"&C4HO\7S)33I+W<)U/@*BYH;^C321G8()A+=3N1'^+I;
M9##<7\3GX=$5TXBZFIK+58;,O1].0.,NL*DP;A&R]T:$;([)*>- F)Z\YZ(-
M<=B8'<$G:$B8 MO:DJ\N?->/DZY4A/SBD:+RG\;*&P!\+(],K6;S8.3#W&D
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M!:27A=-3I.^8NU7,G.#L(</>Q;21+IJJ!C*;<K"RGT^:5:+QA!HBY(92E?R
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M6E';X>ISGNY[=!QO"SBU K$SYX4H5DY.'7);<(NU?&?DD[GL+7OW-#0%JN\
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MWPF>"O>FXWQHKE']($T ">9JBC YM*'9*\%%6M?R_$ 4>@R1=*4=ZK4AV%!
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MCS'C?D2G)'->)W,($>Z?[P^!74MV!E\0A!]:$ U&%PG3KZZ\APUR 0V4^NI
MC^%O&:JCD9SHB*EWYO.E)]FZJCQDJ= #@X4%B;&8*@1QLIHV)5I7F'C3*=7B
MG6&09EH\GL'UC? ?>6>((\.F%>H8 CR((O?JP;C1!6.&'UR_O+98><GD\ 6<
M#UVS1?:_OBE>I-.#PQ?C=#H[>'&8I?LOGAX=Y5EV,'EQ\'SOQ8NG_V_\[.B;
M^Z-SUD36(-G[("#A;LL<%^%I.N=3\/UOA"QX:KVG+/F%-^DM4Z$T-[1"GN(F
M1 8*_F@^:[\]P"=T?0$UNFR_W<$G7Q6J%#K".SJ_8]^?/XQ]/T">DW1.D_P"
M%I#3O$3S<MCOAV%A?JI]>SY^&/MVN)O\A-C$:3H#AVIHMOZS[=?AP]BO(^>^
M4%3R=7 [[LU.K75HA_?NT?2QFP:%'I/W$A0[KFM8JW3[WIMY;9R%$B<Y.T-;
MQSG2<II?N!V;H!%Z_'3ONX.]D6 >E(30'E70^PB\KPJC[*M4?"6/AH!IGJ8[
MXT>SQ\FPK?\X^<_BX[?N53^C%XMJJ$O<D._RF5N@G:??)&6Z<&N53[-O\;SQ
MWN1H[%;_F%OE?IBG9]\D+&+N 'ULOYT5'_/,K>.\R;^A4S7;>;J/4W/CU_Q<
ME7=_D[-_I(OO/Y]$;_QK]]\C(2WFCIX[#^]]O2C;FX[NZ6W6X<YO>?;-7UMB
M2DIOL Q)RF5</HN?AJ,EO5WL\:%UKID)T%@ O?*\8CYK3'8<RYX;O1,^=WXK
M)NL  (#YBX]QFW<V:P1U?>CI3QKX.%P?^+C-A?;LFWL=+G'+,]UQZX[DU+<<
M4UA]=__NVZ>[3EC/BTDQ<!W]]3];RF)XP:N=?._ L4TOFOQ;_8_OG-/H3N+J
MVZ*DE]"/.E/%,J-%!-E2D4022OYSV('=/=Z%MG;_F^F;Y<^[[D]/^I^_V#TX
M>#'XE[W=\2T_=T)WJU^L&].S@UVGTN_9H,;[NT\/GF]\U!-:>%Y\M[\0B/_U
MS<$W'1%HJXMO]R_:A#*^"<15W57W\<=DK,XJ;S0\V.[F\[[?3?H/CY(?(<9K
MI/_%C81?A#[YN0KZN<WN/N\]S%I6]E,M'.OJ>[=TKP),W@V6[H8+U/O:S25Q
M_+LDT3WA&]%VGUX3=Q=T^$8<[W;A\7[W<G[!Y9G-/NOR\  S1.K)&?R6K"Q\
MRXTK';QM<S[;W]V+02;G-4SD\[:]:+Y]\N3JZFK7C77WK+I\<EQ/SQ%$?Y)G
M9VG]!&1R3\9/G^T_??[\B1OS>/SB8+Q_M'\T?O9B[]GAD^S%X='SIP=9_M$I
M\O/6J0 ./AZ?U;DD-+C\1@#HQOOJD$V$"25OK\"9>SQIIH7SS!AZ0@N=WK^R
MP<M'OYP>/TY^_/$D>32CO@GGH:G.'._N*P +88V=[AR,DA^0[7/:-#DX.-C9
M?_[BZ' \2OBG[O7]5U9E=YQ29>(A,;($4>V"V G<&N;$SO78J>NT:WM]<>US
MIT/TM=3+OE$OGVREMNKCWJN/I_O/]Y_O[8_WQ@=/GXZ?R+3VQSO-QW$Z9@WB
M=0<=OK?D3\^2G_(:DQ.UP4A)O1,\2MZ#T:ZEF"K3+<GO3I>3Y/4H>5U.=Z_Y
MDOL65 RIGZHM2(?QSUB3$33H(:F'\8 B<I+=443CKB(Z>G9T='"=(B((H.?R
MFJT6^BQ:Z&"KA?[,6NA@;W__\-F+)^G!>&?_X./>TX_CPQ1G\:,4[J6BD*2,
M3TJO6SJ!)]C.&3>!.O7TVI].2:_W#W5?5QQT=,7SG?]M=(4;Z,[AWM/#I]>K
MBA*A:=(5!UM=\;ETQ?Y65_QY=<7^WH&S6@[48G$:X_G'#Y/5/+UJ-BB)E_0%
MS3M]097P*I]2&BP9'Y%:V-^JA<^C%@ZW)L2?62TX1^9P;_^9JH7#<;,S3@\D
M$H(:3*<5D&]&GPE! D9V0__X'WY*[V'\@MV'[;&^P['>WO9_[F/MKOM#?ZSW
M$9_@4_VZ"[WQ#D,R$<\X1(&3_,X387#U=V G ORLX;QK),3P9MI6='GS =X;
M5!3=>.==%041G?PYX@Q?-:-RN-LM,M@JEC^=8CERBN7P:5 LASONW!V.]SY^
M8.VBJH*.YSK-HCF3 =UR#,!H $3_5$SKRKD!EP5UH]L )B,\_CTME\#0?2:)
MCB$5<QBIF/%>QQ?9OYDO\E/JUB89<RSSZ#%IC^UFN\U^N(KTJP5AQKOC?]\:
M9@]<?_H8RA@'XNBW W<D?N,C$;PC":.>G!?YS*DD!61\(SBL%P;H\!WUMHT/
MTIWQ(9CHH C'1YG\*U1 FE1RU*'G7C-^<7!(F!W*6G$Q *1XL.=)*=>S,F\/
M]1T.]?[V4/]A#O7^30]U0+?9'NH_WJ'>WQW_Q_90_T$.]?XGNJG'SPE6[&37
M'[_QP='>M6?TQ=[3[1G]+&=T?WM&_S!G]!-=O-LS>I_.Z'AOO/OZY].O9Q_[
MTOZO%3S=8]Y<0G/[/R_?_8CV58*B2UX)N/A6H&XI4*<G_[45J"!0[]./55DM
M5LYX:7-BL4E.I^?Y(MU*V%TE[.3XQZV$;92PDW0^%2#QY,>B_$!(MEMYNZ.\
MO?K^AZV\;92W5X R*+;B]DG$[<?CEUMQVRAN/Z:3?+Z5M-\M:6_??;^5M(V2
M]K;.&S!R;E7;)Q"XPZ^=B/E:4S\A-I"WX.UZC0[WE!F97J5MRB4/CQ@I1@HH
M"B.3C.A)_'L,%>1[4O?&CS]_-[K^7:=S2 @>=VW!_MT]W)_[ ;]KM9X0#L@
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MD% :JD(TC(B0X> RV^9+N0(N%/]='6W@.[N!EP@(()#$0 JD0B&?D@7,L8S
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M,Q#!5F]J<5S9SD?BZ52P3P_W0]5M$+F!+#\RHM?1M 9!>FW_^0#K'GM&-(2
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M:D=KW]6<:A<5'[I(:-).!Q_+_;G=1KE-,O @R]VX'OUWB;-5T!2(]8C:6!%
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MT[0$0QMO^ML[2WU9QZ8=&!4/1@TH^.5')#+?+=,K7JY<_YJF>D%IU\/6HO3
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MX=G)>&6R/UH5V3W\:+R^L3ZA5AT^;SOSG2J62N2*F<[YIUI-49^JW(<3GO'
M@WB==@/+CO*,!V,3+[ZC$8PG=JVN27W9ZY[")T/X.FHMG_UZ]A(3ZQV71RMH
MS3_^(UG&_KAS=3]T\/5<KM]J4%X"K!.38KO>*@/]5,NUNHF_Z7^\W\%P#AA$
M;[$D/39O=L4XVF$RNN@PCU,%C7#B^C4&B993MU=X_2884C<,-3?'_>%",&G<
MDC<=)03$FM'P6,<$QZR]'RHI,O&L[+%3H-N,BUXBEH=E(ST]3Y?$\I3'#AJK
M;8^&3X[4+D%OZ>E?58O]_ :%_'I1]]OB\>R!D17HV72 _N"S8/N*'[*W4(N%
M' >P'9G/.T)^"0V#=8]J0WC?X?:146V;ZN55=(;^J 5>8\Y8N>M842&5X\WG
M%G 1)DU5P&.MZ6M#+4O_3J50O\:>4O65,[-=RWG?)E(=XMW>5SY=&9,S.S[2
MJJ>)+XU_L[9E)U+A*B<NM[NSD[(>@C\UI,O;]PP)*?[=)=-PJJ2V.LC).9E]
M,\1-$C>\7P;M37SQ&'%PW6H,308PCYZ%EBRWGB,#C93NWT4AQ.44#KO#T?G7
M-B,H@@"3@4>FQQ?G)2AA!"&*QR*NR>R3 6P1)8JV4=YX?S(P?*]\M89"Z^^1
M@9C06T353C)P+'"7#%1YDX&;+U:4[NC"F(A <%4\>'FHF8D,/(@A P<R68>F
M@K [X6UD@+-9N7#SA9>&9 7.=WZ:Q!1D<*11)M9;HN;MN$$'78MMUGYG%_IU
MGG7XX:BG\YCGH7515K^$N9*;S1)K_YOG@?)B@3QYGW=:WD'#NW+/9!B->BI+
MY?]\&ZG_.<>9$;DL?J]4[4%R^UK6B6OT4_>&]HU"T[TQ>.9QO.]A0I?>2VBK
ME3EGE4>_=<G0X:T#^9=Y+)5:O*214Y/4(^M6*E;<ZT?ZR;*ZS[B)*[_@-#]C
M5YKYR8#$#,:<U'&*TM8FRVN)65HJ;A-9FG4Q*/RFN@R1TW!$6>8X7>3!@\^]
M+='\P(OXO2]+*]]]X0PSUS$<'6!AZ"/*BIR81E4JJ^.F^94%7R=)?TCX(G-)
M#/8%51=;A*3371<W^UKSY.9":"^OX<,EF_*>[GWS]+-7Q*93$@RUG+UE5-)_
M_$++R9LW#OG+V.+YYZ?WIG6S^%\M%I;VB6*JBEK!N#IY:H(U>BW&)*YD0R#G
M1T229@[!=DA<MEVL]^CU\\L3+/&)M<EO<0Q(UP[\Y"'B%&YUI'MDFE-)P.%5
MW'E#D2M4T2ZLFC%W-I.[@_2[3:,S\GA@[L&5<Y(I2=$5V^V#J<QKC]8:EE-"
M#*LNS[???NTL_FW:72*G(L3AUTG@UOX'F+3Y.^)K4>4+2DO?OWO[.WPO]JBO
M=QPBR9*&AG!'G1BW]>*9#<[^DFLI]ANGW]?8.M#@U\^UJ[%>4G<\T.+5Y5V;
MZ+K;-9A;V*251)6!W)MVZ&43U(?G'4[*E/\F'.+F%,(A\)MPK-L5_Z^H4=H-
M?EJK?%^YAQ+Y8V2 A9!Y8D5AN9M1&/1_H]+^+?^;Q&J5(0ZFZH_DX'[T3&[+
M13W[PO1IAC?/H2)'M/?#9SDA)8=]N 6D:@3I_)8G7"\2^]2LU.?#T,U"XH%(
M\I:O3/=WQ6/'?&%]5V&2ZPRZ_I3.^0KS&>T![IO8.>5@[];=,K#RKZH6.#+U
M]R[F^34R0%-,!E#OR4"DR>\-P&MQ>03V##(06Y5%:N\.3)HG WU$52)\ )$"
M]R4#RTEA[_\KHPOQ#+SSX& R($(&('M5RWFSB&/1Q3*970C.:3=RX8"Q@0RT
MK<-Q9> _J_JWJX(G".7'DD?R) .<="Q^@L2OCJPG4E^$HZ]"2-))?U;S\8G]
MTA%BC^.0#$B3#(E?*257B[F@]? ?+?N3HBTA*RAQEQ#^OV>**# #U&&_)U=J
MY*DMHT-P=O]UVB1^EK'L7+7;O7DWB9J5^NT@IF9)]&:PFX"2BGGCR^!(EW1+
MT&Z#&,>#%_;^(1>MGT//&.7,FVW71:UJW.DZ->AACKWT)(*[]LAS>M>H,EJJ
M(!:;%,,L5?#\KXK6(V(=0=4?CLQCW[S=XS!CDNOF*HJCS5=)T;PL?'E#OP(6
M BGC"W@%F3'T]F<-5-FKG(AU8DW49-3@=+"&XV4)*JT-[HB/#K/U=\-VG.WP
M;).@*-Z]AL0[YKS6X\7BE4?XI'$U[_A+QPY,]S_YI-[Q^J'R3#7$W*/<M>VN
MU3P"W;_ AOC%Z4<&7@Q3FNY=>*?D[\WIM[J#) 8C,M!ME48,C]T%M5"8T&'>
M)LF"D(JG>%D,QJL;LDD&6'/0,Z07?&#<67DRP*M/4 SL]#ZAM2,#BT\1! O0
MI%HE!K]PS'!"!M+@8J05,M /HKL#>48&_G25._^@"LLNTQQZ1-(F(58@_> &
M^)Y^^W_%W#O_P]I7\*ICJSW3'0@A&6W!>U3U9]/^0=%]5%/O+GP9]#_-4;QD
M_4B@EEB;\$;N2:"?=">KX5'.Y/,RS7X1J_62L*=!&IJ+<PPW,\[;"K($6_73
MKHA::*IM3U-BGXYP"FWU7)YN-2&_FQ=-RU(ZMYKL1QQ>WB8H$#8;J_(']M;O
M!Q7?F3?]=#S!@Q'7P(R41(7'GPNLW$;H'5""HF5I\2^CG%9>8F6SJG\1S*%I
MM#@^SMZ&T272Y.WKA(</#NFH>O$ZXZT;'Y*X<?IZF'=_3(?6EVB7VB@,9B@2
M1S:*?$MF.1U<'H2?;(-<<G)VDDJ0LTBG/Q8^#&@,N7<7M^3DYBDE?6.6V74E
MII($+W\24/K%U'<G1(6A7L[PS^L&D?RW<#E9^^\ON\[_&\M3^1#8E=*OYZ&%
MJ(4HKF&^-%DOU.A%?@7\%Y3_PU[-FL_PMO)-T)],V"4(HH\Z\SBVA6<Z3VX)
M//85:I*P7B"N/;Q'DFCTF>)U&XLOZ[=67Z=X*B@H0_C^!O*168=YAD:JPYZA
MS'J(X%5I"E.;)&C\'[UUP=$KK#1$$L*I6V/TH^5/=^H.RXFU-'VY;S(Y9*A&
MD^X83R>4<HU?S'(EE(*EV]VU1&=Q@8L3X1JBWN=[6D5&5YNRCX(S"VMO'.O
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MIX_HRE?66KV>K$8<;]I=HE56$QH"^7^]#ZBQBH7I$M-" =((O"8J5DLF]$?
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M'5F42POCU9!^WZN=?D52+!7R -Y^CA"4;P^-0\';R< I.[EF+<VAKH!(/<
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M\YH_/E0K?M2SH_^Q0*$788:XN,67Q)'U7'9T75,)S*(./0_3_;!PTSAG.*1
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MSN&J\#>@F]VFR$T$T^![R&K(:3) TI*3N'%OV5#MC.>OKC J6M1S+4I_#U.
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MV&C.#)HMLCN2>HX!U*#HF:=75][_4\N)_LSDNC6EX'RH3A0$P4?5C;>(ZX,
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M!.E*S/CKS84T4J8#ZQ'VGD)X9R+'V[2YPK7^$*CH%@,0 ]--B/0(G!J$VT7
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M7)\-BX$&R7R<7S^N+7O]>;&WT]*U/:H%+DF#MH^K:H]&3(M9O^8Q8(WAC"2
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M;+TFA3F-3U.>XFF>H.RWD133QA0O^V<5BA,WLAH2-O[9,@NMTDG&_B6-5A*
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MS\CB[.S%0XL.%)>J,SJI/W X;6==X#6\_5U;D+M*??-T4)#4LS/8T*;G@R2
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M<L_L;.AOG+6L>AWXC9,C[8]7UL4U4N?8WGPG/*V+-GTP"++=H5AEK/,*MRO
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MKP 8^S5Z)-0OM/3[Q4[P/DNQV[J4FVZNE7Q_H*.X-J.S_<V,17(S,_M>C()
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M.@O2^1CH)QPVC,MF^E="J XD$EJU8L2,^?0[M*ZZ)D5;5MJD+,U6J]O90R\
M69Z1\RU$&N7"M*&T].ZX58[Q>S;_G.X+E5SN1S2YZ=9H[?GJ]DCS0I<PHGA3
M CB41^C!^BJ]%L4C2 6A<].;H1KE$L9Y'1>-5R7(5:.WTSQ9BI,T^?1E7+<,
MW]+VMZD<&W&=)9[[\\XEP9PVJN$IEL@VZ/$ZWD3:4KWOFHW-F<4G@*/ZM P
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ME+"CO<A\PYY<F_!YVW$>=3>-.CM,2=*_4_/)HZ,<@BEHV$S@/RPO):Z$-_^
M&<\8O#8_^)\EGZ[/OZSDT^<XPS!8Z<*" YO5U\=SZ-W%FXXYC1H9I_9%\::^
MBZJB/RT7%W/TIY$H+D(R^#7TD(ELHW%)FHI%[J#7(/@U>*5T>9F!1S?*5F%/
MS,]AQOFS 91_9U?5(.)&B?7@+_UB^W(3_X0>%#W9D53UM=O=72[!F_U^:TB&
MAD0-U4<W35[ .8_*V 51-[V+N#L6H]?#GR;KE69L/7$/6E88;P9V,10+%\0M
MS:PNMW^I8Z"?3DP_$3' V=JKAK6Y7)B8OL-7^5U)Y[-;FQ2#S]3MH,(SW[A?
M4<H.CH*"/;M5=.8OT3Y(X@NUO-U)715.<YN%QY3;_^)H!X/8BIC3=AM5UA?#
M^]XF)OM?]=48X@9_E6\"(O$2@3_.M)O\\-%H][XWT7"'4;Z\AKRQ;@W*@6;/
M?%*<4NT"1B_ 0ZP8,"Z=T) 9F9%*_T@0'4X#;XBGTXM9YHW9VS+I9>C$C6MW
ME])+C/56I%5I,!SMT,/.YHOH#GR+8K&DH8K[$3R&K'&LGN$?ACN QIH6.DI]
MS>KS(O?@UTUC\5*JT=Q=/8MN&C_2KM[$?T_E4OG#DBIB6Q@J#I)& V6^W5C:
M>["IK"7MUX7PAXEM9._Z!72IT9L.92;_TJ[5_^#@2I315PM4@#X-^?D#=<*%
M#T Z C<&W.YK'7Y _4KF1):/Y>(MSM<V3-QQ<>WJ923 ?+F*:]I)\&V$Q4F2
M'E'9ZI*:'W2"X1/E4-:1 =A_'?$>HAH,LRKA86,P,?0V!5-I\C' M%U&&F,_
M U7OT,:JJ*)) )1MRG6V>8[HX[P_WDER!UXL*]%[5(D(' /O/B"G7!@E".N
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MOG@W%0R^_0,\,Z9^JJO0>J8.-B%L48J6RT'[&PQ@W//L]3\4OY.7NIEI-XG
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MQ=7H9 $;/8GZ6GO)02&%.:(R:T1X7)U*<$9,:7WZ .XBZDSFU#XK8W]%#;U
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MPZHDJ0'1:V=/W3MTFO&Z'.-1>]4RJ5)8GO2GJSH?M*^Y:\C[V%9&H*!$5>L
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MB=Q]?1.198$$H+Z#F,B^YK#":<B4!HP$L*C@)>B:2<"^>,\K7BR3/0EHT2)
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M@&KX/)3:W]/U&O^A*>90_,%W.6AXT/"_54.8&U9QILMZ&A1@->0V><PNE6*
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M8C_MP2:Z-?W:>7GW\E6NM=8GVQ5K_61F:QZJD_2]4X.%HCK-2OM]U;W/QI
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M8-8():5.83SG4 -5"H'V>2/+QI'O+\Y6? H]H<.N;F.TYW&? W8$^O93/6P
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M(:CX ZEK!SI%5BU3>N:'YT-\HP-KSLRO-DEA2MS<_EP*(;Y&^(=H02;_$1-
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M,ORDN5"5FS3SLC+Z@>V-TDJ#E;=V.IICBJ5&R"GM^4?/,A-I:,POYXL8&9,
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MZ1Y61,666 P^2(BL-WJ3=W(D,GAT^$>?/:P]928B1U$DW?A0QZV_U<MI<W7
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M:4:^.F$[V"@*:[Z\HT8+E:U$A,C<R6SW;OBLR"@[8A8QM2[O$3HK?J_U!4,
ME>5"/P5PY)Q5[[BKA/?$T:$LF\]>(&_X"_5/I$S04 I^U]Y4JW 6^R]]6ZI:
MF=.WJ!990Z@.N0"&9#3XXH]&NF$6C?%*G[,7U'1/.NRP)%:'W_YQIH:2YV.?
M#60QCW"IJ#US(K.\,]B-RJ]LN9%#\8WEANS9^KJPHQU.2^P[NC*R:;R7N00;
M5,+"B'0E,/R\NPP3SC\$8R0!)TB7+"%W(KK,;$ONK-]]$Q1P2K-+H8N*U7W.
M>QSCV4*V%6Y$JR,3'M3"_!IQ^,C*GQ$G6I=C8*.&FL!4BETBNME>B;4UXHNG
MC$6!E(Y.XCFP0<HDX 74O]=?9&MGW]<H;XG[L U^5S]2[E6DV['C1NMW'E^A
MS( /1P![,TR^BMC8UJ)GGW$F$6XF-$VSB<E/1JY5Z%*6TD0):>+E.QN9<$<)
MQE"3-F^UES>'64J%(W^49AMN]\JUN0;M0] \JRN'=_$;Q-.V.,\.8WX<+(I[
MV*Y8C[-A9#ZD5(]9UY6AI,)BA/>Z+D;\'C6U.T_[3$B&-!F=GO^@,<.8KS3:
MR[V$=^?X=\;;V?JYV<<4CK>G?S%[PUZ4H=":37.K)<!_#2*41U##.I2@%:7N
MFJ.G3F^UG>_F5,LQ6%;O=H.S^[;?/O']])I=E'-01M(FXUHJ"3A^)777D^R>
M G.PR<'O<&<[H]UN%UOO[>V%7*N4/VD^=?K&G3EQ<=ITR10\'_'4)UCQ,@*K
MOD:[U_; &7WFK?O;RJON3#$:+F/5)XQ^W$-.]CXS-9U3IUYO_V<\!_4M.CQ&
M OK(2<G$<QR(.#D^JK-H<L)?=,F$F;QC)(B]'^O_,N>L76SZ0NWA\X$90_W5
M&4X?Q7VZ-[?3V&GOO:.3_6?45\^;X+DZ"6\R6P4/7Y* I:'UQD*XY%%&(QE7
MA67S$26:_:695ZYUR@!2*M7@*,/%"T)_;[**7L+JY67IDW#9/_>)_>\&2OC]
MC,1@04167&8'76C&W9%*EE['<U#!0[7#:_U,& 4'_PF'CP,+V5<MD1&G5RV:
MY^:<[[%'_MDS* P9.TG )1OC8W@Z'$<;4KC7L=BJD7FDDN]&.F6AVMGB>+EV
MU8= #RW=B3KDEAK24;%QG 0\GXDX>/[6PCE_&=)(/UI28K=VS?IY!J0\25-8
MEJI<Z-RQ $5.BGN,C0"T7!.WT00+)7*//3>(-M?'CJ46&'\)/V_L56(>+W?Z
MUL5+3YW$&:;_,GOY'YA7\>?VQ/[=<)R?V_<?'DQQD>)'Q7_21!T+:%$;$O:"
M<+L('Z2;IK^DKY,V/NZ:$==*S^A!8%#Q9R%V@YCKSZ-AD\FZ^%Y<6)O'-'N%
M(ERD2*<N1B]I?<Y1X*1<F]W)^ ?::>8]^D?7R(XM<]E?/'/7NA:;'"!U TUW
MT6;Z>GU,QP\K9KN]:/OGB/JDS!Y=)&NA_(#ZVI*)!+$'C%5T/(&?F0T-0]-%
M8*%%LKB8K*$^T>2++7TEU[9.M\7+<LH&):DOBG=@;[<#OL-Y!%NL29,)_CH.
M1P("1/ BCF&>!^/ITGUE4LXE.3] -@]B"ITO*,S+W3ZL@%? 9BN_@';ML08W
M:/+:G5[=GXW]- 6)]I]$8)7/<J <6\_>;0.?<$,PX/.>Q&HH"&Z_HWTO9% K
MRADCGG5V\[,Z5$H&VF[M/^Q-UPZ+,<&JPH(.[ =:,R]_AZX\&G_Z::0B^[T1
MRXS ]-@"9XU5?<,A&\VCFLO?VRR%*>9,*!!F("0$'=N,H(5F-\/H;V['GE[V
MV.!_G4+D0%19?558[GD:<RWR-8T3K<1>,6C"1*7V* [LV'>F-?.2E)!]_@K<
M[U)*LLL4T_&D]HG[9[<=:"?N<"XZ==%VSEN4=J($.^&3YK,#K>F,341FO I:
M8=N(F_O%^)KQ\?IX'5T/_R?OJ).E9=U-RBU7;7&8W<"C F%X) E@$5Z9HN]O
MU:P>+5T<NZ8@(,A9??WK9*?=+0V91YI*A2'43#; @>-N/UF3;E"6W??X2('J
M+'SC3//,!8>;KWV*Y$XY)6/EPU][7?E>)G K;K\H"75?TPL>[L_AWP^JE%^E
M>"\66>'(;"@8;/<\2MD+U:>KR'_U)LI\:XU+A^H2KX2<X4>J3:'O_L,F93QK
M8MB'NR]&_ 5\9<:D'F+V\S[[I-K[/+Z&T0IDR:G??>>[S#B/#!],(KOC6@E0
M. FXB+ '(X=;6E&-);,JOM80UT?5+ZE#GPW'HY):>9 \<0^NA:E/:;AD2U^G
M7$,$@K#J.V27\Y3?$R,8M>W1,%K/X7,IH0AIS:51.N=ECU&,>Q(0&-)#+Q25
MC?G([DD"Z&KPY-^/-MI(P!YQYF<4_A[V=.#;0>^NWU%J9P#!S#87'T\"].KL
M(8:5GP,%[&E6.<Z<@VBRF9_K[ 9!A6B>08K)X9VD+SD'R#*;G2'PK('Q4X#F
M40I1VCJS M'"SX<^$9=KM'2).;B\[75R<0GOY1RK;BY%UD0>'#P=/)M##FKA
ML6#;LZ#F/9E3(V[-8J$A&-&$?(6OE9,J<YOQIOFF5YO.5OAV+C#LRH?YWL[&
M@Q4CE;^ZI;)=>!Q>+F^19\!5?_U)?-LUX(0B)ZY;9!-.N.B)$B.?KA'@,R59
M>#":+Y\?M<6HAYU*++)W+FAS#F+]?GMRZT2D$RU+#84"=3M1@*QX"=M&6CQ%
M(;YEHU-=$:,B]#A!N^9K?._1Q9.8.XK'!A8LT@"GPP?QMP-D;+(/^0D..+$V
M$SR9\QHC=@LRPC,RW(*\"4G13BA7O.D1S[AE]EWMH&+SOL8WA=9W@(LGZ#+8
MWL\'98>@YL$F1Y4*+]G#RKGB"(+BC;8J=32"SO.QK^ ]AH0V=[L+)BXDH%F&
M!)C=1;P 4=;;YQ+D7@B5XHDSJ]ZER31%UY!Z)^>BS01J3CS@2?RD*<][PF,N
MP M..'_Z8$PMA!S:WOP*GWPZQI^32+GEY4AQ*FXI,6&G%$(\D^1G,^3+4GY<
M?^=$B1#@_RSJ*(HF]H$VYFC8^,X,!0FP >-Y\MKMGQZB^A,*H6%R=0_/C0K;
M\U?RW5TQ;>O<#4]ZTG[M</:%ZABOBR5V8+7Y4)XX@V"Y*:6(LWP\6G_W?<O'
M=L]"6]&S>9RB-FUO[&8MCK^9[[IR_G6OF%2 _WMB'XBV'ESD/P"FJE1Q;4W1
MS88O-=(./:U"-'Z*,$C5V%50?!276.9RXAY'G,E;\KD!)N1,ML%V[^"S]XTA
MJ_UO<R>MD/8Y(8E\CI:V]/>I;NR9RU+HR'\$3A-2CI*)IWP?8?<(#!PF..."
M6<$+2XV7$MID.-Z*]#:PH_D88S3<Y\737UV%?*]3=9H,%4H!CAS^&;?4X$DP
M4Y/]SS.'-Z<Y2,"D]\_JQ]G^&NRB(3F<6R0RC'@X'\6VBXUE<!RR);Z>K/PP
ML5O.O6UR>S_VCL"\PZW.?]*AZ%M$SC(_DX"$"W@+$N ,/I(T^DO(63Y&AM:6
M2;U]5AYUT\.)().Z!IIX:6;!E<;!2']STLQ-SF3FE&L2DX144,JV_C\_BIC+
MI)>A5L,,Q"*H_3GDBSHMZ0)@5;Y3TN\$QC,=*I^<&/]^S([O\QSK(JLZ=<G@
MG]V,B0OGTWG']];/:M#+[5:UP8WL@X+N[A5>4I\D7E G7K5C>U]E+BX^H+1B
M^]LA)X [Z*2O*P_9@P9/G\9%547F]:+9Z'LAMH\2OIQCFE54.M'TG=%?*##-
MK;2JONCOM&[Z^J?&J":\Q*\D8-,OLTSLJ&_FP#:&',=SXN.PDC!V7S_\71RS
MM/%=<5_*H_*%I34*C_I#]\(FT<;9"V9&G5<6Q=$!T@[_21-)CD7L*^^6XE/1
MF<<)CX:+*Z1=5AY7)"C%/(\X0:'\-O=XK7M+/H&OG9PB^1$>D(#WY1HDH+$3
M#QEX*E0H[EV6<[T._G#[,3451HB&7TI'\I.2S:XG8LX_8M DW03;2+P*^SJ1
M3P)FS G724#('NX,,;1/GG@(0I&-<^4XW1PL;#\CC/#P.XQ #".J$.5_E##L
MCY* ,QMHQJ.S*;%'N^"66+P)[!SBA]T(;.,3\2*L^"(XC@A: .'HG$G U@%H
M7VP?E%4!6800!!'A)MNB-N"];R3@-/AO\6H0/ZH3Y?&P-[ V:7(R,? #-C?S
M!U#*'S0_W >AB&8DX-P>B 2 R>E1 BSN@$_6WQW6<H@GN_Z'S[-)@%\L-IO(
M.-,F>, B CI<A86 _HW<+VZ_N/WB]HO;+V[_"+???5<7\9L/*15#P6,K'<D!
M=(L."3B9%^& (2+'2W?2#;IK],1L+MAO]9JO5_?4&(^,GU.W(<03P%_"4$1I
M14'[LWZPKB/Y+(0DXC?$_U:8R?]&B!RZ_5+R+VZ_N/WB]B=S\S$AT&.(C]50
MR4?D'&9[R=-$!S+?V;P!LIFAD6%=8F?"@B,<T-C*V/1=X>H:/77'MW,)-))$
MW'2=X-]@FCFGKE*JZ ]:>"0%[NSG-48R'Y" /R  P9T789O@5D(O"0CWB24!
MF>3TI1O1=<3P'_K&V'][9ROQZCJ8"'M( KA) ,>V;@1A^3?*^8U4QDZ#ND@
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MC*O)CR2/<E*6/Z?E?/Z\<%%MZF]Q_SA"Z'^GM?H-^!OPOQ'0!(QS(8F*QA7
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MSGV2#;$PEG4EB2K:*S_QH$\T9N1F1<PR5U54QTFMFYW5!N*/KUU:TN#C-.F
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M9N]+B26&81Y)!;)KHF]6Q\G2J1D.-3PSZ3.>@1:OMT^8$*,H:601 LC\8^F
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M6>_/UFV&*AJ0P$&RI0&N$(JRY<]= BT=:9^0($:1(&_@5_K.2<MWR9GN:27
M$*7=!N(X;7[/9BU)-B'&MUR+_R-'MGA$2X;<SR/;#M^D3!\G'.C@7[:MC6F+
MJ@-+S[CD,"]YT.;<GN$ERZ@JU;28,[_^S%8BB+0?:'?I-D+IJ,+>J==>.VU'
M<[>8)679RKWQT,&6QVN/YGZZQWNI:?HG<?6>WI(2A@:LCA.@_U][9QX.Y?O^
M_1O)6I:L6<N2HHB0""W(UM""R*ADBS%$#,:,)3L)192=5&C*GFTPEI LDVT0
M,Z-DRPP:DV'FI^-Y_O@]?9[C^?8[GN_W^'Y^OV/^./^9XS[>]^N\K^LZS^N\
MCWNNTP*K\EI3RFRCS;ZZNCR[R%(%VT.Y^\HX-B_=]19@Q24?IL2Z\<<'=*^!
MQM-,FP<,?L5=UQ(7WY([-F#!(<CKLN\$]^<15RKCP-K&0*DR*_=#3ME(<,8_
MN?_\[^?M;+YJ7-S9M')LZ1 -$F7VZ 6^O*.=_EF6Y$3)I1@]T^A\.+E=,74S
MM\_X;'^UD/!8;V3W>\*_(,O]H?$=ILXS #40#<H JA9[2A=TFTZ-,  W'"3_
MW7AVL]?-FKG7&NO"3G2!965Z>#J2NC<7;RBC;NUDN9,?3A<C!]3[&0 +=DN)
M =P/,6, >2ZY=+82JA7'AT>V6"0IV<-IG;>2 ;3X,P!N [ST$/J;N!L#")NG
M"[&L*0BO3V_)X6RWV508 $G*H"V9:E*%VMQ]C0',G$+N[&^[C4*U=T()Y3$#
M,.PUV.( D0J9'$P.)L>_DN/QC$S%H:T1%.UPUC1]$#6(^C]N$K31ND&]3 !1
M+=%X 'L"M<ZW;]H.%KF$<W9@ .UXK=!2Q+K3\9\6[]_9+'4)L<Q6_4V\^KL\
MW3_@"#F$X8LA6D:?=K).V#[>>3.J2RUY16";N,F'R*XCT=.+!)Z/1^CL,D3C
M[?^+/1Q0?SF]Q#8;T6\_A\D5A,L,:,K<?SN.(6U"JY"N"E&/TGT2KU^HA$0-
MBB/A"A^OW)Y=W>LYZ/[/_1;WM_X6.SR_^KM*&23K_^KOFB2-DGJFST(?7_.G
MA#6 0^N';T@X^7"]>4U\Z/?,UU"Z]I]9I?ZRZQD=*Y+=) Q>.PGN+%RP($@-
M.=\T/#(XN]K^E5/:*NI-0/1XX@SQM'(YZLAV&7)V1%\=.999Q@#F>3^Q?((?
M('_(W4??!U/N5,<=RU6-]3<_ZE@N"%(S= M74))@\W&D?MSM.U2/6T6-Z](M
MG6>FM^.RM.D/,>#2?_V6)(U@TC*_%?3K ^9V]Q^P)3R)C]+_M*2*';>V/%(*
MX&AAEE&!DI'/B/'_@@^8_U^F_%45AZ502!E+D01''A.R:LR]<E?'6X/?\1EF
MJV9YMF/GN*2"YK&:,SN+D@:*RET_2,70?U8S .(GEDUE(\0])&997P0YD$#D
MHWW=*;Z3K1D 7Q5U9]6>54TT6'GJ1#]M*%-093MGNZ6/Q;MM<S:K,8!F")+Z
M0X:IQ]1CZC'U_AOK.6G3.W*X1K>$&0#/-"W$I''(H+I9V1-7'C-QX/CVJX].
M<CTY>MNSD/)H2<G]/Q?I,AZD2OI])S'DM!9Z*SB9&EK2UK\I\.OO=?"=RIR\
M &P+%Z!/H?&47!Z#;T;DF.TU3P;0]8(!Q.#@.]NB?-%.F8T^% .0SN,;M%=>
M*V4*,@69@O] ,!\YDXW@&J5+(;ID^!I/$T*EU\Z,[EQ3I3]8,MUV*^OH9E3O
M\R]ZB87*?*["ZU%_\Y##U&/J_5M3GB8\@.SZKI ^/EWQ/>YFV8*(_;&WO[IJ
M4]*SH?[DB>D@>W\H7[;8@=MC[17?.3QTQ#37&,#ORG[V&UO"E3,&<8T>>*3(
M I)7[UH@094WM)0F_3-K4K,$YRP JN)JR_X&Z(9WGNP $-G63ME.O^/\[I@5
MQ[=RX5_']__FGLGOMP<0\8-,/:;>_R"]T?_*H8"VK>C?[CW<N>7! "*:M[2H
MF22_+@3_6Y);?#FT\4S>]+P:R.=H8]ULSA3!!FYV<>#ZOK"+[  B%:Y-CLXF
M\^"GHQJO%D[TN15Y9EU]7>(&]8E/-=HU4)92^BKU5:L=*XNL0*OFX.B7KE8H
M57D% XU&<NAQX7E6=L->+= PFWNBT_0HA(G>U M'AQ1O?\A;5N 2!V9&7?Y.
M,8^IQ]1CYMR_7\QCZC'U_EOHK8[^.@*$G8T4N'R/:.F$04B0OKXKO#Z?%?1)
MX>G5U;/J07'2PV-+?AD<N6:;Z?_7-_5ZE431)32I@4C/+W&"&Y*B4'''UK]E
M25QSRW+'G;C%H_I]ZJZZQD?/?B1^8KH2NBTX9<  V+P9 /5'J+(1 -_Q:._G
M[:?(;^GS.[])!/[O:AF*Z$.OF_OO1(L]#;^V >OE0BQKMENZ(10( RAP*&$
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MWSZN=4@(*C+*?B1X,+1H^4"@M+(S87J9IQ"N0MZ=AD\(%74@ER15NX._]F/
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M.*>>\B5_HVR4P"*QF./ZB,$@# E$ ;)@1(( A@0YH<<("@-^&=U,ZAF/8QR
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MAW4JF_\'[*^<.^Z;W36U0[$F ^S0 1I"P/<?\[+\X0)T>]J1!'HTU<GY/:K
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M N4&$_T4:_TMD=,WLS-:32WM\GB+X 7HH=B:9AQ)P?KW@O5;W+B=UN$-D[R
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M6>9HRN,\L5[? @/?8VZ0BAF98O;"7.55"ILG9\-^8UNBIL@-E&#UR@IZA%R
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M44R\T(DM*;-Z$,K4$MC K1V@W5=1S9X>YM&P"!JC7%$.=8B6%CTIHH8.1[Y
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M%H[KN,BS$QA%E-^=/>2(.2$6)'Y"F6@T$*I-[#X/G<E%M4:NF1W6H0>^</Q
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ME02.K11L48$^L:B(X9C/14X8HV4S\5YT?</9*\B3A!7JA:A*G)6,O$S%+\4
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MY-[77_ZH:H_QU5/V>$>DVT,-KS*QV'#@C$,7;L4. =#,)&Z"".#J201BY5.
M1G@R+&-FV:$F;Y*<N !WC"]@JCV4'+5:"4 C2\^6_2-'8C_U1_*-,R*9!R'7
M7L+!N]?M(VT^0E,I4_<SO,FXVJCOF0<AU@]YD;"T6O,OV5]9^O@D K@O_.1^
M9'7SP_>X8MLY)5%";<OB5P3F,W[8)M2!V"(6C&V:$.Q$GF"$:A3US<F:6%OU
M4#$3OGUSAJF$CM\<V7ER@'9;\?5:C(E^0L=RA=JDH*;=:(_4-CQ6)X.UU%Z
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MQ]:5UV/,ZLVY"P1C[QJ="1-SWZF[0%!G+MA=,IK!?1K^K[OU%[%6H42#O<?
MZX[]E5X;TKNU]^7#[5&0WV0/,B2&Z?V'!0D 380F> ?[D FL9M=N!L:<[]K-
M.*BC:S<3CUYPN)M/Q_/SE_'\+FI_N]W4&[DDE*O[%^6,OPKE!<G?JTX\JD;:
MEB[EZOX8+I+4%QGU?<22!".<D1QE?NBCV(^HG_I$^!FH\O K8'!L8TZJJN\9
M\7J<>(J5YOCW6=#*Z/1WYID'G *_W?F<_31X?][; W:F\O[P-V+Y4/AUIL;F
MX?#,".8_)'Z=*3I[6/Q*K+RU7*?CE"R-[C912@*2A2CEJ=S(1YBA/&0Y$D50
M\"@*@C"A;S$M][4;W/3S=M]F<QOHEP!8--\"OV]Z*35, /YOZG-C.)UO/C<+
MBNN_)'/+<#I?*Q?95<\;M4.^J[AD^&;%[\K-4KLJR_%;CE>GAH9^9.@%HNF
MD#D8F"F^JZCRROJ65\6">?F]Y,VN8Q0G*.YS'I)1N.?%4+-%><Y#Z =W!IZ
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M654C8[AVEI=+;T_;.Q 'Y%&-"6!ZDVL+.]!Q'H!M.WM* YQ9!M78P/-E46G
M.\JDTGG>M+>9<B)[L4P_3_T$9P5B:1$@+!(5WN49BHL\8P5)?,*TBG(.$7!_
MVKMWBJ&-QUY(0F\EO00?3/<Z:&[CN4-PK#4!>S'\S&V^SH,[;>0U\)RYCI5M
MRJG*3%ZO-N7J7JR8.J/9=YHYU'*3>U.>4DH1YU@@'.,092FGB&$2ABR+XEB
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M9(QG29I(OSI27;N)_",3-$!^3..0BH0*&H.OP<J!YTH94+0,;KLJZ/KI 5!
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M:72:3/9WZUHR5*[$S48\UHN(TX#S*%=MK:7BXS!'A/ 0I7%2Y!G-@B )0&U
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M(2I\AA$6D=Q_1")"":9)'L2$8!%"]A]CQ%PG472DO6I/VZ"Q]JBT]/8<MF0
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MB_T"4BEED!)H(32NF+)YD-]NV= U..T;%I.>SEH!#U/:/DFOI>G]TE$=WD&
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M3/=PJ\:^_4^Y>7@GORRYE:SVUV<7"2DP3Q."XMQG".=YCF@@9R5BA$=A'K
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M(I;F(?43Z:#G&)$L3"D1<5$P'^*@#U)RO)[OZ>YN(0!/'H8EI*?J5G##-/P
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MH@H":&EYU:,YZT(+$L/+)1?V,LPJU-5FT?05%-43K3;/*L>O*>^5I5F,XS!
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M=NEM3 _0M%U>IKUE7YTD]J:Y1> =(+R!8NWZ<G[MHNT:G/X<Q=OU16ZMB#N
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MA%^2"=L(_@/)'Y\M3N;KY?=GBXP3)RB,S=I3*(V5'4YF+>8,,L92+$\A1]T
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M\-YJ'9RQUA[VMGG;JKMAH.-+R8-%V44X\.QD6<6U?8.KD"8=G*PFA6472I;
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M?$;R(K4JKO#0.K7N)A7CWAP,A*4#A=W!U=./@M])QJ1L;2SC5*RI?6I3'>3
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M@<(Z.8@V,.BL4U$YABQ:7\0^*H,CIR ^ MC[Q4O7Y_S1US"=5=;*8KD*,_R
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MHLFW#/-\WO=D418GRTN_=(#)VW>IIHW>]F?R<=K!)1%=",% -"P37(,'^EZ
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MM2(MO<-EJAK[A!.;*%SU=4@5UCNS0'LAR%P@<2EJ<!.R]@_%SOU+[@0>\^3
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M<J-"\+_0WB7M1N6*4Q!0.+)I 4F[U=V0218TQ3C;>M3A8_$V;AW_?Y&=]R
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M[I\RVL^C^*/5ZN1X>W=S-,^_X_KS(B]FBT_?SP,3:8)"9QAD:2,HK@.$0%;
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M,HZVPVX@AON :"#M7Y(\W;R/_<]\R:_5D]C%Z^_DKSFX;QU,W\$YI 7TP=-
M,Y S_G-%TD0D=*/]$_GQ@6=<)-7D8HE1 ^H[JH<TA[ZXFF42THVE)-LH_''Y
MK#K^R0FL>X3 Q&[C1M17&P!D%,.0-6<'!AGBM8C55T  L DS,]9K4!!X'WTL
MMA>)1N6ZNC$RZ%0@YZ7<%S[R/U=)L?,K,$YYP#"]2#8J]34<0U.K@!Y>YJH
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M[E3M1/(;JBI>"KBZXD2,NWLT.VM_%]*E /5GN#7Y@PL,M/(N?:QA12EZT!D
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M4KA0FRI?>8%8_A:O,P_,:]3_ 5!+ P04    " "X@6Q;&NBTN\($  !E%0
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M,"YH=&U02P$"% ,4    " "X@6Q;.-$@?D<*  #B7@  $0
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M+FAT;5!+ 0(4 Q0    ( +B!;%M&S:?.QP0  $T5   9              "
M 1U(!0!E>&AI8FET,S(Q+3(P,C5Q,S$P>'$N:'1M4$L! A0#%     @ N(%L
M6QKHM+O"!   914  !D              ( !&TT% &5X:&EB:70S,C(M,C R
A-7$S,3!X<2YH=&U02P4&      L "P#H @  %%(%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>absi-20250930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:absi="http://www.absci.com/20250930"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="absi-20250930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:TechnologyDevelopmentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:ShelfRegistrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:ShelfRegistrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:ShelfRegistrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:TDSecuritiesUSALLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:TDSecuritiesUSALLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">absi:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:AdvancedMicroDevicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:AdvancedMicroDevicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">absi:AdvancedMicroDevicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2021StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2021StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2023InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2020StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">absi:A2020StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:DrugCreationAndPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">absi:ExternalPreClinicalAndClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">absi:SegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001672688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="partner">
        <measure>absi:partner</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>absi:segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-30">0001672688</dei:EntityCentralIndexKey>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-5" id="f-95">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-6" id="f-96">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-97">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-7" id="f-98">http://fasb.org/us-gaap/2025#LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40646</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">ABSCI CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">85-3383487</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">18105 SE Mill Plain Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">98683</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">360</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">949-1041</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock. $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">ABSI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-23">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">150371531</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">9476000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">41213000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">16342000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">15947000</us-gaap:RestrictedCash>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">142999000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">71212000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">5177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">5459000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">174994000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">133831000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">3190000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">3968000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">23016000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">29167000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">42356000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">44883000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">1053000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">1054000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">383000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">705000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">244992000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">213608000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">4586000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">3529000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">8229000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">6842000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">12750000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">12750000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">1306000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">2733000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">1754000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">1608000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">2000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">78000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">1081000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">1116000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">29708000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">28656000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">65000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">1257000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">3093000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">4429000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">1786000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">133000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">34652000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">34475000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-79" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-80" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">805047000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">688726000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">-595222000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">-509601000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">-4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">210340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">179133000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">244992000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">213608000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">378000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">1701000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">2150000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">3869000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">19249000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">17985000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">56071000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">45482000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">8441000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-108" unitRef="usd">9256000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">26441000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">27346000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">2842000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-112" unitRef="usd">3355000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">8914000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">10155000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">30532000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">30596000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">91426000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">82983000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">-30154000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">-28895000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">-89276000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">-79114000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">45000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">130000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">180000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">456000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">1597000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">1664000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">4066000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">5496000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">1552000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">1534000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">3886000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">5040000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">-28602000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">-27361000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">-85390000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-138" unitRef="usd">-74074000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">104000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-140" unitRef="usd">37000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">231000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-142" unitRef="usd">49000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">-28706000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">-27398000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">-85621000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">-74123000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-155" unitRef="shares">143769552</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-156" unitRef="shares">143769552</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-157" unitRef="shares">113613488</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-158" unitRef="shares">113613488</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-159" unitRef="shares">132114850</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-160" unitRef="shares">132114850</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-161" unitRef="shares">108665095</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-162" unitRef="shares">108665095</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">-28706000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-164" unitRef="usd">-27398000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">-85621000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-166" unitRef="usd">-74123000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-167" unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-168" unitRef="usd">161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">415000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-170" unitRef="usd">157000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-171" unitRef="usd">175000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-172" unitRef="usd">204000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">89000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-174" unitRef="usd">131000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-175" unitRef="usd">-28517000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-176" unitRef="usd">-27033000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">-85117000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">-73835000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-179" unitRef="shares">115362265</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-180" unitRef="usd">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-181" unitRef="usd">688726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-182" unitRef="usd">-509601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-183" unitRef="usd">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-184" unitRef="usd">179133000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-12" decimals="-3" id="f-185" unitRef="usd">744000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-13"
      decimals="INF"
      id="f-186"
      unitRef="shares">10983477</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-187" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-188" unitRef="usd">39158000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-12" decimals="-3" id="f-189" unitRef="usd">39159000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-13"
      decimals="INF"
      id="f-190"
      unitRef="shares">1195012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-14" decimals="-3" id="f-191" unitRef="usd">1914000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-12" decimals="-3" id="f-192" unitRef="usd">1914000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-193" unitRef="usd">4913000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-194" unitRef="usd">4913000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-195" unitRef="usd">77000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-196" unitRef="usd">77000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-197" unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-198" unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-199" unitRef="usd">-26346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-200" unitRef="usd">-26346000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-201"
      unitRef="shares">127540754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-202" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-203" unitRef="usd">734711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-204" unitRef="usd">-535947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-205" unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-206" unitRef="usd">198796000</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-22"
      decimals="INF"
      id="f-207"
      unitRef="shares">136426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-23" decimals="-3" id="f-208" unitRef="usd">102000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-24" decimals="-3" id="f-209" unitRef="usd">102000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-210" unitRef="usd">4752000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-211" unitRef="usd">4752000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-25" decimals="-3" id="f-212" unitRef="usd">324000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-24" decimals="-3" id="f-213" unitRef="usd">324000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-25" decimals="-3" id="f-214" unitRef="usd">-32000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-24" decimals="-3" id="f-215" unitRef="usd">-32000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-216" unitRef="usd">-30569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-24" decimals="-3" id="f-217" unitRef="usd">-30569000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-218"
      unitRef="shares">127677180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-219" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-220" unitRef="usd">739565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-221" unitRef="usd">-566516000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-222" unitRef="usd">311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-223" unitRef="usd">173373000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-6" decimals="-3" id="f-224" unitRef="usd">3710000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-32"
      decimals="INF"
      id="f-225"
      unitRef="shares">21778560</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-226" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="-3" id="f-227" unitRef="usd">60647000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-6" decimals="-3" id="f-228" unitRef="usd">60649000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-32"
      decimals="INF"
      id="f-229"
      unitRef="shares">290295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-33" decimals="-3" id="f-230" unitRef="usd">451000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-6" decimals="-3" id="f-231" unitRef="usd">451000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-232" unitRef="usd">4384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-233" unitRef="usd">4384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-34" decimals="-3" id="f-234" unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-34" decimals="-3" id="f-236" unitRef="usd">175000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-237" unitRef="usd">175000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-238" unitRef="usd">-28706000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-239" unitRef="usd">-28706000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-36"
      decimals="INF"
      id="f-240"
      unitRef="shares">149746035</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-241" unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-242" unitRef="usd">805047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-243" unitRef="usd">-595222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-244" unitRef="usd">500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-245" unitRef="usd">210340000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-246"
      unitRef="shares">93087675</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-247" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-248" unitRef="usd">582699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-249" unitRef="usd">-406495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-250" unitRef="usd">-37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-251" unitRef="usd">176176000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-45" decimals="-3" id="f-252" unitRef="usd">411000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-46"
      decimals="INF"
      id="f-253"
      unitRef="shares">19205000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-46" decimals="-3" id="f-254" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-47" decimals="-3" id="f-255" unitRef="usd">80825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-45" decimals="-3" id="f-256" unitRef="usd">80827000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-46"
      decimals="INF"
      id="f-257"
      unitRef="shares">706247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-47" decimals="-3" id="f-258" unitRef="usd">1630000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-45" decimals="-3" id="f-259" unitRef="usd">1630000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-47" decimals="-3" id="f-260" unitRef="usd">3544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-45" decimals="-3" id="f-261" unitRef="usd">3544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-48" decimals="-3" id="f-262" unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-45" decimals="-3" id="f-263" unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-48" decimals="-3" id="f-264" unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-45" decimals="-3" id="f-265" unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-49" decimals="-3" id="f-266" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c-50" decimals="-3" id="f-267" unitRef="usd">-21975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-268" unitRef="usd">-21975000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-51"
      decimals="INF"
      id="f-269"
      unitRef="shares">112998922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-270" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-271" unitRef="usd">668698000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-272" unitRef="usd">-428470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-273" unitRef="usd">-132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-274" unitRef="usd">240107000</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-56"
      decimals="INF"
      id="f-275"
      unitRef="shares">483455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-57" decimals="-3" id="f-276" unitRef="usd">760000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-49" decimals="-3" id="f-277" unitRef="usd">760000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-57" decimals="-3" id="f-278" unitRef="usd">5353000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-3" id="f-279" unitRef="usd">5353000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-56"
      decimals="INF"
      id="f-280"
      unitRef="shares">37886</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-58" decimals="-3" id="f-281" unitRef="usd">43000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-49" decimals="-3" id="f-282" unitRef="usd">43000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-58" decimals="-3" id="f-283" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-49" decimals="-3" id="f-284" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-7" decimals="-3" id="f-285" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c-59" decimals="-3" id="f-286" unitRef="usd">-24750000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-49" decimals="-3" id="f-287" unitRef="usd">-24750000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-60"
      decimals="INF"
      id="f-288"
      unitRef="shares">113444491</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-289" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-290" unitRef="usd">674811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-291" unitRef="usd">-453220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-292" unitRef="usd">-114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-293" unitRef="usd">221488000</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-65"
      decimals="INF"
      id="f-294"
      unitRef="shares">746063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-66" decimals="-3" id="f-295" unitRef="usd">1390000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures contextRef="c-7" decimals="-3" id="f-296" unitRef="usd">1390000</absi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-3" id="f-297" unitRef="usd">5490000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-298" unitRef="usd">5490000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-67" decimals="-3" id="f-299" unitRef="usd">161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-300" unitRef="usd">161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-67" decimals="-3" id="f-301" unitRef="usd">204000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-302" unitRef="usd">204000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-68" decimals="-3" id="f-303" unitRef="usd">-27398000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-304" unitRef="usd">-27398000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-69"
      decimals="INF"
      id="f-305"
      unitRef="shares">114190554</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-3" id="f-306" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-70" decimals="-3" id="f-307" unitRef="usd">681691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-71" decimals="-3" id="f-308" unitRef="usd">-480618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-3" id="f-309" unitRef="usd">251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-3" id="f-310" unitRef="usd">201335000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">-85621000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-312" unitRef="usd">-74123000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">8914000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-314" unitRef="usd">10155000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">14064000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-316" unitRef="usd">14384000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">2016000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-5" decimals="-3" id="f-318" unitRef="usd">2961000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">-308000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-5" decimals="-3" id="f-320" unitRef="usd">1320000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">1000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-322" unitRef="usd">-739000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">283000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-324" unitRef="usd">992000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <absi:IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">-412000</absi:IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities>
    <absi:IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities contextRef="c-5" decimals="-3" id="f-326" unitRef="usd">-635000</absi:IncreaseDecreaseOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">-249000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-5" decimals="-3" id="f-328" unitRef="usd">72000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">1057000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-330" unitRef="usd">161000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">1153000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-5" decimals="-3" id="f-332" unitRef="usd">-1055000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">460000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-334" unitRef="usd">-2359000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">-63743000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-336" unitRef="usd">-55438000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">1210000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-338" unitRef="usd">381000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">134871000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-5" decimals="-3" id="f-340" unitRef="usd">159483000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">65191000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-342" unitRef="usd">99000000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">1183000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-344" unitRef="usd">244000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">-69707000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-346" unitRef="usd">-60620000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">2619000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-5" decimals="-3" id="f-348" unitRef="usd">2489000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">77000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-5" decimals="-3" id="f-350" unitRef="usd">578000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">102336000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-5" decimals="-3" id="f-352" unitRef="usd">84607000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">2467000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-5" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">102107000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-356" unitRef="usd">81540000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">-31343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-358" unitRef="usd">-34518000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-359" unitRef="usd">58214000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-360" unitRef="usd">89667000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-361" unitRef="usd">26871000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-73" decimals="-3" id="f-362" unitRef="usd">55149000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-364" unitRef="usd">433000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-365">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Organization and nature of operations&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Absci Corporation (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company advancing potential breakthrough antibody therapeutics with generative AI. The Company&#x2019;s Integrated Drug Creation platform comprises, in part, cutting edge AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was organized in the State of Oregon in August 2011 as a limited liability company and converted to a limited liability company (&#x201c;LLC&#x201d;) in Delaware in April 2016. In October 2020, the Company converted from a Delaware LLC to a Delaware corporation. The Company&#x2019;s headquarters are located in Vancouver, Washington.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepared its interim condensed consolidated financial statements that accompany these notes in conformity with accounting principles generally accepted in the United States, consistent in all material respects with those applied in its Annual Report on Form 10-K for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made estimates and judgments affecting the amounts reported in its condensed consolidated financial statements and the accompanying notes. The actual results that the Company experiences may differ materially from its estimates. The interim financial information is unaudited and reflects all normal adjustments that are, in the Company&#x2019;s opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the consolidated financial statements in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-366">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Revenue recognition&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of the satisfaction of performance obligations. As of September&#160;30, 2025 and December&#160;31, 2024, contract liabilities were $1.6 million and $1.1&#160;million, respectively. During the three and nine months ended September 30, 2025, the Company recognized $0.2 million and $0.8 million, respectively, as revenue that had been included in deferred revenue at the beginning of the period. During the three and nine months ended September 30, 2024, the Company recognized $0.8 million and $3.0 million, respectively, as revenue that had been included in deferred revenue at the beginning of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2025, two partners represented approximately 93% and three partners represented 98% of total partner program revenue, respectively. During the three and nine months ended September 30, 2024, two partners represented 100% of total partner program revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-5" id="f-367" unitRef="usd">1600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-5" id="f-368" unitRef="usd">1100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-6" decimals="-5" id="f-369" unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-370" unitRef="usd">800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-7" decimals="-5" id="f-371" unitRef="usd">800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-5" decimals="-5" id="f-372" unitRef="usd">3000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <absi:NumberOfPartners
      contextRef="c-74"
      decimals="INF"
      id="f-373"
      unitRef="partner">2</absi:NumberOfPartners>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-374" unitRef="number">0.93</us-gaap:ConcentrationRiskPercentage1>
    <absi:NumberOfPartners
      contextRef="c-75"
      decimals="INF"
      id="f-375"
      unitRef="partner">3</absi:NumberOfPartners>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-376" unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
    <absi:NumberOfPartners
      contextRef="c-76"
      decimals="INF"
      id="f-377"
      unitRef="partner">2</absi:NumberOfPartners>
    <absi:NumberOfPartners
      contextRef="c-77"
      decimals="INF"
      id="f-378"
      unitRef="partner">2</absi:NumberOfPartners>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-379" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-380" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-381">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Collaborative arrangements&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the Company has collaborative arrangements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin that involve joint research and development activities and for which the parties are exposed to significant risks and rewards dependent on the commercial success of such activities. The Company performs drug creation activities to co-develop product candidates. These arrangements include rights for the parties to share in the potential value created by the programs, as well as cost sharing which may result in payments and/or credits between the parties. The Company&#x2019;s accounting policy is to present cost sharing payments to and from the Company&#x2019;s collaborators within research and development expense on the condensed consolidated statements of operations and comprehensive loss. The Company received $0.8 million of cost sharing payments and credits related to collaborative arrangements during the three and nine months ended September 30, 2025. The Company did not have cost sharing payments related to collaborative arrangements during the three or nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <absi:ProceedsFromCollaborativeArrangement contextRef="c-6" decimals="-5" id="f-382" unitRef="usd">800000</absi:ProceedsFromCollaborativeArrangement>
    <absi:ProceedsFromCollaborativeArrangement contextRef="c-1" decimals="-5" id="f-383" unitRef="usd">800000</absi:ProceedsFromCollaborativeArrangement>
    <absi:ProceedsFromCollaborativeArrangement contextRef="c-5" decimals="-5" id="f-384" unitRef="usd">0</absi:ProceedsFromCollaborativeArrangement>
    <absi:ProceedsFromCollaborativeArrangement contextRef="c-7" decimals="-5" id="f-385" unitRef="usd">0</absi:ProceedsFromCollaborativeArrangement>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock contextRef="c-1" id="f-386">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Investments&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities are classified as available-for-sale and are recorded at fair value on the condensed consolidated balance sheets, with any unrealized gains and losses reported in accumulated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other comprehensive loss, which is reflected as a separate component of stockholders&#x2019; equity on the Company&#x2019;s condensed consolidated balance sheets, until realized. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company considers all marketable securities to be current assets as they are available for use in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and fair value of investments are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from maturities of available-for-sale securities were $39.0 million and $65.2&#160;million for the three and nine months ended September 30, 2025, respectively. Proceeds from maturities of available-for-sale securities were $43.0 million and $132.1&#160;million for the three and nine months ended September 30, 2024, respectively. As of September&#160;30, 2025, the Company held $32.6 million of marketable securities with a remaining maturity of greater than one year. There were no realized gains or losses on securities for the three and nine months ended September 30, 2025 and 2024. Unrealized gains and losses on securities were primarily due to changes in interest rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-387">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and fair value of investments are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-78" decimals="-3" id="f-388" unitRef="usd">192000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-78" decimals="-3" id="f-389" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-78" decimals="-3" id="f-390" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-78" decimals="-3" id="f-391" unitRef="usd">192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-79" decimals="-3" id="f-392" unitRef="usd">142849000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-79" decimals="-3" id="f-393" unitRef="usd">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-79" decimals="-3" id="f-394" unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-79" decimals="-3" id="f-395" unitRef="usd">142999000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-396" unitRef="usd">143041000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-397" unitRef="usd">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-398" unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-399" unitRef="usd">143191000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-80" decimals="-3" id="f-400" unitRef="usd">192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-81" decimals="-3" id="f-401" unitRef="usd">142999000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-402" unitRef="usd">143191000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-82" decimals="-3" id="f-403" unitRef="usd">2134000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-82" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-82" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-82" decimals="-3" id="f-406" unitRef="usd">2134000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-83" decimals="-3" id="f-407" unitRef="usd">71151000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-83" decimals="-3" id="f-408" unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-83" decimals="-3" id="f-409" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-83" decimals="-3" id="f-410" unitRef="usd">71212000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-411" unitRef="usd">73285000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-412" unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-414" unitRef="usd">73346000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-84" decimals="-3" id="f-415" unitRef="usd">2134000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-85" decimals="-3" id="f-416" unitRef="usd">71212000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-417" unitRef="usd">73346000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-6" decimals="-5" id="f-418" unitRef="usd">39000000.0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-5" id="f-419" unitRef="usd">65200000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-7" decimals="-5" id="f-420" unitRef="usd">43000000.0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-5" decimals="-5" id="f-421" unitRef="usd">132100000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-3" decimals="-5" id="f-422" unitRef="usd">32600000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesRealizedGainLoss contextRef="c-86" decimals="INF" id="f-423" unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss contextRef="c-87" decimals="INF" id="f-424" unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss contextRef="c-88" decimals="INF" id="f-425" unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss contextRef="c-89" decimals="INF" id="f-426" unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-427">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Fair value measurements&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) has defined fair value to establish a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2 inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews trading activity and pricing for its available-for-sale securities as of the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no change to the value of liabilities measured at fair value using significant unobservable inputs (Level 3) for the nine months ended September 30, 2025. The contingent consideration liability is related to the acquisition of Totient, Inc. and is included in contingent consideration on the condensed consolidated balance sheet as of September&#160;30, 2025 and December&#160;31, 2024. The fair value estimate is based on a probability-weighted approach on conditions that existed as of September 30, 2025 (See Note 11: Subsequent events) . The contingent consideration of $15.0&#160;million held in escrow shall be paid upon the achievement of the milestone of either entering into agreements meeting certain financial criteria with third parties using, or relating to, Totient technology or the first commercial sale of a Totient product. The contingent consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;held in escrow is included in restricted cash on the condensed consolidated balance sheets as of September&#160;30, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of long-term debt approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-90" decimals="-3" id="f-429" unitRef="usd">192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-91" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-92" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-93" decimals="-3" id="f-432" unitRef="usd">192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-94" decimals="-3" id="f-433" unitRef="usd">19656000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-95" decimals="-3" id="f-434" unitRef="usd">123343000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-96" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-97" decimals="-3" id="f-436" unitRef="usd">142999000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-437" unitRef="usd">19848000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-438" unitRef="usd">123343000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-440" unitRef="usd">143191000</us-gaap:AssetsFairValueDisclosure>
    <absi:ContingentConsiderationFairValue contextRef="c-98" decimals="-3" id="f-441" unitRef="usd">0</absi:ContingentConsiderationFairValue>
    <absi:ContingentConsiderationFairValue contextRef="c-99" decimals="-3" id="f-442" unitRef="usd">0</absi:ContingentConsiderationFairValue>
    <absi:ContingentConsiderationFairValue contextRef="c-100" decimals="-3" id="f-443" unitRef="usd">12750000</absi:ContingentConsiderationFairValue>
    <absi:ContingentConsiderationFairValue contextRef="c-101" decimals="-3" id="f-444" unitRef="usd">12750000</absi:ContingentConsiderationFairValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-98" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-99" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-100" decimals="-3" id="f-447" unitRef="usd">12750000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-101" decimals="-3" id="f-448" unitRef="usd">12750000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-102" decimals="-3" id="f-449" unitRef="usd">2134000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-103" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-104" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-105" decimals="-3" id="f-452" unitRef="usd">2134000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-106" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-107" decimals="-3" id="f-454" unitRef="usd">71212000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-108" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-109" decimals="-3" id="f-456" unitRef="usd">71212000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-457" unitRef="usd">2134000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-458" unitRef="usd">71212000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-113" decimals="-3" id="f-460" unitRef="usd">73346000</us-gaap:AssetsFairValueDisclosure>
    <absi:ContingentConsiderationFairValue contextRef="c-110" decimals="-3" id="f-461" unitRef="usd">0</absi:ContingentConsiderationFairValue>
    <absi:ContingentConsiderationFairValue contextRef="c-111" decimals="-3" id="f-462" unitRef="usd">0</absi:ContingentConsiderationFairValue>
    <absi:ContingentConsiderationFairValue contextRef="c-112" decimals="-3" id="f-463" unitRef="usd">12750000</absi:ContingentConsiderationFairValue>
    <absi:ContingentConsiderationFairValue contextRef="c-113" decimals="-3" id="f-464" unitRef="usd">12750000</absi:ContingentConsiderationFairValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-110" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-111" decimals="-3" id="f-466" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-112" decimals="-3" id="f-467" unitRef="usd">12750000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-113" decimals="-3" id="f-468" unitRef="usd">12750000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:EscrowDeposit contextRef="c-3" decimals="-5" id="f-469" unitRef="usd">15000000</us-gaap:EscrowDeposit>
    <us-gaap:EscrowDeposit contextRef="c-4" decimals="-5" id="f-470" unitRef="usd">15000000</us-gaap:EscrowDeposit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-471">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Commitments and contingencies&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has access to compute capacity and other services through an agreement with Oracle Cloud Infrastructure (OCI) through early 2028. The remaining financial commitments for the years 2025, 2026, 2027, and 2028 are $0.7 million, $4.6 million, $8.3 million, and $2.3 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear contextRef="c-114" decimals="-5" id="f-472" unitRef="usd">700000</us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths contextRef="c-114" decimals="-5" id="f-473" unitRef="usd">4600000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear contextRef="c-114" decimals="-5" id="f-474" unitRef="usd">8300000</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitmentDueInThirdYear contextRef="c-114" decimals="-5" id="f-475" unitRef="usd">2300000</us-gaap:OtherCommitmentDueInThirdYear>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-476">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Common stock&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shelf registration statement on Form S-3&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company filed a shelf registration statement on Form S-3 (the Prior Shelf Registration Statement) with the SEC relating to the registration of up to an aggregate of $250.0&#160;million in shares of the Company&#x2019;s common stock, preferred stock, debt securities, warrants and units or any combination thereof. In July 2025, the Company has issued 16,670,000 shares and received $46.7 million in net proceeds from the sale of securities pursuant to the Prior Shelf Registration Statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2025, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement) with the SEC relating to the registration of up to an aggregate of $400.0&#160;million in shares of the Company&#x2019;s common stock, preferred stock, debt securities, warrants and units or any combination thereof.  During the nine months ended September 30, 2025, the Company has not issued any shares pursuant to the Shelf Registration Statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;At-the-market offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, the Company entered into a Sales Agreement with Cowen and Company, LLC, as Sales Agent (the &#x201c;Prior Sales Agreement&#x201d;), with respect to an &#x201c;at the market offering&#x201d; program under which the Company had the ability to offer and sell, from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $100.0&#160;million through the Sales Agent. The Company agreed to pay the Sales Agent a commission up to 3.0% of the gross sales proceeds of any shares sold under the Prior Sales Agreement. During the nine months ended September 30, 2025, the Company has issued 10,377,752 shares and received $35.7 million in net proceeds from the sale of securities pursuant to the Prior Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2025, the Company entered into a Sales Agreement with TD Securities (USA) LLC, as Sales Agent (the &#x201c;Sales Agreement&#x201d;), with respect to an &#x201c;at the market offering&#x201d; program under which the Company may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0&#160;million through the Sales Agent. The Company has agreed to pay the Sales Agent a commission of up to 3.0% of the gross proceeds of any shares sold under the Sales Agreement. Upon execution, the Sales Agreement terminated and superseded the Prior Sales Agreement in its entirety. During the nine months ended September 30, 2025, the Company did not issue any shares of common stock under the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private investment in public equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2025, the Company entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD) and sold an aggregate of 5,714,285 shares of the Company&#x2019;s common stock to AMD for net proceeds of $20.0 million through a private investment in public equity (PIPE). This strategic collaboration with AMD has a goal to optimize the performance of AMD Instinct&lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; accelerators and ROCm&lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;software to support the Company&#x2019;s AI drug creation, including its de novo antibody design models. The issuance of stock to AMD was at a premium of approximately $2.5 million over the market price on the issuance date. The premium was recorded to accrued expenses and other long-term liabilities on the condensed consolidated balance sheet and will be recognized as a credit to research and development expense over the collaboration term. The amortization of the premium was $0.2 million and $0.5 million for the three and nine months ended September 30, 2025, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <absi:SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction contextRef="c-115" decimals="INF" id="f-477" unitRef="usd">250000000</absi:SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-116"
      decimals="INF"
      id="f-478"
      unitRef="shares">16670000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-116" decimals="-5" id="f-479" unitRef="usd">46700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <absi:SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction contextRef="c-117" decimals="INF" id="f-480" unitRef="usd">400000000</absi:SaleOfStockNumberOfSharesAuthorizedForIssuancesInTransaction>
    <us-gaap:SharePrice
      contextRef="c-118"
      decimals="INF"
      id="f-481"
      unitRef="usdPerShare">0.0001</us-gaap:SharePrice>
    <absi:SaleOfStockMaximumAggregateOfferingPrice contextRef="c-119" decimals="-5" id="f-482" unitRef="usd">100000000</absi:SaleOfStockMaximumAggregateOfferingPrice>
    <absi:SaleOfStockSalesAgentCommissionPercentage contextRef="c-118" decimals="3" id="f-483" unitRef="number">0.030</absi:SaleOfStockSalesAgentCommissionPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-120"
      decimals="INF"
      id="f-484"
      unitRef="shares">10377752</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-120" decimals="-5" id="f-485" unitRef="usd">35700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <absi:SaleOfStockMaximumAggregateOfferingPrice contextRef="c-121" decimals="-5" id="f-486" unitRef="usd">100000000</absi:SaleOfStockMaximumAggregateOfferingPrice>
    <absi:SaleOfStockSalesAgentCommissionPercentage contextRef="c-122" decimals="3" id="f-487" unitRef="number">0.030</absi:SaleOfStockSalesAgentCommissionPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-123"
      decimals="INF"
      id="f-488"
      unitRef="shares">5714285</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-123" decimals="-5" id="f-489" unitRef="usd">20000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-123" decimals="-5" id="f-490" unitRef="usd">2500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <absi:AmortizationOfEquityIssuanceDiscountPremium contextRef="c-124" decimals="-5" id="f-491" unitRef="usd">-200000</absi:AmortizationOfEquityIssuanceDiscountPremium>
    <absi:AmortizationOfEquityIssuanceDiscountPremium contextRef="c-125" decimals="-5" id="f-492" unitRef="usd">-500000</absi:AmortizationOfEquityIssuanceDiscountPremium>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c-1" id="f-493">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Stock-based compensation&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants stock options, restricted stock units, and stock appreciation rights (&#x201c;SARs&#x201d;) under the 2021 Stock Option and Incentive Plan (&#x201c;2021 Plan&#x201d;) and the 2023 Inducement Plan (the &#x201c;2023 Inducement Plan&#x201d;). On January 1, 2025, the number of shares of common stock reserved for future issuance under the 2021 Plan was increased by 5,768,113 shares pursuant to an automatic annual increase. As of September&#160;30, 2025, 5,483,484 &lt;span id="id6b2bc6cd52b4e3e8449d294cd04927c_1482"&gt;&lt;/span&gt;shares were available for future grant under the 2021 Plan. As of September&#160;30, 2025, 1,724,200 shares were available for future grant under the 2023 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to all of the Company&#x2019;s stock-based awards was recorded in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value (in thousands $)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,177,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,512,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(864,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,738&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,293,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(626,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,905,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,105,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, total unrecognized stock-based compensation related to stock options was $22.0 million, which the Company expects to recognize over a remaining weighted average period of 2.1 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Determination of fair value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated grant-date fair value of all the Company&#x2019;s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.8-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.0-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.5-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.5-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;91%-91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82%-84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;90%-92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81%-84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8%-4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7%-4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8%-4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7%-4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for restricted stock units is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.914%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,711,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,667,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(469,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(489,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,420,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, there was $5.9&#160;million of unrecognized compensation expense related to the outstanding restricted stock units expected to be recognized over a remaining weighted-average period of 1.9 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-126"
      decimals="INF"
      id="f-494"
      unitRef="shares">5768113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-127"
      decimals="INF"
      id="f-495"
      unitRef="shares">5483484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-128"
      decimals="INF"
      id="f-496"
      unitRef="shares">1724200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-497">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to all of the Company&#x2019;s stock-based awards was recorded in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="-3" id="f-498" unitRef="usd">1982000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-3" id="f-499" unitRef="usd">2010000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-3" id="f-500" unitRef="usd">6020000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-3" id="f-501" unitRef="usd">5577000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-502" unitRef="usd">2414000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-503" unitRef="usd">3498000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-504" unitRef="usd">8073000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-136" decimals="-3" id="f-505" unitRef="usd">8824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-506" unitRef="usd">4396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-507" unitRef="usd">5508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-508" unitRef="usd">14093000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-509" unitRef="usd">14401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value (in thousands $)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,177,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,512,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(864,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,738&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,293,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(626,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,905,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,105,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-511" unitRef="shares">19177571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-512"
      unitRef="usdPerShare">3.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-137" id="f-513">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-514" unitRef="usd">7317000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-515" unitRef="shares">6512400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-516"
      unitRef="usdPerShare">3.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-517" unitRef="shares">864563</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-518"
      unitRef="usdPerShare">2.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-519" unitRef="usd">1738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-520" unitRef="shares">2293910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-521"
      unitRef="usdPerShare">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-522" unitRef="shares">626082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-523"
      unitRef="usdPerShare">7.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-524" unitRef="shares">21905416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-525"
      unitRef="usdPerShare">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-526">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-527" unitRef="usd">9804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-528" unitRef="shares">10105606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-529"
      unitRef="usdPerShare">3.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-530">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-531" unitRef="usd">6621000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-138" decimals="-5" id="f-532" unitRef="usd">22000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-139" id="f-533">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-534">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated grant-date fair value of all the Company&#x2019;s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.8-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.0-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.5-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.5-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;91%-91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82%-84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;90%-92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81%-84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8%-4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7%-4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8%-4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7%-4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-140" id="f-535">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-141" id="f-536">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-142" id="f-537">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-143" id="f-538">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-144" id="f-539">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-145" id="f-540">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-146" id="f-541">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-147" id="f-542">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-140" decimals="2" id="f-543" unitRef="number">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-141" decimals="2" id="f-544" unitRef="number">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-142" decimals="2" id="f-545" unitRef="number">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-143" decimals="2" id="f-546" unitRef="number">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-144" decimals="2" id="f-547" unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-145" decimals="2" id="f-548" unitRef="number">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-146" decimals="2" id="f-549" unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-147" decimals="2" id="f-550" unitRef="number">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-6" decimals="3" id="f-551" unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-6" decimals="3" id="f-552" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-7" decimals="3" id="f-553" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-7" decimals="3" id="f-554" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-1" decimals="3" id="f-555" unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-1" decimals="3" id="f-556" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-5" decimals="3" id="f-557" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-5" decimals="3" id="f-558" unitRef="number">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-6" decimals="INF" id="f-559" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-7" decimals="INF" id="f-560" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-561" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-5" decimals="INF" id="f-562" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c-1" id="f-563">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for restricted stock units is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.914%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,711,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,667,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(469,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(489,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,420,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-148"
      decimals="INF"
      id="f-564"
      unitRef="shares">3711710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-148"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-149"
      decimals="INF"
      id="f-566"
      unitRef="shares">1667362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-149"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-149"
      decimals="INF"
      id="f-568"
      unitRef="shares">469008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-149"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">3.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-149"
      decimals="INF"
      id="f-570"
      unitRef="shares">489704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-149"
      decimals="2"
      id="f-571"
      unitRef="usdPerShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-150"
      decimals="INF"
      id="f-572"
      unitRef="shares">4420360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-150"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-150" decimals="-5" id="f-574" unitRef="usd">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-149" id="f-575">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-576">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.82pt"&gt;Net loss per share&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities, presented based on amounts outstanding at period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,905,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,565,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,420,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,348,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;99,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,325,776&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,012,997&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-577">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities, presented based on amounts outstanding at period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,905,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,565,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,420,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,348,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;99,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,325,776&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,012,997&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-151" decimals="0" id="f-578" unitRef="shares">21905416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-152" decimals="0" id="f-579" unitRef="shares">19565154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-153" decimals="0" id="f-580" unitRef="shares">4420360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-154" decimals="0" id="f-581" unitRef="shares">4348657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-155" decimals="0" id="f-582" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-156" decimals="0" id="f-583" unitRef="shares">99186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-584" unitRef="shares">26325776</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="0" id="f-585" unitRef="shares">24012997</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-586">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.7pt"&gt;Segment reporting&lt;/span&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Chief Operating Decision Maker (the &#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating performance. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses by expense category and the CODM makes decisions using this information on a consolidated basis. There are no other measures of profitability used by the CODM, other than those disclosed in these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the significant segment expenses (in thousands) provided to the Company&#x2019;s CODM on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Drug creation programs and platform &lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;External preclinical and clinical development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Personnel &lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General &amp;amp; administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asset and goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;91,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) &#x201c;Drug creation programs and platform&#x201d; consists of research and development costs incurred related to the Company&#x2019;s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company&#x2019;s Integrated Drug Creation platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) &#x201c;External preclinical and clinical development&#x201d; expense consists of external costs incurred following the Company&#x2019;s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &#x201c;Personnel&#x201d; expense consists of all employee wages, taxes, benefits, other employee related costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-587"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-588">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the significant segment expenses (in thousands) provided to the Company&#x2019;s CODM on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 45 Light',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Drug creation programs and platform &lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;External preclinical and clinical development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Personnel &lt;/span&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General &amp;amp; administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asset and goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;91,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) &#x201c;Drug creation programs and platform&#x201d; consists of research and development costs incurred related to the Company&#x2019;s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company&#x2019;s Integrated Drug Creation platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) &#x201c;External preclinical and clinical development&#x201d; expense consists of external costs incurred following the Company&#x2019;s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &#x201c;Personnel&#x201d; expense consists of all employee wages, taxes, benefits, other employee related costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-157" decimals="-3" id="f-589" unitRef="usd">5669000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-158" decimals="-3" id="f-590" unitRef="usd">4144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-159" decimals="-3" id="f-591" unitRef="usd">14963000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-160" decimals="-3" id="f-592" unitRef="usd">11635000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-161" decimals="-3" id="f-593" unitRef="usd">3606000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-162" decimals="-3" id="f-594" unitRef="usd">2852000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-163" decimals="-3" id="f-595" unitRef="usd">11660000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-164" decimals="-3" id="f-596" unitRef="usd">5178000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-165" decimals="-3" id="f-597" unitRef="usd">10488000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-166" decimals="-3" id="f-598" unitRef="usd">9813000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-167" decimals="-3" id="f-599" unitRef="usd">30638000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-168" decimals="-3" id="f-600" unitRef="usd">29137000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-165" decimals="-3" id="f-601" unitRef="usd">4396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-166" decimals="-3" id="f-602" unitRef="usd">5508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-167" decimals="-3" id="f-603" unitRef="usd">14093000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-168" decimals="-3" id="f-604" unitRef="usd">14401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-165" decimals="-3" id="f-605" unitRef="usd">3531000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-166" decimals="-3" id="f-606" unitRef="usd">3799000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-167" decimals="-3" id="f-607" unitRef="usd">11158000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-168" decimals="-3" id="f-608" unitRef="usd">11352000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges contextRef="c-165" decimals="-3" id="f-609" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-166" decimals="-3" id="f-610" unitRef="usd">1125000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-167" decimals="-3" id="f-611" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-168" decimals="-3" id="f-612" unitRef="usd">1125000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-165" decimals="-3" id="f-613" unitRef="usd">2842000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-166" decimals="-3" id="f-614" unitRef="usd">3355000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-167" decimals="-3" id="f-615" unitRef="usd">8914000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-168" decimals="-3" id="f-616" unitRef="usd">10155000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses contextRef="c-165" decimals="-3" id="f-617" unitRef="usd">30532000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-166" decimals="-3" id="f-618" unitRef="usd">30596000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-167" decimals="-3" id="f-619" unitRef="usd">91426000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-168" decimals="-3" id="f-620" unitRef="usd">82983000</us-gaap:OperatingExpenses>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-621">&lt;span style="color:#000000;font-family:'Frutiger LT 55 Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.7pt"&gt;Subsequent events&lt;/span&gt;In October 2025, the Company entered into an agreement with the selling stockholders of Totient to settle the contingent consideration liability for a payment of approximately $7.6&#160;million and to release the remaining $8.7&#160;million, held as restricted cash on the condensed consolidated balance sheets, from escrow to the Company.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-169" decimals="-5" id="f-622" unitRef="usd">7600000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-169" decimals="-5" id="f-623" unitRef="usd">8700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-624">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-6" id="f-625">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-6" id="f-626">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-6" id="f-627">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
